December 2011

Volume 18 Number 3

Editors: Kaye Wilson, Rebecca Bloor & Donna Jennings email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am – 5pm weekdays)

Circulation

r

Published each April, August and December. Changes to the contents are published in monthly updates. Annual subscription includes three Pharmaceutical Schedule books, 12 updates and occasional information on rule changes and news items. The Schedule is distributed free of charge to over 9,000 health professionals, and is also available on an annual subscription.

Prices

\$22.22 One Schedule book

\$4.44 One Update

\$120.00 Annual subscription

All prices include postage and exclude GST.

Production

Typeset automatically from XML and TEX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/pub/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/. Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Introducing	PHARM	AC 2
-------------	-------	------

Section A

General Rules 13

Section BAlimentary Tract & Metabolism26Blood & Blood Forming Organs40Cardiovascular System47Dermatologicals56Genito Urinary System66Hormone Preparations – Systemic72Infections – Agents For Systemic Use79Musculoskeletal System97Nervous System114Oncology Agents & Immunosuppressants140Respiratory System & Allergies159Sensory Organs166Various171

Section C Extemporaneous Compounds (ECPs)171Section DSpecial Foods178Section EPractitioner's Supply Orders198Rural Areas202Section FDispensing Period Exemptions203Section GSafety Cap Medicines205

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to five members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases.

Members of the PHARMAC Board

Stuart McLauchlan	Kura Denness	David Kerr
Anne Kolbe	Jens Mueller	

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

The following attend PHARMAC's Board meetings as observers

- Murray Georgel, CE MidCentral DHB
- Kate Russell, Chair Consumer Advisory Committee
- Carl Burgess, Chair Pharmacology and Therapeutics Advisory Committee (PTAC)

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Maori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;

- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC and the Pharmaceutical Schedule:

PHARMAC manages the national Pharmaceutical Schedule, which lists:

- Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and
- some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC.

In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as 'only if prescribed for a dialysis patient' or 'Special Authority - Retail Pharmacy', to ensure that Pharmaceuticals are used by those people who are most likely to benefit from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule.

Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals. Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals.

A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identifies those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets without specific Hospital Exceptional Circumstances approval.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Carl Burgess	MBChB, MD, MRCP (UK), FRACP, FRCP, physician/clinical pharmacologist, Chair
Howard Wilson	BSc, PhD, MB, BS, Dip Obst, FRNZCGP, FRAGCP Deputy Chair
Chris Cameron	MBChB, FRACP, MClin Pharm
Melissa Copland	PhD, BPharm(Hons), RegPharmNZ, FNZCP
Stuart Dalziel	MBChB, PhD, FRACP
lan Hosford	MBChB, FRANZCP, psychiatrist
Sisira Jayathissa	MMedSc (Clin Epi), MMBS, MD, MRCP (UK), FRCP (Edin), FRACP, FAFPHM, Dip Clin Epi,
•	Dip OHP, Dip HSM, MBS
George Laking	PhD, MD, FRACP
Dee Mangin	MBChB, DPH, RNZCGP
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician
Mark Weatherall	BA, MBChB, MApplStats, FRACP

Contact PTAC C/-Advisory Committee Manager , Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz

PHARMAC's consumer advisors

Consumer Advisory Committee (CAC)

The Consumer Advisory Committee is an advisory committee to the PHARMAC Board. It provides written reports to the Board, and its Chair attends Board meetings as an observer to report on the activities and findings of the Committee, and to comment on consumer issues. While accountable to the Board, the Committee's general working relationship is with the staff of PHARMAC. The Committee is made up of people from a range of backgrounds and interests including the health of Māori people, Pacific peoples, older people, women and mental health.

For current membership of the Consumer Advisory Committee, visit our website. The Consumer Advisory Committee can be contacted by email: CAC@pharmac.govt.nz, or you can write to the Consumer Advisory Committee at PHARMAC's postal address.

The PHARMAC Team

The PHARMAC team has a wide range of expertise in health, medicine, economics, commerce, critical analysis, and policy development and implementation.

opment and implemental			
Steffan Crausaz	Acting Chief Executive	Marcus Kim	Tender Analyst
Paul Alexander	Health Economist	Helen Knight	Accounts Payable Co-ordinator
Richard Anderson	Network and Systems	Geoff Lawn	Applications Developer / Team
	Administrator		Leader IT
Katie Appleby	Community and Cancer	Bridget Macfarlane	Access and Optimal Use
i allo i ippico)	Exceptional Circumstances	Dragot mastanano	Programme Manager
	Panel Co-ordinator	Janet Mackay	Access & Optimal Use
Jason Arnold		Janet Mackay	•
	Team Leader, Analysis	D 1 1 M 1	Programme Manager
Graham Beever	General Counsel	Rachel Mackay	Manager, Schedule and
Diana Beswetherick	HR Manager		Contracts
Rebecca Bloor	Schedule Analyst	Trish Mahoney	Contract Manager
Stephen Boxall	Creative Director	Scott Metcalfe	Chief Advisor Population
Lisa Buxton	Senior Receptionist		Medicine / Public Health
Davina Carpenter	Records Manager		Physician
Angela Cathro	Māori Health Programmes'	Peter Moodie	Medical Director
	Assistant	Christina Newman	Executive Assistant to Chief
Christine Chapman	Therapeutic Group Manager		Executive & Board Secretary
Mary Chesterfield	High Cost Drugs Co-ordinator	Deborah Nisbet	Receptionist
Andrew Davies	Acting Manager, Funding and	Hew Norris	Analyst
	Procurement	Leigh Parish	PA to Medical Director
Natalie Davis	Therapeutic Group Manager	Marama Parore	
Rachelle Davies	Office Manager & HR	Marama Parore	Manager, Access & Optimal
ridenelle Davies	Administrator		Use & Māori Health
lassias Dougharty		Chris Peck	Analyst
Jessica Dougherty	Corporate Team Executive	Matthew Poynton	Analyst/Health Economist
	Assistant	Dilky Rasiah	Deputy Medical Director
Sean Dougherty	Funding Systems Development	Awhimai Reynolds	Māori Health Manager
	Manager	Alexander Rodgers	Health Economist
Anrik Drenth	Web Developer	Brian Roulston	Contract Manager
Kim Ellis	Access & Optimal Use	Fiona Rutherford	Senior Policy Analyst
	Co-ordinator	Rico Schoeler	Manager, Analysis and
Jackie Evans	Senior Therapeutic Group		Assessment
	Manager	Carsten Schousboe	Health Economist
John Geering	Systems Architect	Merryn Simmons	PHARMAC Seminar Series
Anne Glennie	Hospital Exceptional		Co-ordinator
	Circumstances Panel	Liz Skelley	Finance Manager
	Co-ordinator	Jude Urlich	Manager, Corporate and
Lauren Caalau			External Relations
Lauren Gooley	Funding and Procurement	Les and All All for a	
	Assistant	Jayne Watkins	Team Leader, Medical Team
Rachelle Harker	PTAC Secretary & Panel	Simon England	Communications Manager
	Co-ordinator	Rachel Werner	Health Economist
David Harland	Health Economist	Bryce Wigodsky	Policy Analyst
Ben Healey	Analyst	Greg Williams	Therapeutic Group Manager
Hayden Holmes	Panel Co-ordinator (Growth	Lisa Williams	Legal Counsel
	Hormone/PAH)	Kaye Wilson	Senior Schedule Analyst
Karen Jacobs	Access & Optimal Use	Stephen Woodruffe	Therapeutic Group Manager
	Programme Manager	Sue Anne Yee	Therapeutic Group Manager
Donna Jennings	Schedule Analyst	Michael Young	Analyst
Bornia ooniningo	Conodulo / maryot		

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section A lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section **B** lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO).
- Section E Part II lists rural areas for the purpose of PSOs.
- Section F lists the Community Pharmaceuticals dispensing period exemptions.
- Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H:


- Part I lists the rules in relation to Hospital Pharmaceuticals.
- Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are
 listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if
 applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV)
 Pharmaceuticals and DV Limit.
- Part III lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget.

The index located at the back of the Section H supplement can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg	microgramµg
kilogramkg	milligrammg
international unitiu	millilitreml

millimole	mmol
unit	u

Abbreviations

Ampoule	Amp	Gra
Capsule	.Cap	Infu
Cream	.Crm	Inje
Device	. Dev	Lin
Dispersible	Disp	Liq
Effervescent	Eff	Lor
Emulsion	Emul	Oin
Enteric Coated	EC	Sad
Gelatinous	Gel	Sol

Granules	Gran	Suppository	Supp
Infusion	Inf	Tablet	Tab
Injection	Inj	Tincture	Tinc
Linctus	Linc	Trans Dermal Delivery	
Liquid	Liq	System	TDDS
Long Acting	LA		
Ointment			
Sachet	Sach		
Solution			

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

- CE Compounded Extemporaneously.
- CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.
- FCP Extemporaneously Compounded Preparation.

HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

- OP Original Pack - subsidy is rounded up to a multiple at whole packs.
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

- Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner.
- * Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed "close control" or "cc" and the endorsement is initialled by the prescriber.
- Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations. ±
- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a manufacturer's surcharge.

This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners S29 prescribing this medication should:

- a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent): and
- c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

Definitions			
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements	
[HP3]	Subsidised when dispensed from pharmacies that	Available from selected pharmacies that have an ex-	
	have a Special Foods Service appended to their Phar-	clusive contract to dispense Special Foods.	
	macy Services Agreement by their DHB.		
[HP4]	Subsidised when dispensed from pharmacies that	Avaliable from selected pharmacies that have an ex-	
	have the Monitored Therapy Variation (for Clozapine	clusive contract to dispense 'Hospital Pharmacy' [HP4]	
	Services)	pharmaceuticals.	

Patient costs

Community Pharmaceuitical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a \checkmark in the product's Schedule listing.

SALBUTAMOL

Aerosol inhaler 100 µg per dose		Fully subsidised brand
	(6.00)	Higher priced brand

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee.

PRESCRIPTION CHARGE

From 1 September 2008, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$3 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$3 co-payments.

Prescriptions from the following providers are approved for \$3 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, opthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

Manufacturer's surchage to patient = (price - subsidy) \times 1.86

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surchage of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being

\$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the relevant DHB hospital Funder from its own budget. Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) are funded through the Combined Pharmaceutical Budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions. The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the

Community Pharmaceutical. Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patients name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and Medical Council registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Exceptional Circumstances policies

The purpose of the Exceptional Circumstances policies are to provide:

- funding from within the Pharmaceutical Budget for medication, to be used in the community, in circumstances where the
 provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be
 provided through the Pharmaceutical Schedule ("Community Exceptional Circumstances"); or
- an assessment process for the DHB Hospitals to determine whether they can fund medication, to be used in the community, in circumstances where the medication is neither a Community Pharmaceutical nor a Discretionary Community Supply Pharmaceutical and where the patient does not meet the criteria for Community Exceptional Circumstances ("Hospital Exceptional Circumstances"); or
- funding from the Pharmaceutical Budget for pharmaceuticals for the treatment of cancer in their DHB Hospital, or in association with Outpatient services provided in their DHB hospital, in circumstances where the pharmaceutical is not identified as a Pharmaceutical Cancer Treatment ("Cancer Exceptional Circumstances") in Sections A-H of the Pharmaceutical Schedule.

Upon receipt of an application for approval for Community Exceptional Circumstances or Hospital Exceptional Circumstances, the Exceptional Circumstances Panel first decides whether an application will be assessed initially under the Community Exceptional Circumstances criteria or the Hospital Exceptional Circumstances criteria. Cancer Exceptional Circumstances is a separate process.

Hospital Exceptional Circumstances

If the application is first assessed but not approved under the Community Exceptional Circumstances criteria, the Exceptional Circumstances Panel may recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances.

If the application is first assessed under the Hospital Exceptional Circumstances criteria, the Exceptional Circumstances Panel may:

- a) recommend against the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget, in which case a DHB Hospital must not fund the pharmaceutical from its own budget;
- b) recommend the funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances, in which case a DHB Hospital may, but is not obliged to, fund the pharmaceutical from its own budget;
- c) defer its decision until further assessment under the Community Exceptional Circumstances criteria can undertaken; or
- d) recommend interim funding of the pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances until further assessment under the Community Exceptional Circumstances criteria can be undertaken.

Permission to fund a pharmaceutical for use in the community by a specific patient from a DHB Hospital's own budget under Hospital Exceptional Circumstances will only be granted by PHARMAC where it has been demonstrated that such funding is cost-effective for the relevant DHB in the region in which the patient resides.

If the patient being treated with a pharmaceutical under Hospital Exceptional Circumstances usually resides in a district other than that within the jurisdiction of the DHB initiating the treatment, then the DHB initiating the treatment must either agree to fund any on-going treatment required once the patient has returned to his/her usual DHB, or obtain written consent from the DHB or DHBs in which the patient will reside following the commencement of treatment.

Applications for Hospital Exceptional Circumstances should be made on the standard application form available from the PHARMAC website www.pharmac.govt.nz or the address below:

The Coordinator, Hospital Exceptional Circumstances Panel PHARMAC, PO Box 10 254 Wellington

Phone: (04) 916 7521 or fax (09) 523 6870 Email: ecpanel@pharmac.govt.nz

Cancer Exceptional Circumstances

Permission to fund a pharmaceutical for the treatment of cancer under Cancer Exceptional Circumstances will only be granted by PHARMAC where it has been demonstated that the proposed use meets the criteria.

Community Exceptional Circumstances

In order to qualify for Community Exceptional Circumstances approval one of the following criteria must be met:

- a) the condition must be rare; or
- b) the reaction to alternative funded treatment must be unusual; or
- c) an unusual combination of circumstances applies.

Rare and unusual are considered to be in the order of less than 10 people nationally.

Where one of the above Community Exceptional Circumstances entry criteria is met, the application may then be further examined under supplementary criteria, assessing suitability of the pharmaceutical, clinical benefit, the cost effectiveness of the treatment, and the patient's ability to pay for the treatment. Where these documented criteria are met, a subsidy sufficient to fully fund the pharmaceutical will be made available to the specific patient on whose behalf the application was made.

Community Exceptional Circumstances funding is only available where the criteria are met and is not available for financial reasons alone.

Applications for Community Exceptional Circumstances, Hospital Exceptional Circumstances and Cancer Exceptional Circumstances should be made on the standard application form available from the PHARMAC website www.pharmac.govt.nz or the address below:

The Coordinator, Community Exceptional Circumstances Panel PO Box 10 254 Wellington Phone (04) 916 7553 or fax (09) 523 6870 Email: ecpanel@pharmac.govt.nz

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 December 2011 and is to be referred to as the Pharmaceutical Schedule Volume 18 Number 3, 2011. Distribution will be from 20 December 2011. This Schedule comes into force on 1 December 2011.

PART I

INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria" means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

a) have limited physical mobility;

- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

"Act" means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee" means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy" means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation" means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Assessed Pharmaceuticals" means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC.

"Authority to Substitute" means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order" means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability

Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Cancer Exceptional Circumstances" means the policies and criteria administered by PHARMAC relating to the ability to fund, pharmaceuticals for the treatment of cancer that are not identified as Pharmaceutical Cancer Treatments in Sections A-H of the Pharmaceutical Schedule.

"Class B Controlled Drug" means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

"Close Control" means dispensing:

- in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot) for a Community Pharmaceutical referred to in Section F Part I, or
- in quantities less than a Monthly Lot for any other Community Pharmaceutical, where any of A), or B) or C) apply.
- This Close Control rule defines patient groups or medicines which are eligible for more frequent dispensing periods and the conditions that must be met to enable any claim for payment for additional dispensing to be made.
- A) Frequency of dispensing for persons in residential care

Pharmaceuticals can be dispensed in quantities of not less than 28 days to:

- any person whose placement in a Residential Disability Care institution is funded by the Ministry of Health or a DHB; or
- a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met:

- i) the quantity or period of supply to be dispensed at any one time is not less than 28 days' supply (except under conditions outlined in B.i below); and
- ii) the prescribing Practitioner or dispensing pharmacist has
 - 1) included the name of the patient's residential placement or facility on the prescription; and
 - 2) included the patient's NHI number on the prescription; and
 - 3) specified the maximum quantity or period of supply to be dispensed at any one time.

Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with B.i below.

B) Flexible periods of supply for trial periods or safety

The Schedule specifies for community patients a default length of dispensing (monthly/three monthly) for each pharmaceutical. Prescribers can request, and pharmacists may dispense, a higher frequency of dispensing in the following circumstances:

If the prescribing Practitioner has met the prescribing conditions set out in B.iii below, and the pharmaceutical or patient fits within the provisions of B.i and B.ii below, a pharmacist may dispense more frequently than the Schedule default period of supply.

i) Trial Periods

The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only); or

- ii) Safety
 - 1) the Community Pharmaceutical is any of the following:
 - a) a tri-cyclic antidepressant; or
 - b) an antipsychotic; or
 - c) a benzodiazepine; or
 - d) a Class B Controlled Drug; or
 - 2) The Community Pharmaceutical has been prescribed for a patient who:
 - a) is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in clause A above; and
 - b) in the opinion of the prescribing Practitioner, is intellectually impaired or frail, infirm or unable to manage their medicine without additional support.
- For B.i and B.ii all of the following conditions must be met:
 - iii) The prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Close Control" or "CC"; and
- 2) initialled the endorsement in their own handwriting; and
- 3) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4) For trial periods each Community Pharmaceutical on the Prescription must be endorsed with either "Close Control Trial" or "CCT" and the period of supply included e.g. CC Trial 1 week.
- C) Pharmaceutical Supply Management

More frequent dispensing may be required from time to time to manage stock supply issues or emergency situations.

Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:

- i) PHARMAC has approved and notified pharmacists to annotate prescriptions for a specified Community Pharmaceutical(s) "Close Control" without prescriber endorsement for a specified time; and
- ii) the dispensing pharmacist has:
 - clearly annotated each of the approved Community Pharmaceuticals that appear on the prescription with the words "Close Control" or "CC"; and
 - 2) initialled the annotation in their own handwriting; and
 - has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

If a dispensing frequency is expressly stated in the Medicines Act, Medicines Regulations or Pharmacy Services Agreement a pharmacy can dispense at that specified dispensing frequency. However, no claim shall be made to any DHB for subsidised payment for dispensing fees in any case where dispensing occurs more frequently than authorised by the provisions of the Schedule.

"Community Exceptional Circumstances" means the policies and criteria administered by the Exceptional Circumstances Panel relating to funding from the Community Exceptional Circumstances budget for medication, to be used in the community, in circumstances where the provision of a funded community medication is appropriate, but funding from the Pharmaceutical Budget is not able to be provided through the Pharmaceutical Schedule.

"Community Pharmaceutical" means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor" means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug" means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply" means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply.

"Dentist" means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber" means a registered nurse practising in diabetes health who has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site.

"Dietitian" means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB" means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital" means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Discretionary Community Supply Pharmaceutical" means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

"Doctor" means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical" means a discretionary variance Pharmaceutical, that does not have HSS and which:

a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or

b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements" - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Exceptional Circumstances Panel" means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for administering policies in relation to Community Exceptional Circumstances and Hospital Exceptional Circumstances.

"Funder" means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST" means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator" means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Exceptional Circumstances" means the policies and criteria administered by the Exceptional Circumstances Panel relating to the ability to fund, from a DHB Hospital's own budget, pharmaceuticals for use in the community by a specific patient where a subsidy is not available from the Pharmaceutical Budget or under Community Exceptional Circumstances.

"Hospital Pharmaceuticals" means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals.

"Hospital Pharmacy" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner. "Hospital Pharmacy-Specialist" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - i) endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;
- d) except in emergencies consultation to precede annotation of the Prescription; and
- e) both the specialist and the General Practitioner must keep a written record of the consultation.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

"Hospital Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS" means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination" means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit" means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical. "Licensed Hospital" means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot" means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price" means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife" means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month" means a period of 30 consecutive days.

"Monthly Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"National Contract Pharmaceutical" means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

"National DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Not In Combination" means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Prescriber" means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice including, for the avoidance of doubt, a Diabetes Nurse Prescriber.

"Optometrist" means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

"Outpatient" , in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT" means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only" means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution" means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC" means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

"Pharmaceutical" means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule.

"Pharmaceutical Benefits" means the right of:

a) a person; and

b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget" means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment" means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Practitioner" means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber or an Optometrist as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order" means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription" means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine" means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations 1984.

"Private Hospital" means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Residential Disability Care Institution" means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home" means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine" means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist" means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,
- b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - i) endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as:

- a) follows a substantive consultation with an appropriate Specialist;
- b) the consultation to relate to the Patient for whom the Prescription is written;
- c) consultation to mean communication by referral, telephone, letter, facsimile or email;

d) except in emergencies consultation to precede annotation of the Prescription; and

e) both the Specialist and the General Practitioner must keep a written record of consultation.

"Retail Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist. For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Schedule" means this Pharmaceutical Schedule and all its sections and appendices.

"Section B" of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies included in the Schedule.

"Section C" of this Pharmaceutical Schedule means the list of community extemporaneously compounded preparations and galenicals eligible for Subsidies included in the Schedule.

"Section D" of this Pharmaceutical Schedule means the list of community special foods eligible for Subsidies included in the Schedule.

"Section E Part I" of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for Subsidies and available on a Practitioner's Supply Order included in the Schedule.

"Section E Part II" of this Pharmaceutical Schedule means the list of rural areas for the purpose of community Practitioner's Supply Orders included in the Schedule.

"Section F Part I" of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots, and requirement to dispense in 90 Day Lots or 180 Day Lots, as applicable, in respect of the Community Pharmaceuticals referred to in this part of Section F;

"Section F Part II" of this Pharmaceutical Schedule means the part of Section F relating to the exemption from dispensing in Monthly Lots in respect of the Community Pharmaceuticals referred to in this part of Section F;

"Section G" of this Pharmaceutical Schedule means the list of Community Pharmaceuticals eligible for reimbursement of safety caps.

"Section H" of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals and the lists of National Contract Pharmaceuticals and any associated DV Pharmaceuticals, of Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals included in Section H of the Schedule. "Section H Part I" of this Pharmaceutical Schedule means the general rules for Hospital Pharmaceuticals.

"Section H Part II" of this Pharmaceutical Schedule means the list of National Contract Pharmaceuticals, the relevant Price, an indication of whether the Pharmaceutical has HSS and any associated DV Pharmaceuticals and DV Limit.

"Section H Part III" of this Pharmaceutical Schedule means the list of Discretionary Community Supply Pharmaceuticals. "Special Authority" means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

a)

- i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and
- ii) the doctor's vocational scope of practice is one of those listed below: anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology;
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine;
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine;
- d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy" means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dispensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order" means a Bulk Supply Order or a Practitioner's Supply Order.

"Unapproved Indication" means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 4.6.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II

COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 4.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless

the Community Pharmaceuticals so supplied:

- 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
- 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
- 2.2.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
- 2.2.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers' and Optometrists' Prescriptions (other than oral contraceptives)

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber or Optometrist unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate, only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
 - b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
 - a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.

- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is Close Control,
 - The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is Close Control; or
 - b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.
- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical in a Prescription is Close Control and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.

3.3 Original Packs, and Certain Antibiotics

- 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
 - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
- 3.3.2 If a Community Pharmaceutical is the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:
 - a) the difference the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eq; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
 - b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Dietitians' Prescriptions

The following provisions apply to every Prescription written by a Dietitian:

- 3.4.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian,
 - providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.
- 3.4.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

3.5 Diabetes Nurse Prescribers' Prescriptions

- The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:
- 3.5.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical listed below, being an item that has been identified as being able to be prescribed by a Diabetes Nurse Prescriber, but which is not classified as a Prescription Medicine or a Restricted Medicine:

aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.5.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

Note: A list of Diabetes Nurse Prescribers will be published periodically in the Update of the Pharmaceutical Schedule for the duration of an initial pilot scheme. After this period there will be no approved DHB demonstration sites and hence no Diabetes Nurse Prescribers.

PART IV MISCELLANEOUS PROVISIONS

4.1 Bulk Supply Orders

- The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:
- 4.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 4.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 4.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 4.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 4.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 4.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 4.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.
- 4.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 4.2.1 Subject to clause 4.2.3, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 4.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 4.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)

4.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:

- a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
- b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 4.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.

4.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

4.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

4.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 4.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 4.3.1 and 4.3.2, for the individual Patient.
- 4.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 4.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

4.4 Pharmaceutical Cancer Treatments

- 4.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 4.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Cancer Exceptional Circumstances approval;
 - b) has Community Exceptional Circumstances or Hospital Exceptional Circumstances approval;
 - c) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - d) is being used and funded as part of a paediatric oncology service; or
 - e) was being used to treat the patient in question prior to 1 July 2005.
- 4.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the

Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:

- a) Part 1;
- b) clauses 2.1 to 2.3;
- c) clauses 3.1 to 3.4; and
- d) clause 4.4,
- of Section A of the Schedule
- 4.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 4.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 direction from the Minister of Health as to pharmaceuticals and indications for which DHBs must provide funding. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under the Medicines Act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Comissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.

4.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

4.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

a) there is a clinical reason why substitution should not occur; or

b) the prescriber has marked the prescription with a statement such as 'no brand substitution premitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget.

When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

4.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

4.8 Conflict in Provisions

If any rules in Sections B-G of this Schedule conflict with the rules in Section A, the rules in Sections B-G apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's F \$	Price) Su Per	Fully Brand or bsidised Generic Manufacturer	
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	4.50	30	✓ Gaviscon Infant	
CALCIUM CARBONATE WITH AMINOACETIC ACID * Tab 420 mg with aminoacetic acid 180 mg – Higher subsidy of \$6.30 per 100 tab with Endorsement		100	Titralac	
Additional subsidy by endorsement is available for pregnar SIMETHICONE	()	rescription mu		
 Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml 	1.50 (4.26)	500 ml	Mylanta P	
SODIUM ALGINATE * Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80 (8.60)	60	Gaviscon Double Strength	
 Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml 		500 ml	Acidex	
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE Tab 600 mg Antidiarrhoeals	12.56	100	🖌 Alu-Tab	
Agents Which Reduce Motility				
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPH * Tab 2.5 mg with atropine sulphate 25 µg	3.90	100	🗸 Diastop	
LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a * Tab 2 mg * Cap 2 mg		400 400	 ✓ Nodia ✓ <u>Diamide Relief</u> 	
Rectal and Colonic Anti-inflammatories				
BUDESONIDE				
Cap 3 mg – Special Authority see SA1155 on the next page – Retail pharmacy		90	 Entocort CIR 	

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA1155 Special Authority for Subsidy

Initial application — (Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an Unapproved Indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)	21.1 g OP	✓ Colifoam
MESALAZINE		
Tab 400 mg49.50	100	Asacol
Tab EC 500 mg	100	Asamax
Tab long-acting 500 mg59.05	100	Pentasa
Enema 1 g per 100 ml45.96	7	Pentasa
Suppos 500 mg22.80	20	✓ Asacol
Suppos 1 g50.96	28	Pentasa
OLSALAZINE		
Tab 500 mg59.86	100	Dipentum
Cap 250 mg	100	 Dipentum
SODIUM CROMOGLYCATE		
Cap 100 mg	100	Nalcrom
SULPHASALAZINE		
 Tab 500 mg - For sulphasalazine oral liquid formulation refer. 		
o	100	
page 172		Salazopyrin
* Tab EC 500 mg12.89	100	Salazopyrin EN

	Subsidy (Manufacturer's P	rice) Sub	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Antihaemorrhoidals			
Corticosteroids			
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVA	ALATE AND CINC	CHOCAINE	
Oint 950 µg, with fluocortolone pivalate 920 µg, and cin- chocaine hydrochloride 5 mg per g		30 g OP	✓ Ultraproct
Suppos 630 µg, with fluocortolone pivalate 610 µg, and cin-		00 g 01	• Ontapioer
chocaine hydrochloride 1 mg	2.66	12	 Ultraproct
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g	15.00	30 g OP	Proctosedyl
Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		12	✓ Proctosedyl
Antispasmodics and Other Agents Altering Gut	Motility		
ATROPINE SULPHATE			
* Inj 600 μg, 1 ml – Up to 5 inj available on a PSO		50	AstraZeneca
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg	1.48	20	✓ Gastrosoothe
* Inj 20 mg, 1 ml – Up to 5 inj available on a PSO		5	✓ <u>Buscopan</u>
MEBEVERINE HYDROCHLORIDE	10.00	00	
* Tab 135 mg Antiulcerants		90	✓ <u>Colofac</u>
Antisecretory and Cytoprotective			
MISOPROSTOL		100	
* Tab 200 µg		120	✓ Cytotec
Helicobacter Pylori Eradication			
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement	10.05	14	Apo-Clarithromycin
rab 500 mg - Subsidy by endorsement	23.30	14	 Klamycin
 a) Maximum of 14 tab per prescription b) Subsidised only if prescribed for helicobacter pylori erac 	diaction and proc	orintian is and	aroad accordingly
Note: the prescription is considered endorsed if clarithromycin is			0,7
amoxycillin or metronidazole.			
H2 Antagonists			
CIMETIDINE – Only on a prescription	F 00	100	
* Tab 200 mg	5.00 (7.50)	100	Apo-Cimetidine
* Tab 400 mg		100	
	(12.00)		Apo-Cimetidine
FAMOTIDINE – Only on a prescription * Tab 20 mg	8.10	250	✓ Famox
* Tab 40 mg		250	Famox

	Subsidy (Manufacturer's Pr	ice) Su Per	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
RANITIDINE HYDROCHLORIDE – Only on a prescription	0.70	050	
₭ Tab 150 mg		250	Arrow-Ranitidine
K Tab 300 mg		250	Arrow-Ranitidine
Oral liq 150 mg per 10 ml		300 ml 5	 Peptisoothe Zantac
k Inj 25 mg per ml, 2 ml	0./0	5	
Proton Pump Inhibitors			
ANSOPRAZOLE			
₭ Cap 15 mg	3.27	28	Lanzol Relief
	3.50		V Solox
₭ Cap 30 mg	4.34	28	Lanzol Relief
	4.65		Solox
DMEPRAZOLE			
For omeprazole suspension refer, page 175			4
₭ Cap 10 mg	0.97	30	Dr Reddy's
			Omeprazole
	2.91	90	Omezol Relief
₭ Cap 20 mg	1.26	30	Dr Reddy's
			Omeprazole
	3.78	90	Omezol Relief
₭ Cap 40 mg	1.86	30	Dr Reddy's
· -			Omeprazole
	5.57	90	Omezol Relief
Powder – Only in combination		5 g	✓ Midwest
Only in extemporaneously compounded omeprazole susp		- 3	
k lnj 40 mg		5	Dr Reddy's
, ,			Omeprazole
Dr Reddy's Omeprazole Cap 10 mg to be delisted 1 January 20 Dr Reddy's Omeprazole Cap 20 mg to be delisted 1 January 20 Dr Reddy's Omeprazole Cap 40 mg to be delisted 1 January 20	12)		<u> </u>
PANTOPRAZOLE			
k Tab 20 mg		28	✓ Dr Reddy's
			Pantoprazole
₭ Tab 40 mg		28	✓ Dr Reddy's
· ····································			Pantoprazole
🖌 Inj 40 mg	6.50	1	✓ Pantocid IV
Site Protective Agents			
-			
SUCRALFATE	07 75	100	
Tab 1 g		120	
	(48.28)		Carafate
Diabetes			
Hyperglycaemic Agents			
GLUCAGON HYDROCHLORIDE			

	Cubaidu		Fully Drand ar
	Subsidy (Manufacturer's I \$	Price) Sub Per	Fully Brand or osidised Generic ✓ Manufacturer
Inculin Chart acting Drenarctions	Ŷ	rei	
Insulin - Short-acting Preparations			
INSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP	 ✓ Actrapid ✓ Humulin R
▲ Inj human 100 u per ml, 3 ml	42.66	5	 Actrapid Penfill Humulin R
Insulin - Intermediate-acting Preparations			
NSULIN ISOPHANE			
Inj human 100 u per ml	17.68	10 ml OP	✓ Humulin NPH
▲ Inj human 100 u per ml, 3 ml	29.86	5	 Protaphane Humulin NPH Protaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL			• • • • • • • • • • • • • • • • • • • •
▲ Inj human with neutral insulin 100 u per ml	25.26	10 ml OP	 Humulin 30/70 Mixtard 30
Inj human with neutral insulin 100 u per ml, 3 ml	42.66	5	 ✓ Humulin 30/70 ✓ PenMix 30 ✓ PenMix 40 ✓ PenMix 50
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE			
▲ Inj lispro 25% with insulin lispro protamine 75% 100 u per ml,			
3 ml ▲ Inj lispro 50% with insulin lispro protamine 50% 100 u per ml.3		5	Humalog Mix 25
 Inj iispio 50% with insulin iispio protanine 50% roo u per mi,s ml 		5	Humalog Mix 50
Insulin - Long-acting Preparations			·
NSULIN GLARGINE			
Note: Only for patients meeting one of the following criteria:			
a) Type 1 diabetes; or			
 b) Other condition related diabetes (e.g. Cystic Fibrosis, diabete) c) Type 2 diabetes after there has been unacceptable hypogly 			
d) Type 2 diabetes who require insulin therapy and who require			
their insulin injections. ▲ Inj 100 u per ml, 10 ml	60.00	1	✓ Lantus
▲ Inj 100 u per ml, 3 ml		5	✓ Lantus
 Inj 100 u per ml, 3 ml disposable pen 		5	 Lantus SoloStar
Insulin - Rapid Acting Preparations			
NSULIN ASPART			
▲ Inj 100 u per ml, 3 ml	51.19	5	NovoRapid Penfill
Inj 100 u per ml, 10 ml		1	NovoRapid
NSULIN GLULISINE			
▲ Inj 100 u per ml, 10 ml		1	✓ Apidra
▲ Inj 100 u per ml, 3 ml		5 5	✓ Apidra
Inj 100 u per ml, 3 ml disposable pen	40.07	5	 Apidra SoloStar

	bsidy turer's Price)	Full Subsidise	d Generic
	\$ P	er 🖌	Manufacturer
NSULIN LISPRO			
▲ Inj 100 u per ml, 10 ml34.	92 10 ml	OP 🖌	Humalog
 Inj 100 u per ml, 3 ml59. 	52 5	~	Humalog
Alpha Glucosidase Inhibitors			
ACARBOSE			
* Tab 50 mg16.	50 90	~	<u>Glucobay</u>
* Tab 100 mg26.	70 90	~	Glucobay
Oral Hypoglycaemic Agents			
GLIBENCLAMIDE			
* Tab 5 mg	00 100) 🗸	Daonil
GLICLAZIDE			
* Tab 80 mg	60 500		Apo-Gliclazide
		•	Apo anolazido
GLIPIZIDE	F0 10		Ministiah
₭ Tab 5 mg3.	50 100		Minidiab
METFORMIN HYDROCHLORIDE			
* Tab immediate-release 500 mg8.			Apotex
* Tab immediate-release 850 mg6.	67 250) 🗸	Apotex
PIOGLITAZONE - Special Authority see SA0959 below - Retail pharmacy			
Tab 15 mg2.	61 28	~	Pizaccord
Tab 30 mg5.	23 28	~	Pizaccord
Tab 45 mg7.	80 28	~	Pizaccord

➡SA0959 Special Authority for Subsidy

Initial application — (Patients with type 2 diabetes) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 Patient has not achieved glycaemic control on maximum doses of metformin or a sulphonylurea or where either or both are contraindicated or not tolerated; or
- 2 Patient is on insulin.

Diabetes Management

Ketone Testing

KETONE BLOOD BETA-KETONE ELECTRODES - Maximum of 20 strip per pre	escription	
Test strip – Not on a BSO7.07	10 strip OP	 Optium Blood Ketone Test Strips
SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescription * Test strip – Not on a BSO14.14	50 strip OP	✓ Ketostix

	Subsidy (Manufacturer's Pri \$	ce) Per	Fully Subsidised	Brand or Generic Manufacturer
Blood Glucose Testing				
BLOOD GLUCOSE DIAGNOSTIC TEST METER – Subsidy by (a) Maximum of 1 meter per prescription b)	endorsement			
 A diagnostic blood glucose test meter is subsidis. March 2005 or is prescribed for a pregnant womar Only one meter per patient. No further prescriptio ingly. 	n with diabetes.	-		
Meter	6.00 9.00	1	✓ C ✓ F	areSens POP areSens II reeStyle Lite n Call Advanced
	19.00			ptium Xceed ccu-Chek Performa
 BLOOD GLUCOSE DIAGNOSTIC TEST STRIP The number of test strips available on a prescription is restr 1) Prescribed with insulin or a sulphonylurea but are on a dii 2) Prescribed on the same prescription as insulin or a sulph or 	ferent prescription a			
 Prescribed for a pregnant woman with diabetes and endo SensoCard blood glucose test strips are subsidised only if preso SensoCard Plus Talking Blood Glucose Monitor. 		who is sev	verely visua	Ily impaired and is using a
Blood glucose test strips	21.65	50 test C	✔ F	ccu-Chek Performa reeStyle Lite ptium 5 second

		test
26.20		SensoCard
Blood glucose test strips \times 50 and lancets \times 5	50 test OP	On Call Advanced
19.60		CareSens

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
Insulin Syringes and Needles				
Subsidy is available for disposable insulin syringes, needles, an the supply of insulin or when prescribed for an insulin patient an INSULIN PEN NEEDLES – Maximum of 100 dev per prescription	d the prescription is en			
* 29 g × 12.7 mm		30	V B	-D Micro-Fine
·	10.50	100	✓ B· ✓ A	-D Micro-Fine BM
	11.75		🖌 S(C Profi-Fine
* 31 g × 5 mm	11.75	100		-D Micro-Fine C Profi-Fine
* 31 g × 6 mm		100	🗸 A	BM
C C	11.75		🖌 Fi	ne Ject
	10.50			
	(26.00)		N	ovoFine
* 31 g × 8 mm		30	🖌 В-	-D Micro-Fine
	10.50	100	✓ B· ✓ Al	-D Micro-Fine BM
	11.75		🖌 S(C Profi-Fine
* 32 g × 4 mm		100	🖌 B-	-D Micro-Fine
INSULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLI	E – Maximum of 100 (lov nor r	rescriptio	n
* Syringe 0.3 ml with 29 g \times 12.7 mm needle		100		
	1.30	10	• 1	Dim
	(1.99)	10	B.	-D Ultra Fine
	13.00	100		-D Ultra Fine
	10.00	100		M Ject
* Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100		
	1.30	10	• 1	Dim
	(1.99)	10	B	D Ultra Fine II
	13.00	100		-D Ultra Fine II
	10.00	100		M Ject
* Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	V A	
	1.30	10	• •	
	(1.99)		B-	D Ultra Fine
	13.00	100		-D Ultra Fine M Ject
* Syringe 0.5 ml with 31 g × 8 mm needle		100	🗸 A	BM
, , ,	1.30	10		
	(1.99)		B-	-D Ultra Fine II
	13.00	100		-D Ultra Fine II M Ject
* Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100		BM M Ject
	1.30	10		- /
	(1.99)	-	B-	D Ultra Fine
	13.00	100		-D Ultra Fine
* Syringe 1 ml with 31 g × 8 mm needle		100	✓ A	
	1.30	10		
	(1.99)		B-	D Ultra Fine II
	13.00	100	🖌 В-	-D Ultra Fine II
			🖌 Di	M Ject

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME				
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease		100	V C	reon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease	94.38	100	V C	reon Forte
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease	94.40	100	V P	anzytrat
URSODEOXYCHOLIC ACID - Special Authority see SA1003 bel	ow – Retail pharmac	y		
Cap 300 mg – For ursodeoxycholic acid oral liquid formula- tion refer, page 172		100	🗸 A	ctigall

■SA1003 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 Patient diagnosed with cholestasis of pregnancy; or
- 2 Both:
 - 2.1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
 - 2.2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis).
- Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

MUCILAGINOUS LAXATIVES – Only on a prescription * Dry * Sugar Free	3.31	500 g OP 275 g OP	✓ <u>Konsyl-D</u>
MUCILAGINOUS LAXATIVES WITH STIMULANTS * Dry	(8.72) 6.02	200 g OP 500 g OP	Mucilax Normacol Plus
Faecal Softeners	(17.32)		Normacol Plus
DOCUSATE SODIUM – Only on a prescription * Cap 50 mg * Cap 120 mg * Enema conc 18% DOCUSATE SODIUM WITH SENNOSIDES * Tab 50 mg with total sennosides 8 mg	3.48 5.40	100 100 100 ml OP 200	✓ <u>Laxofast 50</u> ✓ <u>Laxofast 120</u> ✓ Coloxyl ✓ <u>Laxsol</u>

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Su Per	bsidised Generic Manufacturer
	Ŷ	101	• Manufacturor
POLOXAMER – Only on a prescription Not funded for use in the ear.			
K Oral drops 10%	3.78	30 ml OP	✓ Coloxyl
Osmotic Laxatives			
BLYCEROL			
Suppos 3.6 g – Only on a prescription	6.00	20	🖌 PSM
ACTULOSE – Only on a prescription k Oral liq 10 g per 15 ml	7.68	1,000 ml	✓ Laevolac
ACROGOL 3350 - Special Authority see SA0891 below - Re			
Powder 13.125 g, sachets - Maximum of 60 sach per pr			
scription		30	Movicol
SA0891 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals y	valid for 6 months	where the na	tient has problematic constinutio
equiring intervention with a per rectal preparation despite an			
vhere lactulose is not contraindicated.			
Renewal from any relevant practitioner. Approvals valid for 12	2 months where the	e patient is c	ompliant and is continuing to gai
enefit from treatment.			
CODIUM ACID PHOSPHATE – Only on a prescription Enema 16% with sodium phosphate 8%	2 50	1	Fleet Phosphate
			Enema
ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE	E – Only on a pres	cription	Enema
ODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n	, ,	cription	Enema
	nl,	cription 50	Enema
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n	nl,		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml Stimulant Laxatives	nl,		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml Stimulant Laxatives BISACODYL – Only on a prescription	nl, 25.00	50	✓ <u>Micolette</u>
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml Stimulant Laxatives BISACODYL – Only on a prescription F Tab 5 mg	nl, 		
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml Stimulant Laxatives BISACODYL – Only on a prescription	nl,	50 200	✓ <u>Micolette</u>
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml Stimulant Laxatives BISACODYL – Only on a prescription Tab 5 mg Suppos 5 mg	nl,	50 200 6	✓ <u>Micolette</u> ✓ <u>Lax-Tab</u> ✓ Dulcolax
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml Stimulant Laxatives BISACODYL – Only on a prescription K Tab 5 mg Suppos 5 mg Suppos 10 mg	nl,	50 200 6	✓ <u>Micolette</u> ✓ <u>Lax-Tab</u> ✓ Dulcolax
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 300 ml	✓ <u>Micolette</u> ✓ <u>Lax-Tab</u> ✓ Dulcolax ✓ Dulcolax ✓ Pinorax
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6	✓ <u>Micolette</u> ✓ <u>Lax-Tab</u> ✓ Dulcolax ✓ Dulcolax
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 6 300 ml 300 ml	✓ <u>Micolette</u> ✓ <u>Lax-Tab</u> ✓ Dulcolax ✓ Dulcolax ✓ Pinorax
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 300 ml	 <u>Micolette</u> <u>Lax-Tab</u> Dulcolax Dulcolax Pinorax Pinorax Forte
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 300 ml 300 ml 20	✓ <u>Micolette</u> ✓ <u>Lax-Tab</u> ✓ Dulcolax ✓ Dulcolax ✓ Pinorax
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 6 300 ml 300 ml	 <u>Micolette</u> <u>Lax-Tab</u> Dulcolax Dulcolax Pinorax Pinorax Forte
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 300 ml 300 ml 20	 Micolette Lax-Tab Dulcolax Dulcolax Pinorax Pinorax Forte Senokot
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 300 ml 300 ml 20	 Micolette Lax-Tab Dulcolax Dulcolax Pinorax Pinorax Forte Senokot
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 300 ml 300 ml 20	 Micolette Lax-Tab Dulcolax Dulcolax Pinorax Pinorax Forte Senokot
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 6 300 ml 300 ml 20 100	 Micolette Lax-Tab Dulcolax Dulcolax Pinorax Pinorax Forte Senokot
Enema 90 mg with sodium lauryl sulphoacetate 9 mg per n 5 ml	nl,	50 200 6 6 6 300 ml 300 ml 20 100	 Micolette Lax-Tab Dulcolax Dulcolax Pinorax Pinorax Forte Senokot

	Subsidy		Fully Brand or
	(Manufacturer's		osidised Generic
	\$	Per	 Manufacturer
► SA0473 Special Authority for Subsidy	treast Densi		
Special Authority approved by the Gaucher's Treat Notes: Subject to a budgetary cap. Applications w		subject to fund	ing availability
Application details may be obtained from PHARM			nig availability.
The Co-ordinator. Gaucher's Treatment Panel	Phone: (04) 460 4990		
PHARMAC, PO Box 10 254 Facsimile: (04) 916 7571			
Wellington	Email: gaucherpanel@pharn	nac.govt.nz	
Mouth and Throat			
Agents Used in Mouth Ulceration			
BENZYDAMINE HYDROCHLORIDE			
Soln 0.15%		200 ml	
	(7.14)		Difflam
	9.00	500 ml	
	(15.36)		Difflam
CHLORHEXIDINE GLUCONATE	•		
Mouthwash 0.2%		200 ml OP	Rivacol
CHOLINE SALICYLATE WITH CETALKONIUM CI		45 00	
* Adhesive gel 8.7% with cetalkonium chloride		15 g OP	Bonjela
	(5.62)		Dulijela
SODIUM CARBOXYMETHYLCELLULOSE With pectin and gelatin paste	17.20	56 g OP	✓ Stomahesive
with pectin and gelatin paste	1.52	5 g OP	• Stomanesive
	(3.60)	0 9 01	Orabase
	4.55	15 g OP	
	(7.90)		Orabase
With pectin and gelatin powder		28 g OP	0
	(10.95)		Stomahesive
TRIAMCINOLONE ACETONIDE	4.04	5 × 00	
0.1% in Dental Paste USP	4.34	5 g OP	✓ <u>Oracort</u>
Oropharyngeal Anti-infectives			
AMPHOTERICIN B			
Lozenges 10 mg		20	Fungilin
MICONAZOLE			
Oral gel 20 mg per g	8.70	40 g OP	Daktarin
NYSTATIN	-		4 m m m
Oral liq 100,000 u per ml		24 ml OP	✓ <u>Nilstat</u>
Other Oral Agents			
For folinic mouthwash, pilocarpine oral liquid or sa	aliva substitute formula refer, pa	ge 175	
HYDROGEN PEROXIDE			
 Soln 10 vol – Maximum of 200 ml per prescri 	ption1.28	100 ml	🖌 PSM
THYMOL GLYCERIN			
* Compound, BPC	9.15	500 ml	✔ PSM

36

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Pr \$	ice) Subs Per	sidised	Brand or Generic Manufacturer
Vitamins				
Alpha tocopheryl acetate is available fully subsidised for specific to PHARMAC website www.pharmac.govt.nz for the "Alpha tocopheryl acetate"				
Vitamin A				
VITAMIN A WITH VITAMINS D AND C Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops	4.50	10 ml OP	🖌 Vit	adol C
Vitamin B				
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO PYRIDOXINE HYDROCHLORIDE	6.15	3	✓ <u>AB</u> <u>⊦</u>	<u>M</u> Iydroxocobalamin
 a) No more than 100 mg per dose b) Only on a prescription * Tab 25 mg - No patient co-payment payable * Tab 50 mg 		90 500		ridoxADE o-Pyridoxine
THIAMINE HYDROCHLORIDE – Only on a prescription * Tab 50 mg VITAMIN B COMPLEX	5.62	100	🖌 Ар	o-Thiamine
* Tab, strong, BPC	4.70	500	✓ <u>B-F</u>	PlexADE
Vitamin C				
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription * Tab 100 mg	13.80	500	🗸 Vita	ala-C
Vitamin D		000	• <u></u>	
ALFACALCIDOL Cap 0.25 µg Cap 1 µg Oral drops 2 µg per ml	87.98	100 100 20 ml OP	🖌 On	e-Alpha e-Alpha e-Alpha
CALCITRIOL * Cap 0.25 μg * Cap 0.5 μg * Oral liq 1 μg per ml	3.03 5.62	30 30 10 ml OP	✓ <u>Air</u> ✓ <u>Air</u> ✓ Ro	
CHOLECALCIFEROL * Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescriptio	n7.76	12	🖌 Ca	l-d-Forte
Multivitamin Preparations				
MULTIVITAMINS – Special Authority see SA1036 on the next page Powder	· ·	acy 200 g OP	🖌 Pae	ediatric Seravit

ALIMENTARY TRACT AND METABOLISM

	a · · · ·		
	Subsidy (Manufacturer's Pri	ce) Su	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
►SA1036 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals va	lid without further	renewal unle	ess notified where the patient ha
inborn errors of metabolism.			
Renewal from any relevant practitioner. Approvals valid without	further renewal un	less notified	where patient has had a previous
approval for multivitamins.			
VITAMINS			
* Tab (BPC cap strength)		1,000	✓ <u>MultiADE</u>
Cap (fat soluble vitamins A, D, E, K) – Special Authority see SA1002 below – Retail pharmacy		60	✓ Vitabdeck
SA1002 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals vali the following criteria:	d without further re	enewal unles	ss notified for applications meeting
Either:			
 Patient has cystic fibrosis with pancreatic insufficiency; or Patient is an infant or child with liver disease or short gut s 	syndrome		
, and the second se			
Minerals			
Calcium			
CALCIUM CARBONATE			
* Tab eff 1.75 g (1 g elemental)	6.21	30	Calsource
* Tab 1.25 g (500 mg elemental)	6.38	250	Arrow-Calcium
			Calci-Tab 500
* Tab 1.5 g (600 mg elemental)	7.66	250	Calci-Tab 600
CALCIUM GLUCONATE			
* Inj 10%, 10 ml	21.40	10	Mayne
Fluoride			
SODIUM FLUORIDE			
Tab 1.1 mg (0.5 mg elemental)	5.00	100	✓ PSM
lodine			
POTASSIUM IODATE			
Tab 256 μg (150 μg elemental iodine)	7.55	90	NeuroKare
Iron			
FERROUS FUMARATE	1.05	100	1 Forma tab
Tab 200 mg (65 mg elemental)		100	 Ferro-tab
FERROUS FUMARATE WITH FOLIC ACID	4 75		/·
Tab 310 mg (100 mg elemental) with folic acid 350 μg	4.75	60	Ferro-F-Tabs
FERROUS SULPHATE			
* Tab long-acting 325 mg (105 mg elemental)		30	
	(4.26)	450	Ferrograd
	5.06	150	Forrograd
*‡ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)	(15.58)	500 ml	Ferrograd Ferodan
		500 111	

ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Pric \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
FERROUS SULPHATE WITH FOLIC ACID				
* Tab long-acting 325 mg (105 mg elemental) with folic acid 350 μg	1.80 (3.73)	30	F	errograd-Folic
IRON POLYMALTOSE Inj 50 mg per ml, 2 ml		5	✓ <u>F</u>	errum H
Magnesium				
For magnesium hydroxide mixture refer, page 175 MAGNESIUM SULPHATE Inj 49.3%, 5 ml		10	¥ 1	layne
Zinc				
ZINC SULPHATE * Cap 137.4 mg (50 mg elemental)	11.00	100	✓ <u>Z</u>	<u>lincaps</u>
Agents Used in the Treatment of Poisonings				
CHARCOAL				
* Tab 300 mg		100	-	Red Seal
 * Oral liq 50 g per 250 ml a) Up to 250 ml available on a PSO b) Only on a PSO 	(9.77) 43.50 2	250 ml C	•	Carbosorb-X
SODIUM CALCIUM EDETATE				
* Inj 200 mg per ml, 5 ml	53.31 (156.71)	6	C	Calcium Disodium Versenate

	Subsidy (Manufacturer's Pric \$	ce) Per	Fully Subsidised	Brand or Generic Manufacturer
Antianaemics				
Hypoplastic and Haemolytic				
 ⇒SA0922 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid Both: Both: Both: Patient in chronic renal failure; and Haemoglobin ≤ 100g/L; and 2 Any of the following: Both: Both: Both: Both: Both: Both: Both: Both: Initial application only from a relevant specialist. Approvals valid Both: Haemoglobin ≤ 100g/L; and 2 Any of the following: Both: Both: Both: Both: Both: Initial application rate ≤ 30ml/min; or Both: <l< td=""><td>ears where the treat ia associated with o toring of iron stores filtration rate (GFR $4 \times$ serum creatin by - Retail pharma </td><td>atment r chronic r and iror) in perso ine (mmo</td><td>emains appr renal failure n replacemen ons 18 years</td><td>ropriate and the patient is (CRF) where no cause fo ht therapy. s and over: prex</td></l<>	ears where the treat ia associated with o toring of iron stores filtration rate (GFR $4 \times$ serum creatin by - Retail pharma 	atment r chronic r and iror) in perso ine (mmo	emains appr renal failure n replacemen ons 18 years	ropriate and the patient is (CRF) where no cause fo ht therapy. s and over: prex
Inj human recombinant 3,000 iu, prefilled syringe Inj human recombinant 4,000 iu, prefilled syringe Inj human recombinant 5,000 iu, prefilled syringe Inj human recombinant 6,000 iu, prefilled syringe Inj human recombinant 10,000 iu, prefilled syringe	166.87 193.13 243.26 291.92	6 6 6 6		prex prex prex prex
ERYTHROPOIETIN BETA – Special Authority see SA0922 abov Inj 2,000 iu, prefilled syringe	e – Retail pharmac 	•		eoRecormon eoRecormon eoRecormon eoRecormon eoRecormon eoRecormon
Megaloblastic				
FOLIC ACID * Tab 0.8 mg * Tab 5 mg Oral liq 50 μg per ml	10.21	1,000 500 25 ml O	🖌 A	po-Folic Acid po-Folic Acid omed

40

	Subsidy (Manufacturer's Price)	S	Fully Brand or ubsidised Generic
	\$	Per	Manufacturer
Antifibrinolytics, Haemostatics and Local Sclero	osants		
SODIUM TETRADECYL SULPHATE			
* Inj 0.5% 2 ml		5	
	(45.52)		Fibro-vein
* Inj 1% 2 ml	25.00	5	
	(48.98)	_	Fibro-vein
* Inj 3% 2 ml		5	
	(55.91)		Fibro-vein
TRANEXAMIC ACID			
Tab 500 mg		100	Cyklokapron
Vitamin K			
PHYTOMENADIONE			
Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO		5	Konakion MM
Inj 10 mg per ml, 1 ml - Up to 5 inj available on a PSO	9.21	5	Konakion MM
Antithrombotic Agents			
Antiplatelet Agents			
ASPIRIN			
* Tab 100 mg	14.00	990	Ethics Aspirin EC
CLOPIDOGREL			
Tab 75 mg – For clopidogrel oral liquid formulation refer, page			
172		90	Apo-Clopidogrel
DIPYRIDAMOLE			
* Tab 25 mg - For dipyridamole oral liquid formulation refer,			
page 172		84	✓ Persantin
* Tab long-acting 150 mg		60	✓ Pytazen SR
Heparin and Antagonist Preparations			
ENOXAPARIN SODIUM - Special Authority see SA1174 below -	. Retail pharmaou		
Inj 20 mg	, ,	10	Clexane
Inj 40 mg		10	✓ <u>Clexane</u>
Inj 60 mg		10	✓ <u>Clexane</u>
Inj 80 mg		10	Clexane
Inj 100 mg		10	✓ Clexane
Inj 120 mg		10	✓ <u>Clexane</u>
Inj 150 mg		10	✓ <u>Clexane</u>

➡SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	S	Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml		10	Mayne
	66.80	50	Mayne
	11.44	10	Pfizer
	46.30	50	Pfizer
Inj 1,000 iu per ml, 35 ml		1	Mayne
Inj 5,000 iu per ml, 1 ml		5	Mayne
Inj 5,000 iu per ml, 5 ml		50	Pfizer
Inj 25,000 iu per ml, 0.2 ml		5	 Mayne
HEPARINISED SALINE			
* Inj 10 iu per ml, 5 ml		50	 Pfizer
PROTAMINE SULPHATE			
* Inj 10 mg per ml, 5 ml		10	
	(95.87)		Artex

Oral Anticoagulants

DABIGATRAN

Dabigatran will not be funded Close Control in amounts	less than 4 weeks of t	reatment.	
Cap 75 mg – No more than 2 cap per day	148.00	60 OP	Pradaxa
Cap 110 mg		60 OP	Pradaxa
Cap 150 mg	148.00	60 OP	Pradaxa
RIVAROXABAN - Special Authority see SA1066 on the nex	t page – Retail pharm	acy	
Tab 10 mg	153.00	15	Xarelto
	306.00	30	Xarelto

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	
\$	Per 🖌	Manufacturer

➡SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

1 For the prophylaxis of venous thromboembolism following a total hip replacement; or

2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg	50	Coumadin
	5.69	100	Marevan
*	Tab 2 mg4.31	50	Coumadin
*	Tab 3 mg8.00	100	Marevan
*	Tab 5 mg5.93	50	Coumadin
	9.64	100	🖌 Marevan

Fluids and Electrolytes

Intravenous Administration

DEXTF	ROSE
-------	------

DEXTROSE			
* Inj 50%, 10 ml – Up to 5 inj available on a PSO		5	Biomed
* Inj 50%, 90 ml - Up to 5 inj available on a PSO		1	V Biomed
POTASSIUM CHLORIDE			4 • • • -
* Inj 75 mg per ml, 10 ml	55.00	50	AstraZeneca
SODIUM BICARBONATE			
Inj 8.4%, 50 ml		1	Biomed
a) Up to 5 inj available on a PSO			
b) Not in combination			
Inj 8.4%, 100 ml	20.50	1	Biomed
a) Up to 5 inj available on a PSO	20.00		•
b) Not in combination			
SODIUM CHLORIDE			
Not funded for use as a nasal drop. Only funded for nebuli	ser use when in col	njunction with a	an antibiotic intended for nebuliser
use.			
Inf 0.9% – Up to 2000 ml available on a PSO	3.06	500 ml	 Baxter
	4.06	1,000 ml	 Baxter
Only if prescribed on a prescription for renal dialysis, n	naternity or post-na	tal care in the	home of the patient, or on a PSO
for emergency use. (500 ml and 1,000 ml packs)			
Inj 23.4%, 20 ml		5	Biomed
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO		50	✓ Multichem
	15.50		 Pfizer
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO		50	Pfizer
,,	16.10		✓ Multichem
Inj 0.9%, 20 ml		6	✓ Pharmacia
	11.79	30	✓ Pharmacia
	8.41	20	✓ Multichem
	0.41	20	♥ Multioneni

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or sidised Generic
	\$	Per	 Manufacturer
TOTAL PARENTERAL NUTRITION (TPN) - Retail pharmacy-Sp		4.05	
Infusion	CBS	1 OP	V TPN
1) On a properintian or Breatitionaria Supply Order only who	n on the come	form on on inio	ation listed in the Dharmacoutical
 On a prescription or Practitioner's Supply Order only whe Schedule requiring a solvent or diluent; or On a bulk supply order; or When used in the extemporaneous compounding of eye d Purified for inj, 5 ml – Up to 5 inj available on a PSO 	rops. 9.20	50	✓ Multichem
Purified for inj, 10 ml – Up to 5 inj available on a PSO		50	Multichem
Purified for inj, 20 ml – Up to 5 inj available on a PSO	5.00	20	 Multichem
Oral Administration			
CALCIUM POLYSTYRENE SULPHONATE Powder		300 g OP	 Calcium Resonium
COMPOUND ELECTROLYTES			
Powder for soln for oral use 4.4 g – Up to 10 sach available		5	
	1.12	5	<u>Electral</u>
DEXTROSE WITH ELECTROLYTES Soln with electrolytes	6.60	1,000 ml OP	✓ Pedialyte -
		1,000 111 01	Bubblegum
	6.75		 Pedialyte - Fruit Pedialyte - Plain
POTASSIUM BICARBONATE			
Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg For phosphate supplementation		100	Phosphate-Sandoz
POTASSIUM CHLORIDE			
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	(60	014
* Tab long-acting 600 mg	(11.85)	200	Chlorvescent Span-K
SODIUM BICARBONATE		200	
Cap 840 mg		100	✓ Sodibic
SODIUM POLYSTYRENE SULPHONATE			
Powder		450 g OP	Resonium-A
Lipid Modifying Agents			
Fibrates			
BEZAFIBRATE			
* Tab 200 mg * Tab long-acting 400 mg		90 30	FibalipBezalip Retard
GEMFIBROZIL Tab 600 mg	14.00	60	✓ Lipazil
Other Lipid Modifying Agents			
ACIPIMOX			
* Cap 250 mg	18.75	30	 Olbetam

44

	Subsidy (Manufacturer's Price) \$	S Per	Fully Subsidised	Brand or Generic Manufacturer
NICOTINIC ACID				
* Tab 50 mg		100		po-Nicotinic Acid
* Tab 500 mg		100	✓ <u>A</u>	po-Nicotinic Acid
Resins				
CHOLESTYRAMINE WITH ASPARTAME				
Sachets 4 g with aspartame		50	Q	uestran-Lite
COLESTIPOL HYDROCHLORIDE				
Sachets 5 g		30	V C	olestid
HMG CoA Reductase Inhibitors (Statins)				
Prescribing Guidelines Treatment with HMG CoA Reductase Inhibitors (statins) is recor cardiovascular risk of 15% or greater.	nmended for patients	with dy	/slipidaem	ia and an absolute 5 yea
ATORVASTATIN – See prescribing guideline below				
* Tab 10 mg		30	🖌 L	ipitor
🖌 Tab 20 mg	26.70	30	🖌 L	ipitor
🖌 Tab 40 mg		30	🖌 L	ipitor
₭ Tab 80 mg	110.50	30	🖌 L	ipitor
PRAVASTATIN – See prescribing guideline below				
Tab 10 mg	27.46	30	🖌 Р	ravachol
Tab 20 mg	5.44	30	V C	holvastin
	(42.58)		Р	ravachol
Tab 40 mg	9.28	30	🖌 C	holvastin
	(65.31)		Р	ravachol
Pravachol Tab 10 mg to be delisted 1 March 2012) Pravachol Tab 20 mg to be delisted 1 February 2012) Pravachol Tab 40 mg to be delisted 1 February 2012)				
SIMVASTATIN - See prescribing guideline below				
K Tab 10 mg	1.40	90	🗸 A	rrow-Simva 10mg
* Tab 20 mg	1.95	90	✓ A	rrow-Simva 20mg
* Tab 40 mg	3.18	90	✓ A	rrow-Simva 40mg
* Tab 80 mg	9.31	90	✓ <u>A</u>	rrow-Simva 80mg
Selective Cholesterol Absorption Inhibitors				
EZETIMIBE – Special Authority see SA1045 below – Retail phar Tab 10 mg	,	30	V F	zetrol

➡SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than 10 × normal) when treated with one statin; or
 - 3.2 The patient is intolerant to both simvastatin and atorvastatin; or

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
`\$	Per 🖌	

continued...

3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg	30	🖌 Vytorin
Tab 10 mg with simvastatin 20 mg	30	Vytorin
Tab 10 mg with simvastatin 40 mg	30	Vytorin
Tab 10 mg with simvastatin 80 mg	30	Vytorin

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to ≤ 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Iron Overload			
DEFERIPRONE – Special Authority see SA1042 below – Retail phar Tab 500 mg Oral liq 100 mg per 1 ml	533.17	100 250 ml OP	✔ Ferriprox✔ Ferriprox
► SA1042 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid w been diagnosed with chronic transfusional iron overload due to conge Note: For the purposes of this Special Authority, a relevant specialist	enital inherite	ed anaemia.	

DESFERRIOXAMINE MESYLATE

*	Inj 500 mg99.00	10	 Mayne
---	-----------------	----	---------------------------

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
Alpha Adrenoceptor Blockers				
DOXAZOSIN MESYLATE				
* Tab 2 mg		500	~	Apo-Doxazosin
* Tab 4 mg		500	~	Apo-Doxazosin
PHENOXYBENZAMINE HYDROCHLORIDE				
* Cap 10 mg		30	~	Dibenyline S29
	26.05	100	v 1	Dibenyline S29
PHENTOLAMINE MESYLATE				-
* Inj 10 mg per ml, 1 ml		5		
	(31.65)		I	Regitine
PRAZOSIN HYDROCHLORIDE				-
* Tab 1 mg	5.53	100	~	Apo-Prazo
* Tab 2 mg		100	~	Apo-Prazo
* Tab 5 mg	11.70	100	~	Apo-Prazo
TERAZOSIN HYDROCHLORIDE				
* Tab 1 mg		28	~	Arrow
* Tab 2 mg		28	~	Arrow
* Tab 5 mg		28	~	Arrow

Agents Affecting the Renin-Angiotensin System

Perindopril and trandolapril will be funded to the level of the ex-manufacturer price listed in the Schedule for patients who were taking these ACE inhibitors for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". **Definition of Congestive Heart Failure** At the request of some prescribers the PTAC Cardiovascular subcommittee has provided a definition of congestive heart failure for the purposes of the funding of the manufacturer's surcharge: "Clinicians should use their clinical judgement. Existing patients would be eligible for the funding of the surcharge if the patient shows signs and symptoms of congestive heart failure, and requires or has in the patient required concomitant treatment with a diurefic. The definition could also be considered to include patients post myocardial infarction with an ejection fraction of less than 40%."

ACE Inhibitors

CAPTOPRIL * Tab 12.5 mg	100 100 100 95 ml OP	 ✓ <u>m-Captopril</u> ✓ <u>m-Captopril</u> ✓ <u>m-Captopril</u> ✓ <u>Capoten</u>
CILAZAPRIL		
* Tab 0.5 mg0.95	30	✓ Zapril
* Tab 2.5 mg6.18	90	✓ Zapril
* Tab 5 mg9.84	90	Zapril
ENALAPRIL		
* Tab 5 mg1.98	90	Arrow-Enalapril
* Tab 10 mg2.44	90	Arrow-Enalapril
* Tab 20 mg - For enalapril oral liquid formulation refer, page		
172	90	Arrow-Enalapril

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy (Manufacturer's Price)	Subs	Fully	Brand or Generic
	\$	Per	~	Manufacturer
LISINOPRIL				
* Tab 5 mg	2.06	30	V A	rrow-Lisinopril
* Tab 10 mg	2.36	30	VA	rrow-Lisinopril
* Tab 20 mg	2.87	30	V A	rrow-Lisinopril
PERINDOPRIL				
* Tab 2 mg - Higher subsidy of \$18.50 per 30 tab with En-				
dorsement		30		
	(18.50)		С	Coversyl
* Tab 4 mg - Higher subsidy of \$25.00 per 30 tab with En-	()			· · ·)
dorsement		30		
	(25.00)		С	Coversyl
QUINAPRIL	. ,			
* Tab 5 mg	1.60	30		ccupril
* Tab 10 mg		30		
* Tab 20 mg		30		
TRANDOLAPRIL	2.00		• •	
* Cap 1 mg – Higher subsidy of \$18.67 per 28 cap with En-	2.06	00		
dorsement		28	0	Conton
* Can 0 mg Uigher subsidy of \$97.00 per 00 con with En	(18.67)		e	aopten
* Cap 2 mg – Higher subsidy of \$27.00 per 28 cap with En- dorsement	4.49	28		
uorsement	(27.00)	20	G	Gopten
	(27.00)		C	lopien
ACE Inhibitors with Diuretics				
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE				
* Tab 5 mg with hydrochlorothiazide 12.5 mg	5.36	28	✓ <u>Ir</u>	nhibace Plus
ENALAPRIL WITH HYDROCHLOROTHIAZIDE				
* Tab 20 mg with hydrochlorothiazide 12.5 mg		30		
, , , , , , , , , , , , , , , , , , ,	(8.70)		С	Co-Renitec
QUINAPRIL WITH HYDROCHLOROTHIAZIDE	· · ·			
* Tab 10 mg with hydrochlorothiazide 12.5 mg	3.37	30	~ A	ccuretic 10
 * Tab 20 mg with hydrochlorothiazide 12.5 mg 		30		ccuretic 20
			• •	
Angiotension II Antagonists				
CANDESARTAN - Special Authority see SA0933 on the next page	e – Retail pharmacv			
* Tab 4 mg - No more than 1.5 tab per day		30	🗸 A	tacand
	48.66	90	V 0	andestar
* Tab 8 mg – No more than 1.5 tab per day	19.30	30	🗸 A	tacand
	57.90	90	V 0	andestar
* Tab 16 mg – No more than 1 tab per day	23.54	30		tacand
	70.62	90		andestar
* Tab 32 mg – No more than 1 tab per day		30		tacand
	115.50	90		andestar

	Subsidy (Manufacturer's Prio \$	ce) S Per	Fully ubsidised	Brand or Generic Manufacturer
 SA0933 Special Authority for Subsidy nitial application from any relevant practitioner. Approva he following criteria: ither: 1 Both:	erate, two ACE inhibitors, CE inhibitor at any time in the last 2 years; or	due to per the past or	sistent co who have	ugh; or experienced angioeden
 2.2 Use of fully funded beta blockers or diuretics pressure adequately at appropriate doses; ar 2.3 Either: 2.3.1 Has been treated with, and cannot tole 2.3.2 Has experienced angioedema on an A((even if not using an ACE inhibitor) in t 	nd erate, two ACE inhibitors, CE inhibitor at any time in	due to per	sistent co	ugh; or
OSARTAN	,			
₭ Tab 12.5 mg	2.88	90	🖌 Lo	ostaar
-	0.96	30		
	(10.45)			ozaar
• Tab 25 mg	3.20	90	🖌 Lo	ostaar
	1.07	30		
	(10.45)		Co	ozaar
Tab 50 mg	5.22	90	🖌 Lo	ostaar
	1.74	30		
	(8.70)			ozaar
Tab 50 mg with hydrochlorothiazide 12.5 mg	4.89	30		row-Losartan & Hydrochlorothiazide
	(10.45)		Hy	/zaar
• Tab 100 mg	8.68	90	🖌 Lo	ostaar
	2.89	30		
	(10.45)		Co	ozaar
Cozaar Tab 12.5 mg to be delisted 1 March 2012)				
Cozaar Tab 25 mg to be delisted 1 March 2012)				
Cozaar Tab 50 mg to be delisted 1 March 2012) Hyzaar Tab 50 mg with hydrochlorothiazide 12.5 mg to be	delisted 1 March 2012)			
Cozaar Tab 100 mg to be delisted 1 March 2012)				
,				
Antiarrhythmics				
or lignocaine hydrochloride refer to NERVOUS SYSTEM,	Anaesthetics, Local. page	e 114		
MIODARONE HYDROCHLORIDE	, , , , , , , , , , , , , , , , , , , ,			
Tab 100 mg – Retail pharmacy-Specialist	18 65	30	🖌 Ar	atac
		00		ordarone-X
	00.50	~~		

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
DIGOXIN				
* Tab 62.5 μg – Up to 30 tab available on a PSO	5.56	200	V L	anoxin PG
	6.67	240	V L	anoxin PG
* Tab 250 μg – Up to 30 tab available on a PSO		100	• -	anoxin
	14.52	240	V L	anoxin
*‡ Oral liq 50 μg per ml	16.60	60 ml	V L	anoxin
DISOPYRAMIDE PHOSPHATE				
▲ Cap 100 mg		100		
	(23.87)		F	Rythmodan
▲ Cap 150 mg		100	🖌 R	lythmodan
FLECAINIDE ACETATE – Retail pharmacy-Specialist				
▲ Tab 50 mg	45.82	60	V T	ambocor
▲ Tab 100 mg - For flecainide acetate oral liquid formulation			• •	
refer, page 172		60	V T	ambocor
▲ Cap long-acting 100 mg		30	V T	ambocor CR
▲ Cap long-acting 200 mg		30	V T	ambocor CR
Inj 10 mg per ml, 15 ml		5	V T	ambocor
PROPAFENONE HYDROCHLORIDE - Retail pharmacy-Specia				
▲ Tab 150 mg		50	V B	lytmonorm
		00	• 1	lytinononin
Antihypotensives				
MIDODRINE – Special Authority see SA0934 below – Retail pha	armacy			
Tab 2.5 mg		100	V G	autron
Tab 5 mg		100	🖌 G	autron
BSA0934 Special Authority for Subsidy				

SA0934 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Disabling orthostatic hypotension not due to drugs; and
- 2 Patient has tried fludrocortisone (unless contra-indicated) with unsatisfactory results; and
- 3 Patient has tried non pharmacological treatments such as support hose, increased salt intake, exercise, and elevation of head and trunk at night.

Notes: Treatment should be started with small doses and titrated upwards as necessary.

Hypertension should be avoided, and the usual target is a standing systolic blood pressure of 90 mm Hg.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Beta Adrenoceptor Blockers

ATENOLOL		
* Tab 50 mg6.18	500	Pacific Atenolol
12.36	1,000	Atenolol Tablet USP
* Tab 100 mg10.73	500	Pacific Atenolol
21.46	1,000	Atenolol Tablet USP
CARVEDILOL		
Tab 6.25 mg21.00	30	 Dilatrend
Tab 12.5 mg27.00	30	 Dilatrend
Tab 25 mg - For carvedilol oral liquid formulation refer, page		
172	30	 Dilatrend
CELIPROLOL		
* Tab 200 mg	180	🗸 Celol

-							
		Subsidy					
		(Manufacturer's Price) \$	Per	Subsidised	Generic Manufacturer		
LΔF	BETALOL						
*	Tab 50 mg	8 23	100	~	Hybloc		
~ *	-	0.20	100	•	Tybloc		
*	Tab 100 mg – For labetalol oral liquid formulation refer, page	10.00	100		lubles		
	172		100		Hybloc		
*	Tab 200 mg		100	V 1	Hybloc		
*	Inj 5 mg per ml, 20 ml		5	-	Trandate		
	TOPROLOL SUCCINATE	(00.00)			nandate		
		0.10	30	~	Betaloc CR		
*	Tab long-acting 23.75 mg	2.10	30				
					Metoprolol - AFT CR		
	Tabless estima 47.5 mm	0.74	00		Myloc CR		
*	Tab long-acting 47.5 mg	2.74	30		Betaloc CR		
					Metoprolol - AFT CR		
					Myloc CR		
*	Tab long-acting 95 mg	4.71	30		Betaloc CR		
					Metoprolol - AFT CR		
				V I	Myloc CR		
*	Tab long-acting 190 mg	8.51	30	V I	Betaloc CR		
				V I	Metoprolol - AFT CR		
				v 1	Myloc CR		
ME	TOPROLOL TARTRATE						
*	Tab 50 mg - For metoprolol tartrate oral liquid formulation						
	refer, page 172		100	~	opresor		
*	Tab 100 mg		60		opresor		
*	Tab long-acting 200 mg		28		Slow-Lopresor		
*	Inj 1 mg per ml, 5 ml		5		Lopresor		
~		24.08	0		Lopicson		
					Betaloc		
		(34.00)		1	Detailoc		
NAI *	DOLOL Tab 40 mg	14 97	100		Apo-Nadolol		
~ *	Tab 40 mg		100		Apo-Nadolol		
	DOLOL		100	•	Apo-Nauoloi		
*	Tab 5 mg	5 40	100	~	Apo-Pindolol		
*	Tab 10 mg		100		Apo-Pindolol		
•	Tab 15 mg		100		Apo-Pindolol		
	DPRANOLOL		100	• 1			
*	Tab 10 mg	3 55	100	~	Cardinol		
*	Tab 40 mg		100		Cardinol		
•	5		100		Cardinol LA		
*	Cap long-acting 160 mg		100	•			
	FALOL	07.55					
*	Tab 80 mg – For sotalol oral liquid formulation refer, page 172		500		<u>Mylan</u>		
*	Tab 160 mg		100		<u>Mylan</u>		
*	Inj 10 mg per ml, 4 ml	65.39	5	~	Sotacor		
TIM	OLOL MALEATE						
*	Tab 10 mg		100	V	Apo-Timol		
	J	-					

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic ✔ Manufacturer
Calcium Channel Blockers			
Dihydropyridine Calcium Channel Blockers (DHF	P CCBs)		
MLODIPINE			
Tab 2.5 mg	2.45	100	Apo-Amlodipine
Tab 5 mg – For amlodipine oral liquid formulation refer, page	0.05	100	
172 Tab 10 mg		100	✓ <u>Apo-Amlodipine</u>
	4.15	100	Apo-Amlodipine
ELODIPINE			
Tab long-acting 2.5 mg – No more than 1 tab per day		30	✓ Plendil ER
Tab long-acting 5 mg		90	Felo 5 ER
Tab long-acting 10 mg		90	Felo 10 ER
RADIPINE			
Cap long-acting 2.5 mg		30	✓ Dynacirc-SRO
Cap long-acting 5 mg	7.85	30	Dynacirc-SRO
IFEDIPINE			
Tab long-acting 10 mg		60	Adalat 10
Tab long-acting 20 mg		100	Nyefax Retard
Tab long-acting 30 mg	8.56	30	✓ Adefin XL
	5 50		Arrow-Nifedipine XR
	5.50		Adolat Oxac
Tab long-acting 60 mg	(19.90)	20	Adalat Oros Adefin XL
Tab long-acting 60 mg		30	 Adefin XL Arrow-Nifedipine XR
	8.00		
	(29.50)		Adalat Oros
Other Calcium Channel Blockers	(20100)		
ILTIAZEM HYDROCHLORIDE			
• Tab 30 mg	4.60	100	V Dilzem
Tab 60 mg – For diltiazem hydrochloride oral liquid formula-		100	
tion refer, page 172	8 50	100	✓ <u>Dilzem</u>
Cap long-acting 120 mg		30	Cardizem CD
Cap long-acting 180 mg		30	Cardizem CD
Cap long-acting 240 mg		30	Cardizem CD
RHEXILINE MALEATE – Special Authority see SA0256 below			
		100	✓ Pexsig
Tab 100 mg SA0256 Special Authority for Subsidy	02.30	100	+ ready

Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Refractory angina; and

2 Patient is already on maximal anti-anginal therapy.

Renewal only from a cardiologist or general physician. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Pri \$	ce) S Per	Fully Brand or subsidised Generic V Manufacturer	
VERAPAMIL HYDROCHLORIDE				
* Tab 40 mg	7.01	100	✓ <u>Isoptin</u>	
* Tab 80 mg – For verapamil hydrochloride oral liquid formula- tion refer, page 172	11 74	100	✓ Isoptin	
* Tab long-acting 120 mg		250	Verpamil SR	
* Tab long-acting 240 mg	25.00	250	Verpamil SR	
* Inj 2.5 mg per ml, 2 ml – Up to 5 inj available on a PSO	7.54	5	 Isoptin 	
Centrally Acting Agents				
CLONIDINE * TDDS 2.5 mg, 100 μg per day – Only on a prescription	22.20	4	✓ Catapres-TTS-1	
 * TDDS 5 mg, 200 µg per day – Only on a prescription 		4	Catapres-TTS-2	
 TDDS 7.5 mg, 300 µg per day – Only on a prescription 		4	✓ Catapres-TTS-3	
CLONIDINE HYDROCHLORIDE				
* Tab 150 μg		100	✓ <u>Catapres</u>	
* Inj 150 μg per ml, 1 ml	15.45	5	Catapres	
METHYLDOPA				
* Tab 125 mg		100 100	ProdopaProdopa	
* Tab 250 mg * Tab 500 mg		100	✓ Prodopa	
Diuretics		100	• Houopu	
Loop Diuretics				
BUMETANIDE				
* Tab 1 mg		100	 Burinex 	
* Inj 500 μg per ml, 4 ml	7.95	5	 Burinex 	
FUROSEMIDE	10.75	4 000	A Dissis 40	
 * Tab 40 mg – Up to 30 tab available on a PSO * Tab 500 mg 		1,000 50	 ✓ <u>Diurin 40</u> ✓ Urex Forte 	
* 1 Oral lig 10 mg per ml		30 ml OP	✓ Lasix	
* Infusion 10 mg per ml, 25 ml		5	✓ Lasix	
* Inj 10 mg per ml, 2 ml - Up to 5 inj available on a PSO	1.30	5	Frusemide-Claris	
Potassium Sparing Diuretics				
AMILORIDE	00.00	05		
Cral liq 1 mg per ml		25 ml OP	 Biomed 	
SPIRONOLACTONE	4.60	100	1 Spiratora	
* Tab 25 mg * Tab 100 mg		100 100	 Spirotone Spirotone 	
tab foo hig f Oral lig 5 mg per ml		25 ml OP	✓ <u>Spirotone</u> ✓ Biomed	
Potassium Sparing Combination Diuretics				
AMILORIDE WITH FRUSEMIDE				
* Tab 5 mg with frusemide 40 mg	8.63	28	🖌 Frumil	
AMILORIDE WITH HYDROCHLOROTHIAZIDE				
* Tab 5 mg with hydrochlorothiazide 50 mg	5.00	50	✓ Moduretic	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber.

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Subs Per	sidised Generic Manufacturer
This ride and Deleted Diverties			
Thiazide and Related Diuretics			
BENDROFLUAZIDE	C 40	500	
* Tab 2.5 mg – Up to 150 tab available on a PSO	0.48	500	Arrow- Bendrofluazide
May be supplied on a PSO for reasons other than emerg	•	500	
* Tab 5 mg	9.95	500	Arrow- Bendrofluazide
CHLOROTHIAZIDE			
Cral liq 50 mg per ml	22.60	25 ml OP	Biomed
CHLORTHALIDONE	0.00	50	
* Tab 25 mg	8.00	50	 Hygroton
INDAPAMIDE * Tab 2.5 mg	2.95	90	🗸 Dapa-Tabs
Nitrates			
GLYCERYL TRINITRATE * Tab 600 µg – Up to 100 tab available on a PSO	8 00	100 OP	✓ Lycinate
 * Oral pump spray 400 μg per dose – Up to 250 dose availab 		100 01	• <u>Lycinate</u>
on a PSO		250 dose OP	 Nitrolingual
* TDDS 5 mg	16 56	30	Pumpspray ✔ Nitroderm TTS
* TDDS 10 mg		30	✓ <u>Nitroderm TTS</u>
ISOSORBIDE MONONITRATE			
* Tab 20 mg		100	✓ <u>Ismo 20</u>
Tab long-acting 40 mg Tab long-acting 60 mg		30 90	 ✓ <u>Corangin</u> ✓ Duride
Sympathomimetics			
ADRENALINE Inj 1 in 1,000, 1 ml – Up to 5 inj available on a PSO	4 98	5	Aspen Adrenaline
	5.25	0	Mayne
Inj 1 in 10,000, 10 ml – Up to 5 inj available on a PSO	27.00	5	🖌 Mayne
ISOPRENALINE HYDROCHLORIDE	00.00	05	
* Inj 200 μg per ml, 1 ml		25	Isuprel
Vasodilators	,)		•
AMYL NITRITE * Ampoule, 0.3 ml crushable	62 92	12	
		12	Baxter
HYDRALAZINE			
* Inj 20 mg per ml, 1 ml	25.90	5	Apresoline
OXYPENTIFYLLINE Tab 400 mg	26.04	50	
	(42.26)	50	Trental 400
PAPAVERINE HYDROCHLORIDE	. /		
* Inj 12 mg per ml, 10 ml	73.12	5	Mayne

54

S29 Unapproved medicine supplied under Section 29 Sole Subsidised Supply

				_
Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
on Panel bsite <u>http://www.phar</u> jovt.nz	mac.g	ovt.nz or:		
pharmacy 4,585.00 4,585.00 rmacy 4,585.00 4,585.00	30 30 60 60	✓ V ✓ T	olibris	
on Panel bsite <u>http://www.phar</u> jovt.nz	mac.g	ovt.nz or:		
armacy 	4 4 4	✔ V	iagra	
on Panel bsite <u>http://www.phar</u> jovt.nz macy 1,185.00	mac.g 30		entavis	
	(Manufacturer's Price) \$ on Panel bsite http://www.phar povt.nz pharmacy4,585.004,585.00 on Panel bsite http://www.phar povt.nz armacy	(Manufacturer's Price) Per on Panel bsite http://www.pharmac.g jovt.nz pharmacy pharmacy 4,585.00 30 4,585.00 30 rmacy 4,585.00 60 on Panel bsite http://www.pharmac.g jovt.nz 4,585.00 60 on Panel bsite http://www.pharmac.g jovt.nz	(Manufacturer's Price) Subsidised § Per on Panel bsite bsite http://www.pharmac.govt.nz or: <u>jovt.nz</u> pharmacy pharmacy 4,585.00 30 ✓ V 4,585.00 30 ✓ V on Panel bsite http://www.pharmac.govt.nz or: on Panel bsite http://www.pharmac.govt.nz or: <u>jovt.nz</u> armacy	(Manufacturer's Price) Subsidised Per Generic Manufacturer on Panel bsite http://www.pharmac.govt.nz or: povt.nz pharmacy 4,585.00 30 ✓ Volibris rmacy 4,585.00 30 ✓ Volibris rmacy 4,585.00 60 ✓ Tracleer on Panel bsite http://www.pharmac.govt.nz or: on Panel bsite http://www.pharmac.govt.nz or: ovt.nz armacy

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials,	page 79			
ADAPALENE				
a) Maximum of 30 g per prescription				
b) Only on a prescription				
Crm 0.1%		30 g OF	° 🖌 D	ifferin
Gel 0.1%		30 g OF	• 🖌 D	ifferin
ISOTRETINOIN - Special Authority see SA0955 below - Retail p	harmacy			
Cap 10 mg		180	V 0	ratane
Cap 20 mg	69.70	180	✓ 0	ratane

➡SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
 - 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
 - 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
 - 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g – Maximum of 50 g per prescription	13.90	50 g OP	ReTrieve
---	-------	---------	----------

	Subsidy (Manufacturer's \$	Price) Sul Per	Fully Brand or osidised Generic ✓ Manufacturer	
Antibacterials Topical				
For systemic antibacterials, refer to INFECTIONS, Antibacteria	als, page 79			
FUSIDIC ACID				
Crm 2%	3.25	15 g OP	Foban	
a) Maximum of 15 g per prescription				
b) Only on a prescription				
c) Not in combination Oint 2%	2.05	15 g OP	Foban	
a) Maximum of 15 g per prescription		15 y OF		
b) Only on a prescription				
c) Not in combination				
HYDROGEN PEROXIDE				
* Crm 1%	8.56	10 g OP	Crystacide	
MUPIROCIN		Ū	•	
Oint 2%	6.60	15 g OP		
	(9.26)	- 0 -	Bactroban	
a) Only on a prescription				
b) Not in combination				
SILVER SULPHADIAZINE				
Crm 1%	12.30	50 g OP	Flamazine	
a) Up to 250 g available on a PSO				
b) Not in combination				
Antifungals Topical				
For systemic antifungals, refer to INFECTIONS, Antifungals, pa	age 84			
AMOROLFINE	0			
a) Only on a prescription				
b) Not in combination				
Nail soln 5%		5 ml OP		
	(61.87)		Loceryl	
CICLOPIROXOLAMINE				
a) Only on a prescription				
b) Not in combination				
Nail soln 8%		3.5 ml OP	Batrafen	
Soln 1%		20 ml OP	Batrafen	
	(11.54)		Dallaiell	
	0.54	00 - 00		
* Crm 1%	0.54	20 g OP	Clomazol	
a) Only on a prescriptionb) Not in combination				
* Soln 1%	4.36	20 ml OP		
	(7.55)	20	Canesten	
a) Only on a prescription	. ,			
b) Not in combination				

	Subsidy (Manufacturer's	Price) Sul	Fully Brand or bsidised Generic
	(manalaotaroro \$	Per	Manufacturer
ECONAZOLE NITRATE			
Crm 1%	1.00	20 g OP	
	(7.48)		Pevaryl
a) Only on a prescription			
b) Not in combination	0.00		
Foaming soln 1%, 10 ml sachets		3	Deveral
a) Only on a prescription	(17.23)		Pevaryl
b) Not in combination			
,			
	0.40	15 - 00	Multicher
 Crm 2%a) Only on a prescription 	0.46	15 g OP	Multichem
b) Not in combination			
k Lotn 2%	4.36	30 ml OP	
	(10.03)	00 111 01	Daktarin
a) Only on a prescription	(10100)		
b) Not in combination			
₭ Tinct 2%	4.36	30 ml OP	
	(12.10)		Daktarin
a) Only on a prescription			
b) Not in combination			
VYSTATIN			
Crm 100,000 u per g	1.00	15 g OP	
	(7.90)		Mycostatin
a) Only on a prescription			
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination			
Crm, aqueous, BP		100 g	✓ healthE
Lotn, BP	16.70	2,000 ml	✓ <u>API</u>
ROTAMITON			
 a) Only on a prescription 			
b) Not in combination			
Crm 10%	3.79	20 g OP	Itch-Soothe
IENTHOL – Only in combination			
Only in combination with aqueous cream, 10% urea cre mineral oil lotion, and glycerol, paraffin and cetyl alcoho		eral oil lotion, 1	% hydrocortisone with wool fat a
Crystals		25 g	🖌 PSM
-	6.92	0	✓ MidWest
	29.60	100 g	✓ MidWest

58

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Corticosteroids Topical			
For systemic corticosteroids, refer to CORTICOSTEROIDS AND	RELATED AGE	NTS, page 72	
Corticosteroids - Plain			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%		15 g OP	
	(6.91)	50 × 00	Diprosone
	8.97	50 g OP	Diamagna
	(18.36)	00 × 0D	Diprosone
Crm 0.05% in propylene glycol base		30 g OP	Diaragana OV
Oint 0.05%	(13.83)	15 a OB	Diprosone OV
0int 0.05%		15 g OP	Diprosono
	(6.51) 8.97	50 g OP	Diprosone
		50 y OF	Diprocono
Oint 0.05% in propylene glycol base	(17.11)	30 g OP	Diprosone
	4.33 (13.83)	30 y OF	Diprosone OV
	(13.65)		Diplosofie OV
BETAMETHASONE VALERATE			
* Crm 0.1%		50 g OP	✓ Beta Cream
* Oint 0.1%		50 g OP	 Beta Ointment
* Lotn 0.1%	10.05	50 ml OP	 Betnovate
CLOBETASOL PROPIONATE			
* Crm 0.05%	3.48	30 g OP	 Dermol
* Oint 0.05%	3.48	30 g OP	✓ Dermol
CLOBETASONE BUTYRATE		·	
Crm 0.05%	5 38	30 g OP	
	(7.09)	00 g 01	Eumovate
	16.13	100 g OP	Lamovato
	(22.00)	100 g 01	Eumovate
	(==:00)		2000100
	0.07	50 × 00	
Crm 0.1%		50 g OP	Nericono
Eatty aint 0 19/	(15.86)	50 a OB	Nerisone
Fatty oint 0.1%	8.97 (15.86)	50 g OP	Nerisone
	(15.00)		Nelisone
HYDROCORTISONE			
* Crm 1% – Only on a prescription		500 g	Pharmacy Health
Powder – Only in combination		25 g	✓ <u>ABM</u>
Up to 5% in a dermatological base (not proprietary Top galenicals. Refer, page 171	ical Corticosteri	od – Plain) with	h or without other dermatological
HYDROCORTISONE BUTYRATE			
Lipocream 0.1%	2.30	30 g OP	Locoid Lipocream
	6.85	100 g OP	 Locoid Lipocream
Oint 0.1%		100 g OP	✓ Locoid
Milky emul 0.1%	6.85	100 ml OP	Locoid Crelo
HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL			
Lotn 1% with wool fat hydrous 3% and mineral oil – Only or	ı		
a prescription		250 ml	✓ DP Lotn HC

METHYLPREDNISOLONE ACEPONATE Crm 0.1%	(Manufacturer's I \$	Per	 Manufacturer
Crm 0.1%			
		15 g OP	Advantan
Oint 0.1%	4.95	15 g OP	Advantan
IOMETASONE FUROATE			
Crm 0.1%	2.38	15 g OP	✓ <u>m-Mometasone</u>
	4.55	45 g OP	✓ <u>m-Mometasone</u>
Oint 0.1%	2.38	15 g OP	m-Mometasone
	4.55	45 g OP	✓ <u>m-Mometasone</u>
Lotn 0.1%	7.35	30 ml OP	Elocon
RIAMCINOLONE ACETONIDE			
Crm 0.02%	6.63	100 g OP	✓ Aristocort
Oint 0.02%	6.69	100 g OP	Aristocort
Corticosteroids - Combination			
BETAMETHASONE VALERATE WITH CLIOQUINOL - Only on	a prescription		
Crm 0.1% with clioquinol 3%		15 g OP	
	(4.90)	- 5 -	Betnovate-C
Oint 0.1% with clioquinol 3%		15 g OP	
	(4.90)		Betnovate-C
ETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%	3.49	15 g OP	
	(10.45)	-	Fucicort
 a) Maximum of 15 g per prescription 			
b) Only on a prescription			
YDROCORTISONE WITH MICONAZOLE - Only on a prescrip	ption		
Crm 1% with miconazole nitrate 2%	2.10	15 g OP	Micreme H
YDROCORTISONE WITH NATAMYCIN AND NEOMYCIN - O	Only on a prescrip	tion	
Crm 1% with natamycin 1% and neomycin sulphate 0.5%	, , ,	15 g OP	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%	2.79	15 g OP	Pimafucort
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYC	IN AND NYSTAT	IN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg			
and gramicidin 250 µg per g – Only on a prescription		15 g OP	
	(6.60)	ũ	Viaderm KC

CHLORHEXIDINE GLUCONATE – Subsidy by endorsement

	a) No more than 500 ml per month		
	b) Only if prescribed for a dialysis patient and the prescription is endorsed	accordingly.	
*	Handrub 1% with ethanol 70%4.60	500 ml	
*	Soln 4%	500 ml	1

✓ <u>healthE</u>
 ✓ Orion

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b)			
 a) Only if prescribed for a patient identified with N surgery in hospital and the prescription is endors b) Only if prescribed for a patient with recurrent SI 	sed accordingly; or		
cordingly Soln 1%	4.50 5.90	500 ml OP	✓ Pharmacy Health✓ healthE
Barrier Creams and Emollients			
Barrier Creams			
ZINC AND CASTOR OIL Oint BP	5.11	500 g	✔ PSM
Emollients			
AQUEOUS CREAM * Crm		500 g	✓ <u>AFT</u>
CETOMACROGOL * Crm BP	3.15	500 g	✓ <u>PSM</u>
EMULSIFYING OINTMENT * Oint BP	3.04	500 g	✓ <u>AFT</u>
DIL IN WATER EMULSION ₭ Crm	2.80	500 g	✓ healthE Fatty Cream
JREA 卷 Crm 10%		100 g OP	✓ Nutraplus
NOOL FAT WITH MINERAL OIL – Only on a prescription * Lotn hydrous 3% with mineral oil	1.40 (3.50)	250 ml OP	DP Lotion
	5.60 (10.90) 1.40	1,000 ml 250 ml OP	DP Lotion
	(3.50) 5.60	250 mi OP	Hydroderm Lotion
	(9.54) (20.53) 1.40	250 ml OP	Hydroderm Lotion Alpha-Keri Lotion
	(7.73) 5.60	1,000 ml	BK Lotion
	(23.91)		BK Lotion

	Subsidy (Manufacturer's P		Fully Brand or osidised Generic	
Other Dermatological Bases	\$	Per	 Manufactu 	irer
-				
ARAFFIN White soft – Only in combination	3 58	500 g		
	(7.78)	500 y	IPW	
	20.20	2,500 g	✓ IPW	
	3.58	500 g		
	(8.69)	•	PSM	
Only in combination with a dermatological galenical or as	a diluent for a pro	prietary Topic	al Corticosteroid -	Plain.
Minor Skin Infections				
OVIDONE IODINE				
Oint 10%	3.27	25 g OP	 Betadine 	
a) Maximum of 100 g per prescription				
b) Only on a prescription				
Antiseptic soln 10%		15 ml		
	(3.27)	100	Betadine	
	1.28	100 ml	Betadine	
	(6.01) 6.20	500 ml	✓ Betadine	
	1.28	100 ml	Detaume	
	(4.20)	100 111	Riodine	
	6.20	500 ml	✓ Riodine	
Skin preparation, povidone iodine 10% with 30% alcohol		100 ml		
	(3.60)		Betadine Sk	in Prep
	10.00	500 ml	Betadine SI	in Prep
Skin preparation, povidone iodine 10% with 70% alcohol		100 ml		
	(6.04)		Orion	
	8.13	500 ml	<u>.</u>	
	(18.63)		Orion	
Parasiticidal Preparations				
AMMA BENZENE HEXACHLORIDE				
Crm 1%	3.50	50 g OP	Benhex	
IALATHION	0.00	00 g 0.		
Liq 0.5%	2 70	200 ml OP	✓ A-Lices	
Liq 0.5%		30 ml OP	✓ <u>A-Lices</u> ✓ A-Lices	
•	2.00	50 m O	▼ <u>A EI000</u>	
ERMETHRIN Crm 5%	4 20	20 a OP	Lyderm	
Lotn 5%		30 g OP 30 ml OP	✓ <u>Lyderm</u> ✓ A-Scabies	
Psoriasis and Eczema Preparations			• <u>A OCADICS</u>	
	D			
CITRETIN – Special Authority see SA0954 on the next page –		00		
Cap 10 mg		60 100	Novatretin	
Cap 25 mg	75.80	100 60	 Neotigason Novatretin 	
0ap 23 mg	162.96	100	✓ Novatretin	
	102.30	100		

	Subsidy		Fully	Brand or
	(Manufacturer's I \$	Price) Su Per	bsidised V	Generic Manufacturer
SA0954 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	l for 1 vear for an	nlications mee	ting the	following criteria.
All of the following:	nor rycar for ap		ang the	ionowing onterna.
1 Applicant is a vocationally registered dermatologist, vocati	onally registered	general practi	tioner, or	nurse practitioner working
in a relevant scope of practice; and	<i>y</i> 0	0 1		1 0
2 Applicant has an up to date knowledge of the treatment o	ptions for psorias	is and of diso	rders of l	keratinisation and is aware
of the safety issues around acitretin and is competent to p	prescribe acitretin	; and		
3 Either:				
 3.1 Patient is female and has been counselled and un nancy and the applicant has ensured that the possi of the treatment and that the patient is informed tha of two years after the completion of the treatment; 3.2 Patient is male. 	bility of pregnanc It she must not be	y has been ex	cluded p	rior to the commencement
Renewal from any relevant practitioner. Approvals valid for 1 year	ar for applications	meeting the fe	ollowing	criteria:
All of the following:		0		
1 Applicant is a vocationally registered dermatologist, vocati	onally registered	general practi	tioner, or	nurse practitioner working
in a relevant scope of practice; and				
2 Applicant has an up to date knowledge of the treatment o			rders of I	keratinisation and is aware
of the safety issues around acitretin and is competent to p 3 Either:	prescribe acitretin	; and		
 3.1 Patient is female and has been counselled and un nancy and the applicant has ensured that the possiof the treatment and that the patient is informed that of two years after the completion of the treatment; 3.2 Patient is male. 	bility of pregnanc It she must not be	y has been ex	cluded p	rior to the commencement
BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL				
Oint 500 µg with calcipotriol 50 µg	26 12	30 g OP	v D	aivobet
Topical gel 500 µg with calcipotriol 50 µg		30 g OP		aivobet
CALCIPOTRIOL				
Crm 50 µg per g	16.00	30 g OP	v D	aivonex
	45.00	100 g OP		aivonex
Oint 50 µg per g		30 g OP		aivonex
	45.00	100 g OP	V D	aivonex
Soln 50 µg per ml	16.00	30 ml OP	🖌 D	aivonex
	33.79	60 ml OP	🖌 D	aivonex
COAL TAR				
Soln BP – Only in combination		200 ml	🖌 M	lidwest
Up to 10 % Only in combination with a dermatological b With or without other dermatological galenicals.		y Topical Cort	icosterio	d – Plain, refer, page 171
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULI	PHUR			
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and				
allantoin crm 2.5%		30 g OP		
	(4.35)	0 -	E	gopsoryl TA
	6.59	75 g OP		
	(8.00)	-	E	gopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR				
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	✔ C	oco-Scalp

	Subsidy (Manufacturer's		Fully Brand or osidised Generic
	\$	Per	 Manufacturer
ALICYLIC ACID	10.00	050	(
Powder – Only in combination		250 g	PSM Diala or collection flowible, rafe
 Only in combination with a dermatological base page 171 	or proprietary topica	al Conticosteroio	u – Plain of collocion liexible, rele
2) With or without other dermatological galenicals.			
3) Maximum 20 g or 20 ml per prescription when p		e soft paraffin o	r collodion flexible.
ULPHUR			
Precipitated – Only in combination	6.35	100 g	✓ Midwest
 Only in combination with a dermatological base With or without other dermatological galenicals. 		al Corticostero	id – Plain, refer, page 171
AR WITH TRIETHANOLAMINE LAURYL SULPHATE AND F	-LUORESCEIN - C	Only on a prescr	ription
Soln 2.3% with triethanolamine lauryl sulphate and fluc	ores-		
cein sodium		500 ml	✓ <u>Pinetarsol</u>
	5.82	1,000 ml	Pinetarsol
Scalp Preparations			
ETAMETHASONE VALERATE			
Scalp app 0.1%	7.22	100 ml OP	Beta Scalp
LOBETASOL PROPIONATE			
Scalp app 0.05%	6.36	30 ml OP	✓ <u>Dermol</u>
YDROCORTISONE BUTYRATE			
Scalp lotn 0.1%	3.65	100 ml OP	Locoid
ETOCONAZOLE			
Shampoo 2%	3.08	100 ml OP	Sebizole
a) Maximum of 100 ml per prescription			
b) Only on a prescription			
Sunscreens			
UNSCREENS, PROPRIETARY – Subsidy by endorsement			
Only if prescribed for a patient with severe photosensiti	vity secondary to a	defined clinica	I condition and the prescription
endorsed accordingly. Crm	2 55	100 g OP	
	(5.89)	100 g OI	Hamilton Sunscreen
Lotn	()	100 ml OP	✓ Marine Blue Lotion
			SPF 30+
	5.10	200 ml OP	 Marine Blue Lotion SPF 30+
	3.19	125 ml OP	
	(6.94)		Aquasun 30+
Wart Preparations			
or salicylic acid preparations refer to PSORIASIS AND ECZ			
/IIQUIMOD – Special Authority see SA0923 on the next page Crm 5%		y 12	✓ Aldara
UIII J/0	02.00	14	✓ <u>Aluaia</u>

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully bsidised	Brand or Generic Manufacturer
■SA0923 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid	l for 4 months for	applications m	neeting t	he following criteria:
 Any of the following: 1 The patient has external anogenital warts and podophylloi 2 The patient has external anogenital warts and podophylloi 3 The patient has confirmed superficial basal cell carcinoma contraindicated or inappropriate. 	toxin is unable to	be applied acc	curately	to the site; or
 Notes: Superficial basal cell carcinoma Surgical excision remains first-line treatment for superficia and allows histological assessment of tumour clearance. Imiquimod has not been evaluated for the treatment of s nose, mouth or ears. 			0	
 Iniquimod is not indicated for recurrent, invasive, infiltratin External anogenital warts 	ng, or nodular bas	al cell carcino	ma.	
 Imiquimod is only indicated for external genital and perian Renewal from any relevant practitioner. Approvals valid for 4 mo Any of the following: 			,	ng criteria:
 Inadequate response to initial treatment for anogenital wa New confirmed superficial basal cell carcinoma where oth cated or inappropriate; or Inadequate response to initial treatment for superficial basa 	er standard treatr	,	ıg surgic	al excision, are contraindi-
Note: Every effort should be made to biopsy the lesion to confirm			l carcinc	oma.
PODOPHYLLOTOXIN Soln 0.5% a) Maximum of 3.5 ml per prescription b) Only on a prescription	33.60	3.5 ml OP	✔ C	ondyline
Other Skin Preparations				
Antineoplastics				
FLUOROURACIL SODIUM Crm 5%	26.49	20 g OP	🗸 E	fudix
Topical Analgesia				
For aspirin & chloroform application refer, page 175 CAPSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia or accordingly.	diabetic peripher	al neuropathy	and the	e prescription is endorsed
Crm 0.075%		45 g OP	🗸 Z	ostrix HP
Wound Management Products				
MAGNESIUM SULPHATE Paste	2.98 (4.90)	80 g	P	SM

	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	(Wahalactale) \$	Per	V	Manufacturer
Contraceptives - Non-hormonal				
Condoms				
ONDOMS				
49 mm – Up to 144 dev available on a PSO	1.11	12		old Knight
	13.36	144		old Knight
				arquisTantiliza
				hield 49
52 mm – Up to 144 dev available on a PSO		144		arquis Selecta
				arquis Sensolite
E0 mm outro otronoth	0 10.00	1 4 4		arquis Supalite
52 mm extra strength – Up to 144 dev available on a PS		144		arquis Protecta
53 mm – Up to 144 dev available on a PSO		12 144		hield Blue hield Blue
	1.11	144		old Knight
	13.36	144		old Knight
	10.00	144		arquis Black
				arquis Titillata
53 mm (chocolate) – Up to 144 dev available on a PSO.	1.11	12		old Knight
	13.36	144		old Knight
53 mm (strawberry) – Up to 144 dev available on a PSO		12		old Knight
	13.36	144		old Knight
53 mm extra strength – Up to 144 dev available on a PS	01.11	12		old Knight
5	13.36	144		old Knight
54 mm, shaped – Up to 144 dev available on a PSO	1.12	12		·
	(1.24)		Li	festyles Flared
	13.36	144		
	(14.84)			festyles Flared
€ 55 mm – Up to 144 dev available on a PSO		12		old Knight
	13.36	144		old Knight
				arquis Conforma
56 mm – Up to 144 dev available on a PSO		144		urex Extra Safe
			V D	urex Select
			4 -	Flavours
56 mm, shaped – Up to 144 dev available on a PSO		12		urex Confidence
00 mm - Units ddd day gwrliathia yn a DOO	13.36	144		urex Confidence
60 mm – Up to 144 dev available on a PSO	13.36	144	V 5	hield XL
Contraceptive Devices				
IAPHRAGM – Up to 1 dev available on a PSO				
One of each size is permitted on a PSO.	40.00	1		rtho All-flex
65 mm 70 mm		1		rtho All-flex
70 mm		1		rtho All-flex
₹ 75 mm		1		rtho All-flex
••			÷Ŭ	
ITRA-UTERINE DEVICE				
a) Up to 40 dev available on a PSO				
b) Only on a PSO • IUD	30 50	1	• M	ultiload Cu 375
		I		ultiload Cu 375 SL
			V IVI	unnoau Cu 3/3 SL

Subsidy		Fully
Manufacturer's Price)		Subsidised
۹.	Por	1

Brand or Generic Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

(

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit: or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 μg with desogestrel 150 μg6.62 (16.50)	63	Mercilon 21
	a) Higher subsidy of \$13.80 per 63 tab with Special Authority see SA050	0 above	
	b) Up to 63 tab available on a PSO		
*	Tab 20 µg with desogestrel 150 µg and 7 inert tab	84	
	(16.50)		Mercilon 28
	 a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 b) Up to 84 tab available on a PSO 	0 above	
*	Tab 30 µg with desogestrel 150 µg6.62	63	
	(16.50)		Marvelon 21
	 a) Higher subsidy of \$13.80 per 63 tab with Special Authority see SA0500 b) Up to 63 tab available on a PSO 	0 above	
*	Tab 30 µg with desogestrel 150 µg and 7 inert tab	84	
	(16.50)		Marvelon 28
	 a) Higher subsidy of \$13.80 per 84 tab with Special Authority see SA0500 b) Up to 84 tab available on a PSO 	0 above	

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 50 μg with levonorgestrel 125 μg and 7 inert tab – Up t				
84 tab available on a PSO		84	~	Microgynon 50 ED
* Tab 30 μg with levonorgestrel 150 μg		63		
a) Higher subsidy of \$15.00 per 63 tab with Special Author	(16.50) ority see SA0500 on th	e nrei		Microgynon 30
b) Up to 63 tab available on a PSO		e prot	boanig pag	10
 Tab 30 μg with levonorgestrel 150 μg and 7 inert tab 	6.62	84	~	Levlen ED
			~	Monofeme
	(14.49)			Nordette 28
	(16.50)			Microgynon 30 ED
 a) Higher subsidy of up to \$15.00 per 84 tab with Special b) Up to 84 tab available on a PSO 	I Authority see SA0500	on th	e precedin	ig page
ETHINYLOESTRADIOL WITH NORETHISTERONE				
* Tab 35 μg with norethisterone 1 mg – Up to 63 tab availabl on a PSO	6.62	63	~	Brevinor 1/21
* Tab 35 μg with norethisterone 1 mg and 7 inert tab – Up t 84 tab available on a PSO		84	~	Brevinor 1/28
* Tab 35 μg with norethisterone 500 μg – Up to 63 tab availabl on a PSO		63	~	Brevinor 21
* Tab 35 µg with norethisterone 500 µg and 7 inert tab – Up t 84 tab available on a PSO		84		Norimin
NORETHISTERONE WITH MESTRANOL				
* Tab 1 mg with mestranol 50 µg and 7 inert tab	6.62	84		
	(13.80)		I	Norinyl-1/28
 a) Higher subsidy of \$13.80 per 84 tab with Special Authors b) Up to 84 tab available on a PSO 	ority see SA0500 on th	e preo	ceding pag	je
Combined Oral Contraceptives - Other				
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 μg with levonorgestrel 100 μg and 7 inert tab – Up t	to			
84 tab available on a PSO	6.62	84		
	(16.50) (16.50)			Loette Microgynon 20 ED
Progestogen-only Contraceptives				
riogeologen-only contraceptives				

►SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

68

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

	Subsidy (Manufacturer's Pric		Fully	Brand or Generic
	\$	Per	~	Manufacturer
continued Notes: The approval numbers of Special Authorities approved a	fter 1 November 199	99 are interd	hangea	ble between Mercilon and
Marvelon. The additional subsidy will fund Mercilon and Marvelon up to th the Schedule at 1 November 1999.	e manufacturer's pri	ce for each	of these	products as identified on
Special Authorities approved before 1 November 1999 remain va are still either:	lid until the expiry da	ate and can	be rene	wed providing that women
 on a Social Welfare benefit; or have an income no greater than the benefit. 				
The approval numbers of Special Authorities approved before 1 bined oral contraceptives and progestogen-only contraceptives g				
LEVONORGESTREL	6 60	84		
* Таb 30 µg	(16.50)	04	М	icrolut
a) Higher subsidy of \$13.80 per 84 tab with Special Autho		the precedi		
b) Up to 84 tab available on a PSO				
* Subdermal implant (2 × 75 mg rods)	133.65	1	✓ <u>Ja</u>	adelle
MEDROXYPROGESTERONE ACETATE * Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a P	SO7.15	1	V D	epo-Provera
NORETHISTERONE				
* Tab 350 μg – Up to 84 tab available on a PSO	7.15	84	✓ <u>N</u>	oriday 28
Emergency Contraceptives				
LEVONORGESTREL				
 * Tab 1.5 mg a) Up to 5 tab available on a PSO b) Maximum of 0 tab accuration 	12.50	1	V Po	ostinor-1
b) Maximum of 2 tab per prescription Antiandrogen Oral Contraceptives				
Prescribers may code prescriptions "contraceptive" (code "O") w	han used as indicate	d for contro	contion	The period of supply and
prescription charge will be as per other contraceptives, as follows			ception.	The period of supply and
• \$3.00 prescription charge (patient co-payment) will apply.				
 prescription may be written for up to six months supply. 	tracantiva procoriati	an abarraa	and the	non contropontivo nariad
Prescriptions coded in any other way are subject to the non con of supply. ie. Prescriptions may be written for up to three months		on charges,	and the	non-contraceptive period
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL * Tab 2 mg with ethinyloestradiol 35 µg and 7 inert tabs		84	✓ <u>G</u>	inet 84
Gynaecological Anti-infectives				
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC	ACID			
Jelly with glacial acetic acid 0.94%, hydroxyquinoline su	-			
phate 0.025%, glycerol 5% and ricinoleic acid 0.75% wit applicator		100 g OP		
FF	(24.00)		A	ci-Jel
CLOTRIMAZOLE				
* Vaginal crm 1% with applicators		35 g OP		lomazol
* Vaginal crm 2% with applicators	2.50	20 g OP	✓ <u>C</u>	lomazol

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic ✓ Manufacturer
MICONAZOLE NITRATE			
 Vaginal crm 2% with applicator 	2.75 (3.70)	40 g OP	Micreme
IYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	✓ Nilstat
Myometrial and Vaginal Hormone Preparations			
RGOMETRINE MALEATE Inj 500 μg per ml, 1 ml – Up to 5 inj available on a PSO		5	✓ DBL Ergometrine
DESTRIOL ₭ Crm 1 mg per g with applicator ₭ Pessaries 500 µg		15 g OP 15	✓ Ovestin✓ Ovestin
DXYTOCIN – Up to 5 inj available on a PSO			
Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml		5 5	 ✓ <u>Syntocinon</u> ✓ <u>Syntocinon</u>
Inj 5 iu with ergometrine maleate 500 µg per ml, 1 ml		5	✓ <u>Syntometrine</u>
Pregnancy Tests - hCG Urine			
REGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO			
Cassette	22.80	40 test OP	Innovacon hCG One Step Pregnancy Test
Urinary Agents for urinary tract Infections refer to INFECTIONS, Antibacterials, p	bage 93		
5-Alpha Reductase Inhibitors			
INASTERIDE – Special Authority see SA0928 below – Retail pl Tab 5 mg		30	 ✓ Fintral ✓ Rex Medical
Fintral Tab 5 mg to be delisted 1 February 2012)			
SA0928 Special Authority for Subsidy itial application from any relevant practitioner. Approvals valid re following criteria: Both:	d without further	renewal unles	s notified for applications meeting
 Patient has symptomatic benign prostatic hyperplasia; and 2 Either: 			
2.1 The patient is intolerant of non-selective alpha block2.2 Symptoms are not adequately controlled with non-slote: Patients with enlarged prostates are the appropriate candid	elective alpha b	lockers.	
Alpha-1A Adrenoreceptor Blockers			
AMSULOSIN HYDROCHLORIDE – Special Authority see SA10 Cap 400 μg		bage – Retail pł 30	narmacy ✔ <u>Tamsulosin-Rex</u>

	Subsidy (Manufacturer's \$	Price) S Per	Fully ubsidised	Brand or Generic Manufacturer
 SA1032 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid the following criteria: Both: Patient has symptomatic benign prostatic hyperplasia; and 	without further	r renewal unle	ess notified	I for applications meeting
2 The patient is intolerant of non-selective alpha blockers or t	hese are contra	aindicated.		
Other Urinary Agents				
OXYBUTYNIN * Tab 5 mg * Oral liq 5 mg per 5 ml		500 473 ml OP		oo-Oxybutynin oo-Oxybutynin
POTASSIUM CITRATE Oral liq 3 mmol per ml – Special Authority see SA1083 below – Retail pharmacy		200 ml OP	🖌 Bi	omed
 SA1083 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid f Both: 1 The patient has recurrent calcium oxalate urolithiasis; and 	or 12 months fo	or application	s meeting t	the following criteria:
2 The patient has had more than two renal calculi in the two y Renewal from any relevant practitioner. Approvals valid for 2 ye benefitting from the treatment.				opriate and the patient is
SODIUM CITRO-TARTRATE				
* Grans eff 4 g sachets		28	✓ <u>Ur</u>	al
SOLIFENACIN SUCCINATE – Special Authority see SA0998 belo Tab 5 mg		rmacy 30	Ve	sicare
Tab 10 mg		30		sicare
►SA0998 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali overactive bladder and a documented intolerance of oxybutynin.	d without furthe	er renewal ur	nless notifi	ed where the patient has
Detection of Substances in Urine				
ORTHO-TOLIDINE				
* Compound diagnostic sticks	7.50 (8.25)	50 test OP		emastix
TETRABROMOPHENOL			_	
* Blue diagnostic strips		100 test OF		

(13.92)

Albustix

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

	Subsidy (Manufacturer's F	Prico) C	Fully Brand or osidised Generic
	(IVIAIIUIACIUIEISF	Per Sul	Manufacturer
Anabolic Agents			
NANDROLONE DECANOATE – Retail pharmacy-Specialist			
Inj 50 mg per ml, 1 ml	21.16	1	Deca-Durabolin
			Orgaject S29
Corticosteroids and Related Agents for System	nic Use		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETH		F	
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml		5	Celestone
	(55.00)		Chronodose
DEXAMETHASONE			
* Tab 1 mg – Retail pharmacy-Specialist		100	✓ Douglas
Up to 30 tab available on a PSO			
* Tab 4 mg – Retail pharmacy-Specialist	61.89	100	✓ Douglas
Up to 30 tab available on a PSO	~~~~		
Oral liq 1 mg per ml – Retail pharmacy-Specialist		25 ml OP	Biomed
Oral liq prescriptions: 1) Must be written by a Paediatrician or Paediatric Ca	ardiologist: or		
2) On the recommendation of a Paediatrician or Pae	-		
DEXAMETHASONE SODIUM PHOSPHATE		•	
Dexamethasone sodium phosphate injection will not be fun	ded for oral use.		
Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	✓ Hospira
Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO	31.00	5	✓ Hospira
FLUDROCORTISONE ACETATE			
* Tab 100 μg	14.32	100	 Florinef
HYDROCORTISONE			
* Tab 5 mg		100	✓ Douglas
* Tab 20 mg – For hydrocortisone oral liquid formulation refe			
page 172		100	✓ <u>Douglas</u>
Inj 50 mg per ml, 2 ml	3.99	1	Solu-Cortef
a) Up to 5 inj available on a PSO b) Only on a PSO			
METHYLPREDNISOLONE – Retail pharmacy-Specialist ₩ Tab 4 mg	48 57	100	✓ Medrol
* Tab 100 mg		20	Medrol
			· <u>······</u>
Inj 40 mg per ml, 1 ml	6.03	1	Depo-Medrol
METHYLPREDNISOLONE ACETATE WITH LIGNOCAINE			- F
Inj 40 mg per ml with lignocaine 1 ml		1	Depo-Medrol with
		,	Lidocaine
METHYLPREDNISOLONE SODIUM SUCCINATE - Retail pha	rmacy-Specialist		
Inj 40 mg per ml, 1 ml		1	✓ Solu-Medrol
	151.40	25	Solu-Medrol
Inj 62.5 mg per ml, 2 ml		1	Solu-Medrol
	412.59	25	Solu-Medrol
Inj 500 mg		1	Solu-Medrol
lnj 1 g		1	✓ <u>Solu-Medrol</u>

	Subsidy (Manufacturer's		Fully Brand or osidised Generic
	\$	Per	 Manufacturer
PREDNISOLONE SODIUM PHOSPHATE * Oral lig 5 mg per ml – Up to 30 ml available on a PSO	0.05	30 ml OP	Redipred
Restricted to children under 12 years of age.	9.95	30 IIII OF	Redipied
PREDNISONE			
* Tab 1 mg		500	Apo-Prednisone
₭ Tab 2.5 mg		500	Apo-Prednisone
₭ Tab 5 mg – Up to 30 tab available on a PSO	11.09	500	Apo-Prednisone
₭ Tab 20 mg		500	Apo-Prednisone
FETRACOSACTRIN			
🕷 Inj 250 μg	177.18	10	Synacthen
k Inj 1 mg per ml, 1 ml		1	Synacthen Depot
RIAMCINOLONE ACETONIDE			
Inj 10 mg per ml, 1 ml	11.11	5	Kenacort-A
Inj 40 mg per ml, 1 ml		5	Kenacort-A40
Sex Hormones Non Contraceptive			
Androgen Agonists and Antagonists			
CYPROTERONE ACETATE – Retail pharmacy-Specialist			
Tab 50 mg	21.10	50	✓ Siterone
Tab 100 mg		50	✓ Siterone
ESTOSTERONE			
Transdermal patch, 2.5 mg per day		60	Androderm
ESTOSTERONE CYPIONATE – Retail pharmacy-Specialist			
Inj long-acting 100 mg per ml, 10 ml		1	Depo-Testosterone
ESTOSTERONE ESTERS – Retail pharmacy-Specialist			
Inj 250 mg per ml, 1 ml	12.98	1	Sustanon Ampoules
ESTOSTERONE UNDECANOATE – Retail pharmacy-Speciali Cap 40 mg		100	✓ Arrow-Testosterone
		100	Anow-restosterone

Hormone Replacement Therapy - Systemic

SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least $2 \times$ normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

		Subsidy (Manufacturer's P \$	rice) Sub Per	Fully Brand or osidised Generic Manufacturer
IRT	cribing Guideline should be taken at the lowest dose for the shortest period of t nthly in line with the updated NZGG "Evidence-based Bes '.			
Oe	strogens			
ES	FRADIOL – See prescribing guideline below			
	āb 1 mg	4.12	28 OP	
	-	(10.55)		Estrofem
1	āb 2 mg	4.12	28 OP	
		(10.55)		Estrofem
1	DDS 25 μg per day	3.01	8	
		(10.86)		Estraderm TTS 25
		(10.86)		Estradot
	a) Higher subsidy of \$10.86 per 8 patch with Special Author	prity see SA1018	on the preced	ding page
	 b) No more than 2 patch per week 			
	c) Only on a prescription			
1	DDS 3.9 mg (releases 50 µg of oestradiol per day)		4	
		(13.18)		Climara 50
		(32.50)		Femtran 50
	 a) Higher subsidy of \$13.18 per 4 patch with Special Author b) No more than 1 patch per week c) Only on a prescription 	prity see SA1018	on the preced	ling page
; 1	DDS 50 µg per day		8	
		(13.18)		Estraderm TTS 50
		(13.18)		Estradot 50 µg
	 a) Higher subsidy of \$13.18 per 8 patch with Special Authors b) No more than 2 patch per week c) Only on a prescription 	prity see SA1018	on the preced	ling page
÷ 1	DDS 7.8 mg (releases 100 µg of oestradiol per day)	7 05	4	
		(16.14)	· ·	Climara 100
		(35.00)		Femtran 100
	 a) Higher subsidy of \$16.14 per 4 patch with Special Authors b) No more than 1 patch per week c) Only on a prescription 		on the preced	
; 1	DDS 100 µg per day	7.05	8	
		(16.14)		Estraderm TTS 100
		(16.14)		Estradot
	a) Higher subsidy of \$16.14 per 8 patch with Special Author b) No more than 2 patch per week	prity see SA1018	on the preced	ling page
stra	c) Only on a prescription aderm TTS 25 TDDS 25 μg per day to be delisted 1 January aderm TTS 50 TDDS 50 μg per day to be delisted 1 January aderm TTS 100 TDDS 100 μg per day to be delisted 1 Janua	2012)		
ES	TRADIOL VALERATE – See prescribing guideline below			
	ab 1 mg	8.24	56	Progynova
	ab 2 mg		56	Progynova

	0.1.11		
	Subsidy (Manufacturer's Prio	(a) Si	Fully Brand or ubsidised Generic
	(Manulacturer ST III	Per	Manufacturer
	*		
OESTROGENS – See prescribing guideline on the preceding pa			
* Conjugated, equine tab 300 μg	3.01	28	
	(11.48)		Premarin
* Conjugated, equine tab 625 μg	4.12	28	
	(11.48)		Premarin
Progestogens			
MEDROXYPROGESTERONE ACETATE - See prescribing guide	eline on the preced	ing page	
* Tab 2.5 mg		30	Provera
* Tab 5 mg		100	✓ Provera
* Tab 10 mg		30	✓ Provera
, , , , , , , , , , , , , , , , , , ,			
Progestogen and Oestrogen Combined Prepara	tions		
OESTRADIOL WITH NORETHISTERONE – See prescribing gu	ideline on the prece	eding page	
* Tab 1 mg with 0.5 mg norethisterone acetate	5.40	28 OP	
5 5	(14.52)		Kliovance
* Tab 2 mg with 1 mg norethisterone acetate		28 OP	
	(14.52)		Kliogest
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg	1		0
oestradiol tab (12) and 1 mg oestradiol tab (6)		28 OP	
······································	(14.52)		Trisequens
OESTROGENS WITH MEDROXYPROGESTERONE - See pres	oribina quidalina a	n tha praca	
		ii ille piece	aling page
* Tab 625 µg conjugated equine with 2.5 mg medroxyproges- terms and tab (20)			
terone acetate tab (28)		28 OP	Dramia 0 E
	(22.96)		Premia 2.5
			Continuous
* Tab 625 μg conjugated equine with 5 mg medroxyproges-			
terone acetate tab (28)		28 OP	
	(22.96)		Premia 5 Continuous
Other Oestrogen Preparations			
ETHINYLOESTRADIOL			
* Tab 10 μg	17.60	100	NZ Medical and
			Scientific
OESTRIOL			
* Tab 2 mg	7.00	30	✓ Ovestin
0			· · · · · · · · · · · · · · · · · · ·
Other Progestogen Preparations			
LEVONORGESTREL			
 Levonorgestrel - releasing intrauterine system 20 µg/24 hr - 	_		
Special Authority see SA0782 on the next page – Retai			
pharmacy		1	Mirena
pilattiacy		1	₩III CIIQ

■SA0782 Special Authority for Subsidy Initial application — (No previous use) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Ether: 3.1 serum fertilin level < 16 µg/l (within the last 12 months); or 3.2 haemoglobin level < 120 g/l. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 heavent specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Note: Applicant to state date of the previous insertion. Note: Applicant to state date of the previous insertion. Net: Applicant to state date of the previous insertion. Setting: 1 The patient had a clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of		Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
applications meeting the following criteria: All of the following: All of the following: 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Wenstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 µgl (within the last 12 months); or	►SA0782 Special Authority for Subsidy				
Ali of the following 1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 µg/ (within the last 12 months); or 3.2 haemoglobin level < 120 g/. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 monts for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following riteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed excepted within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist	Initial application - (No previous use) only from a relevant	specialist or general p	ractitione	r. Appro	vals valid for 6 months for
1 The patient has a clinical diagnosis of heavy menstrual bleeding; and 2 The patient has lailed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3 Ether: 3.1 serum ferritin level < 16 µgl (within the last 12 months); or 3.2 haemoglobin level < 120 gl.	applications meeting the following criteria:				
 2 The patient has failed to respond to or is unable to tolerate other appropriate pharmaceutical therapies as per the Heavy Menstrual Bleeding Guidelines; and 3.1 serum ferritin level < 16 µg/ (within the last 12 months); or 3.2 haemoglobin level < 120 g/l. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Initial application – (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion. MEDROXYPROGESTENONE ACETATE ★ Tab 100 mg – Retail pharmacy-Specialist. 40.50 40.50 40.50 40.50 50.100 ✓ Primolut N Thyroid and Antithyroid Agents 70.50 <	All of the following:				
Menistrual Bleeding Guidelines; and 3 Either: 3.1 serum ferritin level < 16 µg/l (within the last 12 months); or					
3 Either: 3.1 serum ferritin level < 16 µgfl (within the last 12 months); or		ate other appropriate	pharmace	eutical th	erapies as per the Heavy
3.1 serum ferritin level < 16 μg/l (within the last 12 months); or	2				
3.2 haemoglobin level < 120 g/l.		atha), ar			
Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Pitient: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist		iuns), or			
Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 3 Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1 Either: 1 Either: 1 Either: 1 Either: 1 A Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg – Retail pharmacy-Specialist	° °	recention excent wher	o thou m	oot tho a	hove criteria
valid for ⁶ months for applications meeting the following criteria: All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist					
All of the following: 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist	· · · · · · · · · · · · · · · · · · ·		poolaliot	or gono	
 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and 3 Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and					
 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and 3 Applicant to state date of the previous insertion. Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist. 96.50 100 Provera * Tab 5 mg - Up to 30 tab available on a PSO. 26.50 100 Primolut N Thyroid and Antithyroid Agents CARBIMAZOLE * Tab 5 mg 10.80 100 Neo-Mercazole LEVOTHYROXINE * Tab 50 µg 43.24 1,000 Synthroid 43.24 1,000 Synthroid 43.24 1,000 Synthroid 4.28 Goldshield 4.05 90 Synthroid 4.28 Eltroxin 	8	eeding; and			
Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria. Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg – Retail pharmacy-Specialist. 96.50 100 Y Provera NORETHISTERONE * Tab 5 mg – Up to 30 tab available on a PSO. 26.50 100 ✓ Primolut N Thyroid and Antithyroid Agents CARBIMAZOLE 3.89 90 ✓ Synthroid * Tab 25 µg 3.89 90 ✓ Synthroid ‡ Safety cap for extemporaneously compounded oral liquid preparations. * * Goldshield 4.05 90 ✓ Synthroid 43.24 1,000 ✓ Synthroid 45.04 1,000 ✓ Synthroid 42.28 ✓ Eltroxin * Tab 50 µg 1.71 28 ✓ Goldshield 4.05 <td< td=""><td>2 Patient demonstrated clinical improvement of heavy mens</td><td>trual bleeding; and</td><td></td><td></td><td></td></td<>	2 Patient demonstrated clinical improvement of heavy mens	trual bleeding; and			
Renewal only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both: 1 1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * * Tab 100 mg - Retail pharmacy-Specialist. 96.50 100 / Provera * Tab 200 mg - Retail pharmacy-Specialist. 70.50 30 / Provera NORETHISTERONE * Tab 5 mg - Up to 30 tab available on a PSO. 26.50 100 / Primolut N Thyroid and Antithyroid Agents CARBIMAZOLE * Tab 5 mg	3 Applicant to state date of the previous insertion.	-			
criteria: Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist					
Both: 1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist	, , , ,	Approvals valid for 6 m	onths for	applicat	ions meeting the following
1 Either: 1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist					
1.1 Patient demonstrated clinical improvement of heavy menstrual bleeding; or 1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist					
1.2 Previous insertion was removed or expelled within 3 months of insertion; and 2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist		w monotrual blooding	or		
2 Applicant to state date of the previous insertion. MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist	•	, U			
MEDROXYPROGESTERONE ACETATE * Tab 100 mg - Retail pharmacy-Specialist			and		
 * Tab 100 ng - Retail pharmacy-Specialist					
 * Tab 200 mg - Retail pharmacy-Specialist		96.50	100	🖌 Pi	rovera
NORETHISTERONE * Tab 5 mg - Up to 30 tab available on a PSO					
 * Tab 5 mg - Up to 30 tab available on a PSO	o 1 <i>y</i> 1				
Thyroid and Antithyroid Agents CARBIMAZOLE * Tab 5 mg 10.80 100 ✓ Neo-Mercazole LEVOTHYROXINE 3.89 90 ✓ Synthroid * Tab 25 µg 3.89 90 ✓ Synthroid 43.24 1,000 ✓ Synthroid ‡ Safety cap for extemporaneously compounded oral liquid preparations. * Y * Tab 50 µg 1.71 28 ✓ Goldshield 45.00 1,000 ✓ Synthroid 45.00 45.00 1,000 ✓ Synthroid 64.28 * Tab 100 µg 1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000		26 50	100	V P	rimolut N
CARBIMAZOLE * Tab 5 mg			100	<u> </u>	
 * Tab 5 mg	Invroid and Antithyroid Agents				
LEVOTHYROXINE * Tab 25 µg					
 * Tab 25 μg	* Tab 5 mg	10.80	100	V N	eo-Mercazole
43.24 1,000 ✓ Synthroid ‡ Safety cap for extemporaneously compounded oral liquid preparations. * Tab 50 μg1.71 28 ✓ Goldshield 4.05 90 ✓ Synthroid 45.00 1,000 ✓ Synthroid 64.28 ✓ Eltroxin ‡ Safety cap for extemporaneously compounded oral liquid preparations. * Tab 100 μg1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin	LEVOTHYROXINE				
‡ Safety cap for extemporaneously compounded oral liquid preparations. ★ Tab 50 μg	* Tab 25 μg		90	🖌 S	ynthroid
 * Tab 50 μg		43.24	1,000	🗸 S	ynthroid
4.05 90 ✓ Synthroid 45.00 1,000 ✓ Synthroid 64.28 ✓ Eltroxin * Tab 100 µg 1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin		1 1			
45.00 1,000 ✓ Synthroid 64.28 ✓ Eltroxin ★ Safety cap for extemporaneously compounded oral liquid preparations. ★ Tab 100 μg1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin	* Tab 50 μg				
64.28 ✓ Eltroxin ‡ Safety cap for extemporaneously compounded oral liquid preparations. ✓ Goldshield ★ Tab 100 µg 1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin					·
‡ Safety cap for extemporaneously compounded oral liquid preparations. ★ Tab 100 μg1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin			1,000		
* Tab 100 µg 1.78 28 ✓ Goldshield 4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin	+ Cofety con for externational contained and the			V E	itroxin
4.21 90 ✓ Synthroid 66.78 1,000 ✓ Eltroxin			28	10	oldshield
66.78 1,000 🖌 Eltroxin	- ταυ του μy				
			•••		
	± Safety cap for extemporaneously compounded oral liqu		.,000	ΨL	

(М	Subsidy anufacturer's Price) \$	Subsi Per	Fully Brand or dised Generic ✔ Manufacturer
Trophic Hormones			
Growth Hormones			
■ SA0755 Special Authority for Subsidy special Authority approved by the Growth Hormone Committee lotes: Subject to budgetary cap. Applications will be considered and splication details may be obtained from PHARMAC's website <u>http://</u> IZGHC Coordinator PHARMAC, PO Box 10-254, WELLINGTON rel: 0800 808 476, Fax: (09) 929 3221, Email: growthhormone@pha	www.pharmac.gov		availability.
OMATROPIN – Special Authority see SA0755 above Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg)		1 1	 ✓ <u>Genotropin</u> ✓ <u>Genotropin</u>
GnRH Analogues			
GOSERELIN ACETATE Inj 3.6 mg Ini 10.8 mg		1	 ✓ Zoladex ✓ Zoladex
UPRORELIN Inj 3.75 mg Inj 3.75 mg prefilled syringe Inj 7.5 mg Inj 11.25 mg Inj 11.25 mg Inj 12.5 mg Inj 12.5 mg Inj 13.00 mg Inj 30 mg Inj 30 mg prefilled syringe Inj 30 mg prefilled syringe Inj 45 mg	221.60 221.60 166.20 591.68 591.68 443.76 591.68 1,109.40	1 1 1 1 1 1 1 1	 Lucrin Depot Lucrin Depot PDS Eligard Lucrin Depot PDS Lucrin Depot PDS Eligard Eligard Lucrin Depot PDS Eligard Eligard Lucrin Depot PDS Eligard
Vasopressin Agonists			
DESMOPRESSIN Nasal drops 100 μg per ml – Retail pharmacy-Specialist Nasal spray 10 μg per dose – Retail pharmacy-Specialist		ml OP nl OP	 ✓ Minirin ✓ Desmopressin- PH&T
Inj 4 µg per ml, 1 ml – Special Authority see SA0090 below – Retail pharmacy	67.18	10	✓ Minirin

Initial application only from a relevant specialist. Approvals valid for 2 years where the patient cannot use desmopressin nasal spray or nasal drops.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Brand or Generic Manufacturer
Other Endocrine Agents				
CABERGOLINE				
Tab 0.5 mg - Maximum of 2 tab per prescription; can	be			
waived by Special Authority see SA1031 below		2	V D	Oostinex
	66.00	8	• -	ostinex
	16.50	2		rrow-Cabergoline
	66.00	8	🗸 A	rrow-Cabergoline
nitial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia				
	blogist. Approvals valid	withou	t further ren	newal unless notified whe
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE	plogist. Approvals valid has expired and the tr	withou eatmer	t further ren nt remains a	newal unless notified whe appropriate and the patie
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg	plogist. Approvals valid has expired and the tr	withou	t further ren nt remains a	newal unless notified whe
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist	blogist. Approvals valid has expired and the tri 	withou eatmer 10	t further rer nt remains a	newal unless notified whe appropriate and the patie Serophene
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist Cap 100 mg	plogist. Approvals valid has expired and the tr 	withou eatmer 10 100	t further rer nt remains a v S v A	newal unless notified whe appropriate and the patie Serophene Izol
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist Cap 100 mg Cap 200 mg	plogist. Approvals valid has expired and the tr 	withou eatmer 10	t further rer nt remains a	newal unless notified whe appropriate and the patie Serophene Izol
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist Cap 100 mg Cap 200 mg GESTRINONE – Retail pharmacy-Specialist	blogist. Approvals valid has expired and the tr 	withou eatmer 10 100	t further ren nt remains a S S S S S S S S S S S S S S S S S S S	newal unless notified whe appropriate and the patie Gerophene Izol
notified where the patient has pathological hyperprolactinemia Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist Cap 100 mg Cap 200 mg	blogist. Approvals valid has expired and the tr 	withou eatmer 10 100	t further ren nt remains a S S S S S S S S S S S S S S S S S S S	newal unless notified wh appropriate and the pati Serophene Izol

Cap 250 mg – Retail pharmacy-Specialist238.00 50

✓ Metopirone

	Cubaidu		Fully Drand or
	Subsidy (Manufacturer's Pri	ice) Su	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
Anthelmintics			
MEBENDAZOLE – Only on a prescription			
Tab 100 mg	24.19	24	✓ <u>De-Worm</u>
Oral liq 100 mg per 5 ml		15 ml	
	(7.17)		Vermox
Antibacterials			
 a) For topical antibacterials, refer to DERMATOLOGICALS, page b) For anti-infective eye preparations, refer to SENSORY ORGAN 			
Cephalosporins and Cephamycins			
CEFACLOR MONOHYDRATE			
Cap 250 mg	24.57	100	 Cefaclor Sandoz
	28.90		Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml	3.53	100 ml	Ranbaxy-Cefaclor
CEFAZOLIN SODIUM – Subsidy by endorsement			
Only if prescribed for dialysis or cystic fibrosis patient and the		idorsed acco	
Inj 500 mg Inj 1 g		5 5	 ✔ Hospira ✔ Hospira
CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy by		0	• noopilu
Only if prescribed for dialysis or cystic fibrosis patient and the		idorsed acco	rdinaly
Inj 1 g		5	Mayne
CEFTRIAXONE SODIUM – Subsidy by endorsement			-
a) Up to 5 inj available on a PSO			
b) Subsidised only if prescribed for a dialysis or cystic fibro	osis patient, or the	treatment o	f confirmed ciprofloxacin-resistant
gonorrhoea, or the treatment of suspected meningitis in patie	nts who have a kn	own allergy	to penicillin, and the prescription or
PSO is endorsed accordingly. Inj 500 mg	2 70	1	✓ Veracol
Inj 1 g		5	✓ Aspen Ceftriaxone
CEFUROXIME AXETIL – Subsidy by endorsement			· _ · · · · · · · · · · · · · · · · · ·
Only if prescribed for prophylaxis of endocarditis and the pres	scription is endors	ed according	ly.
Tab 250 mg		50	🖌 Zinnat
CEFUROXIME SODIUM			
Inj 250 mg – Maximum of 3 inj per prescription; can be waived	I		
by endorsement		10	Mayne
Inj 750 mg – Maximum of 1 inj per prescription; can be waived		_	
by endorsement		5	Zinacef
Inj 1.5 g – Retail pharmacy-Specialist – Subsidy by endorse- ment		1	Zinacef
Only if prescribed for dialysis or cystic fibrosis patient and		•	
CEPHALEXIN MONOHYDRATE	•		- *
Cap 500 mg	8.90	20	 Cephalexin ABM
Grans for oral liq 125 mg per 5 ml		100 ml	<u>Cefalexin Sandoz</u>
Grans for oral liq 250 mg per 5 ml	11.50	100 ml	Cefalexin Sandoz

	Subsidy (Manufacturer's Pri \$	ce) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
Macrolides				
AZITHROMYCIN – Subsidy by endorsement; can be waived t a) Maximum of 2 tab per prescription; can be waived by S b) Up to 8 tab available on a PSO c) Subsidised only if prescribed for patients with uncomplica trachomatis and their sexual contacts and prescription or F SA1130. Tab 500 mg	pecial Authority see S ated urethritis or cervi 2SO is endorsed acco	A1130 belo	or presur be waive	
 Special Authority for Waiver of Rule Initial application — (Cystic Fibrosis) only from a respirator unless notified for applications meeting the following criteria: All of the following: The applicant is part of multidisciplinary team experience The patient has been definitively diagnosed with cystic The patient has chronic infection with Pseudomonas defined by two positive respiratory tract cultures at leas The patient has negative cultures for non-tuberculous n Notes: Caution is advised if using azithromycin as an antibiotic Testing for non-tuberculosis mycobacteria should occur annua initial application — (bronchiolitis obliterans syndrome) applications meeting the following criteria: All of the following: Patient has received a lung transplant; and Azithromycin is to be used for prophylaxis of bronchiolit The applications meeting the following criteria: Bothier of the applications meeting the following criteria: Bothier of applications meeting the following criteria: The patient remains well and free from bronchiolits oblitiing the applications is experienced in managing patients who Note: Indications marked with * are Unapproved Indications 	eed in the manageme fibrosis*; and aeruginosa or Pseud three months apart* nycobacteria. in the treatment of c lly. only from a relevant is obliterans syndrom have received a lung a relevant specialist. erans syndrome*; an	nt of cystic f lomonas rel and ystic fibrosis specialist. e*; and transplant. Approvals v	iibrosis; a lated gra s patients Approva	Ind m negative organisms a with pneumonia. Ils valid for 12 months fo
CLARITHROMYCIN – Maximum of 500 mg per prescription; o Tab 250 mg	, ,	cial Authorit 14	΄ 🖌 Α 🖌 Κ	po-Clarithromycin lacid
Grans for oral liq 125 mg per 5 ml	23.12	70 ml		lamycin Iacid
■SA1131 Special Authority for Waiver of Rule Initial application — (Mycobacterial infections) only from a Approvals valid for 2 years for applications meeting the followir Either: 1 Atypical mycobacterial infection; or 2 Mycobacterium tuberculosis infection where there is dru Renewal — (Mycobacterial infections) only from a respirato valid for 2 years where the treatment remains appropriate and	ng criteria: ug-resistance or intole ry specialist, infectiou	erance to sta	andard pl	narmaceutical agents.

	Subsidy	Drice) Cul	Fully Brand or
	(Manufacturer's) \$	Price) Sur Per	osidised Generic Manufacturer
ERYTHROMYCIN ETHYL SUCCINATE			
Tab 400 mg – Up to 30 tab available on a PSO		100	E-Mycin
Grans for oral lig 200 mg per 5 ml - Up to 200 ml available			
on a PSO		100 ml	🖌 E-Mycin
Grans for oral liq 400 mg per 5 ml - Up to 200 ml available			
on a PSO		100 ml	🖌 E-Mycin
ERYTHROMYCIN LACTOBIONATE			-
Inj 1 g		1	Erythrocin IV
ERYTHROMYCIN STEARATE			
Tab 250 mg – Up to 30 tab available on a PSO	1/ 05	100	
	(22.29)	100	ERA
Tab 500 mg		100	
	(44.58)		ERA
ROXITHROMYCIN	(
Tab 150 mg	8 08	50	✓ Arrow-
	0.30	50	Roxithromycin
Tab 300 mg	16.48	50	✓ Arrow-
			Roxithromycin
Penicillins			
AMOXYCILLIN			
Cap 250 mg – Up to 30 cap available on a PSO	16.18	500	Alphamox
Cap 500 mg		500	✓ <u>Alphamox</u>
Grans for oral liq 125 mg per 5 ml - Up to 200 ml available			
on a PSO		100 ml	Ospamox
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available			1.0
on a PSO		100 ml	✓ <u>Ospamox</u>
Drops 125 mg per 1.25 ml	4.00	30 ml OP	✓ Ospamox Paediatric
1-1 0 5 0 mm	10.00	10	Drops
Inj 250 mg		10 10	 ✓ <u>Ibiamox</u> ✓ Ibiamox
Inj 500 mg Inj 1 g – Up to 5 inj available on a PSO		10	✓ Ibiamox
	21.34	10	
AMOXYCILLIN CLAVULANATE			
Tab amoxycillin 500 mg with potassium clavulanate 125 mg		100	
- Up to 30 tab available on a PSO		100	 Synermox
Grans for oral liq amoxycillin 125 mg with potassium clavu-			
lanate 31.25 mg per 5 ml – Up to 200 ml available on a PSO		100 ml	Curam
Grans for oral liq amoxycillin 250 mg with potassium clavu-		100 111	
lanate 62.5 mg per 5 ml – Up to 200 ml available on a			
PSO		100 ml	Curam
BENZATHINE BENZYLPENICILLIN			
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO	315.00	10	Bicillin LA
, , ,		10	
BENZYLPENICILLIN SODIUM (PENICILLIN G)	14 50	10	(Condor
Inj 600 mg – Up to 5 inj available on a PSO		10	✓ <u>Sandoz</u>

	Subsidy		Fully Brand or
	(Manufacturer's F		bsidised Generic
	\$	Per	 Manufacturer
LUCLOXACILLIN SODIUM			4 · · · ·
Cap 250 mg – Up to 30 cap available on a PSO		250	AFT
Cap 500 mg		500	✓ <u>AFT</u>
Grans for oral liq 125 mg per 5 ml - Up to 200 ml available			
on a PSO	3.12	100 ml	✓ <u>AFT</u>
Grans for oral liq 250 mg per 5 ml - Up to 200 ml available			
on a PSO		100 ml	✓ <u>AFT</u>
Inj 250 mg		10	Flucloxin
Inj 500 mg		10	Flucloxin
Inj 1 g – Up to 5 inj available on a PSO	14.28	10	Flucloxin
HENOXYMETHYLPENICILLIN (PENICILLIN V)			
Cap potassium salt 250 mg – Up to 30 cap available on a PS	O9.71	50	Cilicaine VK
Cap potassium salt 500 mg	11.70	50	Cilicaine VK
Grans for oral liq 125 mg per 5 ml - Up to 200 ml available			
on a PSO	1.68	100 ml	✓ AFT
Grans for oral liq 250 mg per 5 ml - Up to 200 ml available			
on a PSO	1.78	100 ml	✓ AFT
ROCAINE PENICILLIN			
Inj 1.5 mega u – Up to 5 inj available on a PSO		5	 Cilicaine
			<u> </u>
Tetracyclines			
OXYCYCLINE HYDROCHLORIDE			
 Tab 50 mg – Up to 30 tab available on a PSO 	2.90	30	
	(6.00)		Doxy-50
← Tab 100 mg – Up to 30 tab available on a PSO		250	✓ Doxine
INOCYCLINE HYDROCHLORIDE			
 Tab 50 mg 	5.79	60	
	(12.05)		Mino-tabs
⊱ Cap 100 mg		100	
	(52.04)		Minomycin
Other Antibiotics	()		. , .
or topical antibiotics, refer to DERMATOLOGICALS, page 57			
IPROFLOXACIN			
Tab 250 mg – Up to 5 tab available on a PSO	2.20	28	 Cipflox
	2.36	30	
	(3.35)		Rex Medical
Tab 500 mg – Up to 5 tab available on a PSO	3.00	28	 Cipflox
	3.21	30	
	(4.90)		Rex Medical
Tab 750 mg – Retail pharmacy-Specialist	5.15	28	 Cipflox
	5.52	30	
	(7.54)		Rex Medical
Rex Medical Tab 250 mg to be delisted 1 March 2012)			
Rex Medical Tab 500 mg to be delisted 1 March 2012)			
Rex Medical Tab 750 mg to be delisted 1 March 2012)			

	Subsidy (Manufacturer's Price) \$) Per	Full Subsidise	d Generic
CLINDAMYCIN				
Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip- tion; can be waived by endorsement - Retail pharmacy - Specialist Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-		16	V	Dalacin C
Specialist	160.00	10	~	Dalacin C
CO-TRIMOXAZOLE				
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg – Up to 30 tab available on a PSO		500	~	Trisul
 Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml – Up to 200 ml available on a PSO 	2.15	100 ml	~	Deprim
COLISTIN SULPHOMETHATE – Retail pharmacy-Specialist – Su Only if prescribed for dialysis or cystic fibrosis patient and the Inj 150 mg	prescription is endo			/. Colistin-Link
FUSIDIC ACID				
Tab 250 mg – Retail pharmacy-Specialist Inj 500 mg sodium fusidate per 10 ml – Retail pharmacy-		12	~	Fucidin
Specialist – Subsidy by endorsement		1		Fucidin
Only if prescribed for a dialysis or cystic fibrosis patient and	the prescription is	endors	ed accord	dingly.
GENTAMICIN SULPHATE				
Inj 10 mg per ml, 1 ml – Subsidy by endorsement		5		Mayne
Only if prescribed for a dialysis or cystic fibrosis patient or accordingly.				
Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or accordingly.		10 ndocar		<u>Pfizer</u> the prescription is endorsed
LINCOMYCIN – Retail pharmacy-Specialist				
Inj 300 mg per ml, 2 ml		5	~	Lincocin
MOXIFLOXACIN – Special Authority see SA1065 below – Retail p No patient co-payment payable	oharmacy			
Tab 400 mg		5	~	Avelox

➡SA1065 Special Authority for Subsidy

Initial application only from a respiratory specialist or infectious disease specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Both:

- 1.1 Active tuberculosis*; and
- 1.2 Any of the following:
 - 1.2.1 Documented resistance to one or more first-line medications; or
 - 1.2.2 Suspected resistance to one or more first-line medications (tuberculosis assumed to be contracted in an area with known resistance), as part of regimen containing other second-line agents; or
 - 1.2.3 Impaired visual acuity (considered to preclude ethambutol use); or
 - 1.2.4 Significant pre-existing liver disease or hepatotoxicity from tuberculosis medications; or
 - 1.2.5 Significant documented intolerance and/or side effects following a reasonable trial of first-line medications; or
- 2 Mycobacterium avium-intracellulare complex not responding to other therapy or where such therapy is contraindicated.*.

	Subsidy (Manufacturer's Price \$	e) Su Per	Fully ubsidised	Brand or Generic Manufacturer
continued	Ŷ			
Note: Indications marked with * are Unapproved Indications (re tions) and Part IV (Miscellaneous Provisions) rule 4.6).	fer to Section A: Gen	eral Rules	s, Part I (Interpretations and Defini-
Renewal only from a respiratory specialist or infectious disease appropriate and the patient is benefiting from treatment.	specialist. Approvals	valid for	l year wh	ere the treatment remains
TOBRAMYCIN Inj 40 mg per ml, 2 ml – Subsidy by endorsement		5		BL Tobramycin
Only if prescribed for dialysis or cystic fibrosis patient and TRIMETHOPRIM	d the prescription is e	ndorsed a	ccordingl	y.
* Tab 300 mg – Up to 30 tab available on a PSO	8.69	50	🗸 TI	MP
VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement Only if prescribed for a dialysis or cystic fibrosis patient or i endocarditis and the prescription is endorsed accordingly.				
Inj 500 mg	3.58	1	✓ <u>M</u>	<u>ylan</u>
Antifungals	-			
 a) For topical antifungals refer to DERMATOLOGICALS, page 5' b) For topical antifungals refer to GENITO URINARY, page 69 	7			
FLUCONAZOLE				
Cap 50 mg – Retail pharmacy-Specialist		28	V 0	
Cap 150 mg – Subsidy by endorsement	6.82 0.91	1	V Pa	acific zole
	1.30	1		acific
a) Maximum of 1 cap per prescription; can be waived by				
b) Patient has vaginal candida albicans and the practitic recommended and the prescription is endorsed accordin				
Cap 200 mg – Retail pharmacy-Specialist		28	v 0	
Powder for oral suspension 10 mg per ml – Special Authorii see SA1148 below – Retail pharmacy		35 ml	🗸 D	iflucan
SA1148 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals value Both:	d for 6 weeks for appl	ications m	eeting th	e following criteria:
1 Patient requires prophlaxis for, or treatment of systemic c	andidiasis; and			
2 Patient is unable to swallow capsules.				
Renewal from any relevant practitioner. Approvals valid for 6 we Both:	eks for applications n	neeting the	e followin	g criteria:
 Patient requires prophlaxis for, or treatment of systemic c Patient is unable to swallow capsules. 	andidiasis; and			
ITRACONAZOLE – Retail pharmacy-Specialist Cap 100 mg	4.25	15	✓ <u>ltı</u>	razole
KETOCONAZOLE Tab 200 mg – Retail pharmacy-Specialist		30	🖌 N	izoral
NYSTATIN				
Tab 500,000 u Cap 500,000 u		50 50	V <u>N</u>	<u>ilstat</u> ilstat
	-			

	Subsidy (Manufacturer's Price	e) Per	Fully Brand or Subsidised Generic Manufacturer
	\$	Per	Manulacturer
TERBINAFINE			
Tab 250 mg – For terbinafine oral liquid formulation refer, page 172		14	✓ Dr Reddy's
			Terbinafine
	12.75	100	
(An a Table Car Table 250 marks hards listed of Falser and 2040)	(25.50)		Apo-Terbinafine
Apo-Terbinafine Tab 250 mg to be delisted 1 February 2012)			
Antimalarials			
HYDROXYCHLOROQUINE SULPHATE			
₭ Tab 200 mg		100	Plaquenil
Antitrichomonal Agents			
IETRONIDAZOLE	0.50	100	Trickerste
Tab 200 mg – Up to 30 tab available on a PSO		100 100	 Trichozole Trichozole
Tab 400 mg Oral lig benzoate 200 mg per 5 ml		100 ml	
Suppos 500 mg		100 11	✓ Flagyl
ORNIDAZOLE	24.40	10	• Tidgyi
Tab 500 mg	12 38	10	✓ Tiberal
	16.50	10	Arrow-Ornidazole
Tiberal Tab 500 mg to be delisted 1 May 2012)	10.00		
Antituberculotics and Antileprotics			
		1.11	
Note: There is no co-payment charge for all pharmaceuticals list mmigration status.	ed in the Antituber	culotics	and Antileprotics group regardless
•			
DAPSONE – No patient co-payment payable Tab 25 mg	95.00	100	✓ Dapsone
Tab 100 mg		100	✓ Dapsone
THAMBUTOL HYDROCHLORIDE – No patient co-payment pay		100	• Bapoono
Tab 100 mg		56	Myambutol
Tab 400 mg		56	✓ Myambutol
SONIAZID – Retail pharmacy-Specialist			•,
No patient co-payment payable			
 Tab 100 mg 	20.00	100	V PSM
K Tab 100 mg with rifampicin 150 mg		100	✓ Rifinah
K Tab 150 mg with rifampicin 300 mg		100	 Rifinah
PYRAZINAMIDE – Retail pharmacy-Specialist			
No patient co-payment payable			
 Tab 500 mg – For pyrazinamide oral liquid formulation refer, 			
page 172		100	AFT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist			-
No patient co-payment payable			
 Cap 150 mg – For rifabutin oral liquid formulation refer, page 			
172		30	Mycobutin

	Subsidy (Manufacturer's Pric \$	e) Sub Per	Fully Brand or osidised Generic ✔ Manufacturer
RIFAMPICIN – Retail pharmacy-Specialist No patient co-payment payable * Tab 600 mg * Cap 150 mg * Cap 300 mg * Oral liq 100 mg per 5 ml Antivirals For eye preparations refer to Eye Preparations, Anti-Infective Pre	58.66 122.36 12.66	30 100 100 60 ml	 ✔ Rifadin ✔ Rifadin ✔ Rifadin ✔ Rifadin
Hepatitis B Treatment			
ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Tab 10 mg ►>SA0829 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious disc		30	✔ Hepsera
 the following criteria: All of the following: Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as: Patient has raised serum ALT (> 1 × ULN); and Patient has HBV DNA greater than 100,000 copies per mL Detection of M204I or M204V mutation; and Either: S.1 Both: S.1.1 Patient is cirrhotic; and S.1.2 adefovir dipivoxil to be used in combination v S.2 Both: S.2.1 Patient is not cirrhotic; and S.2.2 adefovir dipivoxil to be used as monotherapy Renewal only from a gastroenterologist or infectious disease space. 	., or viral load ≥ 10 with lamivudine; or		
treating physician, treatment remains appropriate and patient is b Notes: Lamivudine should be added to adefovir dipivoxil if a patie as:	enefiting from treat	ment.	
 i) raised serum ALT (> 1 × ULN); and ii) HBV DNA greater than 100,000 copies per mL, or viral loa iii) Detection of N236T or A181T/V mutation. Adefovir dipivoxil should be stopped 6 months following HBeAg se adefovir dipivoxil. The recommended dose of adefovir dipivoxil is no more than 10m In patients with renal insufficiency adefovir dipivoxil dose should the Adefovir dipivoxil should be avoided in pregnant women and child ENTECAVIR – Special Authority see SA0977 on the next page – Tab 0.5 mg 	eroconversion for pa ng daily. pe reduced in accor Iren. • Retail pharmacy	tients who v	

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

➡SA0977 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
 - 4.1 ALT greater than upper limit of normal; or
 - 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and

5 Either:

- 5.1 HBeAg positive; or
- 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and
- 6 No continuing alcohol abuse or intravenous drug use; and
- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA0832 below - Retail pharmacy

Tab 100 mg	 	143.00	28	Zeffix
Oral liq 5 mg per ml	 	90.00	240 ml	🖌 Zeffix

SA0832 Special Authority for Subsidy

Initial application only from a gastroenterologist, infectious disease specialist, paediatrician or general physician. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 All of the following:
 - 1.1.1 HBsAg positive for more than 6 months; and
 - 1.1.2 HBeAg positive or HBV DNA positive defined as > 100,000 copies per ml by quantitative PCR at a reference laboratory; and
 - 1.1.3 ALT greater than twice upper limit of normal or bridging fibrosis or cirrhosis (Metavir stage 3 or 4 or equivalent) on liver histology clinical/radiological evidence of cirrhosis; or
 - 1.2 HBV DNA positive cirrhosis prior to liver transplantation; or
 - 1.3 HBsAg positive and have had a liver, kidney, heart, lung or bone marrow transplant; or
 - 1.4 Hepatitis B surface antigen positive (HbsAg) patient who is receiving chemotherapy for a malignancy, or who has received such treatment within the previous two months; and
- 2 All of the following:
 - 2.1 No continuing alcohol abuse or intravenous drug use; and
 - 2.2 Not coinfected with HCV or HDV; and
 - 2.3 Neither ALT nor AST greater than 10 times upper limit of normal; and
 - 2.4 No history of hypersensitivity to lamivudine; and
 - 2.5 No previous lamivudine therapy with genotypically proven lamivudine resistance.

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully osidised	Brand or Generic Manufacturer
 continued Renewal only from a gastroenterologist, infectious disease special for applications meeting the following criteria: Any of the following: Renewal for patients who have maintained continuous treat 1 All of the following: 1.1 Have maintained continuous treatment with lamivu 1.2 Most recent test result shows continuing biochemic 1.3 HBV DNA <100,00 copies per ml by quantitative Prenewal when given in combination with adefovir dipivoxi 2 All of the following: 2.1 Lamivudine to be used in combination with adefovi 2.2 Patient is cirrhotic; and Documented resistance to lamivudine, defined as: 2.3 Patient has HBV DNA greater than 100,000 copies 2.5 Detection of M204I or M204V mutation; or Renewal when given in combination with adefovir dipivoxi 3 All of the following: 3.1 Lamivudine to be used in combination with adefovir dipivoxi 3.4 Difference of M204I or M204V mutation; or Renewal when given in combination with adefovir dipivoxi 3.1 Lamivudine to be used in combination with adefovir dipivoxi 	atment and response t dine; and al response (normal A CR at a reference labo for patients with cirrho r dipivoxil; and per mL, or viral load = for patients with resis r dipivoxil; and	to lamivud ALT); and oratory; or osis and r = 10 fold c tance to a	line esistanc over nadi	e to lamivudine ir; and dipivoxil
Herpesvirus Treatments				
ACICLOVIR * Tab dispersible 200 mg * Tab dispersible 400 mg * Tab dispersible 800 mg	6.64	25 56 35		ovir
VALACICLOVIR – Special Authority see SA0957 below – Retail Tab 500 mg SA0957 Special Authority for Subsidy		30	🗸 Va	altrex

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal - (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application - (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application - (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE - Subsidy by endorsement; can be waived by Special Authority see SA1047 on the next page

Endorsement for treatment of HIV/AIDS: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1025 and the prescription is annotated accordingly by the Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1025, page 90

Tab 300 mg	531.00	30	~	Viread
------------	--------	----	---	--------

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	~	Manufacturer

SA1047 Special Authority for Waiver of Rule

Initial application — (Confirmed Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Fither:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased $\geq~$ 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Initial application — (Pregnant) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria: Both:

1 Patient is HBsAg positive and pregnant; and

2 Either:

- 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
- 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Either:
 - 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
 - 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent Pregnancy) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative
 prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Antiretrovirals

➡SA1025 Special Authority for Subsidy

Initial application — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:
 - 2.3.1 Patient aged 1 to 5 years; and
 - 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts $< 1000 \text{ cells/mm}^3$; or
 - 2.3.2.2 CD4 counts $< 0.25 \times$ total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or

2.4 Both:

- 2.4.1 Patient aged 6 years and over; and
- 2.4.2 CD4 counts < 350 cells/mm³.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Prevention of maternal foetal transmission; or

2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
 - 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Either:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

1 Treatment course to be initiated within 72 hours post exposure; and

2 Either:

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ - Special Authority see SA1025 on the pr	eceding page - Retail pharr	nacy	
Tab 50 mg		30	Stocrin S29
Tab 200 mg		90	Stocrin
Tab 600 mg		30	 Stocrin
ETRAVIRINE – Special Authority see SA1025 on the p Tab 100 mg	01 0 1	rmacy 120	✓ Intelence
NEVIRAPINE - Special Authority see SA1025 on the	preceding page – Retail pha	rmacy	
Tab 200 mg		60	Viramune
Oral suspension 10 mg per ml		240 ml	Viramune
			Suspension

Nucleosides Reverse Transcriptase Inhibitors

ABACAVIR SULPHATE – Special Authority see SA102 Tab 300 mg Oral liq 20 mg per ml		Retail pharma 60 240 ml OP	v ✓ <u>Ziagen</u> ✓ <u>Ziagen</u>
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Note: Kivexa counts as two anti-retroviral medication Tab 600 mg with lamivudine 300 mg	ons for the purposes of the		0 1 1
DIDANOSINE [DDI] – Special Authority see SA1025 or Cap 125 mg Cap 200 mg Cap 250 mg Cap 400 mg		ail pharmacy 30 30 30 30 30	 ✓ Videx EC ✓ Videx EC ✓ Videx EC ✓ Videx EC
EMTRICITABINE – Special Authority see SA1025 on the Cap 200 mg	1 01 0	pharmacy 30	 Emtriva

	Subsidy (Manufacturer's \$	Price) Sub: Per	Fully Brand or sidised Generic Manufacturer
LAMIVUDINE – Special Authority see SA1025 on page 90 – Ret Tab 150 mg Oral liq 10 mg per ml		60 240 ml OP	✓ <u>3TC</u> ✓ <u>3TC</u>
STAVUDINE [D4T] – Special Authority see SA1025 on page 90 - Cap 30 mg Cap 40 mg		60 60	✓ Zerit✓ Zerit
ZIDOVUDINE [AZT] – Special Authority see SA1025 on page 90 Cap 100 mg Oral liq 10 mg per ml		acy 100 200 ml OP	 ✓ <u>Retrovir</u> ✓ <u>Retrovir</u>
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see Combivir counts as two anti-retroviral medications for the pur Tab 300 mg with lamivudine 150 mg	rposes of the an	, ,	
Protease Inhibitors			
ATAZANAVIR SULPHATE – Special Authority see SA1025 on pa Cap 150 mg Cap 200 mg		harmacy 60 60	✓ Reyataz✓ Reyataz
DARUNAVIR – Special Authority see SA1025 on page 90 – Reta Tab 300 mg Tab 400 mg Tab 600 mg (Prezista Tab 300 mg to be delisted 1 January 2012)	1,190.00 	120 60 60	 Prezista Prezista Prezista
INDINAVIR – Special Authority see SA1025 on page 90 – Retail Cap 200 mg Cap 400 mg		360 180	CrixivanCrixivan
LOPINAVIR WITH RITONAVIR – Special Authority see SA1025 Tab 100 mg with ritonavir 25 mg Tab 200 mg with ritonavir 50 mg Oral liq 80 mg with ritonavir 20 mg per ml		etail pharmacy 60 120 300 ml OP	✓ Kaletra✓ Kaletra✓ Kaletra
RITONAVIR – Special Authority see SA1025 on page 90 – Retai Tab 100 mg Oral liq 80 mg per ml		30 90 ml OP	NorvirNorvir
Strand Transfer Inhibitors			
RALTEGRAVIR POTASSIUM – Special Authority see SA1025 or Tab 400 mg		ail pharmacy 60	Isentress
Antiretrovirals - Additional Therapies			
HIV Fusion Inhibitors			
ENFUVIRTIDE – Special Authority see SA0845 on the next page Powder for inj 90 mg per ml × 60	•	acy 1	✔ Fuzeon

0 1 11			D 1
Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	~	Manufacturer

►SA0845 Special Authority for Subsidy

Initial application only from a named specialist. Approvals valid for 3 months for applications meeting the following criteria: All of the following:

- 1 Confirmed HIV infection; and
- 2 Enfuvirtide to be given in combination with optimized background therapy (including at least 1 other antiretroviral drug that
- the patient has never previously been exposed to) for treatment failure; and
- 3 Either:
 - 3.1 Patient has evidence of HIV replication, despite ongoing therapy; or
 - 3.2 Patient has treatment-limiting toxicity to previous antiretroviral agents; and
- 4 Previous treatment with 3 different antiretroviral regimens has failed; and
- 5 All of the following:
 - 5.1 Previous treatment with a non-nucleoside reverse transcriptase inhibitor has failed; and
 - 5.2 Previous treatment with a nucleoside reverse transcriptase inhibitor has failed; and
 - 5.3 Previous treatment with a protease inhibitor has failed.

Renewal only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 Evidence of at least a 10 fold reduction in viral load at 12; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Immune Modulators

Guidelines for the use of interferon in the treatment of hepatitis C:

Physicians considering treatment of patients with hepatitis C should discuss cases with a gastroenterologist or an infectious disease physician. All subjects undergoing treatment require careful monitoring for side effects.

Patients should be otherwise fit.

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.
- 2) Establishing Active Chronic Liver Disease
 - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging > 1.5 × upper limit of normal. (ALT is the preferable enzyme); or
 - Liver biopsy showing significant inflammatory activity (active hepatitis) with or without cirrhosis. This is not a necessary requirement for those patients with coagulopathy. (Some patients have active disease on histology with normal transaminase enzymes).

Exclusion Criteria

- 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as well as other autoimmune diseases such as thyroid disease).
- 2) Pregnancy.
- 3) Neutropenia (<2.0 \times 10 $^9)$ and/or thrombocytopenia.
- 4) Continuing alcohol abuse and/or continuing intravenous drug users.

Dosage

The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2b administered subcutaneously 3 times a week for 52 weeks (twelve months)

Exit Criteria

The patient's response to interferon treatment should be reviewed at either three or four months. Interferon treatment should be discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment ALT level at this stage.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	
INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist See prescribing guideline on the preceding page				
Inj 3 m iu prefilled syringe		1	~	Roferon-A
Inj 6 m iu prefilled syringe	62.64	1	V	Roferon-A
Inj 9 m iu prefilled syringe	93.96	1	v 1	Roferon-A
INTERFERON ALPHA-2B – PCT – Retail pharmacy-Specialist See prescribing guideline on the preceding page				
Inj 18 m iu, 1.2 ml multidose pen		1	v 1	Intron-A
Inj 30 m iu, 1.2 ml multidose pen		1	v 1	Intron-A
Inj 60 m iu, 1.2 ml multidose pen	626.40	1	v 1	Intron-A
PEGYLATED INTERFERON ALPHA-2A – Special Authority see See prescribing guideline on the preceding page Inj 135 μg prefilled syringe Inj 180 μg prefilled syringe		il pha 1 4 1 4		<u>Pegasys</u> Pegasys Pegasys Pegasys
Inj 135 μg prefilled syringe \times 4 with ribavirin tab 200 mg \times 112		1 OP	~	Pegasys RBV Combination Pack
Inj 135 μg prefilled syringe \times 4 with ribavirin tab 200 mg \times 168		1 OP		Pegasys RBV Combination Pack
Inj 180 μg prefilled syringe \times 4 with ribavirin tab 200 mg \times 112		1 OP	<u>~</u>	Pegasys RBV Combination Pack
Inj 180 µg prefilled syringe \times 4 with ribavirin tab 200 mg \times 168		1 OP	<u>~ </u>	Pegasys RBV Combination Pack

➡SA1134 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

Both:

- 1 Either:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; and

2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml

Initial application — (chronic hepatitis C - genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
 - 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

	Subsidy (Manufacturer's Price) \$) Su Per	Fully bsidised	Brand or Generic Manufacturer
ontinued				
1 Patient has confirmed Hepatitis B infection (HBsAg positiv	e for more than 6 mo	nths); and	ł	
2 Patient is Hepatitis B treatment-naive; and				
 3 ALT > 2 times Upper Limit of Normal; and 4 HBV DNA < 10 log10 IU/ml; and 				
5 Either:				
5.1 HBeAg positive; or				
5.2 serum HBV DNA \geq 2,000 units/ml and significant	fibrosis (> Metavir St	tage F2):	and	
6 Compensated liver disease; and	(,, ,,		
7 No continuing alcohol abuse or intravenous drug use; and				
8 Not co-infected with HCV, HIV or HDV; and				
9 Neither ALT nor AST > 10 times upper limit of normal; and				
10 No history of hypersensitivity or contraindications to pegy	ated interferon: and			
, , , , , , , , , , , , , , , , , , , ,				
11 Maximum of 48 weeks therapy.				
11 Maximum of 48 weeks therapy. otes:				
11 Maximum of 48 weeks therapy.otes:Approved dose is 180 µg once weekly.		lv.		
11 Maximum of 48 weeks therapy. otes:	is 180 µg once weekl		Pegylated	d Interferon-alpha 2a dos
 11 Maximum of 48 weeks therapy. otes: Approved dose is 180 µg once weekly. The recommended dose of Pegylated Interferon-alpha 2a 	is 180 µg once weekl		Pegylated	d Interferon-alpha 2a dos
 Maximum of 48 weeks therapy. Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dos 	is 180 µg once weekl learance less than 50 se should be reduced)ml/min), l	0,	
 Maximum of 48 weeks therapy. Approved dose is 180 µg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 µg once weekly. 	is 180 µg once weekl learance less than 50 se should be reduced)ml/min), l	0,	
 Maximum of 48 weeks therapy. Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dos 	is 180 µg once weekl learance less than 50 se should be reduced)ml/min), l	0,	
 Maximum of 48 weeks therapy. Approved dose is 180 µg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 µg once weekly. In patients with neutropaenia and thrombocytopaenia, dos Pegylated Interferon-alpha 2a is not approved for use in c 	is 180 µg once weekl learance less than 50 se should be reduced)ml/min), l	0,	
 Maximum of 48 weeks therapy. Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine of should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dos Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE 	is 180 µg once weekl learance less than 50 se should be reduced hildren.)ml/min), l	0,	
 Maximum of 48 weeks therapy. Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine of should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dos Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE 	is 180 µg once weekl learance less than 50 se should be reduced hildren.)ml/min), I	ance with	
 Maximum of 48 weeks therapy. Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dos Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE Tab 1 g 	is 180 µg once weekl learance less than 50 se should be reduced hildren.)ml/min), I	ance with	n the datasheet guideline
 Maximum of 48 weeks therapy. Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dose Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE Tab 1 g TROFURANTOIN Tab 50 mg – For nitrofurantoin oral liquid formulation reference 	is 180 µg once weekl learance less than 50 se should be reduced hildren.)ml/min), I	ance with	n the datasheet guideline
 11 Maximum of 48 weeks therapy. approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine or should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dose Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE Tab 1 g TROFURANTOIN Tab 50 mg – For nitrofurantoin oral liquid formulation refe page 172 	is 180 µg once weekl learance less than 50 se should be reduced hildren. 	ýml/min), l in accorda 100 100	ance with H	n the datasheet guideline: iprex ifuran
 11 Maximum of 48 weeks therapy. approved dose is 180 µg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine of should be reduced to 135 µg once weekly. In patients with neutropaenia and thrombocytopaenia, dose Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE Tab 1 g TROFURANTOIN Tab 50 mg – For nitrofurantoin oral liquid formulation references 	is 180 µg once weekl learance less than 50 se should be reduced hildren. 	in accorda	ance with H	n the datasheet guideline
 11 Maximum of 48 weeks therapy. otes: Approved dose is 180 μg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine of should be reduced to 135 μg once weekly. In patients with neutropaenia and thrombocytopaenia, dose Pegylated Interferon-alpha 2a is not approved for use in c Urinary Tract Infections EXAMINE HIPPURATE Tab 1 g Tab 50 mg – For nitrofurantoin oral liquid formulation refe page 172 	is 180 µg once weekl learance less than 50 se should be reduced hildren. 	ýml/min), l in accorda 100 100	ance with H	n the datasheet guideline: iprex ifuran
 11 Maximum of 48 weeks therapy. approved dose is 180 µg once weekly. The recommended dose of Pegylated Interferon-alpha 2a In patients with renal insufficiency (calculated creatinine of should be reduced to 135 µg once weekly. In patients with neutropaenia and thrombocytopaenia, dose Pegylated Interferon-alpha 2a is not approved for use in c Jrinary Tract Infections EXAMINE HIPPURATE Tab 1 g TROFURANTOIN Tab 50 mg – For nitrofurantoin oral liquid formulation refe page 172 Tab 100 mg 	is 180 µg once weekl learance less than 50 se should be reduced hildren. 	ýml/min), l in accorda 100 100	ance with H ✔ N ✔ N	n the datasheet guideline: iprex ifuran

Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Generic	

Vaccines

Influenza vaccine

INFLUENZA VACCINE - Hospital pharmacy [Xpharm]

A) is available 1 March until vaccine supplies are exhausted each year for patients who meet the following criteria, as set by the Ministry of Health:

a) all people 65 years of age and over;

- b) people under 65 years of age with:
 - i) the following cardiovascular disease:
 - 1) ischaemic heart disease,
 - 2) congestive heart disease,
 - 3) rheumatic heart disease,
 - 4) congenital heart disease, or
 - 5) cerebo-vascular disease;
 - ii) the following chronic respiratory disease:
 - 1) asthma, if on a regular preventative therapy, or
 - 2) other chronic respiratory disease with impaired lung function;
 - iii) diabetes;
 - iv) chronic renal disease;
 - v) any cancer, excluding basal and squamous skin cancers if not invasive;
 - vi) the following other conditions:
 - a) autoimmune disease,
 - b) immune suppression,
 - c) HIV,
 - d) transplant recipients,
 - e) neuromuscular and CNS diseases,
 - f) haemoglobinopathies,
 - g) children on long term aspirin, or
 - h) pregnancy.

c) people under 18 years of age living within the boundaries of the Canterbury District Health Board.

The following conditions are excluded from funding:

- a) asthma not requiring regular preventative therapy,
- b) hypertension and/or dyslipidaemia without evidence of end-organ disease,
- B) Doctors are the only Contractors entitled to claim payment from the Funder for the supply of influenza vaccine to patients eligible under the above criteria for subsidised immunisation and they may only do so in respect of the influenza vaccine listed in the Pharmaceutical Schedule.
- C) Individual DHBs may fund patients over and above the above criteria. The claiming process for these additional patients should be determined between the DHB and Contractor.
- D) Influenza Vaccine does not fall within the definition Community Pharmaceutical as it is not funded directly from the Pharmaceutical Budget. Pharmacists are unable to claim for the dispensing of influenza vaccine from the Funder.

Inj	 10	Fluarix
		Fluvax

	Subsidy	() ()	Fully Brand or
	(Manufacturer's F \$	Price) Su Per	Ibsidised Generic Manufacturer
	ą	Pei	Manuacturer
Anticholinesterases			
NEOSTIGMINE			
Inj 2.5 mg per ml, 1 ml		50	AstraZeneca
PYRIDOSTIGMINE BROMIDE			· · · · · · · · · · · · · · · · · · ·
	29.00	100	✓ Mestinon
▲ Tab 60 mg		100	• <u>Mestinon</u>
Non-steroidal Anti-inflammatory Drugs (NSAI	Ds)		
The CA1000 Creatical Authority for Menufacturers Price			
► SA1038 Special Authority for Manufacturers Price	tambar 0010 Annu		
Note: Subsidy for patients with existing approvals prior to 1 Sep	tember 2010. Appro	ovais valid with	nout turther renewal unless notifie
No new approvals will be granted from 1 September 2010.			
DICLOFENAC SODIUM	4.00	50	
* Tab EC 25 mg		50	Diclofenac Sandoz
* Tab 50 mg dispersible – Additional subsidy by Special			
thority see SA1038 above – Retail pharmacy	1.50	20	
	(8.00)		Voltaren D
* Tab EC 50 mg	2.13	50	Diclofenac Sandoz
* Tab long-acting 75 mg		500	Diclax SR
* Tab long-acting 100 mg		500	Diclax SR
* Inj 25 mg per ml, 3 ml	12.00	5	Voltaren
Up to 5 inj available on a PSO			
* Suppos 12.5 mg	1.85	10	Voltaren
* Suppos 25 mg	2.22	10	Voltaren
* Suppos 50 mg	3.84	10	Voltaren
Up to 10 supp available on a PSO			
* Suppos 100 mg	6.36	10	Voltaren
IBUPROFEN - Additional subsidy by Special Authority see SA	A1038 above – Reta	ail pharmacy	
* Tab 200 mg		1,000	Arrowcare
	16.00	1,000	 Ethics Ibuprofen
* Tab 400 mg		30	
	(4.56)		Brufen
* Tab 600 mg	· · · ·	30	2.0.011
	(6.84)	00	Brufen
* Tab long-acting 800 mg		30	✓ Brufen SR
*‡ Oral liq 100 mg per 5 ml		200 ml	✓ Fenpaed
		200 111	• <u>ronpaou</u>
KETOPROFEN	04 50	100	4.0
* Cap long-acting 100 mg		100	✓ Oruvail SR
* Cap long-acting 200 mg		100	Oruvail SR
MEFENAMIC ACID - Additional subsidy by Special Authority	see SA1038 above	- Retail pharr	nacy
* Cap 250 mg	0.50	20	
	(5.60)		Ponstan
	1.25	50	
	(9.16)		Ponstan
NAPROXEN			
* Tab 250 mg	23 70	500	Noflam 250
* Tab 500 mg		250	✓ Noflam 500
* Tab long-acting 750 mg		90	✓ Naprosyn SR 750
 * Tab long-acting 7.00 mg * Tab long-acting 1,000 mg 		90	✓ Naprosyn SR 1000
		50	

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	
SULINDAC - Additional subsidy by Special Authority see SA1038	3 on the preceding pa	ige – Retai	l phar	macy
* Tab 100 mg		100		
	(17.10)	100	[Daclin
* Tab 200 mg	(30.20)	100	[Daclin
TENOXICAM				
* Tab 20 mg		100	1	Filcotil
* Inj 20 mg	9.95	1	V	AFT
TIAPROFENIC ACID				
* Tab 300 mg	19.26	60	19	Surgam
NSAIDs Other				
INDOMETHACIN				
* Suppos 100 mg	14.50	30	V	Arthrexin
MELOXICAM - Special Authority see SA1034 below - Retail pha	rmacy			
Tab 7.5 mg		30	V	Arrow-Meloxicam
➡SA1034 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	l without further rene	wal unless	notifi	ed for applications meeting
the following criteria:				
All of the following:				
 The patient has moderate to severe haemophilia with less the and 	han or equal to 5% of	f normal cir	rculatii	ng functional clotting factor;
2 The patient has haemophilic arthropathy; and				
3 Pain and inflammation associated with haemophilic arthropoptions, or alternative funded treatment options are contrain		/ controlled	d by a	Iternative funded treatment
Antirheumatoid Agents				

WRANOFIN		
Tab 3 mg68.99	60	Ridaura
EFLUNOMIDE		
Tab 10 mg55.00	30	AFT-Leflunomide
79.27		Arava
Tab 20 mg76.00	30	AFT-Leflunomide
108.60		Arava
Tab 100 mg54.44	3	Arava
PENICILLAMINE		
Tab 125 mg61.93	100	D-Penamine
Tab 250 mg	100	D-Penamine
ODIUM AUROTHIOMALATE		
Inj 10 mg per 0.5 ml76.87	10	Myocrisin
Inj 20 mg per 0.5 ml	10	✓ Myocrisin
Inj 50 mg per 0.5 ml217.23	10	✓ Myocrisin
Tumour Necrosis Factor (TNF) Inhibitors		
DALIMUMAB – Special Authority see SA1156 on the next page – Retail pharmac	Ŵ	

ADALINOWAD - Special Automy see SAT150 on the he	xi paye – netali pharmacy	
Inj 40 mg per 0.8 ml prefilled pen		HumiraPen
Inj 40 mg per 0.8 ml prefilled syringe	1,799.92 2	🗸 Humira

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

SA1156 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.
- Initial application (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic
 \$	Per 🖌	Manufacturer

continued...

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- Either:
 - 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
 - 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender:

18-24 years - Male: 7.0 cm; Female: 5.5 cm

25-34 years - Male: 7.5 cm; Female: 5.5 cm

35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or

continued...

- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.
- **Renewal** (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:
- All of the following:
 - 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or
 - 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
 - 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
- Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:

Subsidy (Manufacturer's Pr	rice) S	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
 - 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

ETANERCEPT – Special Authority see SA1157 below – Retail pharmacy

Inj 25 mg	949.96	4	Enbrel
Inj 50 mg autoinjector	1,899.92	4	 Enbrel
Inj 50 mg prefilled syringe	1,899.92	4	 Enbrel

➡SA1157 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and
- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 5 Both:
 - 5.1 Either:
 - 5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or

		Subsidy (Manufacturer's Price) \$	Si Per	Fully ubsidised	Brand or Generic Manufacturer
--	--	---	-----------	--------------------	-------------------------------------

continued...

- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment. **Initial application — (ankylosing spondylitis)** only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	

continued...

- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

(M:	Subsidy	Fully	Brand or
	anufacturer's Price)	Subsidised	Generic
·	\$ I	Per 🗸	Manufacturer

continued...

- 1.1 Applicant is a dermatologist; or
- 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.
- Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
 - 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
 - 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
 - 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Subsidy		Fully	E
(Manufacturer's Price)	Su	lbsidised	(
\$	Per	~	1

Brand or Generic Manufacturer

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score ≤ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD $\geq~$ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score $\leq~$ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score $\leq~$ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene.

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

MUSCULOSKELETAL SYSTEM

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALENDRONATE SODIUM – Special Authority see SA1039 on the preceding page – Retail pharmacy Tab 70 mg

ALENDRONATE SODIUM WITH CHOLECALCIFEROL	- Special Authority see	SA1039 on the	preceding page - Retail phar	macy
Tab 70 mg with cholecalciferol 5.600 iu		4	Fosamax Plus	

Alendronate for Paget's Disease

➡SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

ALENDRONATE SODIUM - Special Authority see SA0949 above - Retail pharmacy

Tab 40 mg133.00	30	Fosamax
Other Treatments		
CALCITONIN * Inj 100 iu per ml, 1 ml110.00	5	✓ <u>Miacalcic</u>
ETIDRONATE DISODIUM – See prescribing guideline below * Tab 200 mg23.95	100	✓ <u>Arrow-Etidronate</u>

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

PAMIDRONATE DISODIUM Pamisol 1 1 Pamisol Inj 6 mg per ml, 10 ml75.00 Pamisol 1 1 Pamisol RALOXIFENE HYDROCHLORIDE - Special Authority see SA1138 on the next page - Retail pharmacy 28 Evista Tab 60 mg53.76

|--|

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \ge 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \le -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score $\leq~$ -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause Osteoporosis).

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by the UK National Institute for Health and Clinical Excellence (NICE) in developing its guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE - Special Authority see SA1139 below - Retail pharmacy

Inj 250 μg per ml, 2.4 ml 490.00 1 🖌 Forteo

➡SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ZOLEDRONIC ACID – Special Authority see SA1035 below – Re Soln for infusion 5 mg in 100 ml		100 ml	🗸 A	clasta

SA1035 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Paget's disease; and
 - 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
 - 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score \leq -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 The patient is receiving systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - 2 Any of the following:
 - 2.1 The patient has documented BMD \geq 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
 - 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and

Subsidy (Manufacturer's Price)	ç	Fully Subsidised	Brand or Generic
 \$	Per	~	Manufacturer

continued...

2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient may not have had an approval in the past 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and

2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient may not have had an approval in the past 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score $\leq~$ -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

MUSCULOSKELETAL SYSTEM

Hyperuricaemia and Antigout LLOPURINOL Tab 100 mg Tab 300 mg For allopurinol oral liquid formulation references page 172	(5.44) 15.90 r,	Per 250 1,000	Manufacturer Apo-Allopurinol Apo-Allopurinol
LOPURINOL Tab 100 mg Tab 300 mg – For allopurinol oral liquid formulation refer	(5.44) 15.90 r,		
 Tab 100 mg Tab 300 mg For allopurinol oral liquid formulation refer 	(5.44) 15.90 r,		
• Tab 300 mg – For allopurinol oral liquid formulation refer	(5.44) 15.90 r,		
o	15.90 [′] ′,	1,000	
o	ſ,	1,000	Apo-Allopurinoi
o			
page 172		100	Apo-Allopurinol
		100	S29 S29
	20.15	500	✓ Apo-Allopurinol
	20.15	500	\$29 S29
	3.35	100	OLD GED
	(4.03)		Apo-Allopurinol
	16.75	500	Apo-Allopurinol
Apo-Allopurinol Tab 100 mg to be delisted 1 March 2012)			
Apo-Allopurinol S29 (\$29) Tab 300 mg to be delisted 1 March 20	12)		
Apo-Allopurinol Tab 300 mg to be delisted 1 March 2012)			
OLCHICINE			
፦ Tab 500 μg	9.60	100	Colgout
ROBENECID			
Tab 500 mg		100	Probenecid-AFT
Muscle Relaxants			
			ļ ,
ACLOFEN			
Tab 10 mg - For baclofen oral liquid formulation refer, page	Э		
172	4.75	100	Pacifen
ANTROLENE SODIUM			
Cap 25 mg		100	
	(65.00)		Dantrium
Cap 50 mg	51.70	100	
	(77.00)		Dantrium
RPHENADRINE CITRATE			
Tab 100 mg		100	 Norflex
UININE SULPHATE			
- Tab 200 mg		250	
	(17.20)		Q 200
‡ Safety cap for extemporaneously compounded oral liqui	(/		
Tab 300 mg ‡ Safety cap for extemporaneously compounded oral liqui		500	🖌 <u>Q 300</u>

	Subsidy (Manufacturer's Price) \$	S Per	Fully Subsidised	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders				
Dopamine Agonists and Related Agents				
AMANTADINE HYDROCHLORIDE		60	S	ymmetrel
APOMORPHINE HYDROCHLORIDE				
▲ Inj 10 mg per ml, 2 ml	110.00	5	🖌 Al	pomine
BROMOCRIPTINE MESYLATE				
* Tab 2.5 mg		100		po-Bromocriptine
* Cap 5 mg	60.43	100	V A	po-Bromocriptine
ENTACAPONE				
▲ Tab 200 mg		100	✓ C	omtan_
LEVODOPA WITH BENSERAZIDE				
* Tab dispersible 50 mg with benserazide 12.5 mg	10.00	100	🖌 M	adopar
		100		Dispersible
* Cap 50 mg with benserazide 12.5 mg	8.00	100		adopar 62.5
* Cap 100 mg with benserazide 25 mg		100		adopar 125
* Cap long-acting 100 mg with benserazide 25 mg		100		adopar HBS
* Cap 200 mg with benserazide 50 mg		100		adopar 250
LEVODOPA WITH CARBIDOPA				
* Tab 100 mg with carbidopa 25 mg - For levodopa with car- bidopa and liquid formulation rates, page 172		50		indopa
bidopa oral liquid formulation refer, page 172		100		inemet
* Tab long-acting 200 mg with carbidopa 50 mg		100		inemet CR
 * Tab long-acting 200 mg with carbidopa 50 mg * Tab 250 mg with carbidopa 25 mg 		100		inemet
		100	• 3i	memer
LISURIDE HYDROGEN MALEATE			4 -	
▲ Tab 200 μg		30	V Do	opergin
PERGOLIDE				
▲ Tab 0.25 mg		100	🖌 <u>Pe</u>	ermax
▲ Tab 1 mg		100	🖌 <u>Pe</u>	ermax
ROPINIROLE HYDROCHLORIDE				
▲ Tab 0.25 mg		84	🖌 Re	opin
▲ Tab 1 mg		84	✓ R	
▲ Tab 2 mg		84	✓ R	
▲ Tab 5 mg		84	✓ R	
SELEGILINE HYDROCHLORIDE				-
* Tab 5 mg	16.06	100	ν Δι	po-Selegiline
				po-Selegiline
				S29 S29
(Apo-Selegiline S29 s29 Tab 5 mg to be delisted 1 March 2012)				
TOLCAPONE	100.00	400		
▲ Tab 100 mg		100	V <u>Ta</u>	asmar

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	
Anticholinergics				
BENZTROPINE MESYLATE				
Tab 2 mg		60		Benztrop
Inj 1 mg per ml, 2 ml a) Up to 5 inj available on a PSO b) Only on a PSO		5		Cogentin
ORPHENADRINE HYDROCHLORIDE Tab 50 mg	31.93	250	~ 1	Disipal
PROCYCLIDINE HYDROCHLORIDE Tab 5 mg	7.40	100	~ 1	Kemadrin
Agents for Essential Tremor, Chorea and Relate				
ETRABENAZINE				
Tab 25 mg	243.00	112	v)	(enazine 25
Anaesthetics				
Local				
IGNOCAINE Gel 2%, 10 ml urethral syringe – Subsidy by endorsement a) Up to 5 each available on a PSO	43.26	10	~ 1	Pfizer
b) Subsidised only if prescribed for urethral or cervical ac IGNOCAINE HYDROCHLORIDE	Iministration and the p	orescrip	tion is end	lorsed accordingly.
Viscous soln 2%	55 00	200 ml	~	Viocaine Viscous
Inj 1%, 5 ml – Up to 5 inj available on a PSO		50		(ylocaine
Inj 2%, 5 ml – Up to 5 inj available on a PSO		50		(ylocaine
Inj 1%, 20 ml – Up to 5 inj available on a PSO		5	<u> </u>	(ylocaine
Inj 2%, 20 ml – Up to 5 inj available on a PSO	15.00	5	V)	(ylocaine
IGNOCAINE WITH CHLORHEXIDINE				
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes	-			
Subsidy by endorsement		10	1	Pfizer
		orescrin	tion is end	lorsed accordingly.
 a) Up to 5 each available on a PSO b) Subsidised only if prescribed for urethral or cervical ad 	iministration and the i			
b) Subsidised only if prescribed for urethral or cervical ac				0,7
, 1	906 below – Retail ph		1	EMLA

condition requiring frequent injections or venepuncture.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's P \$	rice) Sul Per	Fully osidised	Brand or Generic Manufacturer
Analgesics or Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pa	age 97			
Non-opioid Analgesics	.yo o'i			
SPIRIN				
F Tab EC 300 mg		100	10	pec 300
Tab dispersible 300 mg – Up to 30 tab available on a PSO	(8.10) 2.00	100		nics Aspirin
EFOPAM HYDROCHLORIDE				
Tab 30 mg	23.40	90	🖌 Ac	upan
ARACETAMOL			4 -	
Tab 500 mg – Up to 30 tab available on a PSO	9.38 9.60	1,000	✓ Pa	rafast armacare
≑ Oral liq 120 mg per 5 ml		500 ml		nics Paracetamol
	4.42	1,000 ml		racare Junior
a) Up to 200 ml available on a PSO				
b) Not in combination ‡ Oral liq 250 mg per 5 ml	6 70	1,000 ml	A Do	racare Double
		1,000 111		Strength
a) Up to 100 ml available on a PSO			-	
b) Not in combination	7.40	00		
Suppos 125 mg		20 20	✓ Pa	
Suppos 250 mg Suppos 500 mg		20 50		racare
Paracare Junior Oral liq 120 mg per 5 ml to be delisted 1 March		50	• Tu	lacare
RAMADOL HYDROCHLORIDE				
Cap 50 mg	4.95	100	✓ <u>Ar</u>	row-Tramadol
Opioid Analgesics				
ODEINE PHOSPHATE				
Tab 15 mg	5.39	100	🖌 PS	М
Tab 30 mg		100	V PS	
Tab 60 mg	17.76	100	V PS	М
HYDROCODEINE TARTRATE	07.07	00		
Tab long-acting 60 mg	27.27	60	V DH	IC Continus
ENTANYL				
 a) Only on a controlled drug form b) No patient co-payment payable 				
Transdermal patch 12.5 µg per hour	8.90	5	🖌 Mu	lan Fentanvl
	0.00		Ē	Patch
Transdermal patch 25 µg per hour	9.15	5		lan Fentanyl
Transdermal patch 50 µg per hour	11 50	5		P <u>atch</u> Ian Fentanyl
nansuennai paten so py per nour		5		Patch
Transdermal patch 75 µg per hour		5		lan Fentanyl
1 101				
Transdermal patch 100 µg per hour		5		P <u>atch</u> Ian Fentanyl

116

		Subsidy (Manufacturer's Pric		Fully Brand or Ibsidised Generic	
		\$	Per	 Manufacturer 	
FE	NTANYL CITRATE				
	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	Inj 50 μg per ml, 2 ml		10	Boucher and M	
	Inj 50 μg per ml, 10 ml		10	Boucher and M	uir
ЛE	THADONE HYDROCHLORIDE				
	a) Only on a controlled drug form				
	 b) No patient co-payment payable 				
	c) Extemporaneously compounded methadone will only be r	eimbursed at the ra	ate of the cl	neapest form available (methado
	powder, not methadone tablets).				
	d) For methadone hydrochloride oral liquid refer, page 175				
	Tab 5 mg		10	Methatabs	
	Oral liq 2 mg per ml		200 ml	✓ Biodone	
	Oral liq 5 mg per ml		200 ml	Biodone Forte	
	Oral liq 10 mg per ml		200 ml	Biodone Extra I	Forte
	Inj 10 mg per ml, 1 ml	61.00	10	🖌 AFT	
10	ORPHINE HYDROCHLORIDE				
	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	Oral liq 1 mg per ml		200 ml	RA-Morph	
	Oral liq 2 mg per ml		200 ml	RA-Morph	
	Oral lig 5 mg per ml		200 ml	RA-Morph	
	Oral liq 10 mg per ml	21.55	200 ml	✓ RA-Morph	
л	DRPHINE SULPHATE				
vic	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	Tab immediate-release 10 mg	2 80	10	Sevredol	
	Tab long-acting 10 mg		10	✓ Arrow-Morphine	eΙΔ
	Tab immediate-release 20 mg		10	✓ Sevredol	<u> </u>
	Tab long-acting 30 mg		10	Arrow-Morphine	e LA
	Tab long-acting 60 mg		10	✓ Arrow-Morphine	
	Tab long-acting 100 mg		10	 Arrow-Morphine 	
	Cap long-acting 10 mg		10	✓ m-Eslon	
	Cap long-acting 30 mg		10	✓ m-Eslon	
	Cap long-acting 60 mg		10	✓ m-Eslon	
	Cap long-acting 100 mg		10	✓ m-Eslon	
	Inj 5 mg per ml, 1 ml - Up to 5 inj available on a PSO		5	✓ DBL Morphine	
				Sulphate	
	Inj 10 mg per ml, 1 ml - Up to 5 inj available on a PSO	4.79	5	DBL Morphine	
				Sulphate	
	Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.01	5	✓ DBL Morphine	
				Sulphate	
	Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.30	5	✓ DBL Morphine	
				Sulphate	
10	DRPHINE TARTRATE				
	a) Only on a controlled drug form				
	b) No patient co-payment payable				
	Inj 80 mg per ml, 1.5 ml		5	Hospira	
	Inj 80 mg per ml, 5 ml		5	✓ Hospira	
				·	

	Subsidy (Manufacturer's P	Price) Cu	Fully Brand or bsidised Generic
	(IVIAITUIACIUTELS F \$	Per Su	Manufacturer
XYCODONE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) See prescribing guideline below			
c) No patient co-payment payable			
Tab controlled-release 5 mg	7.51	20	OxyContin
Tab controlled-release 10 mg	11.14	20	OxyContin
Tab controlled-release 20 mg		20	OxyContin
Tab controlled-release 40 mg		20	OxyContin
Tab controlled-release 80 mg		20	OxyContin
Cap 5 mg	2.83	20	 OxyNorm
Cap 10 mg	5.58	20	 OxyNorm
Cap 20 mg	9.77	20	 OxyNorm
Oral liq 5 mg per 5 ml	11.20	250 ml	 OxyNorm
Inj 10 mg per ml, 1 ml	14.40	5	OxyNorm
Inj 10 mg per ml, 2 ml		5	 OxyNorm
ARACETAMOL WITH CODEINE Tab paracetamol 500 mg with codeine phosphate 8 mg	2.45 2.70	100	 ✓ ParaCode ✓ Paracetamol + Codeine (Relieve)
ParaCode Tab paracetamol 500 mg with codeine phosphate 8 m	ng to be delisted t	1 February 20	()
ETHIDINE HYDROCHLORIDE			
a) Only on a controlled drug form			
b) No patient co-payment payable			
Tab 50 mg		10	✔ PSM
Tab 100 mg		10	✓ PSM
Inj 50 mg per ml, 1 ml - Up to 5 inj available on a PSO	5.51	5	
		5	DBL Pethidine
		5	DBL Pethidine Hydrochloride
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	5	
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	-	Hydrochloride
	5.83	-	<u>Hydrochloride</u> ✓ <u>DBL Pethidine</u>
Antidepressants	5.83	-	<u>Hydrochloride</u> ✓ <u>DBL Pethidine</u>
Antidepressants	5.83	-	<u>Hydrochloride</u> ✓ <u>DBL Pethidine</u>
Antidepressants Cyclic and Related Agents	5.83	-	<u>Hydrochloride</u> ✓ <u>DBL Pethidine</u>
Antidepressants Cyclic and Related Agents		-	<u>Hydrochloride</u> ✓ <u>DBL Pethidine</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE	2.77	5	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg	2.77 	5	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Hydrochloride</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg Tab 25 mg Tab 50 mg	2.77 	5 50 100	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Hydrochloride</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg Tab 25 mg Tab 50 mg LOMIPRAMINE HYDROCHLORIDE	2.77 1.85 3.60	5 50 100 100	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Amitrip</u> <u>Amitrip</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg Tab 25 mg Tab 50 mg LOMIPRAMINE HYDROCHLORIDE Tab 10 mg		5 50 100	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Amirol</u> <u>Amitrip</u> <u>Amitrip</u> <u>Amitrip</u> <u>Amitrip</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg Tab 25 mg Tab 50 mg LOMIPRAMINE HYDROCHLORIDE Tab 10 mg Tab 25 mg		5 50 100 100	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Amirol</u> <u>Amitrip</u> <u>Amitrip</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg Tab 25 mg Tab 50 mg LOMIPRAMINE HYDROCHLORIDE Tab 10 mg Tab 25 mg OTHIEPIN HYDROCHLORIDE		5 50 100 100 100 100	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Amirol</u> <u>Amitrip</u> <u>Amitrip</u> <u>Amitrip</u> <u>Amitrip</u> <u>Apo-Clomipramine</u> <u>Apo-Clomipramine</u>
Antidepressants Cyclic and Related Agents MITRIPTYLINE Tab 10 mg Tab 25 mg Tab 50 mg LOMIPRAMINE HYDROCHLORIDE Tab 10 mg		5 50 100 100	Hydrochloride <u>DBL Pethidine</u> <u>Hydrochloride</u> <u>Amirol</u> <u>Amitrip</u> <u>Amitrip</u> <u>Amitrip</u> <u>Amitrip</u>

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
DOXEPIN HYDROCHLORIDE				
Cap 10 mg	5.24	100	~	Anten
Cap 25 mg	5.46	100	~	Anten
Cap 50 mg		100	~	Anten
IMIPRAMINE HYDROCHLORIDE				
Tab 10 mg	5.48	50	~	Tofranil
Tab 25 mg	8.80	50	~	Tofranil
MAPROTILINE HYDROCHLORIDE				
Tab 25 mg	25.06	100	~	Ludiomil
Tab 75 mg		30	~	Ludiomil
MIANSERIN HYDROCHLORIDE - Special Authority see SA1048	3 below – Retail phar	macy		
Tab 30 mg		30	~	Tolvon

➡SA1048 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Both:
 - 1.1 Depression; and
 - 1.2 Either:
 - 1.2.1 Co-existent bladder neck obstruction; or
 - 1.2.2 Cardiovascular disease; or

2 Both:

- 2.1 The patient has a severe major depressive episode; and
- 2.2 Either:
 - 2.2.1 The patient must have had a trial of two different antidepressants and was unable to tolerate the treatments or failed to respond to an adequate dose over an adequate period of time (usually at least four weeks); or
 - 2.2.2 Both:
 - 2.2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2.2 The patient must have had a trial of one other antidepressant and either could not tolerate it or failed to respond to an adequate dose over an adequate period of time.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

NORTRIPTYLINE HYDROCHLORIDE Tab 10 mg Tab 25 mg		100 180	✓ Norpress✓ Norpress
Monoamine-Oxidase Inhibitors (MAOIs) - Nor	n Selective		
PHENELZINE SULPHATE Tab 15 mg	95.00	100	✓ Nardil
TRANYLCYPROMINE SULPHATE Tab 10 mg	22.94	50	✓ Parnate
Monoamine-Oxidase Type A Inhibitors			

MOCLOBEMIDE

‡ safety cap				
*Three months	or six months,	as applicable,	dispensed all-at-c	once

	Subsidy	Cub	Fully	Brand or Generic
	(Manufacturer's Price) \$	Per	sidised	Manufacturer
	•			
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE				
* Tab 20 mg	2.34	84	✓ <u>A</u>	rrow-Citalopram
ESCITALOPRAM				
Tab 10 mg	2.65	28	V L	oxalate
Tab 20 mg	4.20	28	VL	oxalate
FLUOXETINE HYDROCHLORIDE				
* Tab dispersible 20 mg, scored – Subsidy by endorsement	2.50	30	🖌 F	luox
Subsidised by endorsement				
1) When prescribed for a patient who cannot swallow v	whole tablets or capsu	les and the	e presc	ription is endorsed accord-
ingly; or				
2) When prescribed in a daily dose that is not a mu				
endorsed. Note: Tablets should be combined with c	•		. •	
* Cap 20 mg	2.70	84	✓ <u>F</u>	luox
PAROXETINE HYDROCHLORIDE				
Tab 20 mg	2.38	30	<u> </u>	oxamine_
SERTRALINE				
Tab 50 mg		90		rrow-Sertraline
Tab 100 mg	9.60	90	<u> </u>	rrow-Sertraline
Other Antidepressants				
MIRTAZAPINE - Special Authority see SA0994 below - Retail pl	narmacy			
Tab 30 mg		30	🖌 A	vanza
Tab 45 mg	35.00	30	🖌 A	vanza
SA0994 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid	for 2 years for application	ations mee	ting the	e following criteria:
Both:				
1 The patient has a severe major depressive episode; and				
2 Either:				ata tha turaturanta ay failad
2.1 The patient must have had a trial of two different ar to respond to an adequate dose over an adequate patient of the second seco				
2.2 Both:	benoù or time (usuan)			<i>k3)</i> , 01
2.2.1 The patient is currently a hospital in-patient a	as a result of an acute	e depressiv	ve episo	ode: and
2.2.2 The patient must have had a trial of one other				
to an adequate dose over an adequate perio				
Renewal from any relevant practitioner. Approvals valid for 2 year	ars where the patient	has a high	ı risk of	relapse (prescriber deter-
mined).				
VENLAFAXINE - Special Authority see SA1061 on the next page	e – Retail pharmacy			
Tab 37.5 mg		28	🗸 A	rrow-Venlafaxine
				XR
Tab 75 mg		28	🗸 A	rrow-Venlafaxine
T 1 450	45.00			XR
Tab 150 mg	45.68	28	V A	rrow-Venlafaxine
0 07 5	10.04	00		XR favor VD
Cap 37.5 mg		28 28		fexor XR fexor XR
Cap 75 mg Cap 150 mg		28 28		fexor XR
oup too my		20	₩	

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

➡SA1061 Special Authority for Subsidy

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 The patient has 'treatment-resistant' depression; and

2 Either:

- 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or
- 2.2 Both:
 - 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
 - 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

Antiepilepsy Drugs

Agents for Control of Status Epilepticus

CLONAZEPAM		
Inj 1 mg per ml, 1 ml19.00	5	Rivotril
DIAZEPAM		
Inj 5 mg per ml, 2 ml – Subsidy by endorsement	5	🖌 Mayne
c) PSO must be endorsed "not for anaesthetic procedures".	F	✓ Stesolid
Rectal tubes 5 mg – Up to 5 tube available on a PSO25.05 Rectal tubes 10 mg – Up to 5 tube available on a PSO	5 5	✓ Stesolid
	5	• Stesoliu
PARALDEHYDE	_	4
* Inj 5 ml1,500.00	5	🗸 AFT
PHENYTOIN SODIUM		
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO69.24	5	Mayne
Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO	5	Mayne
Control of Epilepsy		
CARBAMAZEPINE		
* Tab 200 mg14.53	100	Tegretol
* Tab long-acting 200 mg16.98	100	 Tegretol CR
₭ Tab 400 mg	100	 Tegretol
₭ Tab long-acting 400 mg	100	 Tegretol CR
k‡ Oral liq 100 mg per 5 ml26.37	250 ml	 Tegretol
CLOBAZAM		
Tab 10 mg9.12	50	✓ Frisium
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
CLONAZEPAM		
Tab 500 µg6.26	100	Paxam
Tab 2 mg	100	Paxam
the second	10 ml OP	Rivotril

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
\$	Per	~	Manufacturer
	200	🖌 Z	arontin
	200 ml	🖌 Z	arontin
irmacy			
	100	✓ N	upentin
11.50	100	🖌 <u>N</u>	upentin
	100	✓ N	upentin
	\$ 	\$ Per 	\$ Per ✓

SA1071 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Neuropathic pain) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

GABAPENTIN (NEURONTIN) - Special Authority see SA0973 below - Retail pharmacy

Tab 600 mg	67.50	100	Neurontin
Cap 100 mg		100	Neurontin
Cap 300 mg - For gabapentin (neurontin) oral liquid formu-			
lation refer, page 172	39.76	100	Neurontin
Cap 400 mg		100	 Neurontin

➡SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

LACOSAMIDE - Special Authority see SA1125 on the next page - Retail pharmacy

Tab 50 mg2	5.04	14	Vimpat
Tab 100 mg5		14	 Vimpat
20	0.24	56	 Vimpat
Tab 150 mg7	5.10	14	 Vimpat
30	0.40	56	Vimpat
Tab 200 mg40	0.55	56	 Vimpat

	Cubaidu			Drandar	
	Subsidy			Brand or	
(Manut	acturer's Price)	Subsic	lised	Generic	
	\$	Per	~	Manufacturer	

SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

LAMOTRIGINE

Tab dispersible 2 mg6.74	30	Lamictal
Tab dispersible 5 mg9.64	30	Lamictal
15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg19.38	56	Logem
20.40		Arrow-Lamotrigine
		Mogine
29.09		Lamictal
Tab dispersible 50 mg	56	Logem
34.70		Arrow-Lamotrigine
		Mogine
47.89		Lamictal
Tab dispersible 100 mg56.91	56	Logem
59.90		Arrow-Lamotrigine
		Mogine
79.16		Lamictal
EVETIRACETAM		
Tab 250 mg24.03	60	Levetiracetam-Rex
Tab 500 mg - For levetiracetam oral liquid formulation refer,		
page 172	60	Levetiracetam-Rex
Tab 750 mg45.23	60	Levetiracetam-Rex
HENOBARBITONE		
For phenobarbitone oral liquid refer, page 175		
€ Tab 15 mg	500	PSM
← Tab 30 mg	500	✓ PSM
-	000	
HENYTOIN SODIUM	000	Dilandia Infatala
← Tab 50 mg	200	Dilantin Infatab
♦ Cap 30 mg	200	 Dilantin
← Cap 100 mg	200	✓ Dilantin
¢‡ Oral liq 30 mg per 5 ml19.16	500 ml	 Dilantin
RIMIDONE		
₭ Tab 250 mg	100	Apo-Primidone

(N	Subsidy /anufacturer's Price \$	e) S Per	Ful Subsidise	
	φ	rei		Manulacturer
SODIUM VALPROATE				
* Tab 100 mg	13.65	100		Epilim Crushable
* Tab 200 mg EC	27.44	100	~	Epilim
* Tab 500 mg EC	52.24	100	~	Epilim
*‡ Oral liq 200 mg per 5 ml	20.48	300 ml	~	Epilim S/F Liquid
			~	Epilim Syrup
* Inj 100 mg per ml, 4 ml	41.50	1	~	Epilim IV
TOPIRAMATE				
▲ Tab 25 mg	11.07	60	~	Arrow-Topiramate
	26.04	00		Topamax
▲ Tab 50 mg		60		Arrow-Topiramate
	44.26	00		Topamax
▲ Tab 100 mg		60		Arrow-Topiramate
	75.25	00		Topamax
▲ Tab 200 mg		60		Arrow-Topiramate
Tab 200 mg	129.85	00		Topamax
Sprinkle cap 15 mg		60		Topamax
 Sprinkle cap 15 mg Sprinkle cap 25 mg 		60		Topamax
		00		торашах
VIGABATRIN – Special Authority see SA1072 below – Retail pharm				
▲ Tab 500 mg	119.30	100	~	Sabril

➡SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient has infantile spasms; or
- 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and
- 2 Either:
 - 2.1 Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

	0.1.11			
	Subsidy (Manufacturer's Price	e)	Fully Subsidised	Brand or Generic
	\$	Per		Manufacturer
Antimigraine Preparations				
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page	ge 97			
Acute Migraine Treatment	-			
-				
ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg		100	√ 0	Cafergot
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg	6.77	60	✔ P	aramax
RIZATRIPTAN BENZOATE				
Wafer 10 mg	25.32	3	V N	laxalt Melt
SUMATRIPTAN				
Tab 50 mg		4		rrow-Sumatriptan
T 1 (44	38.83	100		rrow-Sumatriptan
Tab 100 mg		2		rrow-Sumatriptan
Ini 10 mg nor ml. 0.5 ml. Maximum of 10 ini nor procerintian	77.66	100		Arrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml – Maximum of 10 inj per prescription		2 OP	<u>v</u> <u>P</u>	Arrow-Sumatriptan
Prophylaxis of Migraine				
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYS	STEM, page 50			
CLONIDINE HYDROCHLORIDE				
* Tab 25 μg		100	✓ <u>□</u>	<u>Dixarit</u>
PIZOTIFEN				
* Tab 500 μg	21.10	100	✓ <u>s</u>	andomigran_
Antinausea and Vertigo Agents				
For Antispasmodics refer to ALIMENTARY TRACT, page 28				
APREPITANT - Special Authority see SA0987 below - Retail pha				
Cap 2 × 80 mg and 1 × 125 mg		3 OP	V E	mend Tri-Pack
► SA0987 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid f			atient is und	lergoing highly emetogeni
chemotherapy and/or anthracycline-based chemotherapy for the tr Renewal from any relevant practitioner. Approvals valid for 12 mont	0		lorgoing hig	uhly amatagania ahamatha
apy and/or anthracycline-based chemotherapy for the treatment of			lergoing nig	iniy emetogenic chemotre
BETAHISTINE DIHYDROCHLORIDE	manghanoy.			
* Tab 16 mg	9.26	84	• V	/ergo 16
-		04	• •	eigo io
CYCLIZINE HYDROCHLORIDE Tab 50 mg	1 50	10	• / N	lausicalm
-	1.59	10		ausicaliti
	14.05	-		lavala alm
Inj 50 mg per ml, 1 ml	14.95	5	V N	lausicalm
DOMPERIDONE				
* Tab 10 mg – For domperidone oral liquid formulation refer,		400	4 -	
page 172	7.99	100		lotilium
HYOSCINE (SCOPOLAMINE) - Special Authority see SA0939 or				
Patch 1.5 mg	11.95	2	🗸 S	copoderm TTS

	Subsidy (Manufacturer's Price \$) Su Per	Fully bsidised	Brand or Generic Manufacturer
►SA0939 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals val	id for 1 year for applica	ations mee	eting the	following criteria:
All of the following:				
1 Control of intractable nausea, vomiting, or inability to swa			nalignanc	y or chronic disease; and
 Patient cannot tolerate or does not adequately respond t The applicant must specify the underlying malignancy or 		ents; and		
Renewal from any relevant practitioner. Approvals valid for 1		ment rem	ains ann	opriate and the patient is
benefiting from treatment.	year where the treat			ophate and the patient is
HYOSCINE HYDROBROMIDE				
* Inj 400 μg per ml, 1 ml	6.66	5	🗸 M	avne
METOCLOPRAMIDE HYDROCHLORIDE		-		.,
* Tab 10 mg	3 95	100	🗸 M	etamide
 * Inj 5 mg per ml, 2 ml – Up to 5 inj available on a PSO 	4.50	100	P	
ONDANSETRON			•	
Tab 4 mg	5 10	30	• / D	r Reddv's
1ab + 11g		00		Ondansetron
Tab disp 4 mg	1.70	10		r Reddy's
1 3				Ondansetron
Tab 8 mg	1.70	10		r Reddy's
				Ondansetron
Tab disp 8 mg	2.00	10		r Reddy's
				Ondansetron
PROCHLORPERAZINE	F 07	50		
* Tab 3 mg buccal	5.97 (15.00)	50	B	uccastem
* Tab 5 mg – Up to 30 tab available on a PSO		500	-	ntinaus
* Inj 12.5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10		temetil
* Suppos 25 mg		5	V S	temetil
PROMETHAZINE THEOCLATE				
* Tab 25 mg		10		
· · · · · · · · · · · · · · · · · · ·	(6.24)		A	vomine
TROPISETRON	· · /			
a) Maximum of 6 cap per prescription				
b) Maximum of 3 cap per dispensing				
c) Not more than one prescription per month.				
Cap 5 mg	77.41	5	🖌 N	avoban

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

Tab 100 mg Tab 200 mg Tab 400 mg Oral liq 100 mg per ml	97.03 185.44	30 60 60 60 ml	 ✓ Solian ✓ Solian ✓ Solian ✓ Solian
ARIPIPRAZOLE – Special Authority see SA0920 below – Rei Tab 10 mg	ail pharmacy	30	✓ Abilify
Tab 15 mg Tab 20 mg Tab 30 mg	175.28 213.42	30 30 30	 Abilify Abilify Abilify Abilify

➡SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Patient is suffering from schizophrenia or related psychoses; and

- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

CHLORPROMAZINE HYDROCHLORIDE

Tab 10 mg - Up to 30 tab available on a PSO	100 100 100 10	 ✓ Largactil ✓ Largactil ✓ Largactil ✓ Largactil
CLOZAPINE – Hospital pharmacy [HP4]		
Tab 25 mg13.37	50	Clozaril
26.74	100	Clozaril
6.69	50	Clopine
13.37	100	Clopine
Tab 50 mg8.67	50	Clopine
17.33	100	Clopine
Tab 100 mg34.65	50	Clozaril
69.30	100	Clozaril
17.33	50	Clopine
34.65	100	Clopine
Tab 200 mg34.65	50	Clopine
69.30	100	Clopine
Suspension 50 mg per ml17.33	100 ml	 Clopine

	Subsidy (Manufacturaria D	riaa) 0	Fully	Brand or
	(Manufacturer's P \$	rice) Su Per	bsidised ✓	Generic Manufacturer
HALOPERIDOL				
Tab 500 µg – Up to 30 tab available on a PSO	5.42	100	🗸 S	erenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100		erenace
Tab 5 mg – Up to 30 tab available on a PSO		100		erenace
Oral lig 2 mg per ml - Up to 200 ml available on a PSO		100 ml		erenace
Inj 5 mg per ml, 1 ml - Up to 5 inj available on a PSO		10	_	erenace
EVOMEPROMAZINE				
	16.00	100		lozinan
Tab 25 mg		100		lozinan
Tab 100 mg		100		
Inj 25 mg per ml, 1 ml		10		lozinan
ITHIUM CARBONATE				
Tab 250 mg		500	🖌 L	ithicarb
Tab 400 mg	13.50	100	🖌 🖌 L	ithicarb
Tab long-acting 400 mg		100	🖌 P	riadel
Cap 250 mg	9.42	100	V D	ouglas
DLANZAPINE				
	2.00	28		r Reddy's
Tab 2.5 mg	2.00	20	v D	
				Olanzapine
	(= (==)			lanzine
	(51.07)			yprexa
Tab 5 mg	3.85	28	V D	r Reddy's
				Olanzapine
			V 0	lanzine
	(101.21)		Z	yprexa
Tab 10 mg	6.35	28	V D	r Reddy's
				Olanzapine
			V 0	lanzine
	(204.49)		Z	yprexa
ERICYAZINE	(<i>'</i>			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
Tab 2.5 mg	10.40	100	• A N	leulactil
Tab 10 mg		100		leulactil
UETIAPINE				
Tab 25 mg	7.00	60	V D	r Reddy's
				Quetiapine
			🗸 S	eroquel
	16.78	90	V 0	uetapel
Tab 100 mg		60	V D	r Reddy's
0				Quetiapine
			V S	eroquel
	32.59	90		luetapel
Tab 200 mg		60		r Reddy's
145 L00 IIIg		00	÷ 0	Quetiapine
				eroquel
	EC 70	00		
Tob 200 mg	56.70	90 60		luetapel
Tab 300 mg	40.00	00	V D	Pr Reddy's
			4 -	Quetiapine
	0- 10			eroquel
	95.40	90	V Q	luetapel

	Subsidy (Manufacturer's Price	e) S	Fully	Brand or Generic
	(Manulaciale) 31 110 \$	Per	V	Manufacturer
RISPERIDONE				
Tab 0.5 mg	3.51	60		po-Risperidone
				r Reddy's
				Risperidone
	5.00		✓ R	
Tab 1 ma	5.20	20 60		isperdal po-Risperidone
Tab 1 mg		00		r Reddy's
				Risperidone
			🖌 R	•
	30.77			isperdal
Tab 2 mg		60		po-Risperidone
5				r Reddy's
				Risperidone
			🖌 R	idal
	61.53			isperdal
Tab 3 mg	15.00	60		po-Risperidone
				r Reddy's
				Risperidone
	00.00		✓ R	
Tab 4 ma	92.32	60		isperdal Po Bioporidopo
Tab 4 mg	20.00	60		po-Risperidone r Reddy's
				Risperidone
			🖌 R	•
	123.05			isperdal
Oral liq 1 mg per ml		30 ml		po-Risperidone
				isperon
	45.92		🖌 R	isperdal
RIFLUOPERAZINE HYDROCHLORIDE				
Tab 1 mg	9.83	100	🖌 Si	telazine
Tab 2 mg	14.64	100	🖌 Si	telazine
Tab 5 mg	16.66	100	🖌 Si	telazine
IPRASIDONE – Subsidy by endorsement				
Ziprasidone is subsidised for patients suffering from schizop	ohrenia or related p	sychoses	after a tr	ial of an effective dose
risperidone or quetiapine that has been discontinued, or is in		g discontii	nued, bec	ause of unacceptable sid
effects or inadequate response, and the prescription is endor			4 -	
Cap 20 mg		60	✓ Ze	
Cap 40 mg		60		eldox
Cap 60 mg		60 60	✓ Ze	
Cap 80 mg		00	V 20	eluux
UCLOPENTHIXOL HYDROCHLORIDE				
Tab 10 mg		100	V C	lopixol
Depot Injections				
LUPENTHIXOL DECANOATE				
Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	🖌 Fl	uanxol
Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO		5	🖌 Fl	uanxol

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidise	d Generic
FLUPHENAZINE DECANOATE				
Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO	17.60	5	~	Modecate
Inj 25 mg per ml, 1 ml - Up to 5 inj available on a PSO		5	~	Modecate
Inj 100 mg per ml, 1 ml - Up to 5 inj available on a PSO	154.50	5	~	Modecate
HALOPERIDOL DECANOATE				
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO		5	~	Haldol
Inj 100 mg per ml, 1 ml - Up to 5 inj available on a PSO	55.90	5	~	Haldol Concentrate
OLANZAPINE PAMOATE MONOHYDRATE - Special Authority se	e SA1146 below – F	Retail	pharmacy	
Inj 210 mg		1	 V 	Zyprexa Relprevv
Inj 300 mg	460.00	1	~	Zyprexa Relprevv
Inj 405 mg	560.00	1	~	Zyprexa Relprevv

SA1146 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia; and
- 2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had less than 12 months' treatment with olanzapine depot injection; and
 - 1.2 There is no clinical reason to discontinue treatment; or

2 The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of olanzapine depot injection.

Note: The patient should be monitored for post-injection syndrome for at least three hours after each injection.

PIPOTHIAZINE PALMITATE

Inj 50 mg per ml, 1 ml $-$ Up to 5 inj available on a PSO Inj 50 mg per ml, 2 ml $-$ Up to 5 inj available on a PSO		PiportilPiportil
RISPERIDONE - Special Authority see SA0926 below - Re	1 2	
Inj 25 mg per 2 ml		Risperdal Consta
Inj 37.5 mg per 2 ml		Risperdal Consta
Inj 50 mg per 2 ml		 Risperdal Consta

➡SA0926 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had less than 12 months treatment with risperidone depot injection; and
- 1.2 There is no clinical reason to discontinue treatment; or
- 2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ZUCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO	19.80	5	✔ C	lopixol
Orodispersible Antipsychotics				
OLANZAPINE Orodispersible tab 5 mg	6.36	28		r Reddy's Olanzapine
Orodispersible tab 10 mg	8.76	28	V D	Danzine-D Ir Reddy's Olanzapine
Wafer 5 mg		28		Dlanzine-D
Wafer 10 mg	(102.19) 8.76 (204.37)	28		yprexa Zydis yprexa Zydis
RISPERIDONE - Special Authority see SA0927 below - Ret	tail pharmacy			
Orally-disintegrating tablets 0.5 mg Orally-disintegrating tablets 1 mg		28 28		isperdal Quicklet
Orally-disintegrating tablets 2 mg		28	🖌 R	lisperdal Quicklet

➡SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

Both:

- 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.
- Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

Anxiolytics

ALPRAZOLAM		
Таb 250 µg3.15	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 500 μg4.10	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 1 mg7.25	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
BUSPIRONE HYDROCHLORIDE - Special Authority see SA0863 on the next page -	- Retail ph	armacy
Tab 5 mg	100	Pacific Buspirone
Tab 10 mg17.00	100	 Pacific Buspirone

(Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
SA0863 Special Authority for Subsidy				
Initial application from any relevant practitioner. Approvals valid fo	r 2 years for applica	tions r	neeting the	e following criteria:
Both:				
 For use only as an anxiolytic; and Other agents are contraindicated or have failed. 				
Renewal from any relevant practitioner. Approvals valid for 2 year benefiting from treatment.	rs where the treatm	ent re	mains app	propriate and the patient is
DIAZEPAM				
Tab 2 mg		500	🗸 A	rrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid p	preparations.			
Tab 5 mg		500	🗸 A	rrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid p	preparations.			
LORAZEPAM				
Tab 1 mg		250	✓ <u>A</u>	tivan
‡ Safety cap for extemporaneously compounded oral liquid p				
Tab 2.5 mg		100	V <u>A</u>	<u>ttivan</u>
‡ Safety cap for extemporaneously compounded oral liquid p over a state of the s	preparations.			
OXAZEPAM				_
Tab 10 mg		100	<u>v</u> <u>c</u>)x-Pam
‡ Safety cap for extemporaneously compounded oral liquid p Tob 15 mg		100) v Dom
Tab 15 mg ‡ Safety cap for extemporaneously compounded oral liquid p		100	<u>v</u> <u>c</u>	<u>)x-Pam</u>
Multiple Sclerosis Treatments				

➡SA1062 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
MATER AND A STREET	

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
 - a) EDSS score 2.5 5.5 with 2+ relapses:
 - experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
 - b) EDSS score 2.0 with 3+ relapses:
 - experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- 4) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);
 - c) last at least one week;
 - d) follow a period of stability of at least one month;
 - e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
 - f) be distinguishable from the effects of general fatigue; and
 - g) not be associated with a fever (T>37.5 $^{\circ}$ C); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as any of:
 - a) an increase of 2 EDSS points where starting EDSS was 2.0; or
 - b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or
 - c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - d) an increase in EDSS score to 6.0 or more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) pregnancy and/or lactation; or
- within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or

Subsidy (Manufacture's I	Price) Sub	Fully sidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1062 on page 132 Inj 20 mg prefilled syringe1,089.25	5 28	✓ Copaxone
INTERFERON BETA-1-ALPHA – Special Authority see SA1062 on page 132	2	
Inj 6 million iu prefilled syringe1,425.10		✓ Avonex
Inj 6 million iu per vial1,425.10) 4	Avonex
INTERFERON BETA-1-BETA – Special Authority see SA1062 on page 132		
Inj 8 million iu per 1 ml1,322.89	9 15	 Betaferon
Sedatives and Hypnotics		
LORMETAZEPAM		
Tab 1 mg	30	
(23.50	· /	Noctamid
‡ Safety cap for extemporaneously compounded oral liquid preparation	ns.	
MIDAZOLAM		
Tab 7.5 mg10.38	3 100	
(25.00	0)	Hypnovel
‡ Safety cap for extemporaneously compounded oral liquid preparation		
Inj 1 mg per ml, 5 ml10.75		 Hypnovel
(14.73		Pfizer
Inj 5 mg per ml, 3 ml		 Hypnovel Pfizer
(19.64) (Hypnovel Tab 7.5 mg to be delisted 1 March 2012)	+)	Flizer
NITRAZEPAM	100	
Tab 5 mg		Nitrados
(4.98) \$ Safety cap for extemporaneously compounded oral liquid preparation	,	Millados
	13.	
TEMAZEPAM Tab 10 mg1.27	25	✓ Normison
\$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$		
TRIAZOLAM	10.	
Tab 125 µg) 100	
тар т25 µg		Hypam
4 Safety cap for extemporaneously compounded oral liquid preparation		Пураш
Tab 250 µg4.10		
(8.70) (8.70)		Hypam
‡ Safety cap for extemporaneously compounded oral liquid preparation	,	
ZOPICLONE		
Tab 7.5 mg	500	✓ <u>Apo-Zopiclone</u>

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Stimulants/ADHD Treatments				
Stimulants/ADHD treatments				
ATOMOXETINE – Special Authority see SA0951 below – Retail pl	harmacy			
Cap 10 mg	107.03	28	V S	trattera
Cap 18 mg		28	🗸 S	trattera
Cap 25 mg		28	🗸 S	trattera
Cap 40 mg		28	🗸 S	trattera
Cap 60 mg		28	🗸 S	trattera
Cap 80 mg		28	V S	trattera
Cap 100 mg		28	🗸 S	trattera

➡SA0951 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:
 - 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
 - 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
 - 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexampletamine sulphate tablets.

DEXAMPHETAMINE SULPHATE - Special Authority see SA1149 below - Retail pharmacy

Only on a controlled drug form			
Tab 5 mg	16.50	100	🖌 PSM

➡SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and

Subsidy	r Fully	Brand or
(Manufacturer	s Price) Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE – Special Authority see SA1150 below – Retail pharmacy Only on a controlled drug form

Only on a controlled drug form			
Tab immediate-release 5 mg		30	Rubifen
Tab immediate-release 10 mg		30	Ritalin
-			Rubifen
Tab immediate-release 20 mg		30	Rubifen
Tab sustained-release 20 mg		30	Rubifen SR
0	50.00	100	Ritalin SR

➡SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and

2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

1 Tho

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Subsidy	Fully	Brand or
Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE – Special Authority see SA1151 below – Retail pharmacy

only on a controlled drug form	1		
Tab extended-release 18 mg		30	Concerta
		30	Concerta
Tab extended-release 36 mg		30	Concerta
		30	Concerta
		30	Ritalin LA

➡SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustainedrelease) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

➡SA1126 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:

continued...

Modavigil

	Subsidy (Manufacturer's Pr \$	ice) Sı Per	Fully ubsidised	Brand or Generic Manufacturer
continued				
2.1 The patient has a multiple sleep latency test		cy of less th	an or eq	ual to 10 minutes and 2 of
more sleep onset rapid eye movement period 2.2 The patient has at least one of: cataplexy, sle		oic hallucina	ations: an	d
3 Either:	sop paralysis of hypnage	gio nandonio	allonio, all	ŭ
3.1 An effective dose of a subsidised formulation	n of methylphenidate or	dexampheta	mine has	been trialled and discon-
tinued because of intolerable side effects; or 3.2 Methylphenidate and dexamphetamine are control of the state of the sta	ontraindicated			
Renewal only from a neurologist or respiratory specialist.		onths where	the treat	ment remains appropriate
and the patient is benefiting from treatment.				
Treatments for Dementia				
DONEPEZIL HYDROCHLORIDE				
* Tab 5 mg		90	✓ <u>D</u>	onepezil-Rex
* Tab 10 mg	14.06	90	✓ <u>D</u>	onepezil-Rex
Treatments for Opioid Overdose				
NALOXONE HYDROCHLORIDE				
a) Up to 5 inj available on a PSO				
b) Only on a PSO * Inj 400 µg per ml, 1 ml	33.00	5	🖌 M	avne
Treatments for Substance Dependence				.,
BUPROPION HYDROCHLORIDE Tab modified-release 150 mg	65.00	30	VZ	vhan
DISULFIRAM		00	, <u> </u>	,
Tab 200 mg		100	🖌 A	ntabuse
NALTREXONE HYDROCHLORIDE – Special Authority se	e SA0909 below – Retai	I pharmacy		
Tab 50 mg		30	🖌 <u>N</u>	altraccord

Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and
- 2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard.

Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

The patient may not have had more than 1 prior approval in the last 12 months.

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	d Generic
NICOTINE				
Nicotine will not be funded Close Control in amounts less than	4 weeks of treatme	nt.		
Patch 7 mg – Up to 28 patch available on a PSO		28	~	Habitrol
Patch 14 mg - Up to 28 patch available on a PSO		28	~	Habitrol
Patch 21 mg - Up to 28 patch available on a PSO	19.14	28	~	Habitrol
Lozenge 1 mg - Up to 216 loz available on a PSO	19.94	216	~	Habitrol
Lozenge 2 mg – Up to 216 loz available on a PSO	24.27	216	~	Habitrol
Gum 2 mg (Classic) - Up to 384 piece available on a PSO		384	~	Habitrol
Gum 2 mg (Fruit) – Up to 384 piece available on a PSO		384	~	Habitrol
Gum 2 mg (Mint) – Up to 384 piece available on a PSO		384	~	Habitrol
Gum 4 mg (Classic) – Up to 384 piece available on a PSO	42.04	384	~	Habitrol
Gum 4 mg (Fruit) – Up to 384 piece available on a PSO	42.04	384	~	Habitrol
Gum 4 mg (Mint) – Up to 384 piece available on a PSO		384	~	Habitrol
VARENICLINE TARTRATE - Special Authority see SA1161 below		otmo	~+	
a) Varenicline will not be funded Close Control in amounts less				
b) A maximum of 3 months' varenicline will be subsidised on e Tab 1 ma	•	iy app 28		Champiv
Tab 1 mg	07.74 135.48	∠8 56		Champix Champix
Tab 0.5 mg $ imes$ 11 and 1 mg $ imes$ 14		50 25 OP		Champix
■SA1161 Special Authority for Subsidy		20 01	•	onampix

SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:
 - 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
 - 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient may not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's		sidised (Brand or Generic
	\$	Per		Manufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist				
Tab 2 mg	59.50	100	🖌 Myle	eran
CARBOPLATIN – PCT only – Specialist				
Inj 10 mg per ml, 5 ml		1		boplatin Ebewe
Inj 10 mg per ml, 15 ml		1		boplatin Ebewe
Inj 10 mg per ml, 45 ml		1		boplatin Ebewe
Inj 10 mg per ml, 100 ml		1		boplatin Ebewe
Inj 1 mg for ECP	0.15	1 mg	🖌 Bax	ter
ARMUSTINE – PCT only – Specialist				
Inj 100 mg	204.13	1	🖌 BiC	NU
Inj 100 mg for ECP		100 mg OP	🖌 Bax	ter
HLORAMBUCIL – PCT – Retail pharmacy-Specialist		0		
Tab 2 mg	22.35	25		keran FC
5		20	• Leu	Kerdii i C
ISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml	15.00	1		olatin Ebewe
	19.00		🖌 May	
Inj 1 mg per ml, 100 ml	21.00	1		platin Ebewe
	38.00		🖌 May	
Inj 1 mg for ECP	0.27	1 mg	🖌 Bax	ter
YCLOPHOSPHAMIDE				
Tab 50 mg - PCT - Retail pharmacy-Specialist		50	🖌 Cvc	loblastin
Inj 1 g – PCT – Retail pharmacy-Specialist		1	✓ End	
, , , , , , , , , , , , , , , , , , ,	127.80	6	✔ Cyte	oxan
Inj 2 g – PCT only – Specialist		1	End	
Inj 1 mg for ECP – PCT only – Specialist		1 mg	V Bax	
, , , ,		5		
OSFAMIDE – PCT only – Specialist	06.00	1	🖌 Hole	
lnj 1 g		1		
Inj 2 g		-		
Inj 1 mg for ECP	0.10	1 mg	🖌 Bax	ler
OMUSTINE – PCT only – Specialist				
Cap 10 mg	132.59	20	🖌 Cee	
Cap 40 mg		20	🖌 Cee	NU
ELPHALAN				
Tab 2 mg – PCT – Retail pharmacy-Specialist		25	🖌 Alke	eran
Inj 50 mg – PCT only – Specialist		1	✔ Alke	
, , , ,				
XALIPLATIN – PCT only – Specialist – Special Authority s				liplatin Ebourg
Inj 50 mg		1		liplatin Ebewe
1.100	200.00	4	Elo>	
Inj 100 mg		1		liplatin Ebewe
	400.00		Elo>	
Inj 1 mg for ECP	1.20	1 mg	🖌 Bax	ter

	Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic
	\$	Per 🖌	Manufacturer
The CANCOL Creation Authority for Subaidy			

SA0900 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has metastatic colorectal cancer; and
- 1.2 To be used for first or second line use as part of a combination chemotherapy regimen; or

2 Both:

- 2.1 The patient has stage III (Duke's C) colorectal* cancer; and
- 2.2 Adjuvant oxaliplatin to be given in combination with a fluoropyrimidine (fluorouracil or capecitabine).

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 The patient requires continued therapy; or

2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with * are Unapproved Indications, oxaliplatin is indicated for adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of the primary tumour.

THIOTEPA – PCT only – Specialist Inj 15 mgCBS	1	✔ Bedford S29
Antimetabolites		
CALCIUM FOLINATE		
Tab 15 mg – PCT – Retail pharmacy-Specialist	10	 <u>DBL Leucovorin</u> Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist17.10	5	Mayne
Inj 50 mg – PCT – Retail pharmacy-Specialist24.50	5	 Calcium Folinate Ebewe
Inj 100 mg – PCT only – Specialist9.75	1	 Calcium Folinate Ebewe
Inj 300 mg - PCT only - Specialist	1	 Calcium Folinate Ebewe
Inj 1 g – PCT only – Specialist90.00	1	 Calcium Folinate Ebewe
Inj 1 mg for ECP – PCT only – Specialist0.10	1 mg	✓ Baxter
CAPECITABINE - Retail pharmacy-Specialist - Special Authority see SA1049 b	elow	
Tab 150 mg115.00	60	🖌 Xeloda
Tab 500 mg705.00	120	✓ Xeloda

➡SA1049 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has advanced gastrointestinal malignancy; or
- 2 The patient has metastatic breast cancer; or
- 3 The patient has stage III (Duke's stage C) colorectal*# cancer and undergone surgery; or
- 4 Both:
 - 4.1 The patient has stage II (Dukes' stage B) colorectal* cancer and has undergone surgery; and
 - 4.2 Any of the following:
 - 4.2.1 The patient has stage T4 disease; or

	Subsidy (Manufacturer's I \$	Price) Su Per	Fully ubsidised	Brand or Generic Manufacturer
continued				
4.2.2 The patient has vascular invasion; or4.2.3 Fewer than 10 lymph nodes were examined a	t reception: or			
5 All of the following:				
5.1 The patient has locally advanced (clinically or radiolo	nically staged .	T3/T4· N0 1 2) rectal c	ancer: and
5.2 Surgery is planned; and	glouny staged	10/14:10,1,2) 100tai 0	
5.3 Capecitabine to be given prior to surgery (neoadjuva	int): and			
5.4 Capecitabine to be given at a maximum dose of 82		daily in comb	pination v	vith radiation therapy for a
maximum of 6 weeks; or	J	, ,		
6 Both:				
6.1 The patient has poor venous access or needle phobi	ia*; and			
6.2 The patient requires a substitute for single agent fluo	propyrimidine*.			
Note: Indications marked with * are Unapproved Indications, # cap				
Renewal only from a relevant specialist or medical practitioner on	the recommend	dation of a rel	evant spe	ecialist. Approvals valid fo
12 months for applications meeting the following criteria:				
Either:				
1 The patient requires continued therapy; or				
2 The tumour has relapsed and requires re-treatment.				
CLADRIBINE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml		1		itak S29
Inj 1 mg per ml, 10 ml		7		eustatin
Inj 10 mg for ECP		10 mg OP	V B	axter
CYTARABINE				
Inj 100 mg – PCT – Retail pharmacy-Specialist	76.00	5	🖌 P	
	80.00			layne
Inj 500 mg – PCT – Retail pharmacy-Specialist		1	✓ P	
	95.36	5		layne
Inj 1 g – PCT – Retail pharmacy-Specialist		1	✓ P	
Ini 0 a DCT Detail nhormony Chasialist	42.65	4	V P	layne fizer
Inj 2 g – PCT – Retail pharmacy-Specialist	31.00 34.47	1		layne
Inj 1 mg for ECP – PCT only – Specialist		10 mg		axter
Inj 100 mg intrathecal syringe for ECP – PCT only – Specialist		100 mg OP		axter
		Too nig Oi	• 0	axto
FLUDARABINE PHOSPHATE – PCT only – Specialist	007.00	00		ludana Onal
Tab 10 mg		20 5		ludara Oral Iudarabine Ebewe
Inj 50 mg	1.430.00	Э		ludarabine Ebewe
Inj 50 mg for ECP		50 mg OP		axter
		JU III UI	• 0	axici
FLUOROURACIL SODIUM		_		
Inj 50 mg per ml, 10 ml – PCT only – Specialist		5		luorouracil Ebewe
Inj 50 mg per ml, 20 ml – PCT only – Specialist		1		luorouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist Inj 50 mg per ml, 50 ml – PCT only – Specialist		1		layne Iuorouracil Ebewe
Inj 50 mg per ml, 100 ml – PCT only – Specialist		1		luorouracii Ebewe
Inj 1 mg for ECP – PCT only – Specialist				axter
		100 mg	¥ D	avia

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
GEMCITABINE HYDROCHLORIDE - PCT only - Specialist - Sp	ecial Authority see S	SA108	7 below	
Inj 1 g		1	🖌 G	emcitabine Ebewe
	349.20		🖌 G	iemzar
Inj 200 mg		1	🖌 G	emcitabine Ebewe
	78.00		🖌 G	iemzar
Inj 1 mg for ECP	0.07	l mg	🖌 В	axter

SA1087 Special Authority for Subsidy

Initial application — (Hodgkin's Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has Hodgkin's Disease*; and
- 2 Any of the following:
 - 2.1 Disease has failed to respond to second line salvage chemotherapy treatment; or
 - 2.2 Disease has relapsed following transplant; or
 - 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and
- 3 Gemcitabine to be given for a maximum of 6 treatment cycles.

Note: Indications marked with a * are Unapproved Indications.

Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has T-cell Lymphoma*; and
- 2 Gemcitabine to be given for a maximum of 6 treatment cycles.

Note: Indications marked with a * are Unapproved Indications.

Initial application — (Cholangiocarcinoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has locally advanced or metastatic, cholangiocarcinoma*; and
- 2 Gemcitabine to be given for a maximum of 8 treatment cycles.

Notes: Cholangiocarcinoma encompasses epithelial tumours of the hepatobiliary tree, including tumours of bile ducts, ampulla of vater and gallbladder.

Indications marked with a * are Unapproved Indications.

Initial application — (Pancreatic Cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has macroscopically resected (R0) pancreatic carcinoma*; and
- 1.2 Adjuvant gemcitabine to be administered for a maximum of 6 cycles; or

2 Both:

- 2.1 The patient has advanced pancreatic carcinoma; and
- 2.2 The patient is gemcitabine treatment naive.

Note: Indications marked with a * are Unapproved Indications.

Renewal — (Pancreatic Cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has received gemcitabine for advanced pancreatic carcinoma; and
- 2 The patient has not received gemcitabine for adjuvant treatment pancreatic carcinoma; and
- 3 The patient requires continued therapy.

	Subsidy		Fully	Brand or
(M	lanufacturer's Price)	Sub	sidised	Generic
	\$	Per	~	Manufacturer

continued...

Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Any of the following:

- 1 1 The patient has non small cell lung carcinoma (stage Illa, or above); or
- 2 The patient has advanced malignant mesothelioma; or
- 3 The patient has ovarian, fallopian tube* or primary peritoneal carcinoma*; or
- 4 The patient has advanced transitional cell carcinoma of the urothelial tract (locally advanced or metastatic).
- Note: Indications marked with a * are Unapproved Indications.

Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- Either: 1 The patient requires continued therapy: or
 - 2 The tumour has relapsed and requires re-treatment.

IRINOTECAN _ PCT only _ Specialist _ Special Authority see SA0878 helow

		1 OT OTIN	opeoialist	Opeoial A	autonity see OF			
Inj 2	20 mg per	ml, 2 ml				41.00	1	Camptosar
								 Irinotecan-Rex
Inj 2	20 mg per	ml, 5 ml				100.00	1	Camptosar
	•							Irinotecan-Rex
lnj 1	I mg for E	СР				1.04	1 mg	Baxter

➡SA0878 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic colorectal cancer; and
- 2 Either:
 - 2.1 To be used for first or second line use as part of a combination chemotherapy regimen; or
 - 2.2 As single agent chemotherapy in fluropyrimidine-relapsed disease.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

MERCAPTOPURINE – PCT – Retail pharmacy-Specialist

Tab 50 mg	25	Purinethol
METHOTREXATE		
* Tab 2.5 mg – PCT – Retail pharmacy-Specialist5.22	30	Methoblastin
* Tab 10 mg – PCT – Retail pharmacy-Specialist	50	Methoblastin
Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	🖌 Mayne
Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	Hospira
* Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist	1	Hospira
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist	1	Methotrexate Ebewe
Inj 25 mg per ml, 40 ml – PCT – Retail pharmacy-Specialist	1	🖌 DBL
		Methotrexate S29
* Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist125.00	1	Methotrexate Ebewe
* Inj 1 mg for ECP – PCT only – Specialist0.10	1 mg	Baxter
* Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist	5 mg OP	Baxter
THIOGUANINE – PCT – Retail pharmacy-Specialist		
Tab 40 mg	25	Lanvis

	Subsidy (Manufacturer's Price) \$	Sub Per	Fully osidised	Brand or Generic Manufacturer
Other Cytotoxic Agents				
AMSACRINE – PCT only – Specialist Inj 75 mg	CBS	6	🗸 A	msidine S29
ANAGRELIDE HYDROCHLORIDE – PCT only – Specialist – Cap 0.5 mg		SA0879 be 100	🖌 A	grylin S29 eva S29
► SA0879 Special Authority for Subsidy Initial application only from a relevant specialist or medical pra valid for 12 months for applications meeting the following criteria Both:		mendation	of a rele	evant specialist. Approvals
 The patient has primary thrombocythaemia; and Either: 				
2.1 is at high risk (previous thromboembolic disease,2.2 is intolerant or refractory to hydroxyurea or interfer	ron.		,.	
Renewal only from a relevant specialist or medical practitioner of 12 months where the treatment remains appropriate and the particular to a second the treatment with apparellide be initial	tient is benefiting from	treatment.		

Note: It is recommended that treatment with an grelide be initiated only on the recommendation of a haematologist.

BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu	ARSENIC TRIOXIDE – PCT only – Specialist Inj 10 mg	4,817.00	10	✓ AFT \$29
Sulfate Inj 1,000 iu for ECP BORTEZOMIB - PCT only – Specialist – Special Authority see SA1127 below Inj 1 mg		120.00	4	
BORTEZOMIB – PCT only – Specialist – Special Authority see SA1127 below Inj 1 mg	IIIj 15,000 lu	120.00	I	Sulfate
Inj 1 mg540.70 1 ✔ Velcade Inj 3.5 mg1,892.50 1 ✔ Velcade	Inj 1,000 iu for ECP	9.28	1,000 iu	Baxter
Inj 3.5 mg1,892.50 1 Velcade	BORTEZOMIB - PCT only - Specialist - Special Author	rity see SA1127 below		
···) · · · · · · · · · · · · · ·	Inj 1 mg		1	Velcade
Inj 1 mg for ECP 594.77 1 mg 🖌 Baxter	Inj 3.5 mg	1,892.50	1	Velcade
	Inj 1 mg for ECP		1 mg	Baxter

➡SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 The patient has treatment-naive symptomatic multiple myeloma; or
- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.
- Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

1 Either:

- 1.1 The patient has relapsed or refractory multiple myeloma; or
- 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 further treatment cycles.

Note: Indications marked with * are Unapproved Indications.

continued...

	Subs (Manufactur \$		d Generic	
--	---------------------------	--	-----------	--

continued...

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and

2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

a) a known therapeutic chemotherapy regimen and supportive treatments; or

b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses			
COLASPASE (L-ASPARAGINASE) – PCT only – Specialist			
Inj 10,000 iu	102.32	1	Leunase
Inj 10,000 iu for ECP	102.32	10,000 iu OP	Baxter
DACARBAZINE – PCT only – Specialist			
Inj 200 mg		1	Hospira
Inj 200 mg for ECP		200 mg OP	Baxter
DACTINOMYCIN (ACTINOMYCIN D) - PCT only - Specialist			
Inj 0.5 mg		1	 Cosmegen
Inj 0.5 mg for ECP		0.5 mg OP	✓ Baxter
DAUNORUBICIN – PCT only – Specialist		Ū	
Inj 2 mg per ml, 10 ml	118 72	1	✓ Pfizer
Inj 5 mg per ml, 4 ml		1	✓ Mayne
Inj 20 mg for ECP		20 mg OP	✓ Baxter
(Mayne Inj 5 mg per ml, 4 ml to be delisted 1 February 2012)		- 5 -	
DOCETAXEL – PCT only – Specialist			
Inj 20 mg	48.75	1	Docetaxel Ebewe
	460.00		✓ Taxotere
Inj 80 mg	195.00	1	Docetaxel Ebewe
, ,	1,650.00		Taxotere
Inj 1 mg for ECP	2.63	1 mg	Baxter
DOXORUBICIN – PCT only – Specialist			
Inj 10 mg	10.00	1	Doxorubicin Ebewe
Inj 50 mg	40.00	1	🖌 DBL
			Doxorubicin S29
			Doxorubicin Ebewe
Inj 100 mg	80.00	1	Doxorubicin Ebewe
Inj 200 mg	150.00	1	Doxorubicin Ebewe
Inj 1 mg for ECP	0.88	1 mg	Baxter
EPIRUBICIN – PCT only – Specialist			
Inj 2 mg per ml, 5 ml	25.00	1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml	87.50	1	 Epirubicin Ebewe
Inj 2 mg per ml, 50 ml	125.00	1	 Epirubicin Ebewe
Inj 2 mg per ml, 100 ml		1	Epirubicin Ebewe
Inj 1 mg for ECP	1.80	1 mg	Baxter

	Subsidy		Full	
	(Manufacturer's Price \$	e) Per	Subsidise	d Generic Manufacturer
	Ŧ		-	
FOPOSIDE	240 72	20		Vanaaid
Cap 50 mg – PCT – Retail pharmacy-Specialist				Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist		10 1		Vepesid
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist		10		Mayne
Ini 1 mg for ECD DCT only Specialist	612.20			Vepesid Baxter
Inj 1 mg for ECP – PCT only – Specialist	0.30	1 mg	•	Daxiei
TOPOSIDE PHOSPHATE – PCT only – Specialist				
Inj 100 mg (of etoposide base)		1		Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	~	Baxter
YDROXYUREA – PCT – Retail pharmacy-Specialist				
Cap 500 mg		100	~	Hydrea
ARUBICIN HYDROCHLORIDE – PCT only – Specialist				•
Cap 5 mg	115.00	1	~	Zavedos
Cap 10 mg		1		Zavedos
Inj 5 mg		1		Zavedos
Inj 10 mg		1		Zavedos
Inj 1 mg for ECP		1 mg	· · · ·	Baxter
, ,		i ing	•	Burter
ESNA – PCT only – Specialist	040.05			
Tab 400 mg		50		Uromitexan
Tab 600 mg		50	-	Uromitexan
Inj 100 mg per ml, 4 ml		15		Uromitexan
Inj 100 mg per ml, 10 ml		15		Uromitexan
Inj 1 mg for ECP	2.29	100 mg	V	Baxter
ITOMYCIN C – PCT only – Specialist				
Inj 5 mg	72.75	1	~	Arrow
Inj 1 mg for ECP	16.13	1 mg	~	Baxter
ITOZANTRONE – PCT only – Specialist				
Inj 2 mg per ml, 5 ml	110.00	1	~	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml		1		Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml		1		Onkotrone
Inj 1 mg for ECP		1 mg	· · · ·	Baxter
, .			-	
ACLITAXEL – PCT only – Specialist	127 50	5		Paclitaxel Ebewe
Inj 30 mg		э 1		Paclitaxel Actavis
Inj 100 mg		I	-	Paclitaxel Ebewe
lni 150 ma	137 50	1		Anzatax
Inj 150 mg		I	-	Paclitaxel Actavis
				Paclitaxel Ebewe
Ini 300 ma	275.00	1	-	Anzatax
Inj 300 mg		I		Paclitaxel Actavis
				Paclitaxel Ebewe
Inj 600 mg	550.00	1		Paclitaxel Ebewe
Inj 1 mg for ECP		1 mg		Baxter
		i iliy	•	DUALCI
ENTOSTATIN (DEOXYCOFORMYCIN) - PCT only - Specialist				
Inj 10 mg	CBS	1	~	Nipent S29
ROCARBAZINE HYDROCHLORIDE – PCT only – Specialist				
		50		Natulan S29

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	
TEMOZOLOMIDE - Special Authority see SA1063 below - Retai	l pharmacy			
Cap 5 mg		5	🖌 T(emodal
Cap 20 mg		5	🖌 T(emodal
Cap 100 mg	840.00	5	🖌 T(emodal
Cap 250 mg		5	🖌 T	emodal

➡SA1063 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 10 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Patient has newly diagnosed glioblastoma multiforme; or
 - 1.2 Patient has newly diagnosed anaplastic astrocytoma*; and
- 2 Temozolomide is to be (or has been) given concomitantly with radiotherapy; and
- 3 Following concomitant treatment temozolomide is to be used for a maximum of six cycles of 5 days treatment, at a maximum dose of 200 mg/m².

Notes: Indication marked with a * is an Unapproved Indication. Temozolomide is not subsidised for the treatment of relapsed glioblastoma multiforme. Reapplications will not be approved.

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE - PCT only - Specialist - Special Authority see SA1124 below

Cap 50 mg504.00	28	 Thalomid
Cap 100 mg1,008.00	28	Thalomid

SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 The notiont has mult

- 1 The patient has multiple myeloma; or
- 2 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication.

TRETINOIN

Cap 10 mg - PCT - Retail pharmacy-Specialist	100	Vesanoid
VINBLASTINE SULPHATE		
Inj 10 mg – PCT – Retail pharmacy-Specialist	1	Mayne
137.50	5	Mayne
Inj 1 mg for ECP – PCT only – Specialist	1 mg	Baxter
VINCRISTINE SULPHATE		
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	5	Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	5	Hospira
Inj 1 mg for ECP – PCT only – Specialist	1 mg	 Baxter
VINORELBINE - PCT only - Specialist - Special Authority see SA1013 on the	next page	
Inj 10 mg per ml, 1 ml24.00	1	Navelbine
42.00		Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml120.00	1	Navelbine
210.00		Vinorelbine Ebewe
Inj 1 mg for ECP2.71	1 mg	 Baxter

148

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	osidised	Generic	
\$	Per	~	Manufacturer	

SA1013 Special Authority for Subsidy

Initial application — (Hodgkin's Disease) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has Hodgkin's Disease*; and
- 2 Any of the following:
 - 2.1 Disease has failed to respond to second-line salvage chemotherapy treatment; or
 - 2.2 Disease has relapsed following transplant; or
 - 2.3 The patient is unsuitable for, or intolerant to, second-line salvage chemotherapy or high dose chemotherapy and transplant; and
- 3 Vinorelbine to be given for a maximum of 6 treatment cycles.

Initial application — (T-Cell Lymphoma) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has T-cell Lymphoma*; and
- 2 Vinorelbine to be given for a maximum of 6 treatment cycles.

Initial application — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Any of the following:

- 1 The patient has metastatic breast cancer; or
- 2 The patient has non-small cell lung cancer (stage IIIa, or above); or
- 3 All of the following:
 - 3.1 The patient has stage IB-IIIA non-small cell lung cancer; and
 - 3.2 Vinorelbine is to be given as adjuvant treatment in combination with cisplatin; and
 - 3.3 The patient has good performance status (WHO/ECOG grade 0-1).

Renewal — (Other indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither:

- 1 The patient requires continued therapy; or
- 2 The tumour has relapsed and requires re-treatment.

Note: Indications marked with a * are Unapproved Indications.

Protein-tyrosine Kinase Inhibitors

DASATINIB - Special Authority see SA0976 below

Tab 20 mg	60	Sprycel
Tab 50 mg6,214.20	60	Sprycel
Tab 70 mg7,692.58	60	Sprycel
Tab 100 mg6,214.20	30	Sprycel

➡SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website <u>http://www.pharmac.govt.nz</u>, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
Wellington	

Special Authority criteria for CML - access by application

a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^{9} /L, platelets > 100×10^{9} /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB HYDROCHLORIDE - Retail pharmacy-Specialist - Special Authority see SA1044 below

Tab 100 mg	 		30	 Tarceva
Tab 150 mg	 	3,950.00	30	 Tarceva

➡SA1044 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has advanced, unresectable, Non Small Cell Lung Cancer (NSCLC); and
- 2 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
- 3 Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Tab 100 mg		2,400.00	60	 Glivec
------------	--	----------	----	----------------------------

➡SA0643 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
Wellington	

Special Authority criteria for CML – access by application

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🗸	Manufacturer

continued...

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^9 /L, platelets > 100×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

Special Authority criteria for GIST - access by application

- a) Funded for patients:
 - 1) with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).
- SUNITINIB Special Authority see SA1162 below Retail pharmacy

Cap 12.5 mg2,315.38	28	Sutent
Cap 25 mg4,630.77	28	 Sutent
Cap 50 mg9,261.54	28	 Sutent

➡SA1162 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient has metastatic renal cell carcinoma; and
 - 2 Either:
 - 2.1 The patient is sunitinib treatment naive; or
 - 2.2 The patient received sunitinib prior to 1 November 2010 and disease has not progressed; and
 - 3 The patient has good performance status (WHO/ECOG grade 0-2); and
 - 4 The disease is of predominant clear cell histology; and
 - The patient has intermediate or poor prognosis defined as:
 - 5 Any of the following:

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
- 5.2 Haemoglobin level < lower limit of normal; or
- 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
- 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
- 5.5 Karnofsky performance score of \leq 70; or
- 5.6 \geq 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 No evidence of disease progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Notes: Sunitinib treatment should be stopped if disease progresses.

Poor prognosis patients are defined as having at least 3 of criteria 5.1-5.6. Intermediate prognosis patients are defined as having 1 or 2 of criteria 5.1-5.6

Endocrine Therapy			
For GnRH ANALOGUES - refer to HORMONE PREPARATIONS, Trophic H	lormones, pag	e 77	
BICALUTAMIDE - Special Authority see SA0941 below - Retail pharmacy			
Tab 50 mg10.	00 2	в 🖌	Bicalaccord
10.	71 3	0 🖌	Bicalox
(Bicalox Tab 50 mg to be delisted 1 February 2012)			
►SA0941 Special Authority for Subsidy			
Initial application from any medical practitioner. Approvals valid without	further renew	al unless no	tified where the patient has
advanced prostate cancer.			
FLUTAMIDE – Retail pharmacy-Specialist			
Tab 250 mg	00 10	0 🖌	Flutamin
MEGESTROL ACETATE – Retail pharmacy-Specialist			
Tab 160 mg	92 3	n 🗸	Apo-Megestrol
	02 0		Megace
			5
OCTREOTIDE (SOMATOSTATIN ANALOGUE) – Special Authority see SA			2
lnj 50 μg per ml, 1 ml25.			Hospira
43.			Sandostatin
lnj 100 μg per ml, 1 ml48.		-	Hospira
81. 175		• .	Sandostatin
Inj 500 μg per ml, 1 ml175. 399.		-	Hospira Sandostatin
			Sandostatin LAR
Inj LAR 10 mg prefilled syringe	50 I 75 I		Sandostatin LAR
Inj LAR 20 mg prefilled syringe2,358.	10 1	~	Sanuosialin LAR

➡SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and

Inj LAR 30 mg prefilled syringe2,951.25

2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and

continued...

Sandostatin LAR

1

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

3 Octreotide to be given at a maximum dose 1500 µg daily for up to 4 weeks.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or
 - 2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:

2.2.1 Patient has failed surgery; or

2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or

3 Both:

- 3.1 Insulinomas; and
- 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:

5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and

5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

TAMOXIFEN CITRATE

*	Tab 10 mg10	.80 100	Genox
	Tab 20 mg8	.75 100	Genox

	Subsidy (Manufacturer's Pric	e) Si	Fully Brand or ubsidised Generic
	\$	Per	 Manufacturer
Aromatase Inhibitors			
ANASTROZOLE Tab 1 mg	26.55	30	 ✓ Aremed ✓ Arimidex ✓ DP-Anastrozole
EXEMESTANE Tab 25 mg		30	✓ <u>Aromasin</u>
LETROZOLE Tab 2.5 mg		30	✓ Letara
Immunosuppressants			
Cytotoxic Immunosuppressants			
AZATHIOPRINE – Retail pharmacy-Specialist * Tab 50 mg – For azathioprine oral liquid formulation refe page 172 * Inj 50 mg		100 1	✓ <u>Imuprine</u> ✓ Imuran
MYCOPHENOLATE MOFETIL – Special Authority see SA1041		nacy	· <u></u>
Dispensing pharmacy should check which brand to dispens Tab 500 mg		if prescrib 50	ed generically. Ceptolate Cellcept Myaccord
Cap 250 mg	30.00 70.00 85.00	50 100	 Ceptolate Cellcept Myaccord
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement . Mycophenolate powder for oral liquid is subsidised only prescription is endorsed accordingly.		65 ml OP swallow	Cellcept tablets and capsules, and when the
SA1041 Special Authority for Subsidy Initial application only from a relevant specialist or medical pravalid without further renewal unless notified for applications medications.			n of a relevant specialist. Approvals
 Transplant recipient; or Both: Patients with diseases where 2.1 Steroids and azathioprine have been trialled and clinical response; and 2.2 Either: 	discontinued becaus	e of unac	ceptable side effects or inadequate
Patients with diseases where 2.2.1 Cyclophosphamide has been trialled and clinical response; or 2.2.2 Cyclophosphamide treatment is contraindid		e of unace	ceptable side effects or inadequate
Immune Modulators			
ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Speci Inj 50 mg per ml, 5 ml		5	🗸 ATGAM

	Subsidy (Manufacturer's Price) \$	Sı Per	Fully ubsidised	Brand or Generic Manufacturer
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU		1	√ 0i	ncoTICE
RITUXIMAB – PCT only – Specialist – Special Authority see SA Inj 100 mg per 10 ml vial Inj 500 mg per 50 ml vial Inj 1 mg for ECP	1,075.50 2,688.30	2 1 mg	•	abthera abthera axter

SA1152 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.
- Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Fither

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
- 2 The patient is rituximab treatment naive; and
- 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or
 - 3.2 Both:
 - 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
 - 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and

continued...

0.1.11			
Subsidy		Fully	Brand or
(Manufacturer's Price)	Subsid	lised	Generic
\$	Per	~	Manufacturer

continued...

- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

TRASTUZUMAB – PCT only – Specialist – Special Authority see SA1163 below

Inj 150 mg vial	 	1	 Herceptin
Inj 440 mg vial	 	1	 Herceptin
Inj 1 mg for ECP	 9.36	1 mg	 Baxter

➡SA1163 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or FISH+ (including FISH or other current technology); and
- 2 Trastuzumab to be discontinued at disease progression.

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and

continued...

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab.

Initial application — (early breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
 - 2.1.2 Trastuzumab to be discontinued at disease progression; or
 - 2.2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab.

Note: *For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CYCLOSPORIN

Cap 25 mg Cap 50 mg Cap 100 mg Oral liq 100 mg per ml	118.54 237.08	50 50 50 50 ml OP	 Neoral Neoral Neoral Neoral
SIROLIMUS – Special Authority see SA0866 below – Retail Tab 1 mg Tab 2 mg Oral liq 1 mg per ml		100 100 60 ml OP	✓ Rapamune✓ Rapamune✓ Rapamune

SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- · Rapidly progressive transplant vasculopathy; or
- · Rapidly progressive obstructive bronchiolitis; or
- HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Generic
TACROLIMUS – Special Authority see SA0669 below – Retail pha	irmacy			
Cap 0.5 mg	214.00	100	~	Prograf
Cap 1 mg	428.00	100	~	Prograf
Cap 5 mg – For tacrolimus oral liquid formulation refer, page				-
172	1,070.00	50	~	Prograf

➡SA0669 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

	Subsidy		Fully Brand or
	(Manufacturer's Pri		bsidised Generic
	\$	Per	 Manufacturer
Antiallergy Preparations			
BEE VENOM ALLERGY TREATMENT – Special Authority see S	A0053 below – Re	tail pharmac	Cy
Maintenance kit - 6 vials 120 µg freeze dried venom, 6 diluent			
1.8 ml		1 OP	Albay
Treatment kit - 1 vial 550 µg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml		1 OP	✓ Albay
SA0053 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals valid Both:	for 2 years for app	olications me	eeting the following criteria:
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitis	ing agent.		
Renewal only from a relevant specialist. Approvals valid for 2 ye benefiting from treatment.	ears where the tre	atment rema	ains appropriate and the patient is
WASP VENOM ALLERGY TREATMENT - Special Authority see		Retail pharm	acy
Treatment kit (Paper wasp venom) - 1 vial 550 µg freeze dried		4.05	4
polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	Albay
Treatment kit (Yellow jacket venom) - 1 vial 550 µg freeze dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	✓ Albay
►SA0053 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals valid	for 2 years for app	olications me	eeting the following criteria:
Both:			
 RAST or skin test positive; and Patient has had severe generalised reaction to the sensitis 	ing agent		
Renewal only from a relevant specialist. Approvals valid for 2 ye		atment rema	ains appropriate and the patient is
benefiting from treatment.			
Antihistamines			
CETIRIZINE HYDROCHLORIDE			
* Tab 10 mg		100	✓ <u>Zetop</u>
* ‡ Oral liq 1 mg per ml	3.52	200 ml	Cetirizine - AFT
CHLORPHENIRAMINE MALEATE			
*‡ Oral liq 2 mg per 5 ml	8.06	500 ml	 Histafen
DEXTROCHLORPHENIRAMINE MALEATE			
* Tab 2 mg		20	
	(4.93)	40	Polaramine
	2.02 (7.99)	40	Polaramine
*‡ Oral liq 2 mg per 5 ml		100 ml	Foldramme
	(10.29)	100 111	Polaramine
FEXOFENADINE HYDROCHLORIDE	. ,		
* Tab 60 mg	4.34	20	
-	(11.53)		Telfast
* Tab 120 mg		10	
	(11.53)	00	Telfast
	(11.53) 14.22 (29.81)	30	Telfast

	Subsidy (Manufacturer's \$	Price) Sub: Per	Fully Brand or sidised Generic Manufacturer
LORATADINE	Ŧ		
* Tab 10 mg	2.09	100	✓ Loraclear Hayfever Relief
* Oral liq 1 mg per ml PROMETHAZINE HYDROCHLORIDE	3.10	100 ml	✓ Lorapaed
* Tab 10 mg	2.72	50	Allersoothe
* Tab 25 mg	4.44	50	Allersoothe
*‡ Oral liq 5 mg per 5 ml	3.10	100 ml	<u>Promethazine</u> <u>Winthrop Elixir</u>
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO TRIMEPRAZINE TARTRATE	11.00	5	✓ Mayne
transfer to a control c transfer to control c transfer to a control c		100 ml OP	
+ •	(8.06)		Vallergan Forte
Inhaled Corticosteroids			
BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 100 µg per dose CFC-free		200 dose OP	Beclazone 100
Aerosol inhaler, 250 µg per dose CFC-free		200 dose OP	 Beclazone 250
Aerosol inhaler, 50 µg per dose CFC-free	8.54	200 dose OP	 Beclazone 50
BUDESONIDE			
Powder for inhalation, 100 µg per dose	17.00	200 dose OP	 Pulmicort Turbuhaler
Powder for inhalation, 200 µg per dose	15.20	200 dose OP	 Budenocort
	19.00		 Pulmicort Turbuhaler
Powder for inhalation, 400 µg per dose		200 dose OP	Budenocort
	32.00		 Pulmicort Turbuhaler
FLUTICASONE			
Aerosol inhaler, 50 µg per dose CFC-free		120 dose OP	✓ Flixotide
Powder for inhalation, 50 µg per dose	()	60 dose OP	
Develop for introduction, 400 constants	(8.67)	00 11	Flixotide Accuhaler
Powder for inhalation, 100 μg per dose		60 dose OP	Flixotide Accuhaler
Aerosol inhaler, 125 µg per dose CFC-free	(13.87) 13.60	120 dose OP	✓ Flixotide
Aerosol inhaler, 250 µg per dose CFC-free		120 dose OP	 Flixotide
Powder for inhalation, 250 µg per dose of o nee		60 dose OP	
	(24.51)		Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

- For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 µg beclomethasone or budesonide (or 100 µg fluticasone).
- For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 µg beclomethasone or budesonide (or 200 µg fluticasone).

Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

(Subsidy Manufacturer's Price \$) Subs Per	Fully idised	Brand or Generic Manufacturer
EFORMOTEROL FUMARATE - See prescribing guideline on the p	0, 0			
Additional subsidy by endorsement for Oxis Turbuhaler is avail 2011. Pharmacists may annotate prescriptions for patients who				, , ,
which case the prescription is deemed to be endorsed. The ph	01			
history for the patient. The prescription must been endorsed ac	cordingly.			
Powder for inhalation, 6 µg per dose, breath activated –	14.60 60			
Higher subsidy of \$16.90 per 60 dose with Endorsement	14.60 60 (16.90)	dose OP	0	xis Turbuhaler
Powder for inhalation, 12 μg per dose, and monodose device \hdots	()	60 dose	✔ Fe	oradil
SALMETEROL - See prescribing guideline on the preceding page				
Aerosol inhaler CFC-free, 25 µg per dose) dose OP		erevent
Powder for inhalation, 50 µg per dose, breath activated	26.46 60	dose OP	V S	erevent Accuhaler

Inhaled Corticosteroids with Long-Acting Beta-Adrenoceptor Agonists

►SA0958 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient is a child under the age of 12; and
 - 1.2 Both:
 - Has, for 3 months of more, been treated with:
 - 1.2.1 An inhaled long-acting beta adrenoceptor agonist; and
 - 1.2.2 Inhaled corticosteroids at a dose of at least 400 µg per day beclomethasone or budesonide, or 200 µg per day fluticasone; and
 - 1.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product; or
- 2 All of the following:
 - 2.1 Patient is over the age of 12; and
 - 2.2 Both:
 - Has, for 3 months or more, been treated with:
 - 2.2.1 An inhaled long-acting beta adrenoceptor agonist; and
 - 2.2.2 Inhaled corticosteroids at a dose of at least 800 µg per day beclomethasone or budesonide, or 500 µg per day fluticasone; and
 - 2.3 The prescriber considers that the patient would receive additional clinical benefit from switching to a combination product.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Subsidy (Manufacturer	s Price) Sub:	Fully Brand or sidised Generic
\$	Per	Manufacturer
BUDESONIDE WITH EFORMOTEROL – Special Authority see SA0958 on the Additional subsidy by endorsement for budesonide with eformoterol powde for patients where the initial dispensing was before 1 July 2011. Pharmacists being prescribed budesonide with eformoterol powder for inhalation (Symbi the prescription is deemed to be endorsed. The pharmacist must be able t the patient. The prescription must been endorsed accordingly.	r for inhalation (S s may annotate p cort Turbuhaler) p	Symbicort Turbuhaler) is available rescriptions for patients who were prior to 1 July 2011 in which case
Aerosol inhaler 100 µg with eformoterol fumarate 6 µg	120 dose OP	🖌 Vannair
Powder for inhalation 100 μg with eformoterol fumarate 6 μg – Higher subsidy of \$55.00 per 120 dose with Endorsement41.25 (55.00)	120 dose OP	Symbicort Turbuhaler 100/6
Aerosol inhaler 200 µg with eformoterol fumarate 6 µg40.06	120 dose OP	Vannair
Powder for inhalation 200 μg with eformoterol fumarate 6 μg – Higher subsidy of \$60.00 per 120 dose with Endorsement45.00 (60.00)	120 dose OP	Symbicort Turbuhaler 200/6
Powder for inhalation 400 μg with eformoterol fumarate 12 μg 45.00 (60.00)	60 dose OP	Symbicort Turbuhaler 400/12
 a) Higher subsidy of \$60.00 per 60 dose with Endorsement b) No more than 2 dose per day 		
FLUTICASONE WITH SALMETEROL – Special Authority see SA0958 on the p Aerosol inhaler 50 µg with salmeterol 25 µg	receding page – 120 dose OP 120 dose OP	Retail pharmacy ✓ Seretide ✓ Seretide
Powder for inhalation 100 μg with salmeterol 50 μg – No more than 2 dose per day	60 dose OP	Seretide Accuhaler
than 2 dose per day49.69	60 dose OP	 Seretide Accuhaler
Beta-Adrenoceptor Agonists		
SALBUTAMOL		
‡ Oral liq 2 mg per 5 ml	150 ml 10	✓ <u>Salapin</u> Ventolin
Inj 500 μg per ml, 1 ml – Up to 5 inj available on a PSO12.90	5	Ventolin
Inhaled Beta-Adrenoceptor Agonists		
SALBUTAMOL		
Aerosol inhaler, 100 µg per dose CFC free – Up to 1000 dose available on a PSO	200 dose OP	 Respigen Salamol Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	20	✓ <u>Asthalin</u>
Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available on a PSO	20	✓ <u>Asthalin</u>
Powder for inhalation, 250 µg per dose, breath activated	200 dose OP	 Bricanyl Turbuhaler

	Subsidy (Manufacturer's	Price) Subs	Fully Brand or sidised Generic	
	\$	Per	 Manufactu 	rer
Inhaled Anticholinergic Agents				
Inhaled Anticholinergic agents				
IPRATROPIUM BROMIDE Aerosol inhaler, 20 μg per dose CFC-free Nebuliser soln, 250 μg per ml, 1 ml – Up to 40 neb available		200 dose OP	✓ Atrovent	
on a PSO Nebuliser soln, 250 µg per ml, 2 ml – Up to 40 neb available on a PSO	e	20 20	 ✓ <u>Univent</u> ✓ Univent 	
TIOTROPIUM BROMIDE – Special Authority see SA0872 below Powder for inhalation, 18 µg per dose	– Retail pharm		✓ Spiriva	
Initial application only from a general practitioner or relevant s following criteria: All of the following: 1 To be used for the long-term maintenance treatment of bro 2 In addition to standard treatment, the patient has trialled a 3 Either: The patient's breathlessness according to the Medi 3.1 Grade 4 (stops for breath after walking about 100 m 3.2 Grade 5 (too breathless to leave the house, or brea 4 Actual FEV ₁ (litres) < 0.6 × predicted (litres); and 5 Either: 5.1 Patient is not a smoker (for reporting purposes only 5.2 Patient is a smoker and has been offered smoking 6 The patient has been offered annual influenza immunisation Renewal only from a general practitioner or relevant specialist. criteria: All of the following: 1 Patient is compliant with the medication; and 2 Patient has experienced improved COPD symptom contro 3 Applicant must state recent measurement of FEV ₁ (% of p	onchospasm and dose of at least ical Research C neters or after a thiless when dre (); or cessation couns on. Approvals valid I (prescriber def oredicted).	d dyspnoea asso t 40 µg ipratropiu ouncil (UK) dysp few minutes on t essing or undress selling; and for 2 years for a termined); and	ciated with COPD im q.i.d for one mo noea scale is: the level); or sing); and	; and onth; and
Inhaled Beta-Adrenoceptor Agonists with Antic SALBUTAMOL WITH IPRATROPIUM BROMIDE	noimergic A	igents		
 Aerosol inhaler, 100 μg with ipratropium bromide, 20 μg pe dose CFC-free Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg pe vial, 2.5 ml – Up to 20 neb available on a PSO 	12.19 r	200 dose OP 20	 ✓ Duolin HFA ✓ <u>Duolin</u> 	
Mast Cell Stabilisers				
Mast cell stabilisers				
NEDOCROMIL Aerosol inhaler, 2 mg per dose CFC-free		112 dose OP	Tilade	
SODIUM CROMOGLYCATE Powder for inhalation, 20 mg per dose Aerosol inhaler, 5 mg per dose CFC-free		50 dose 112 dose OP	✓ Intal Spinca✓ Vicrom	ps

	Subsidy		Fully Brand or
	(Manufacturer's		sidised Generic
	\$	Per	 Manufacturer
Methylxanthines			
AMINOPHYLLINE			
 * Inj 25 mg per ml, 10 ml – Up to 5 inj available on a PSO 	53 75	5	DBL Aminophylline
		5	
THEOPHYLLINE			
* Tab long-acting 250 mg		100	✓ Nuelin-SR
*‡ Oral liq 80 mg per 15 ml	15.50	500 ml	Nuelin
Mucolytics			
DORNASE ALFA - Special Authority see SA0611 below - Reta	il pharmacy		
Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	Pulmozyme
SA0611 Special Authority for Subsidy			, i i i i i i i i i i i i i i i i i i i
Special Authority approved by the Cystic Fibrosis Advisory Pane	ı		
Notes: Application details may be obtained from PHARMAC's we		w pharmac dout :	az or:
	04) 460 4990		
	: (04) 916 7571		
-	FPanel@pharm		
Prescriptions for patients approved for treatment must be written	n by respiratory	physicians or pa	ediatricians who have experience
and expertise in treating cystic fibrosis.			
SODIUM CHLORIDE			
Not funded for use as a nasal drop. Only funded for nebulise	er use when in c	onjunction with a	an antibiotic intended for nebulise
use.			
Soln 7%	23.50	90 ml OP	Biomed
Nasal Preparations			
Nasai Fieparations			
Allergy Prophylactics			
Allergy Prophylactics			
BECLOMETHASONE DIPROPIONATE			
Metered aqueous nasal spray, 50 µg per dose	2.35	200 dose OP	
	(4.00)	200 0000 01	Alanase
Metered aqueous nasal spray, 100 µg per dose		200 dose OP	handoo
	(4.81)	200 0000 01	Alanase
PUREADNIRE	(4.01)		Alahase
BUDESONIDE	0.05	000 1	
Metered aqueous nasal spray, 50 µg per dose		200 dose OP	
	(4.00)		Butacort Aqueous
Metered aqueous nasal spray, 100 µg per dose		200 dose OP	
	(4.81)		Butacort Aqueous
FLUTICASONE PROPIONATE			
Metered aqueous nasal spray, 50 µg per dose	13.34	120 dose OP	Flixonase Hayfever
			& Allergy
IPRATROPIUM BROMIDE			
Aqueous nasal spray, 0.03%		15 ml OP	Univent
SODIUM CROMOGLYCATE	45.05	00	
Nasal spray, 4%	15.85	22 ml OP	✓ <u>Rex</u>

\$ Per ✓ Manufacturer Respiratory Devices MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2 2.99 1 ✓ EZ-fit Paediatric Mask PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range 11.44 1 ✓ Breath-Alert Normal range 11.44 1 ✓ Breath-Alert 		Subsidy (Manufacturer's Price) Sub	Fully sidised	Brand or Generic
MASK FOR SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2 2.99 PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range Low range 11.44 Normal range		· .		siuiseu V	
a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under Size 2	Respiratory Devices				
PEAK FLOW METER a) Up to 10 dev available on a PSO b) Only on a PSO Low range	a) Up to 20 dev available on a PSO b) Only on a PSO c) Only for children aged six years and under	2.99	1	_	
	a) Up to 10 dev available on a PSO b) Only on a PSO Low range		-	✓ <u>B</u>	reath-Alert
a) Up to 20 dev available on a PSO b) Only on a PSO	SPACER DEVICE a) Up to 20 dev available on a PSO b) Only on a PSO		·	_	
230 ml (single patient)4.72 1 Space Chamber Space Chamber Plus	230 ml (single patient)	4.72	1	✓ <u>s</u>	pace Chamber
800 ml			1		
SPACER DEVICE AUTOCLAVABLE – Only on a PSO 230 ml (autoclavable) – Subsidy by endorsement	230 ml (autoclavable) – Subsidy by endorsement a) Up to 5 dev available on a PSO				
endorsed accordingly. Respiratory Stimulants	endorsed accordingly.				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)14.85 25 ml OP V Biomed	CAFFEINE CITRATE	14.95 0			iomod

	Quitaciatu		Fully Durind an
	Subsidy (Manufacturer's I		Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Ear Preparations			
CETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN	ZETHONIUM		
For Vosol ear drops with hydrocortisone powder refer, page 17	75		
Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02%	6.97	35 ml OP	Vosol
Ear drops 0.5%	2.20	5 ml OP	 Chloromycetin
LUMETASONE PIVALATE			
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viaform
			ED's ✔ Locorten-Vioform
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCIN		INI	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate			
2.5 mg and gramicidin 250 µg per g	5.16	7.5 ml OP	 Kenacomb
Ear/Eye Preparations			
EXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 µg with framycetin sulphate 5 mg and			
gramicidin 50 µg per ml	4.50	8 ml OP	
	(9.27)		Sofradex
RAMYCETIN SULPHATE	4.40		
Ear/Eye drops 0.5%		8 ml OP	Soframycin
Eye Preparations	(0.00)		Contanyon
	, .	1 10/	00/ 1/0/ 1/1
ye preparations are only funded for use in the eye. The exception r oral use pursuant to the Standard Formulae.	n is pilocarpine	eye drops 1%,	2% and 4% which are subside
Anti-Infective Preparations			
CICLOVIR			
Eye oint 3%		4.5 g OP	Zovirax
HLORAMPHENICOL	0.07	4 00	
Eye oint 1% Eye drops 0.5%		4 g OP 10 ml OP	 ✓ <u>Chlorsig</u> ✓ Chlorafast
PROFLOXACIN			<u></u>
Eye Drops 0.3%		5 ml OP	Ciloxan
For treatment of bacterial keratitis or severe bacterial conju	nctivitis resistar	nt to chloramph	enicol.
	4 50		
Eye drops 1%	4.50	5 g OP	 Fucithalmic
ENTAMICIN SULPHATE Eye drops 0.3%	11 40	5 ml OP	✓ Genoptic
BOPAMIDINE ISETHIONATE		0 111 01	- compete
	0.07		

* Eye drops 0.1%2.97

Brolene

10 ml OP

(7.99)

SENSORY ORGANS

	Quitasiatu		Fully Deceder
	Subsidy (Manufacturer's	Price) Sub	Fully Brand or osidised Generic
	`\$	Per	 Manufacturer
TOBRAMYCIN			
Eve oint 0.3%		3.5 g OP	Tobrex
Eye drops 0.3%		5 ml OP	✓ Tobrex
Corticosteroids and Other Anti-Inflammatory Pr	reparations		
DEXAMETHASONE			
BEXAME I RASONE * Eve oint 0.1%	5 86	3.5 g OP	Maxidex
* Eye drops 0.1%		5 ml OP	
DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SU		0	
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxii B sulphate 6,000 u per g		3.5 g OP	✓ Maxitrol
 B subplate 0,000 u per g * Eye drops 0.1% with neomycin sulphate 0.35% and polymy 		5.5 y Oi	
xin B sulphate 6,000 u per ml		5 ml OP	✓ Maxitrol
	4.00	0 111 01	
DICLOFENAC SODIUM * Eye drops 1 mg per ml	12.90	5 ml OP	Voltaren Ophtha
	13.00	5 III OF	
	4.05		
* Eye drops 0.1%	4.05	5 ml OP	✓ <u>FML</u>
LEVOCABASTINE			
Eye drops 0.5 mg per ml		4 ml OP	Line alla
	(10.34)		Livostin
			4 • • • •
Eye drops 0.1%	8.71	10 ml OP	Lomide
PREDNISOLONE ACETATE			
* Eye drops 0.12%		5 ml OP	✓ Pred Mild
* Eye drops 1%	4.50	5 ml OP	Pred Forte
SODIUM CROMOGLYCATE			
Eye drops 2%	1.18	5 ml OP	Rexacrom
Glaucoma Preparations - Beta Blockers			
BETAXOLOL HYDROCHLORIDE			
* Eye drops 0.25%	11.80	5 ml OP	Betoptic S
* Eye drops 0.5%	7.50	5 ml OP	✓ Betoptic
LEVOBUNOLOL			
* Eye drops 0.25%	7.00	5 ml OP	Betagan
* Eye drops 0.5%	7.00	5 ml OP	🗸 Betagan
TIMOLOL MALEATE			
* Eye drops 0.25%	2.08	5 ml OP	Arrow-Timolol
	2.37		🖌 Apo-Timop
Eye drops 0.25%, gel forming	3.30	2.5 ml OP	 Timoptol XE
* Eye drops 0.5%		5 ml OP	Arrow-Timolol
	2.29	0.5	Apo-Timop
* Eye drops 0.5%, gel forming	3.78	2.5 ml OP	Timoptol XE

	Subsidy (Manufacturer's Pri \$	ce) Su Per	Fully ubsidised	Brand or Generic Manufacturer
Glaucoma Preparations - Carbonic Anhydrase In	hibitors			
Prescribing Guidelines Trusopt, Cosopt and Azopt are subsidised for use as either monot Trusopt, Cosopt and Azopt should not be prescribed for a perso glaucoma are not contraindicated unless: 1) that person has previously trialled all other such subsidised 2) those trials have indicated that that person does not respon	n in whom less e agents (except b	expensive fi	rst line a artrate);	gents for the treatment of and
ACETAZOLAMIDE				-
* Tab 250 mg – For acetazolamide oral liquid formulation refer, page 172		100	✓ <u>D</u>	iamox
BRINZOLAMIDE				
Eye Drops 1%	9.77	5 ml OP	🗸 A	zopt
DORZOLAMIDE HYDROCHLORIDE * Eye drops 2%	9.77 (13.95)	5 ml OP	īT	rusopt
OORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE * Eye drops 2% with timolol maleate 0.5%		5 ml OP	✔ C	osopt
Glaucoma Preparations - Prostaglandin Analogu	es			

Prescribing Guideline

Bimatoprost, lantanoprost and travoprost are subsidised for use in the treatment of glaucoma as either monotherapy or as an adjunctive agent for patients in whom prostaglandin analogue monotherapy has been ineffective in controlling intraocular pressure. Bimatoprost, lantanoprost and travoprost should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- 1) That person has previously trialled all other such subsidised agents (beta-blockers, pilocarpine, carbonic anhydrase inhibitors); and
- 2) Those trials have indicated that that person does not respond adequately to treatment with those other agents.

BIMATOPROST – Retail pharmacy-Specialist See prescribing guideline below ▲ Eye drops 0.03%	3 ml OP	🗸 Lumigan
LATANOPROST – Retail pharmacy-Specialist See prescribing guideline below ▲ Eye drops 50 µg per ml, 2.5 ml	2.5 ml OP	✓ <u>Hysite</u>
 TRAVOPROST – Retail pharmacy-Specialist See prescribing guideline below ▲ Eye drops 0.004%	2.5 ml OP	🖌 Travatan
Glaucoma Preparations - Other		
BRIMONIDINE TARTRATE – See prescribing guideline below * Eye Drops 0.2%	5 ml OP	🖌 AFT

Prescribing Guidelines

Brimonidine tartrate is subsidised for use as either monotherapy or as an adjunctive agent for the treatment of glaucoma. Brimonidine tartrate should not be prescribed for a person in whom less expensive first line agents for the treatment of glaucoma are not contraindicated unless:

- that person has previously trialled all other such subsidised agents (except dorzolamide hydrochloride); and
- those trials have indicated that that person does not respond adequately to or does not tolerate treatment with those other agents.

SENSORY ORGANS

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE – See pre ▲ Eye drops 0.2% with timolol maleate 0.5%		ne below 5 ml OP	✓ Combigan
 Prescribing Guidelines Combigan is subsidised for use as either monotherapy or as an a Combigan should only be prescribed when: less expensive first line agents for the treatment of glaucor the response to such subsidised agents is inadequate; or the patient cannot tolerate such subsidised agents. 			nt of glaucoma.
PILOCARPINE * Eye drops 1% * Eye drops 2% * Eye drops 4% * Eye drops 2% single dose – Special Authority see SA0895	5.35 7.99	15 ml OP 15 ml OP 15 ml OP	 ✓ Isopto Carpine ✓ Isopto Carpine ✓ Isopto Carpine
below – Retail pharmacy		20 dose	Minims
1 Patient has to use an unpreserved solution due to an allerg 2 Patient wears soft contact lenses. Note: Minims for a general practice are considered to be "tools of Renewal from any relevant practitioner. Approvals valid for 2 yes benefiting from treatment.	trade" and are n	ot approved as	
Mydriatics and Cycloplegics			
ATROPINE SULPHATE * Eye drops 1%	17.36	15 ml OP	✓ Atropt
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1% HOMATROPINE HYDROBROMIDE		15 ml OP	Cyclogyl
* Eye drops 2% TROPICAMIDE	7.18	15 ml OP	 Isopto Homatropine
* Eye drops 0.5% * Eye drops 1%		15 ml OP 15 ml OP	 <u>Mydriacyl</u> <u>Mydriacyl</u>
Preparations for Tear Deficiency			
For acetylcysteine eye drops refer, page 175 HYPROMELLOSE * Eye drops 0.3% * Eye drops 0.5%		15 ml OP 15 ml OP	✓ Poly-Tears✓ Methopt
POLYVINYL ALCOHOL * Eye drops 1.4% * Eye drops 3%		15 ml OP 15 ml OP	✔ Vistil✔ Vistil Forte

SENSORY ORGANS

	Subsidy (Manufacturer's Pr \$	rice) Subs Per	Fully sidised	Brand or Generic Manufacturer
Other Eye Preparations				
NAPHAZOLINE HYDROCHLORIDE * Eye drops 0.1%	4.15	15 ml OP	✓ <u>N</u>	aphcon Forte
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin	3.63	3.5 g OP	✔ <u>La</u>	acri-Lube
PARAFFIN LIQUID WITH WOOL FAT LIQUID * Eye oint 3% with wool fat liq 3%	3.63	3.5 g OP	🖌 Po	oly-Visc
PHENYLEPHRINE HYDROCHLORIDE * Eye drops 0.12%	4.47	15 ml OP	🖌 Pi	refrin

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).

 c) Menthol crystals only in the following bases: Aqueous cream Urea cream 10% Wool fat with mineral oil lotion Hydrocortisone 1% with wool fat and mineral oil lotion Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- · Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website **www.pharminfotech.co.nz** has evidence-based formulations which are intended to standardise compounded oral liquids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Rifabutin 20 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Sildenafil 2 mg/ml
Amlodipine 1 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sotalol 15 mg/ml
Azathioprine 50 mg/ml	Hydrocortisone 1 mg/ml	Sulphasalazine 100 mg/ml
Baclofen 10 mg/ml	Labetolol 10 mg/ml	Tacrolimus 1 mg/ml
Carvedilol 1 mg/ml	Levetiracetam 100 mg/ml	Terbinafine 25 mg/ml
Clopidogrel 5 mg/ml	Levodopa with carbidopa (5 mg lev-	Ursodeoxycholic acid 50 mg/ml
Diltiazem hydrochloride 12 mg/ml	odopa + 1.25 mg carbidopa)/ml	Valganciclovir 60 mg/ml*
Dipyridamole 10 mg/ml	Metoprolol tartrate 10 mg/ml	Verapamil hydrochloride 50 mg/ml
Domperidone 1 mg/ml	Nitrofurantoin 10 mg/ml	
Enalapril 1 mg/ml	Pyrazinamide 100 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

qs

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF to 100% Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 171) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



Standard Formulae

ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICAT Aspirin Soluble tabs 300 mg Chloroform	ION 12 tabs to 100 ml
CODEINE LINCTUS PAEDIATRIC (3 mg p Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	r 5 ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity su more than 5 days. Maximum 500 ml per pro-	
MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste Methyl hydroxybenzoate Water	275 g 1.5 g 770 ml
METHADONE MIXTURE Methadone powder Glycerol Water	qs qs to 100 ml

METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml c mixture)	10 g to 100 ml
OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml
PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATRI LIQUID (10 mg per ml)	C ORAL
Phenobarbitone Sodium Glycerol BP Water	400 mg 4 ml to 40 ml
PILOCARPINE ORAL LIQUID	
Pilocarpine 4% eye drops	qs
Preservative	qs
Water (Preservative should be used if quantity su more than 5 days.)	to 500 ml pplied is for
SALIVA SUBSTITUTE FORMULA	
Methylcellulose	5 g
Preservative	qs
Water	to 500 ml
(Preservative should be used if quantity su	pplied is for

(Preservative should be used if quantity supplied is for more than 5 days. Maximum 500 ml per prescription.)

VOSOL EAR DROPS

WITH HYDROCORTISONE POWDER 1%	
Hydrocortisone powder	1%
Vosol Ear Drops	to 35 ml

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

(5.10) 24.42 5 (38.00) CHLOROFORM – Only in combination Only in aspirin and chloroform application. Chloroform BP	Full Subsidise Per 🖌	
Inj 200 mg per ml, 10 ml 137.06 (219.75) Inj 200 mg per ml, 30 ml 219.00 BENZOIN 219.00 Tincture compound BP 2.44 (5.10) 24.42 (5.10) 24.42 (38.00) 24.42 CHLOROFORM - Only in combination 25.50 Only in aspirin and chloroform application. 21.62 Chloroform BP 25.50 CODEINE PHOSPHATE 90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine linb b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE 19.30 Collodion flexible 19.30 COMPOUND HYDROXYBENZOATE - Only in combination 0nly in extemporaneously compounded oral mixtures. Soln 34.18 10 GLYCERIN WITH SUCROSE - Only in combination 36.80 4 GLYCERIN WITH SUCROSE - Only in combination 0nly in combination with Ora-Plus. 36.80 4 GLYCEROL * Liquid - Only in combination 17.86 2,6 MAGNESIUM HYDROXIDE Paste 22.61 5		
(219.75) (255.35) Inj 200 mg per ml, 30 ml		
Inj 200 mg per ml, 30 ml 219.00 BENZOIN 2.44 Tincture compound BP 2.44 (5.10) 24.42 (38.00) 24.42 CHLOROFORM - Only in combination Only in aspirin and chloroform application. 25.50 CODEINE PHOSPHATE 25.60 Powder - Only in combination 12.62 (25.46) 63.09 (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion flexible 19.30 1 COMPOUND HYDROXYBENZOATE - Only in combination 0nly in extemporaneously compounded oral mixtures. 34.18 14 GLYCERIN WITH SODIUM SACCHARIN - Only in combination 0nly in combination with Ora-Plus. 36.80 4 GLYCERIN WITH SUCROSE - Only in combination 36.80 4 GLYCEROL * Liquid - Only in combination 17.86 2,4 MagNESIUM HYDROXIDE 22.61 E Paste .22.61 E METHADONE HYDROCHLORIDE a) Only on a controlled drug f	10	Martindale Acetylcysteine
BENZOIN Tincture compound BP 2.44 5 (5.10) 24.42 5 (38.00) CHLOROFORM – Only in combination 0nly in aspirin and chloroform application. Chloroform BP 25.50 5 CODEINE PHOSPHATE 25.46 63.09 Powder – Only in combination 12.62 (25.46) (83.09) (25.46) 63.09 (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine line b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE 19.30 10 Collodion flexible 19.30 11 COMPOUND HYDROXYBENZOATE – Only in combination 0nly in extemporaneously compounded oral mixtures. Soln Soln		Hospira
Tincture compound BP 24.42 5 (5.10) 24.42 5 (38.00) CHLOROFORM – Only in combination 0nly in aspirin and chloroform application. 25.50 5 CODEINE PHOSPHATE 25.50 5 5 CODEINE PHOSPHATE 25.60 63.09 29 (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE 19.30 11 COMPOUND HYDROXYBENZOATE – Only in combination 0nly in extemporaneously compounded oral mixtures. 34.18 11 GLYCERIN WITH SODIUM SACCHARIN – Only in combination 0nly in combination with Ora-Plus. 36.80 4 GLYCERIN WITH SUCROSE – Only in combination 0nly in combination with Ora-Plus. 36.80 4 GLYCEROL * Liquid – Only in combination 17.86 2,6 Only in extemporaneously compounded oral liquid preparations. MAGNESIUM HYDROXIDE 22.61 5	4 🖌	Acetadote
(5.10) 24.42 5 (38.00) CHLOROFORM – Only in combination Only in aspirin and chloroform application. Chloroform BP		
24.42 5 (38.00) CHLOROFORM – Only in combination Only in aspirin and chloroform application. Chloroform BP Chloroform BP	50 ml	
(38.00) CHLOROFORM – Only in combination Only in aspirin and chloroform application. Chloroform BP		PSM
CHLOROFORM - Only in combination 25.50 Only in aspirin and chloroform application. 25.50 CODEINE PHOSPHATE 25.60 Powder - Only in combination 12.62 (25.46) 63.09 (25.46) 63.09 (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE 19.30 Collodion flexible 19.30 COMPOUND HYDROXYBENZOATE - Only in combination 0nly in extemporaneously compounded oral mixtures. Soln	500 ml	2014
Only in aspirin and chloroform application. 25.50 5 CODEINE PHOSPHATE 12.62 (25.46) Powder – Only in combination 12.62 (25.46) (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE 19.30 10 COMPOUND HYDROXYBENZOATE – Only in combination 19.30 10 COMPOUND HYDROXYBENZOATE – Only in combination 34.18 10 CLYCERIN WITH SODIUM SACCHARIN – Only in combination 0nly in combination with Ora-Plus. 36.80 4 GLYCERIN WITH SUCROSE – Only in combination 0nly in combination with Ora-Plus. 36.80 4 GLYCEROL * Liquid – Only in combination 17.86 2,0 Only in extemporaneously compounded oral liquid preparations. MAGNESIUM HYDROXIDE 22.61 5 METHADONE HYDROCHLORIDE a) Only on a controlled drug form 5 5		PSM
Chloroform BP		
CODEINE PHOSPHATE Powder – Only in combination		
Powder – Only in combination 12.62 (25.46) 63.09 (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE 19.30 Collodion flexible 19.30 COMPOUND HYDROXYBENZOATE – Only in combination 0nly in extemporaneously compounded oral mixtures. Soln 34.18 GLYCERIN WITH SODIUM SACCHARIN – Only in combination 0nly in combination Only in combination with Ora-Plus. 36.80 Suspension 36.80 GLYCERIN WITH SUCROSE – Only in combination 0nly in combination Only in combination with Ora-Plus. 36.80 Suspension 36.80 4 GLYCEROL * Liquid – Only in combination MAGNESIUM HYDROXIDE Paste 22.61 5 METHADONE HYDROCHLORIDE a) Only on a controlled drug form 5	500 ml 🖌	PSM
(25.46) 63.09 (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion flexible		
63.09 :: (90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion flexible COMPOUND HYDROXYBENZOATE Only in extemporaneously compounded oral mixtures. Soln Only in extemporaneously compounded oral mixtures. Soln Only in combination Only in combination with Ora-Plus. Suspension Suspension GLYCERIN WITH SUCROSE Only in combination with Ora-Plus. Suspension Suspension 36.80 4 GLYCEROL * Liquid Ponly in combination Only in extemporaneously compounded oral liquid preparations. MAGNESIUM HYDROXIDE Paste .22.61 METHADONE HYDROCHLORIDE a) Only on a controlled drug form	5 g	
(90.09) a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion flexible	-	Douglas
a) Only in extemporaneously compounded codeine linctus diabetic or codeine lin b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion flexible	25 g	
b) ‡ Safety cap for extemporaneously compounded oral liquid preparations. COLLODION FLEXIBLE Collodion flexible		Douglas
Only in extemporaneously compounded oral mixtures. 34.18 14 GLYCERIN WITH SODIUM SACCHARIN – Only in combination 0nly in combination 36.80 Only in combination with Ora-Plus. 36.80 4 GLYCERIN WITH SUCROSE – Only in combination 36.80 4 GLYCERIN WITH SUCROSE – Only in combination 36.80 4 GLYCEROL * Liquid – Only in combination 36.80 4 GLYCEROL * Liquid – Only in combination 17.86 2,0 Only in extemporaneously compounded oral liquid preparations. MAGNESIUM HYDROXIDE 22.61 5 METHADONE HYDROCHLORIDE a) Only on a controlled drug form 5 5	00 ml 🖌	PSM
GLYCERIN WITH SODIUM SACCHARIN – Only in combination Only in combination with Ora-Plus. Suspension		
Only in combination with Ora-Plus. 36.80 4 GLYCERIN WITH SUCROSE – Only in combination 36.80 4 GLYCERIN WITH SUCROSE – Only in combination 36.80 4 GLYCEROL * Liquid – Only in combination 36.80 4 GLYCEROL * Liquid – Only in combination 17.86 2,0 Only in extemporaneously compounded oral liquid preparations. 17.86 2,1 MAGNESIUM HYDROXIDE Paste 22.61 5 METHADONE HYDROCHLORIDE a) Only on a controlled drug form 5	00 ml 🖌	David Craig
GLYCERIN WITH SUCROSE – Only in combination Only in combination with Ora-Plus. Suspension		
Only in combination with Ora-Plus. Suspension	173 ml 🛛 🖌	Ora-Sweet SF
GLYCEROL * Liquid – Only in combination 17.86 2,0 Only in extemporaneously compounded oral liquid preparations. 17.86 2,0 MAGNESIUM HYDROXIDE Paste 22.61 5 METHADONE HYDROCHLORIDE a) Only on a controlled drug form 5		
 Liquid – Only in combination	173 ml 🖌 🖌	Ora-Sweet
Only in extemporaneously compounded oral liquid preparations. MAGNESIUM HYDROXIDE Paste		
Paste	000 ml 🖌	<u>healthE</u>
a) Only on a controlled drug form	500 g 🖌	PSM
 b) No patient co-payment payable c) Extemporaneously compounded methadone will only be reimbursed at the rate 	of the cheapes	st form available (methadone
powder, not methadone tablets).		
Powder	1g 🖌	AFT

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully Brand or bsidised Generic Manufacturer
METHYL HYDROXYBENZOATE			
Powder		25 g	✓ PSM
	8.98		 Midwest
METHYLCELLULOSE			
Powder		100 g	✓ ABM
Quananzian Only in combination	(17.72)	473 ml	MidWest
Suspension – Only in combination			V Ora-Plus
METHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCH			
Suspension		473 ml	Ora-Blend SF
METHYLCELLULOSE WITH GLYCERIN AND SUCROSE - On			
Suspension		473 ml	 Ora-Blend
PHENOBARBITONE SODIUM			
Powder – Only in combination		10 g	✓ MidWest
a) Only in abildren we to 10 years	325.00	100 g	 MidWest
 a) Only in children up to 12 years b) \$\$ Safety cap for extemporaneously compounded oral I 	auid proporations		
PROPYLENE GLYCOL	iquiu preparations		
Only in extemporaneously compounded methyl hydroxybenz	zanto 10% colutio	n	
Lig		500 ml	V PSM
- 9	11.25	000 111	✓ Midwest
	12.00		✓ ABM
SODIUM BICARBONATE			
Powder BP – Only in combination	8.95	500 g	✓ Midwest
,	9.80	0	
	(29.50)		David Craig
Only in extemporaneously compounded omeprazole susp	pension.		
SYRUP (PHARMACEUTICAL GRADE) - Only in combination			
Only in extemporaneously compounded oral liquid preparati			4
Liq	21.75	2,000 ml	 Midwest
WATER			
Tap – Only in combination	0.00	1 ml	Tap water

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

Initial Applications: Only from a relevant specialist or a vocationally registered general practitioner. Reapplications: Only from a dietitian, relevant specialist or a vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or a vocationally registered general practitioner. Other general practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. A supporting letter may be included if desired. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ASCORBIC ACID Tab 100 mg

CALCIUM CARBONATE

- ✓ Tab eff 1.75 g (1 g elemental)
- ✓ Tab 1.25 g (500 mg elemental)
- ✓ Tab 1.5 g (600 mg elemental)

COMPOUND ELECTROLYTES

Powder for soln for oral use 4.4 g
 Powder for soln for oral use 5 g

DEXTROSE WITH ELECTROLYTES Soln with electrolytes

FERROUS FUMARATE ✓ Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID

✓ Tab 310 mg (100 mg elemental) with folic acid 350 µg

FERROUS SULPHATE Tab long-acting 325 mg (105 mg elemental)

✓ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)

FERROUS SULPHATE WITH FOLIC ACID

Tab long-acting 325 mg (105 mg elemental) with folic acid 350 µg

MULTIVITAMINS

POTASSIUM BICARBONATE

✓ Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg

POTASSIUM CHLORIDE

- Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)
- ✔ Tab long-acting 600 mg

PYRIDOXINE HYDROCHLORIDE

- 🖌 Tab 25 mg
- 🖌 Tab 50 mg

SODIUM FLUORIDE

✓ Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE

Tab 50 mg

VITAMIN A WITH VITAMINS D AND C

✓ Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX

✓ Tab, strong, BPC

VITAMINS

- ✓ Tab (BPC cap strength)
- Cap (fat soluble vitamins A, D, E, K)

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
```````````````````````````````````````	Den		
S	Per	~	Manufacturer

## **Nutrient Modules**

### Carbohydrate

### ➡SA1090 Special Authority for Subsidy

**Initial application** — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

- 1 cancer in children; or
- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 failure to thrive; or
- 4 growth deficiency; or
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
  - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
  - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT - Special Authority see SA1090 above - Hospital pharmacy [HP3]

Powder	5.29	400 g OP	Polycal
	36.50	5,000 g	<ul> <li>Morrex Maltodextrin</li> </ul>
	182.50	25,000 g	<ul> <li>Morrex Maltodextrin</li> </ul>
	1.30	368 g OP	
	(12.00)	Ū	Moducal
prrex Maltodextrin Powder to be delisted 1 March 2012)	· · ·		

## **Carbohydrate And Fat**

### SA1091 Special Authority for Subsidy

**Initial application** — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 infant aged four years or under; and
- 2 cystic fibrosis.

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 infant aged four years or under; and
- 2 Any of the following:
  - 2.1 cancer in children; or
  - 2.2 failure to thrive; or
  - 2.3 growth deficiency; or
  - 2.4 bronchopulmonary dysplasia; or
  - 2.5 premature and post premature infants.

**Renewal** — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND FAT SUPPLEMENT Powder (neutral)	,		✓ Duocal Super
		400 g 01	Soluble Powder

### Fat

### ➡SA1092 Special Authority for Subsidy

**Initial application** — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive where other high calorie products are inappropriate or inadequate; or
- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria: Both:

1 The treatment remains appropriate and the patient is benefiting from treatment; and

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT SUPPLEMENT - Special Authority see SA1092 on the preceding page - Hospital pharmacy [HP3]

Emulsion (neutral)		200 ml OP	Calogen
	30.75	500 ml OP	Calogen
Emulsion (strawber	rry)	200 ml OP	Calogen
Oil		250 ml OP	Liquigen
	30.00	500 ml OP	MCT oil (Nutricia)

## Protein

### ➡SA1093 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Either:
  - 1 protein losing enteropathy; or
  - 2 high protein needs (eg burns).

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT - Special Authority see	SA1093 above - Hospital phar	macy [HP3]	
Powder		225 g OP	Protifar
	8.95	227 g OP	✓ Resource
			Beneprotein
Powder (vanilla)		275 g OP	Promod

### Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

### **Respiratory Products**

### ➡SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	Subsidy (Manufacturer's Price) \$	Fu Subsidis Per	
CORD ORAL FEED 1.5KCAL/ML – Special Authority see SA109 Liquid		age – Hospital 7 ml OP 🛛 🖌	

## **Diabetic Products**

### ➡SA1095 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is a type I or and II diabetic who is suffering weight loss and malnutrition that requires nutritional support. **Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see SA1095 above Liquid	– Hospital pharn 1,000 ml OP	
DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1095 above – H Liquid (strawberry)	ospital pharmacy 200 ml OP 200 ml OP 250 ml OP 237 ml OP	[HP3] ✓ Diasip ✓ Diasip ✓ Glucerna Select
(2.10)		Resource Diabetic

## **Fat Modified Products**

### SA1096 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has chylothorax.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED – Special Authority see SA1096 above – Hospital pharmacy [HP3]

### **High Protein Products**

### ➡SA1097 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 Anorexia and weight loss; and

Subsidy	F	Fully	Brand or
(Manufacturer's Price)	_		Generic
\$	Per	~	Manufacturer

continued...

2 Either:

2.1 decompensating liver disease without encephalopathy; or

2.2 protein losing gastro-enteropathy.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

### Paediatric Products For Children Awaiting Liver Transplant

#### SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who is awaiting liver transplant.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML – Special Authority see SA1098 above – Hospital pharmacy [HP3]

## Paediatric Products For Children With Chronic Renal Failure

### ➡SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with chronic renal failure.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML - Special Authority see SA1099 above - Hospital pharmacy [HP3]

Liquid	 	54.00	400 g OP	<ul> <li>Kindergen</li> </ul>

## **Paediatric Products**

### SA1100 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 Infant aged one to eight years; and

	Subsidy (Manufacturer's \$	Price) Sul Per	Fully Brand or osidised Generic Manufacturer	
ontinued	Ť	-		
2 Any of the following:				
2.1 any condition causing malabsorption; or				
2.2 failure to thrive; or				
2.3 increased nutritional requirements.				
tenewal only from a dietitian, relevant specialist, vocationally reg				
nendation of a dietitian, relevant specialist or vocationally register neeting the following criteria:	red general prac	titioner. Approv	als valid for 1 year for applicat	ions
leeling the following chiena. Soth:				
<ol> <li>The treatment remains appropriate and the patient is bene</li> </ol>	fiting from treat	ment: and		
2 General Practitioners must include the name of the dietitiar			ally registered general practitic	oner
and date contacted.	i, ioiovain opeoi		any regionered general practice	01101
AEDIATRIC ENTERAL FEED 1.5KCAL/ML – Special Authority	see SA1100 on	the precedina	page – Hospital pharmacy (HP	231
Liquid		500 ml OP	✓ Nutrini Energy RTH	-1
AEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority se	SA1100 on th	e nrecedina na	ice – Hospital pharmacy [HP3]	I
Liquid		500 ml OP	Nutrini RTH	1
	2.00	000 0.	Pediasure RTH	
AEDIATRIC ORAL FEED 1.5KCAL/ML - Special Authority see	SA1100 on the	nreceding nage	– Hospital pharmacy [HP3]	
Liquid (strawberry)		200 ml OP	✓ Fortini	
		200 111 01	✓ NutriniDrink	
Liquid (vanilla)	1.60	200 ml OP	<ul> <li>Fortini</li> </ul>	
			NutriniDrink	
NutriniDrink Liquid (strawberry) to be delisted 1 May 2012)				
NutriniDrink Liquid (vanilla) to be delisted 1 May 2012)				
AEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see S/		eceding page -	- Hospital pharmacy [HP3]	
Liquid (chocolate)	1.07	200 ml OP	Pediasure	
Liquid (strawberry)		200 ml OP	Pediasure	
Liquid (vanilla)		200 ml OP	Pediasure	
	1.27	237 ml OP	Pediasure	
AEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special A	Authority see SA	1100 on the pr	eceding page – Hospital pharm	nacy
HP3]				
Liquid (chocolate)	1.60	200 ml OP	<ul> <li>Fortini Multi Fibre</li> </ul>	
			NutriniDrink	
	4.00		Multifibre	
Liquid (strawberry)	1.60	200 ml OP	<ul> <li>Fortini Multi Fibre</li> <li>NutriniDrink</li> </ul>	
			Multifibre	
Liquid (vanilla)	1 60	200 ml OP	✓ Fortini Multi Fibre	
	1.00	200 MI OF	✓ NutriniDrink	
			Multifibre	
NutriniDrink Multifibre Liquid (chocolate) to be delisted 1 May 20	12)			
NutriniDrink Multifibre Liquid (strawberry) to be delisted 1 May 20	,			

	Subsidy (Manufacturer's P \$	rice) Per	Fully Subsidised	
Renal Products				
►SA1101 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voc where the patient has acute or chronic renal failure. Renewal only from a dietitian, relevant specialist, vocationally re mendation of a dietitian, relevant specialist or vocationally registe meeting the following criteria: Both:	egistered general p	practitioner	· or genera	I practitioner on the recom-
<ol> <li>The treatment remains appropriate and the patient is ben</li> <li>General Practitioners must include the name of the dietitia and date contacted.</li> </ol>			tionally reg	gistered general practitione
ENTERAL FEED 2KCAL/ML – Special Authority see SA1101 al Liquid		armacy [H 500 ml C		Nutrison Concentrated
RENAL ORAL FEED 2KCAL/ML – Special Authority see SA110 Liquid	2.43	200 ml C		Nepro (strawberry) Nepro (vanilla)
Liquid (apricot)		237 ml C 125 ml C 125 ml C	NP VI	NovaSource Renal Renilon 7.5 Renilon 7.5
Specialised And Elemental Products				
Sality Special Authority for Subsidy Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voc for applications meeting the following criteria: Any of the following:         nalabsorption; or         short bowel syndrome; or         senterocutaneous fistulas; or         a pancreatitis. Notes: Each of these products is highly specialised and would be is hospitalisation.		-		
Elemental 028 Extra is more expensive than other products list have been tried first and/or are unsuitable. <b>Renewal</b> only from a dietitian, relevant specialist, vocationally register mendation of a dietitian, relevant specialist or vocationally register meeting the following criteria:	egistered general p	oractitioner	or genera	I practitioner on the recom
Both: 1 The treatment remains appropriate and the patient is ben 2 General Practitioners must include the name of the dietitia and date contacted.			tionally reg	gistered general practitione
ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Aut Powder		above – H 79 g OF 76 g OF	· 🖌 ۱	armacy [HP3] <b>/ital HN</b> Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML – Special Authority see Liquid (grapefruit) Liquid (pineapple & orange) Liquid (summer fruit)	9.50 9.50	Hospital p 250 ml C 250 ml C 250 ml C		HP3] Elemental 028 Extra Elemental 028 Extra Elemental 028 Extra

## SPECIAL FOODS

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA Powder (unflavoured)				
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Auth [HP3]			eding p	age – Hospital pharmacy
		1,000 ml OP	V Pe	eptisorb

## Undyalised End Stage Renal Failure

### ➡SA1103 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has undialysed end stage renal failure.

Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietitian.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

### Standard Supplements

### SA1104 Special Authority for Subsidy

**Initial application** — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
  - 2.1 The patient has a condition causing malabsorption; or
  - 2.2 The patient has failure to thrive; or
  - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Adults (This category cannot be processed electonically - fax paper copy)) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
  - Patient is Malnourished
  - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
  - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
  - 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

#### continued...

2 Any of the following:

Patient has not responded to first-line dietary measures over a 4 week period by:

- 2.1 Increasing their food intake frequency (eg snacks between meals); or
- 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
- 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
  - Patient is Malnourished
  - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
  - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
  - 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

**Initial application — (Adults transitioning from hospital Discretionary Community Supply)** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:
  - Patient is Malnourished
  - 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
  - 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
  - 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Specific medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery.

**Renewal** — (Specific medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery.

**Initial application** — (Chronic disease OR tube feeding) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Sub	osidised	Generic	
\$	Per	~	Manufacturer	

continued...

- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

ENTERAL FEED 1KCAL/ML - Special Authority see SA1104 on page 187 - Hospital pharmacy [HP3]

Liquid1.24	250 ml OP	<ul> <li>✓ Isosource Standard</li> <li>✓ Osmolite</li> </ul>
2.65	500 ml OP	<ul> <li>Nutrison Standard RTH</li> </ul>
5.29	1,000 ml OP	<ul> <li>Nutrison Standard RTH</li> </ul>
		<ul> <li>Isosource Standard RTH</li> </ul>
2.65	500 ml OP	<ul> <li>Osmolite RTH</li> </ul>
5.29	1,000 ml OP	<ul> <li>Osmolite RTH</li> </ul>
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority see SA1104 on Liquid	page 187 – Hosp 237 ml OP 500 ml OP 1,000 ml OP 500 ml OP 1,000 ml OP	<ul> <li>bital pharmacy [HP3]</li> <li>Jevity</li> <li>Nutrison Multi Fibre</li> <li>Nutrison Multi Fibre</li> <li>Jevity RTH</li> <li>Jevity RTH</li> </ul>
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority see SA1104 o Liquid	,	•

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or osidised Generic ✔ Manufacturer
ORAL FEED 1 KCAL/ML - Special Authority see SA1104 on page	e 187 – Hospita	al pharmacy [HI	23]
Powder (chocolate)	9.50	900 g OP	Ensure
	10.22		<ul> <li>Sustagen Hospital Formula</li> </ul>
Powder (strawberry)	4.22	400 g OP	Ensure
Powder (vanilla)		900 g OP	<ul> <li>Ensure</li> </ul>
	10.22		<ul> <li>Sustagen Hospital Formula</li> </ul>
(Ensure Powder (strawberry) to be delisted 1 March 2012)			
ORAL FEED 1.5KCAL/ML – Special Authority see SA1104 on pay Additional subsidy by endorsement is available for patients be endorsed accordingly.	0 1		-
Liquid (banana) - Higher subsidy of \$1.26 per 200 ml with			
Endorsement		200 ml OP	
	(1.26)		Ensure Plus
	(1.26)		Fortisip
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement		200 ml OP	
	(1.26)	237 ml OP	Ensure Plus
	0.85 (1.33)	237 MI OP	Ensure Plus
	0.72	200 ml OP	LIISULETIUS
	(1.26)	200 111 01	Fortisip
Liquid (coffee latte) - Higher subsidy of up to \$1.33 per	(=0)		i oraolp
237 ml with Endorsement	0.85	237 ml OP	
	(1.33)		Ensure Plus
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml			
with Endorsement	0.72	200 ml OP	
	(1.26)		Ensure Plus
Liquid (strawberry) - Higher subsidy of up to \$1.33 per			
237 ml with Endorsement		200 ml OP	
	(1.26)	007	Ensure Plus
	0.85 (1.33)	237 ml OP	Ensure Plus
	0.72	200 ml OP	LIISULE FIUS
	(1.26)	200 111 01	Fortisip
Liquid (toffee) - Higher subsidy of \$1.26 per 200 ml with En-	(1.20)		i ordolp
dorsement	0.72	200 ml OP	
	(1.26)		Fortisip
Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml	· · · ·		
with Endorsement	0.72	200 ml OP	
	(1.26)		Fortisip
Liquid (vanilla) - Higher subsidy of up to \$1.33 per 237 ml			
with Endorsement		200 ml OP	
	(1.26)		Ensure Plus
	0.85	237 ml OP	
	(1.33)		Ensure Plus
	0.72 (1.26)	200 ml OP	Fortisip
(Ensure Plus Liquid (coffee latte) to be delisted 1 March 2012)	(1.20)		

## SPECIAL FOODS

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
ORAL FEED WITH FIBRE 1.5 KCAL/ML - Special Authority see	SA1104 on page	e 187 – Hospita	al pharm	nacy [HP3]
Additional subsidy by endorsement is available for patients be	eing bolus fed th	nrough a feedir	ng tube.	The prescription must be
endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72	200 ml OP		
	(1.26)		Fo	ortisip Multi Fibre
Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement	0.72	200 ml OP		
Lindoisement	(1.26)	200 111 01	Fo	ortisip Multi Fibre
Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with				
Endorsement	0.72 (1.26)	200 ml OP	F	ortisip Multi Fibre
	(1.20)			

## **Adult Products High Calorie**

### ➡SA1105 Special Authority for Subsidy

**Initial application** — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

All of the following:

- 1 Cystic fibrosis; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

**Initial application** — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
  - 1.1 any condition causing malabsorption; or
  - 1.2 failure to thrive; or
  - 1.3 increased nutritional requirements; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements.

**Renewal** — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ORAL FEED 2KCAL/ML - Special Authority see SA1105 above - Hospital pharmacy [HP3]

Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube. The prescription must be endorsed accordingly.

Liquid (vanilla) - Higher subsidy of \$2.25 per 237 ml with

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per	Brand or Generic Manufacturer
Food Thickeners			
<ul> <li>SA1106 Special Authority for Subsidy         Initial application only from a dietitian, relevant specialist or where the patient has motor neurone disease with swallowing         Renewal only from a dietitian, relevant specialist, vocationally mendation of a dietitian, relevant specialist or vocationally reg meeting the following criteria:         Both:         1 The treatment remains appropriate and the patient is the 2 General Practitioners must include the name of the die and date contacted.     </li> </ul>	<ul> <li>g disorder.</li> <li>y registered general practitionel</li> <li>istered general practitionel</li> <li>penefiting from treatment; a</li> </ul>	tioner or general r. Approvals valio and	practitioner on the recom I for 1 year for application:
FOOD THICKENER – Special Authority see SA1106 above - Powder		•	aricare Food Thickener
Gluten Free Foods			
The funding of gluten free foods is no longer being actively m longer considering the listing of new products, or making subs that the range of funded items will reduce over time. Manage outcomes. A range of gluten free options are available throug ▶SA1107 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist o further renewal unless notified for applications meeting the fo Either:	sidy, or other changes to th ment of Coeliac disease w h retail outlets. r vocationally registered ge	e existing listings vith a gluten free	s. As a result we anticipate diet is necessary for good
1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.			
GLUTEN FREE BAKING MIX - Special Authority see SA110	7 above – Hospital pharm	acy [HP3]	

Powder		1.000 g OP	
	(5.15)	2	Healtheries Simple Baking Mix
GLUTEN FREE BREAD MIX - Special Authority see SA1107 above -	- Hospital p	harmacy [HP3]	
Powder	3.93	1,000 g OP	
	(7.32)		NZB Low Gluten Bread Mix
	4.77		
	(8.71)		Bakels Gluten Free Health Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR - Special Authority see SA1107 above - Hos			
Powder	5.62 (18.10)	2,000 g OP	Horleys Flour

	Subsidy (Manufacturer's Pric \$		Fully Brand or ised Generic Manufacturer
GLUTEN FREE PASTA - Special Authority see SA1107 on the p	receding page - H	ospital pharmad	cy [HP3]
Buckwheat Spirals	2.00	250 g OP	
	(3.11)		Orgran
Corn and Vegetable Shells	2.00	250 g OP	
	(2.92)		Orgran
Corn and Vegetable Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Lasagne Sheets	1.60	200 g OP	
	(3.82)		Orgran
Rice and Corn Macaroni	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Penne	2.00	250 g OP	
	(2.92)		Orgran
Rice and Maize Pasta Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Millet Spirals	2.00	250 g OP	
	(3.11)		Orgran
Rice and corn spaghetti noodles	2.00	375 g OP	
	(2.92)		Orgran
Vegetable and Rice Spirals	2.00	250 g OP	
	(2.92)		Orgran
Italian long style spaghetti	2.00	220 g OP	
	(3.11)		Orgran

## Foods And Supplements For Inborn Errors Of Metabolism

### SA1108 Special Authority for Subsidy

**Initial application** only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

### **Supplements For Homocystinuria**

AMINOACID FORMULA WITHOUT METHIONINE – Special Authority see SA11 Powder	
Supplements For MSUD	
AMINOACID FORMULA WITHOUT VALINE, LEUCINE AND ISOLEUCINE -	- Special Authority see SA1108 above - Hospital

pharmacy [HP3]		
Powder	500 g OP	MSUD Maxamaid
437.22	-	MSUD Maxamum

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
Supplements For PKU	Ţ		
AMINOACID FORMULA WITHOUT PHENYLALANINE – Specia	I Authority see	SA1108 on the	preceding page - Hospital phar-
macy [HP3]			
Tabs		75 OP	Phlexy 10
Sachets (pineapple/vanilla) 29 g		30 OP	Minaphlex
Sachets (tropical)		30	Phlexy 10
Infant formula		400 g OP	PKU Anamix Infant
Powder (orange)		500 g OP	✓ XP Maxamaid
	320.00		V XP Maxamum
Powder (unflavoured)		500 g OP	XP Maxamaid
	320.00		V XP Maxamum
Liquid (berry)		62.5 ml OP	PKU Lophlex LQ
	31.20	125 ml OP	PKU Lophlex LQ
Liquid (citrus)		62.5 ml OP	PKU Lophlex LQ
	31.20	125 ml OP	PKU Lophlex LQ
Liquid (forest berries)		250 ml OP	<ul> <li>Easiphen Liquid</li> </ul>
Liquid (orange)		62.5 ml OP	PKU Lophlex LQ
	31.20	125 ml OP	PKU Lophlex LQ
Liquid (tropical)		250 ml OP	<ul> <li>Easiphen</li> </ul>
Foods			
LOW PROTEIN BAKING MIX – Special Authority see SA1108 on Powder	1 0	page – Hospital 500 g OP	pharmacy [HP3] Loprofin Mix
LOW PROTEIN PASTA - Special Authority see SA1108 on the pr	eceding page -	- Hospital pharm	nacy [HP3]
Animal shapes		500 g OP	✓ Loprofin
Lasagne	5.95	250 g OP	✓ Loprofin
Low protein rice pasta	11.91	500 g OP	✓ Loprofin
Macaroni	5.95	250 g OP	<ul> <li>Loprofin</li> </ul>
Penne	11.91	500 g OP	<ul> <li>Loprofin</li> </ul>
Spaghetti		500 g OP	<ul> <li>Loprofin</li> </ul>
Spirals	11.91	500 g OP	<ul> <li>Loprofin</li> </ul>
Multivitamin And Mineral Supplements			
AMINOACID FORMULA WITH MINERALS WITHOUT PHENYLAI – Retail pharmacy	LANINE – Spe	ecial Authority se	e SA1108 on the preceding page
Powder	23.38	100 g OP	<ul> <li>Metabolic Mineral Mixture</li> </ul>
(Metabolic Mineral Mixture Powder to be delisted 1 May 2012)			
Infant Formulae			
For Premature Infants			
►SA1109 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vo months where the patient is infant weighing less than 1.5 kg at birl PREMATURE BIRTH FORMULA – Special Authority see SA1109 Liquid	th. above – Hosp	0	

Subsidy		Fully	Brand or
(Manufacturer's Price)	S	Subsidised	Generic
\$	Per	~	Manufacturer

### For Williams Syndrome

### ➡SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA - Special Authority see SA1110 above - Hospital pharmacy [HP3]

### **Gastrointestinal and Other Malabsorptive Problems**

AMINO ACID FORMULA - Special Authority see SA1111 below - Hospital pharm	nacy [HP3]	
Powder6.00	48.5 g OP	Vivonex Pediatric
56.00	400 g OP	Neocate
		Neocate LCP
Powder (tropical)56.00	400 g OP	Neocate Advance
Powder (unflavoured)	400 g OP	Elecare
	-	Elecare LCP
		Neocate Advance
Powder (vanilla)56.00	400 g OP	<ul> <li>Elecare</li> </ul>

### SA1111 Special Authority for Subsidy

**Initial application** — (Transition from Old Form (SA0603)) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient is currently receiving funded amino acid formula under Special Authority form SA0603; and
- 2 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and
- 3 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 4 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption; or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken; and

Subsidy (Manufacturer's Price)	ç	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

- 2 The outcome of the assessment is that the infant continues to require an amino acid infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

EXTENSIVELY HYDROLYSED FORMULA -	- Special Authority see SA1112 below -	<ul> <li>Hospital pharmacy [HP3]</li> </ul>

Powder15.21	450 g OP	🖌 Pepti Junior Gold
-------------	----------	---------------------

### ➡SA1112 Special Authority for Subsidy

Initial application — (Transition from Old Form (SA0603)) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: Either:

- 1 All of the following:
  - 1.1 The infant is currently receiving funded amino acid formula under Special Authority form SA0603; and
  - 1.2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
  - 1.3 General Practitioners must include the name of the relevant specialist or vocationally registered general practitioner and the date contacted; or
- 2 All of the following:
  - 2.1 The patient is currently receiving funded extensively hydrolysed formula under Special Authority form SA0603; and
  - 2.2 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
  - 2.3 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
  - 2.4 General Practitioners must include the name of the relevant specialist or vocationally registered general practitioner and the date contacted.

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Both:
  - 1.1 Cows milk formula is inappropriate due to severe intolerance or allergy to its protein content; and
  - 1.2 Either:
    - 1.2.1 Soy milk formula has been trialled without resolution of symptoms; or
    - 1.2.2 Soy milk formula is considered clinically inappropriate or contraindicated; or
- 2 Severe malabsorption; or
- 3 Short bowel syndrome; or
- 4 Intractable diarrhea; or
- 5 Biliary atresia; or
- 6 Cholestatic liver diseases causing malsorption; or
- 7 Chylous ascite; or
- 8 Chylothorax; or
- 9 Cystic fibrosis: or
- 10 Proven fat malabsorption; or
- 11 Severe intestinal motility disorders causing significant malabsorption; or
- 12 Intestinal failure.

**Renewal** only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and

## SPECIAL FOODS

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

continued...

3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

### All of the following:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

## Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml
AMINOPHYLLINE ✓ Inj 25 mg per ml, 10 ml5
AMIODARONE HYDROCHLORIDE Inj 50 mg per ml, 3 ml
AMOXYCILLIN ✓ Cap 250 mg
AMOXYCILLIN CLAVULANATE Tab amoxycillin 500 mg with potassium clavulanate 125 mg
5 ml
ASPIRIN V Tab dispersible 300 mg
АТROPINE SULPHATE ✔ Inj 600 µg, 1 ml
AZITHROMYCIN ✓ Tab 500 mg – Subsidy by endorsement – See note on page 80
BENDROFLUAZIDE ✔ Tab 2.5 mg – See note on page 54150
BENZATHINE BENZYLPENICILLIN ✓ Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE V Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G)
<ul> <li>CEFTRIAXONE SODIUM</li> <li>✓ Inj 500 mg – Subsidy by endorsement – See note on page 79</li></ul>
CHARCOAL V Oral liq 50 g per 250 ml

CHLORPROMAZINE HYDROCHLORIDE       ✓         ✓ Tab 10 mg       30         ✓ Tab 25 mg       30         ✓ Tab 100 mg       30         ✓ Inj 25 mg per ml, 2 ml       5
CIPROFLOXACIN ✓ Tab 250 mg
<ul> <li>CO-TRIMOXAZOLE</li> <li>✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg</li></ul>
COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g
CONDOMS       144         ✓ 49 mm       144         ✓ 52 mm       144         ✓ 52 mm extra strength       144         ✓ 53 mm       144         ✓ 53 mm (chocolate)       144         ✓ 53 mm (strawberry)       144         ✓ 53 mm extra strength       144         ✓ 53 mm extra strength       144         ✓ 53 mm extra strength       144         ✓ 55 mm       144         ✓ 56 mm       144         ✓ 56 mm       144         ✓ 56 mm       144         ✓ 60 mm       144
DEXAMETHASONE ✓ Tab 1 mg – Retail pharmacy-Specialist
DEXAMETHASONE SODIUM PHOSPHATE Inj 4 mg per ml, 1 ml – See note on page 72
DEXTROSE ✓ Inj 50%, 10 ml
DIAPHRAGM ✓ 65 mm – See note on page 66

✓ fully subsidised brand available

## PRACTITIONER'S SUPPLY ORDERS

(continued)

DIAZEPAM ✓ Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 1215 ✓ Rectal tubes 5 mg5 ✓ Rectal tubes 10 mg5
DICLOFENAC SODIUM           ✓ Inj 25 mg per ml, 3 ml           ✓ Suppos 50 mg           10
DIGOXIN ✔ Tab 62.5 μg
DOXYCYCLINE HYDROCHLORIDE           Tab 50 mg
ERGOMETRINE MALEATE ✔ Inj 500 µg per ml, 1 ml
ERYTHROMYCIN ETHYL SUCCINATE Tab 400 mg
ERYTHROMYCIN STEARATE Tab 250 mg
ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 µg with desogestrel 150 µg63 Tab 20 µg with desogestrel 150 µg and 7 inert tab
ETHINYLOESTRADIOL WITH LEVONORGESTREL ✓ Tab 50 µg with levonorgestrel 125 µg and 7 inert tab
<ul> <li>ETHINYLOESTRADIOL WITH NORETHISTERONE</li> <li>✓ Tab 35 µg with norethisterone 1 mg</li></ul>
inert tab84

FLUCLOXACILLIN	SODIUM
LOOLONAULLIN	30010101

<ul> <li>✓ Cap 250 mg</li></ul>
FLUPENTHIXOL DECANOATE ✓ Inj 20 mg per ml, 1 ml
FLUPHENAZINE DECANOATE ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml5 ✓ Inj 25 mg per ml, 1 ml5 ✓ Inj 100 mg per ml, 1 ml5
FUROSEMIDE ✔ Tab 40 mg
GLUCAGON HYDROCHLORIDE ✔ Inj 1 mg syringe kit5
GLYCERYL TRINITRATE ✔ Tab 600 µg 100 ✔ Oral pump spray 400 µg per dose
HALOPERIDOL ✓ Tab 500 μg
HALOPERIDOL DECANOATE ✔ Inj 50 mg per ml, 1 ml5 ✔ Inj 100 mg per ml, 1 ml5
HYDROCORTISONE ✔ Inj 50 mg per ml, 2 ml5
HYDROXOCOBALAMIN ✔ Inj 1 mg per ml, 1 ml6
HYOSCINE N-BUTYLBROMIDE Inj 20 mg, 1 ml5
INTRA-UTERINE DEVICE ✔ IUD40
IPRATROPIUM BROMIDE ✔ Nebuliser soln, 250 µg per ml, 1 ml40 ✔ Nebuliser soln, 250 µg per ml, 2 ml40
LEVONORGESTREL Tab 30 µg
continued

✓ fully subsidised brand available Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

continued)
LIGNOCAINE
✓ Gel 2%, 10 ml urethral syringe – Subsidy by
endorsement - See note on page 1155
LIGNOCAINE HYDROCHLORIDE ✓ Inj 1%, 5 ml
✓ Inj 1%, 5 ml
✓ Inj 1%, 20 ml
✓ Inj 2%, 20 ml
LIGNOCAINE WITH CHLORHEXIDINE
✓ Gel 2% with chlorhexidine 0.05%,
10 ml urethral syringes – Subsidy by
endorsement - See note on page 1155
LOPERAMIDE HYDROCHLORIDE
✓ Tab 2 mg
MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 165
MEDROXYPROGESTERONE ACETATE Inj 150 mg per ml, 1 ml syringe
METOCLOPRAMIDE HYDROCHLORIDE Inj 5 mg per ml, 2 ml
METRONIDAZOLE V Tab 200 mg
-
MORPHINE SULPHATE Inj 5 mg per ml, 1 ml – Only on a controlled
drug form
✓ Inj 10 mg per ml, 1 ml – Only on a controlled
drug form5
✓ Inj 15 mg per ml, 1 ml – Only on a controlled
drug form5 ✓ Inj 30 mg per ml, 1 ml – Only on a controlled
drug form
NALOXONE HYDROCHLORIDE
✓ Inj 400 µg per ml, 1 ml
NICOTINE
✓ Patch 7 mg – See note on page 139
✓ Patch 14 mg – See note on page 139
✓ Patch 21 mg – See note on page 139
✓ Lozenge 1 mg – See note on page 139
<ul> <li>✓ Lozenge 2 mg – See note on page 139</li></ul>
✓ Gum 2 mg (Fruit) – See note on page 139
✓ Gum 2 mg (Mint) – See note on page 139
✓ Gum 4 mg (Classic) – See note on page 139
<ul> <li>✓ Gum 4 mg (Fruit) – See note on page 139</li></ul>
<ul> <li>✓ Gum 2 mg (Mint) – See note on page 139</li></ul>

## NORETHISTERONE NORETHISTERONE WITH MESTRANOL OXYTOCIN ✓ Inj 10 iu per ml, 1 ml ......5 ✓ Ini 5 iu with ergometrine maleate 500 µg per ml, 1 ml......5 PARACETAMOL ✓ Oral lig 120 mg per 5 ml ...... 200 ml ✓ Oral liq 250 mg per 5 ml ..... 100 ml PEAK FLOW METER ✓ Normal range......10 PETHIDINE HYDROCHLORIDE ✓ Ini 50 mg per ml. 1 ml – Only on a controlled drug form ......5 ✓ Inj 50 mg per ml, 2 ml – Only on a controlled drug form ......5 PHENOXYMETHYLPENICILLIN (PENICILLIN V) ✓ Grans for oral lig 125 mg per 5 ml ...... 200 ml ✓ Grans for oral lig 250 mg per 5 ml ...... 200 ml PHENYTOIN SODIUM ✓ Inj 50 mg per ml, 2 ml ......5 ✓ Inj 50 mg per ml, 5 ml ......5 PHYTOMENADIONE ✓ Inj 10 mg per ml, 1 ml ......5 PIPOTHIAZINE PALMITATE ✓ Inj 50 mg per ml, 2 ml ......5 PREDNISOLONE SODIUM PHOSPHATE ✓ Oral lig 5 mg per ml – See note on PREDNISONE PREGNANCY TESTS - HCG URINE PROCAINE PENICILLIN ✓ Inj 1.5 mega u.....5 continued...

## PRACTITIONER'S SUPPLY ORDERS

(continued)

PROCHLORPERAZINE           ✓ Tab 5 mg
PROMETHAZINE HYDROCHLORIDE ✓ Inj 25 mg per ml, 2 ml
SALBUTAMOL ✓ Inj 500 µg per ml, 1 ml
SALBUTAMOL WITH IPRATROPIUM BROMIDE Vebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml20
SILVER SULPHADIAZINE ✓ Crm 1%250 g
SODIUM BICARBONATE ✓ Inj 8.4%, 50 ml

SODIUM CHLORIDE           ✓ Inf 0.9% - See note on page 43
SPACER DEVICE           ✓ 230 ml (single patient)           ✓ 800 ml           20
SPACER DEVICE AUTOCLAVABLE ✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 1655
TRIMETHOPRIM ✓ Tab 300 mg
VERAPAMIL HYDROCHLORIDE Verapa Inj 2.5 mg per ml, 2 ml
WATER ✓ Purified for inj, 5 ml – See note on page 445 ✓ Purified for inj, 10 ml – See note on page 445 ✓ Purified for inj, 20 ml – See note on page 445
ZUCLOPENTHIXOL DECANOATE Inj 200 mg per ml, 1 ml

### **Rural Areas for Practitioner's Supply Orders**

## NORTH ISLAND

#### Northland DHB

Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene **Ruakaka** Russell Tutukaka Waipu Whangaroa

### Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

#### Auckland DHB

Great Barrier Island Oneroa Ostend

#### Counties Manukau DHB

Tuakau Waiuku

### Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

#### **Bay of Plenty DHB**

Edgecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

#### Lakes DHB Mangakino

Turangi Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

#### Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

#### Hawkes Bay DHB

Chatham Islands Waipawa Waipukurau Wairoa **Whanganui DHB** Bulls Waiouru MidCentral DHB Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville Wairarapa DHB Carteron

Marton

Raetihi

Taihape

Ohakune

Featherston Greytown Martinborough

#### SOUTH ISLAND

#### Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

### West Coast DHB

Dobson Greymouth Hokitika Karamea Reefton South Westland Westport Whataroa

### Canterbury DHB

Akaroa Amberley Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura Leeston Lincoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

#### South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

#### Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburgh Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

✓ fully subsidised brand available

## SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is Close Control.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is Close Control.

## SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

- a) the Community Pharmaceutical is identified with a ▲ within the other sections of the Pharmaceutical Schedule and the prescriber has endorsed the Prescription item(s) on the Prescription to which the exemption applies "certified exemption". In endorsing the Prescription items for a certified exemption, the prescriber is certifying that:
  - i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
  - ii) the patient has been stabilised on the same medicine for a reasonable period of time; and

iii) the prescriber has reason to believe the patient will continue on the medicine and is compliant.

b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:

i) have limited physical mobility;

- ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- iii) are relocating to another area;
- iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

The following Community Pharmaceuticals are identified with a A within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM INSULIN ASPART		MUSCULOSKELETAL SYSTEM PYRIDOSTIGMINE BROMIDE
INSULIN GLARGINE		
INSULIN GLULISINE		NERVOUS SYSTEM AMANTADINE HYDROCHLORIDE
INSULIN ISOPHANE		
INSULIN ISOPHANE WITH INSULIN NEUTRAL INSULIN LISPRO INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE INSULIN NEUTRAL		APOMORPHINE HYDROCHLORIDE
		ENTACAPONE
		GABAPENTIN
		GABAPENTIN (NEURONTIN)
INSOLIN NEOTHAL		LACOSAMIDE
CARDIOVASCULAR SYSTEM		LAMOTRIGINE
AMIODARONE HYDROCHL Tab 100 mg	ORIDE Cordarone-X	LISURIDE HYDROGEN MALEATE
Tab 200 mg	Cordarone-X	PERGOLIDE
DISOPYRAMIDE PHOSPH	ATE	ROPINIROLE HYDROCHLORIDE
FLECAINIDE ACETATE Tab 50 mg	Tambocor	TOLCAPONE
Tab 100 mg	Tambocor	TOPIRAMATE
Cap long-acting 100 mg Cap long-acting 200 mg		VIGABATRIN
PROPAFENONE HYDROCH	HLORIDE	
		SENSORY ORGANS BIMATOPROST
HORMONE PREPARATIONS CONTRACEPTIVE HORMONE		BRIMONIDINE TARTRATE WITH TIMO

DESMOPRESSIN Nasal drops 100 µg per Minirin ml Nasal spray 10 µg per Desmopressin-PH&T dose ENSORY ORGANS BIMATOPROST BRIMONIDINE TARTRATE WITH TIMOLOL MALEATE BRINZOLAMIDE LATANOPROST TRAVOPROST

## SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

## **Exemptions**

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular
  person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

### Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

## Safety Caps (NZS 5825:1991)

20 mm	. Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG

## SAFETY CAP MEDICINES

ALIMENTARY TRACT AND MI	ETABOLISM	CLOBAZAM	
FERROUS SULPHATE		Tab 10 mg	Frisium
Oral liq 30 mg per 1 ml (6 mg elemental per	Ferodan	(Extemporaneously compounde	ed oral liquid preparations)
1 ml)		01.0114755444	
,		CLONAZEPAM	Divertril
CARDIOVASCULAR SYSTEM		Oral drops 2.5 mg per ml	Rivotril
AMILORIDE	<b>D</b>	110	
Oral liq 1 mg per ml	Biomed	DIAZEPAM	
CAPTOPRIL		Tab 2 mg	Arrow-Diazepam
Oral liq 5 mg per ml	Capoten	Tab 5 mg	Arrow-Diazepam
CHLOROTHIAZIDE		(Extemporaneously compounde	ed oral liquid preparations)
Oral lig 50 mg per ml	Biomed		
Of an ing 50 mg per mi	Diomed	ETHOSUXIMIDE	
DIGOXIN		Oral liq 250 mg per 5 ml	Zarontin
Oral liq 50 µg per ml	Lanoxin	LORAZEPAM	
FUROSEMIDE		Tab 1 mg	Ativan
Oral lig 10 mg per ml	Lasix	Tab 2.5 mg	Ativan
1 01		(Extemporaneously compounde	
SPIRONOLACTONE	<b>D</b>	(	a orar ngara propulationo)
Oral liq 5 mg per ml	Biomed	LORMETAZEPAM	
HORMONE PREPARATIONS -	SYSTEMIC EXCLUDING	Tab 1 mg	Noctamid
CONTRACEPTIVE HORMONE	S	(Extemporaneously compounde	
LEVOTHYROXINE		(	a orar ngara propulationo)
Tab 25 µg	Synthroid	METHADONE HYDROCHLO	סואַר
Tab 50 µg	Eltroxin	Oral lig 2 mg per ml	Biodone
	Goldshield	Oral liq 5 mg per ml	Biodone Forte
Tab 100 ug	Synthroid Eltroxin	Oral lig 10 mg per ml	Biodone Extra Forte
Tab 100 µg	Goldshield		
	Synthroid	MIDAZOLAM	
(Extemporaneously compounde	,	Tab 7.5 mg	Hypnovel
( ,	······································	(Extemporaneously compounde	eu orai ilquiu preparations)
MUSCULOSKELETAL SYSTE	M		
IBUPROFEN		MORPHINE HYDROCHLOP	
Oral liq 100 mg per 5 ml	Fenpaed	Oral liq 1 mg per ml Oral liq 2 mg per ml	RA-Morph RA-Morph
QUININE SULPHATE		Oral lig 5 mg per ml	RA-Morph
Tab 200 mg	Q 200	Oral liq 10 mg per ml	RA-Morph
Tab 300 mg	Q 300		F
(Extemporaneously compounde	ed oral liquid preparations)	NITRAZEPAM	
	,	Tab 5 mg	Nitrados
NERVOUS SYSTEM		(Extemporaneously compounde	eu oral liquid preparations)
ALPRAZOLAM			
Tab 250 µg	Arrow-Alprazolam	OXAZEPAM	0 . D
Tab 500 µg	Arrow-Alprazolam	Tab 10 mg	Ox-Pam
Tab 1 mg	Arrow-Alprazolam	Tab 15 mg (Extemporaneously compounde	Ox-Pam
(Extemporaneously compounde	ea orai ilquia preparations)	(Enterriporaneously compounde	ο σται πημιώ μτερατατίοπος
CARBAMAZEPINE		OXYCODONE HYDROCHLO	ORIDE
	Tegretol	Oral lig 5 mg per 5 ml	OxyNorm
		2.00. ng 0 mg por 0 mi	

## SAFETY CAP MEDICINES

PARACETAMOL

Oral liq 120 mg per 5 ml

Oral lig 250 mg per 5 ml

PHENYTOIN SODIUM Oral lig 30 mg per 5 ml

Dilantin

SODIUM VALPROATE Oral lig 200 mg per 5 ml Epilim S/F Liquid

Epilim Syrup

Paracare Junior

Ethics Paracetamol

Paracare Double Strength

TEMAZEPAM Normison Tab 10 mg (Extemporaneously compounded oral liquid preparations)

### TRIAZOLAM

Tab 125 µg Hypam Tab 250 µg Hypam (Extemporaneously compounded oral liquid preparations)

### **RESPIRATORY SYSTEM AND ALLERGIES**

CETIRIZINE HYDROCHLORIDE Cetirizine - AFT Oral liq 1 mg per ml

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral lig 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE

Promethazine Oral liq 5 mg per 5 ml Winthrop Elixir

SALBUTAMOL Oral liq 2 mg per 5 ml Salapin

THEOPHYLLINE Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral lig 30 mg per 5 ml Vallergan Forte

#### EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

CODEINE PHOSPHATE Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

- Symbols -
3TC92
- A -
A-Lices
A-Scabies62
Abacavir sulphate91
Abacavir sulphate with
lamivudine91
Abilify127
ABM Hydroxocobalamin
Acarbose
Accu-Chek Performa32
Accupril48
Accuretic 1048
Accuretic 2048
Acetadote176
Acetazolamide168
Acetic acid with 1, 2- propanediol
diacetate and
benzethonium 166
Acetic acid with hydroxyquinoline
and ricinoleic acid69
Acetylcysteine176
Aci-Jel69
Aciclovir
Infection88
Sensory166
Acidex
Acipimox44
Acitretin62
Aclasta111
Actigall
Actrapid
Actrapid Penfill
Acupan116
Adalat 10
Adalat Oros
Adalimumab98
Adapalene
Adefin XL
Adefovir dipivoxil
Adrenaline
Advantan
AFT-Leflunomide
AFT-Pyrazinamide
Agents Affecting the Renin-Angiotensin System47
Agents for Parkinsonism and
Related Disorders
Poisonings
Agrylin145


A.1	404
Alanase	
Albay	
Albustix	
Aldara	64
Alendronate sodium	.109
Alendronate sodium with	
cholecalciferol	109
cholecalciferol Alfacalcidol	37
Alginic acid	26
Alitrag	.186
Alkeran	.140
Allersoothe	.160
Allopurinol	.113
Alpha Adrenoceptor Blockers	47
Alpha-Keri Lotion	61
Alphamox	
Alprazolam	131
Alu-Tab	26
Aluminium hydroxido	20 06
Aluminium hydroxide Amantadine hydrochloride	20
Amantauline hydrochlonde	.114
Ambrisentan	55
Amiloride	53
Amiloride with frusemide	53
Amiloride with	
hydrochlorothiazide	53
Aminophylline	.164
Amiodarone hydrochloride	49
Amirol	.118
Amisulpride	.127
Amitrip	.118
Amitriptyline	.118
Amlodipine	52
Amorolfine	57
Amoxycillin	81
Amoxycillin clavulanate	
Amphotericin B	36
Amsacrine	145
Amsidine	145
Amyl nitrite	5/
Anabolic Agents	
Anaesthetics	115
Anagrelide hydrochloride	- 115
Analgesics	.140
Analgesics	.110
Androderm	
Antabuse	.138
Antacids and Antiflatulants	
Anten	.119
Anthelmintics	79
Antiacne Preparations	56
Antiacne Preparations Antiallergy Preparations	.159
Antianaemics	40

Antiandrogen Oral	
Contraceptives	69
Antiarrhythmics	49
Antibacterials	
Antibacterials Topical	57
Anticholinesterases	97
Antidepressants1	18
Antidiarrhoeals	
Antiepilepsy Drugs1	21
Antifibrinolytics, Haemostatics	
and Local Sclerosants	41
Antifungals	
Antifungals Topical	57
Antihaemorrhoidals	28
Antihistamines1	
Antihypotensives	
Antimalarials	85
Antimigraine Preparations1	25
Antinaus1	
Antinausea and Vertigo	
Agents 1	25
Antipruritic Preparations	58
Antipsychotics1	27
Antiretrovirals	
Antiretrovirals - Additional	
Therapies	92
Antirheumatoid Agents	
Antispasmodics and Other	00
Agents Altering Gut	
Motility	28
Antithrombotic Agents	41
Antithymocyte globulin	- 1
(equine)1	54
Antitrichomonal Agents	85
Antituberculatics and	
Antituberculotics and	
Antileprotics	85
Antileprotics Antiulcerants	85 28
Antileprotics Antiulcerants Antivirals	85 28 86
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47 30
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47 30 30
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47 30 30 13
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47 30 30 13 13
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47 30 30 13 13 52
Antileprotics	85 28 86 31 47 30 30 13 13 52 14
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 86 31 47 30 30 13 13 52 14
Antileprotics Antiulcerants Antivirals Anxiolytics	85 28 31 47 30 30 13 52 14 28
Antileprotics	85 28 31 47 30 30 13 13 52 14 28 28
Antileprotics	85 28 31 47 30 13 13 52 14 28 28 80
Antileprotics	85 28 86 31 47 30 30 13 13 52 14 28 28 80 18

Apo-Doxazosin47
Apo-Folic Acid40
Apo-Gliclazide
Apo-Megestrol152
Apo-Moclobemide119
Apo-Nadolol51
Apo-Nicotinic Acid45
Apo-Oxybutynin71
Apo-Pindolol51
Apo-Prazo47
Apo-Prednisone73
Apo-Primidone
Apo-Pyridoxine
Apo-Risperidone129
Apo-Selegiline114
Apo-Selegiline S29114
Apo-Terbinafine85
Apo-Thiamine
Apo-Timol51
Apo-Timop167
Apo-Zopiclone134
Apomine
Apomorphine hydrochloride114
Aprepitant125
Apresoline
Aquasun 30+64
Aqueous cream61
Aratac
Arava
Aremed154
Arimidex154
Aripiprazole127
Aristocort
Aromasin154
Arrow-Alprazolam131
Arrow-Azithromycin
Arrow-Bendrofluazide
Arrow-Cabergoline
Arrow-Calcium
Arrow-Citalopram
Arrow-Diazepam
Arrow-Enalapril
Arrow-Etidronate
Arrow-Lamotrigine
Arrow-Lisinopril
Arrow-Losartan &
Hydrochlorothiazide
Arrow Molovicom
Arrow-Meloxicam98
Arrow Morphipo I A
Arrow-Morphine LA117
Arrow-Morphine LA117 Arrow-Nifedipine XR52
Arrow-Morphine LA117 Arrow-Nifedipine XR52 Arrow-Norfloxacin95
Arrow-Morphine LA117 Arrow-Nifedipine XR52

Arrow-Roxithromycin81
Arrow-Sertraline120
Arrow-Simva 10mg45
Arrow-Simva 20mg45
Arrow-Simva 40mg45
Arrow-Simva 80mg45
Arrow-Sumatriptan125
Arrow-Testosterone73
Arrow-Timolol167
Arrow-Topiramate124
Arrow-Tramadol116
Arrow-Venlafaxine XR120
Arrowcare97
Arsenic trioxide145
Arthrexin
Asacol27
Asamax27
Ascorbic acid37
Aspec 300116
Aspen Adrenaline54
Aspen Ceftriaxone79
Aspirin
Blood41
Nervous116
Asthalin162
Atacand
Atazanavir sulphate92
Atenolol
Atenolol Tablet USP50
ATGAM154
Ativan
Atomoxetine
Atorvastatin45
Atropine sulphate
Alimentary
Sensory
Atropt
Atrovent
Auranofin
Avanza
Avelox
Avenine
Avonex
Azathioprine154
Azithromycin80
Azol
Azopt168 AZT92
- B - B-D Micro-Fine
B-D Ultra Fine
B-D Ultra Fine II
B-PlexADE37

Bacillus calmette-guerin (BCG)
vaccine155
Baclofen113
Bactroban57
Bakels Gluten Free Health Bread
Mix
Baraclude86
Barrier Creams and
Emollients
Batrafen
Beclazone 100
Beclazone 250
Beclazone 50
Beclomethasone
dipropionate 160, 164
Bee venom allergy treatment
Bendrofluazide
Benhex
Benzathine benzylpenicillin81
Benzoin176
Benztrop115
Benztropine mesylate115
Benzydamine hydrochloride
Benzylpenicillin sodium (penicillin
G) 81
Beta Adrenoceptor Blockers50
Beta Cream
Beta Ointment59
Beta Scalp64
Beta-Adrenoceptor Agonists162
Betadine
Betadine Skin Prep62
Betaferon
Betagan
Betahistine dihydrochloride
Betaloc
Betaloc CR51
Betamethasone dipropionate
Betamethasone dipropionate
with calcipotriol
Betamethasone sodium
phosphate with
betamethasone acetate72
Betamethasone valerate
Betamethasone valerate with
clioquinol60
Betamethasone valerate with
fusidic acid60
Betaxolol hydrochloride167
Betnovate
Betnovate-C60
Betoptic167



Betoptic S         167           Bezafibrate         44           Bezalip Retard         44           Bicalaccord         152           Bicalaccord         152           Bicalutamide         152           Bicalutamide         152           Bicillin LA         81           BiCNU         140           Bimatoprost         168           Biodone         117           Biodone Extra Forte         117           Biodone Forte         117           Bisacodyl         35           BK Lotion         61           Bleomycin sulphate         145           Blood glucose diagnostic test         145
meter
Blood glucose diagnostic test
strip
Bonjela
Bortezomib145
Bosentan55
Breath-Alert165
Brevinor 1/2168
Brevinor 1/2868
Brevinor 21
Bricanyl Turbuhaler
Brimonidine tartrate
Brimonidine tartrate with timolol
maleate
Brinzolamide
Brolene
Bromocriptine mesylate114
Brufen
Brufen SR97
Buccastem126
Budenocort160
Budesonide
Alimentary
Respiratory160, 164
Budesonide with
eformoterol
Bumetanide
Bupropion hydrochloride138
Burinex
Buscopan
Buspirone hydrochloride
Busulphan140
Butacort Aqueous164
•
- C -
Cabergoline78
Cafergot125
Caffeine citrate165

Cal-d-Forte37
Calamine58
Calci-Tab 500
Calci-Tab 60038
Calcipotriol63
Calcitonin109
Calcitriol37
Calcium carbonate38
Calcium carbonate with
aminoacetic acid
Calcium Channel Blockers52
Calcium Disodium Versenate39
Calcium folinate141
Calcium Folinate Ebewe141
Calcium gluconate38
Calcium polystyrene
sulphonate
Calcium Resonium44
Calogen182
Calsource
Camptosar144
Candesartan48
Candestar48
Canesten57
Capecitabine141
Capoten47
Capsaicin65
Captopril47
Carafate29
Carbamazepine121
Carbimazole76
Carboplatin140
Carboplatin Ebewe140
Carbosorb-X39
Cardinol51
Cardinol LA51
Cardizem CD52
CareSens
CareSens II
CareSens POP32
Carmustine140
Carvedilol50
Catapres53
Catapres-TTS-153
Catapres-TTS-253
Catapres-TTS-353
CeeNU140
Cefaclor monohydrate
Cefaclor Sandoz
Cefalexin Sandoz
Cefazolin sodium
Cefoxitin sodium
Ceftriaxone sodium79

Cefuroxime axetil79
Cefuroxime sodium79
Celestone Chronodose72
Celiprolol50
Cellcept154
Celol
Centrally Acting Agents53
Cephalexin ABM
Cephalexin monohydrate79
Ceptolate154
Cerezyme35
Cetirizine - AFT159
Cetirizine hydrochloride
Cetomacrogol61
Champix
Charcoal
Chemotherapeutic Agents140
Chlorafast
Chlorambucil140
Chloramphenicol166
Chlorhexidine gluconate
Alimentary
Allmentary
Dermatological60
Chloroform
Chloromycetin166
Chlorothiazide
Chlorpheniramine maleate159
Chlorpromazine
hydrochloride 127
Chlorsig166
Chlorthalidone54
Chlorvescent44
Cholecalciferol37
Cholestyramine with
Cholestyramine with aspartame
Choline salicylate with
cetalkonium chloride
Cholvastin45
Ciclopiroxolamine57
Cilazapril47
Cilazapril with
hydrochlorothiazide
Cilicaine82
Cilicaine VK82
Ciloxan166
Cimetidine28
Cipflox82
Ciprofloxacin
Infection82
Sensory166
Cisplatin
Cisplatin Ebewe140
Citalopram hydrobromide120
, ,

Daktarin

Cladribine142
Clarithromycin
Alimentary28
Infection80
Clexane41
Climara 10074
Climara 5074
Clindamycin83
Clobazam121
Clobetasol propionate
Clobetasone butyrate
Clomazol
Dermatological
Genito-Urinary69
Clomiphene citrate
Clomipramine hydrochloride118
Clonazepam121
Clonidine
Clonidine hydrochloride
Cardiovascular
Nervous125
Clopidogrel41
Clopine
Clopixol
Clotrimazole Dermatological57
Dermatological
Genito-Urinary69
Clozapine
Clozaril
Co-Renitec
Co-trimoxazole83
Coal tar63
Coal tar with allantoin, menthol,
phenol and sulphur63
Coal tar with salicylic acid and
sulphur63
Coco-Scalp63
Codeine phosphate
Extemporaneous176
Nervous116
Cogentin115
Colaspase (L-asparaginase)146
Colchicine
Colestid45
Colestipol hydrochloride45
Colgout113
Colifoam27
Colistin sulphomethate83
Colistin-Link83
Collodion flexible176
Colofac28
Coloxyl
Combigan169

Combivir92
Compound electrolytes44
Compound
hydroxybenzoate176
Comtan
Concerta137
Condoms
Condyline65
Contraceptives - Hormonal67
Contraceptives -
Non-hormonal
Copaxone134
Corangin
Cordarone-X
Corticosteroids and Related
Agents for Systemic Use
Corticosteroids Topical
Cosmegen146
Cosopt
Coumadin43
Coversyl
Cozaar
Creon 10000
Creon Forte
Crixivan
Crotamiton
Crystacide57
Curam
Cyclizine hydrochloride125
Cyclizine lactate125
Cycloblastin140
Cyclogyl169
Cyclopentolate
hydrochloride 169
Cyclophosphamide140
Cyclosporin157
Cyklokapron41
Cyproterone acetate73
Cyproterone acetate with
ethinyloestradiol 69
Cytarabine142
Cytotec
Cytoxan140
- D -
D-Penamine
d4T92
G. I

Daivonex .....63

Dalacin C83
Danazol78
Danthron with poloxamer35
Dantrium113
Dantrolene sodium113
Daonil
Dapa-Tabs54
Dapsone85
Darunavir
Dasatinib149
Daunorubicin146
DBL Aminophylline164
DBL Bleomycin Sulfate145
DBL Doxorubicin146
DBL Ergometrine70
DBL Leucovorin Calcium
DBL Methotrexate
DBL Morphine Sulphate117
DBL Pethidine
Hydrochloride
DBL Tobramycin
DDI91
De-Worm
Deca-Durabolin Orgaject
Deferiprone
Depo-Medrol72
Depo-Medrol with Lidocaine
Depo-Provera
Depo-Testosterone
Deprim
Dermol
Desferrioxamine mesylate
Desmonressin 77
Desmopressin
Detection of Substances in
Urine
Dexamethasone
Hormone
Sensory167
Dexamethasone sodium
phosphate
Dexamethasone with framycetin
and gramicidin
Dexamethasone with neomycin
and polymyxin b sulphate
Dexamphetamine sulphate
Dextrochlorpheniramine maleate
Inaleate
Dextrose
Dextrose with electrolytes44



DHC Continus116
Diabetes
Diabetes Management
Diamide Relief
Diamox
Diaphragm
Diasip
Diason RTH
Diastop26
Diazepam121, 132
Dibenyline47
Diclax SR97
Diclofenac Sandoz97
Diclofenac sodium
Musculoskeletal System
Sensory167
Didanosine [DDI]91
Differin
Difflam
Diflucan
Diflucortolone valerate
Digestives Including Enzymes
Enzymes
Digoxin50
Dihydrocodeine tartrate116
Dilantin123
Dilantin Infatab123
Dilatrend50
Diltiazem hydrochloride52
Dilzem
Dimetriose
Dipentum27
Diphenoxylate hydrochloride with
atropine sulphate
Diprosone
Diprosone OV
Diprosone OV
Dipyridamole41
Disinfecting and Cleansing
Agents 60
Disipal115
Disopyramide phosphate50
Disulfiram138
Diuretics53
Diurin 4053
Dixarit125
DM Ject
Docetaxel146
Docetaxel Ebewe146
Docusate sodium
Docusate sodium with
sennosides
Domperidone
Donepezil hydrochloride138

Donepezil-Rex138
Dopergin114
Dopergin
Dopress
Dornase alfa164
Dorzolamide hydrochloride168
Dorzolamide hydrochloride with
timolol maleate 168
Dostinex
Dothiepin hydrochloride118
Doxazosin mesylate47
Doxepin hydrochloride119
Doxine
Doxorubicin
Doxorubicin Ebewe
Doxy-50
Doxycycline hydrochloride82
DP Lotion61
DP Lotn HC59
DP-Anastrozole154
Dr Reddy's Olanzapine128, 131
Dr Reddy's Omeprazole29
Dr Reddy's Ondansetron126
Dr Reddy's Pantoprazole29
Dr Reddy's Quetiapine128
Dr Reddy's Risperidone
Dr Reddy's Terbinafine
Drugs Affecting Bone
Metabolism 108
Dulcolax
Duocal Super Soluble
Powder 181
Duolin163
Duolin HFA163
Durex Confidence66
Durex Extra Safe66
Durex Select Flavours
Duride54
Dynacirc-SRO52
-E-
-E-
E-Mycin
Ear Preparations
Ear/Eye Preparations166
Easiphen194
Easiphen Liquid194
Econazole nitrate58
Efavirenz91

 Efexor XR
 120

 Eformoterol fumarate
 161

 Efudix
 65

 Egopsoryl TA
 63

 Elecare
 195

 Elecare LCP
 195

 Electral
 44

Elemental 028 Extra	186
Eligard	
Elocon	
Eloxatin	
Eltroxin	
Emend Tri-Pack	125
EMLA	
Emtricitabine	
Emtriva	
Emulsifying ointment	61
Enalapril	47
Enalapril with	
hydrochlorothiazide	
Enbrel	103
Endocrine Therapy	
Endoxan	
Enfuvirtide	92
Enoxaparin sodium	
Ensure	
Ensure Plus	190
Ensure Plus HN	189
Ensure Plus RTH	
Entacapone	
Entecavir	86
Entocort CIR	
Enuclene	
Epilim	
Epilim Crushable	124
Epilim IV	124
Epilim S/F Liquid	124
Epilim Syrup	124
Epirubicin	146
Epirubicin Ebewe	146
Eprex	40
ERA	
Ergometrine maleate	70
Ergotamine tartrate with	
caffeine	. 125
Erlotinib hydrochloride	150
Erythrocin IV	81
Erythromycin ethyl succinate	81
Erythromycin lactobionate	81
Erythromycin stearate	81
Erythropoietin alpha	40
Erythropoietin beta	
Escitalopram	120
Estraderm TTS 100	74
Estraderm TTS 25	74
Estraderm TTS 50	74
Estradot	74
Estrofem	74
Etanercept	103
Ethambutol hydrochloride	85

Ethics Aspirin1	16
Ethics Aspirin EC	41
Ethics Ibuprofen	97
Ethics Paracetamol1	16
Ethinyloestradiol	75
Ethinyloestradiol with	
desogestrel	67
Ethinyloestradiol with	
levonorgestrel	68
Ethinyloestradiol with	
norethisterone	68
Ethosuximide12	22
Etidronate disodium10	09
Etopophos14	47
Etoposide14	47
Etoposide phosphate14	47
Etravirine	91
Eumovate	59
Evista10	
Exemestane1	54
Extemporaneously Compounded	
Preparations and	
Galenicals1	
Eye Preparations16	66
EZ-fit Paediatric Mask16	
Ezetimibe	
Ezetimibe with simvastatin	46
Ezetimibe with simvastatin	46
Ezetimibe with simvastatin	46 45
Ezetimibe with simvastatin	46 45 28
Ezetimibe with simvastatin	46 45 28 28
Ezetimibe with simvastatin	46 45 28 28 52
Ezetimibe with simvastatin	46 45 28 28 52 52
Ezetimibe with simvastatin	46 45 28 28 52 52 52
Ezetimibe with simvastatin	46 45 28 28 52 52 52 74
Ezetimibe with simvastatin	46 45 28 28 52 52 52 74 74
Ezetimibe with simvastatin	46 45 28 28 52 52 52 74 74 97
Ezetimibe with simvastatin	46 45 28 28 52 52 74 74 97 16
Ezetimibe with simvastatin	46 45 28 28 52 52 74 74 97 16 17
Ezetimibe with simvastatin	46 45 28 52 52 74 74 97 16 17 38
Ezetimibe with simvastatin	46 45 28 52 52 74 97 16 17 38 46
Ezetimibe with simvastatin	46 45 28 52 52 52 74 74 97 16 17 38 6 38
Ezetimibe with simvastatin	46 45 28 52 52 74 74 97 6 17 86 38 38
Ezetimibe with simvastatin	46 45 28 52 52 74 74 97 16 73 846 38 38 38
Ezetimibe with simvastatin	46 45 28 52 52 74 97 16 17 38 6 38 38 39
Ezetimibe with simvastatin	46 45 28 52 52 74 97 16 17 38 6 38 38 39
Ezetimibe with simvastatin	46 45 28 55 52 74 77 74 76 78 63 88 38 38 38 38
Ezetimibe with simvastatin	46 45 28 52 52 74 97 61 78 46 38 39 38 38 38 38 38 38 38 38 38
Ezetimibe with simvastatin	46 45 28 52 52 74 74 76 17 346 38 38 38 38 38 38 38 38 38 38
Ezetimibe with simvastatin	46 45 28 52 52 52 74 74 97 61 73 86 38 38 38 38 38 38 38 38 38 38 38 38 38
Ezetimibe with simvastatin	46 45 28 52 52 52 74 74 76 73 46 38 38 38 38 38 38 38 38 38 39 39

Fibalip       44         Fibro-vein       41         Finasteride       70         Fine Ject       33         Fintral       70         Flagyl       85         Flagyl-S       85         Flamazine       57         Flecainide acetate       50         Fleet Phosphate Enema       35
Flixonase Hayfever &
Allergy
Flixotide
Flixotide Accuhaler
Florinef
Fluanxol
Fluarix
Flucloxin
Flucioxin
Fludara142
Fludara Oral142
Fludarabine Ebewe
Fludarabine phosphate
Fludrocortisone acetate
Fluids and Electrolytes43
Flumetasone pivalate
Fluocortolone caproate with
Fluocortolone caproate with fluocortolone pivalate and
fluocortolone pivalate and
fluocortolone pivalate and cinchocaine28
fluocortolone pivalate and cinchocaine

Forteo110 Fortimel Regular184
Fortini
Fortini Multi Fibre185
Fortisip190
Fortisip Multi Fibre191
Fosamax109
Fosamax Plus109
Framycetin sulphate166
FreeStyle Lite
Frisium121
Frumil53
Frusemide-Claris53
Fucicort60
Fucidin83
Fucithalmic166
Fungilin
Furosemide53
Fusidic acid
Dermatological57
Infection83
Sensory166
Fuzeon
- G -
Gabapentin122
Gabapentin (Neurontin)
Gamma benzene
hovachlarida 62
hexachloride
Gastrosoothe
Gastrosoothe28 Gaviscon Double Strength26
Gastrosoothe28 Gaviscon Double Strength26 Gaviscon Infant26
Gastrosoothe
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemzitabine hydrochloride       143         Gemzitabine hydrochloride       143         Gemzar       143         Generaid Plus       184         Genotropin       77         Gentamicin sulphate       153         Infection       83
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Gemzar       143         Genoticoli       184         Genotropin       77         Gentarcicin sulphate       153         Infection       83         Sensory       166
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Gemzar       143         Genotizoline       184         Genoptic       166         Gentorpin       77         Genox       153         Gentamicin sulphate       116         Infection       83         Sensory       166         Gestrinone       78
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Gemzar       143         Generaid Plus       184         Genotropin       77         Genox       153         Gentamicin sulphate       1         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Genzar       143         Generaid Plus       184         Genoptic       166         Gentorpin       77         Genox       153         Gentamicin sulphate       1         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glatiramer acetate       134
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Genzar       143         Generaid Plus       184         Genoptic       166         Gentorpin       77         Genox       153         Gentamicin sulphate       1         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glatiramer acetate       134         Gibenclamide       31
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Genzar       143         Generaid Plus       184         Genoptic       166         Gentorpin       77         Genox       153         Gentamicin sulphate       1         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glatiramer acetate       134         Gibenclamide       31         Gliclazide       31
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Genzar       143         Generaid Plus       184         Genoptic       166         Gentorpin       77         Genox       153         Gentamicin sulphate       1         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glatiramer acetate       134         Glibenclamide       31         Gliclazide       31
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemfibrozil       44         Gemzar       143         Generaid Plus       184         Genotropin       77         Genox       153         Gentamicin sulphate       1         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glaitramer acetate       134         Glibenclamide       31         Glipizide       31         Glipizide       31
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemzitabine hydrochloride       143         Gemzar       143         Generaid Plus       184         Genotropin       77         Gentamicin sulphate       153         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glaicramer acetate       134         Glibenclamide       31         Glizide       31         Glizide       31         Glivecc       150         Glucagen Hypokit       29
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemzar       143         Generaid Plus       184         Genotropin       77         Gentamicin sulphate       153         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glatiramer acetate       134         Glibenclamide       31         Glizciazide       31         Glivec       150         Glucagen Hypokit       29         Glucagon hydrochloride       29
Gastrosoothe       28         Gaviscon Double Strength       26         Gaviscon Infant       26         Gemcitabine Ebewe       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemcitabine hydrochloride       143         Gemzitabine hydrochloride       143         Gemzar       143         Generaid Plus       184         Genotropin       77         Gentamicin sulphate       153         Infection       83         Sensory       166         Gestrinone       78         Ginet 84       69         Glaicramer acetate       134         Glibenclamide       31         Glizide       31         Glizide       31         Glivecc       150         Glucagen Hypokit       29

INDEX Generic Chemicals and Brands

Glucobay3	
Gluten Free Foods	2
Glycerin with sodium saccharin	6
Glycerin with sucrose	
Glycerol	
Alimentary	5
Extemporaneous17	6
Glyceryl trinitrate	4
Gold Knight6	6
Gopten4	
Goserelin acetate7	
Gutron	0
Gynaecological Anti-infectives	0
- H -	9
наріtrol	٥
Haldol	
Haldol Concentrate	
Haloperidol12	
Haloperidol decanoate13	0
Hamilton Sunscreen64	4
healthE Fatty Cream6	1
Healtheries Simple Baking	
Mix	
Hemastix	
Heparin sodium4	2
Heparinised saline4	2
Hepsera	0 A
Hexamine hippurate	5
Hiprex	
Histafen	
Holoxan14	
Homatropine hydrobromide16	9
Horleys Bread Mix19	2
Horleys Flour192	2
Hormone Replacement Therapy -	_
Systemic	
Humalog	
Humalog Mix 25	
Humira	
HumiraPen9	
Humulin 30/70	
Humulin NPH	
Humulin R	0
Hybloc5	1
Hydralazine5	4
Hydrea14	7
Hydrocortisone	_
Dermatological	
Hormone7	2

Hydrocortisone butyrate59, 64
Hydrocortisone with
cinchocaine28
Hydrocortisone with
miconazole60
Hydrocortisone with natamycin
and neomycin60
Hydrocortisone with wool fat and
mineral oil 59
Hydroderm Lotion61
Hydrogen peroxide
Alimentary36
Dermatological57
Hydroxocobalamin
Hydroxychloroquine sulphate85
Hydroxyurea147
Hygroton
Hyoscine (scopolamine)125
Hyoscine hydrobromide126
Hyoscine N-butylbromide28
Hypam134
Hyperuricaemia and
Antigout113
Hypnovel134
Hypromellose
Hysite168
Hysite168 Hyzaar49
Hysite168 Hyzaar49
Hysite
Hysite
Hysite
Hysite         168           Hyzaar         49           -I -         1           Ibiamox         81           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140
Hysite
Hysite       168         Hyzaar       49         -1 -         Ibiamox       81         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150
Hysite       168         Hyzaar       49         -1 -         Ibiamox       81         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35
Hysite         168           Hyzaar         49           -1-         Ibiamox           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Imipramine hydrochloride         119
Hysite         168           Hyzaar         49           -1 -           Ibiamox         81           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Imipramine hydrochloride         119           Imiquumod         64
Hysite         168           Hyzaar         49           -1 -         Ibiamox           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Imipramine hydrochloride         119           Imiquimod         64           Immune Modulators         93
Hysite         168           Hyzaar         49           -1 -         Ibiamox           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Imipramine hydrochloride         119           Imiquimod         64           Immune Modulators         93           Immunosuppressants         154
Hysite         168           Hyzaar         49           -1-         Ibiamox           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Imipramine hydrochloride         119           Imiquimod         64           Immune Modulators         93           Immunosuppressants         154           Imuprine         154
Hysite       168         Hyzaar       49         -1 -       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Imipramine hydrochloride       119         Imiquimod       64         Immune Modulators       93         Immunosuppressants       154         Imuprine       154
Hysite       168         Hyzaar       49         -1-       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Imiquimod       64         Immune Modulators       93         Immunosuppressants       154         Imuran       154         Indapamide       54
Hysite       168         Hyzaar       49         -1-       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Imiquemod       64         Immune Modulators       93         Immurosuppressants       154         Imuran       154         Indapamide       54         Indinavir       92
Hysite       168         Hyzaar       49         -1 -       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Imipramine hydrochloride       119         Imiquimod       64         Immune Modulators       93         Imuprine       154         Indapamide       54         Indinavir       92         Indomethacin       98
Hysite       168         Hyzaar       49         -I -       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Imipramine hydrochloride       119         Imiquimod       64         Immune Modulators       93         Imuprine       154         Indapamide       54         Indinavir       92         Indomethacin       98         Infant Formulae       194
Hysite       168         Hyzaar       49         -I -       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Imipramine hydrochloride       119         Imiquimod       64         Immune Modulators       93         Immunosuppressants       154         Indapamide       54         Indapamide       54         Indinavir       92         Indomethacin       98         Infant Formulae       194         Influenza vaccine       96
Hysite         168           Hyzaar         49           -I -         Ibiamox           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Immunosuppressants         154           Imuran         154           Indapamide         54           Indarwir         92           Indanter Formulae         194           Influenza vaccine         96           Inhaled Anticholinergic         194
Hysite       168         Hyzaar       49         -I -       Ibiamox         Ibuprofen       97         Idarubicin hydrochloride       147         Ifosfamide       140         Iloprost       55         Imatinib mesylate       150         Imiglucerase       35         Iminpramine hydrochloride       119         Imiquimod       64         Immune Modulators       93         Immunosuppressants       154         Indapamide       54         Indianvir       92         Indinowit con       98         Infant Formulae       194         Influenza vaccine       96         Inhaled Anticholinergic       Agents
Hysite         168           Hyzaar         49           -I -         Ibiamox           Ibuprofen         97           Idarubicin hydrochloride         147           Ifosfamide         140           Iloprost         55           Imatinib mesylate         150           Imiglucerase         35           Immunosuppressants         154           Imuran         154           Indapamide         54           Indarwir         92           Indanter Formulae         194           Influenza vaccine         96           Inhaled Anticholinergic         194

Hydrocortisone acetate ......27


Beta-adrenocepto
------------------

Agonists 160	)
Inhibace Plus48	3
Innovacon hCG One Step	
Pregnancy Test	)
Insulin aspart 30	Ś
Insulin glargine	'n
Insulin glulisine	י ר
	,
Insulin isophane30 Insulin isophane with insulin	,
neutral	
Insulin lispro	I
Insulin lispro with insulin lispro	
protamine	
Insulin neutral	
Insulin pen needles	3
Insulin syringes, disposable with	
attached needle 33	
Intal Spincaps163	
Intelence91	1
Interferon alpha-2a94	ł
Interferon alpha-2b94	ł
Interferon beta-1-alpha134	ł
Interferon beta-1-beta134	ł
Intra-uterine device66	
Intron-A94	ł
Ipratropium bromide163-164	
Irinotecan144	
Irinotecan-Rex144	ŧ
Iron Overload46	
Iron polymaltose	)
Isentress92	2
lsmo 2054	ŧ
Isoniazid85	5
Isoprenaline hydrochloride54	1
Isoptin53	
Isopto Carpine169	
Isopto Homatropine169	
Isosorbide mononitrate54	
Isosource Standard189	)
Isosource Standard RTH189	)
Isotretinoin56	
Isradipine52	
Isuprel	
Itch-Soothe58	
Itraconazole	
Itrazole	
- J -	
Jadelle69	)
Jevity189	)
Jevity RTH189	)
- K -	
Kaletra92	2

Karicare Food Thickener192
Kemadrin115
Kenacomb166
Kenacort-A73
Kenacort-A4073
Ketoconazole
Dermatological64
Infection
Ketone blood beta-ketone
electrodes31
Ketoprofen
Ketostix31
Kindergen184
Kivexa
Klacid80
Klamvcin
Alimentary
Infection80
Kliogest75
Kliovance
Konakion MM41
Konsyl-D34
-1 -
-
Labetalol
Lacosamide
Lactulose35
Lactulose
Lactulose         35           Laevolac         35           Lamictal         123           Lamivudine         87, 92           Lamotrigine         123           Lanoxin         50           Lanoxin PG         50           Lansoprazole         29           Lantus         30
Lactulose
Lactulose         35           Laevolac         35           Lamictal         123           Lamivudine         87, 92           Lamotrigine         123           Lanoxin         50           Lanoxin PG         50           Lansoprazole         29           Lantus         30           Lantus         30           Lantus         144
Lactulose       35         Laevolac       35         Lamictal       123         Lamivudine       87, 92         Lamotrigine       123         Lanoxin       50         Lanoxin PG       50         Lansoprazole       29         Lantus       30         Lanvis       144         Lanzol Relief       29
Lactulose         35           Laevolac         35           Lamictal         123           Lamivudine         87, 92           Lamotrigine         123           Lanoxin         50           Lanoxin PG         50           Lanoty PG         29           Lantus         30           Lantus         30           Lanoxis         144           Lanzol Relief         29           Largactil         127
Lactulose

Levetiracetam	100
Levetiracetam-Rex	
Levlen ED	
Levobunolol	
Levocabastine	167
Levodopa with benserazide	114
Levodopa with carbidopa	114
Levomepromazine	
Levonorgestrel	
Genito-Urinary	60
Hormone	
Levothyroxine	
Lifestyles Flared	
Lignocaine	
Lignocaine hydrochloride	115
Lignocaine with	
chlorhexidine	115
Lignocaine with prilocaine	
Lincocin	
Lincomycin	
Lipazil	
Lipid Modifying Agents	
Lipitor	
Liquigen	100
Lisinopril	40
Lisuride hydrogen maleate	
Litak	
Lithicarb	
Lithium carbonate	
Livostin	
Locacorten-Viaform ED's	
Locasol	195
Loceryl	57
Locoid	
Locoid Crelo	
Locoid Lipocream	
Locorten-Vioform	
Lodoxamide trometamol	
Loette	
Logem	
Lomide	
Lomustine	
Loperamide hydrochloride	
Lopinavir with ritonavir	
Lopresor	
Loprofin	
Loprofin Mix	194
Loraclear Hayfever Relief	160
Lorapaed	160
Loratadine	160
Lorazepam	132
Lormetazepam	
Losartan	49

Lostaar49
Lovir
Loxalate
Loxamine
Lucrin Depot77
Lucrin Depot PDS77
Ludiomil119
Lumigan168
Lycinate
Lyderm62
- M -
m-Captopril47
m-Eslon117
m-Mometasone60
Mabthera155
Macrogol 335035
Madopar 125114
Madopar 250114
Madopar 62.5114
Madopar Dispersible
Madopar HBS
Magnesium hydroxide
Magnesium sulphate
Alimentary
Dermatological65
Malathion
Maprotiline hydrochloride119
Marevan43
Marine Blue Lotion SPF 30+64
Marquis Black66
Marquis Conforma66
Marquis Protecta66
Marquis Selecta66
Marquis Sensolite66
Marquis Supalite66
Marquis Titillata66
MarquisTantiliza66
Martindale Acetylcysteine176
Marvelon 2167
Marvelon 2867
Mask for spacer device165
Mast Cell Stabilisers
Maxalt Melt
Maxidex
Maxitol
MCT oil (Nutricia)182
Mebendazole
Mebeverine hydrochloride
Medrel 70
Medrol
Medroxyprogesterone acetate
Genito-Urinary69
Hormone
Mefenamic acid97



Megace152
Megestrol acetate152
Meloxicam
Melphalan140
Menthol
Mercaptopurine144
Mercilon 2167
Mercilon 2867
Mesalazine27
Mesna
Mestinon
Metabolic Disorder Agents
Metabolic Mineral Mixture
Metamide126
Metformin hydrochloride
Methadone hydrochloride
Extemporaneous176
Nervous117
Methatabs
Methoblastin
Methopt169
Methotrexate144
Methotrexate Ebewe
Methyl hydroxybenzoate177
Methylcellulose177
Methylcellulose with glycerin and
sodium saccharin 177
Methylcellulose with glycerin and
sucrose 177
Methyldopa53
Methylphenidate
hydrochloride 136
Methylphenidate hydrochloride
extended-release137
Methylprednisolone72
Methylprednisolone
aceponate 60
Methylprednisolone acetate72
Methylprednisolone acetate with
lignocaine72
Methylprednisolone sodium
succinate
Methylxanthines164
Metoclopramide
hydrochloride 126
Metoclopramide hydrochloride
with paracetamol
Metopirone
Metoprolol - AFT CR51
Metoprolol succinate51 Metoprolol tartrate51
Metronidazole
Metyrapone78


Miacalcic109
Mianserin hydrochloride119
Micolette
Miconazole
Miconazole nitrate
Dermatological
Genito-Urinary70
Micreme
Micreme H60
Microgynon 20 ED68
Microgynon 30
Microgynon 30 ED68
Microgynon 50 ED68
Microlut69
Midazolam134
Midodrine50
Minaphlex194
Minerals
Minidiab
Minirin77
Mino-tabs82
Minocycline hydrochloride82
Minomycin
Minor Skin Infections62
Mirena75
Mirtazapine120
Misoprostol
Misoprostol
Mitozantrone147
Mitozantrone Ebewe147
Mixtard 30
Moclobemide
Modafinil
Modavigil
Modecate
Moducal
Moduretic
Mogine
Mometasone furoate
Monofeme
Monogen
Morphine hydrochloride
Morphine sulphate117
Morphine tartrate
Morrex Maltodextrin
Motilium125
Mouth and Throat
Movicol
Moxifloxacin83
MSUD Maxamaid193
MSUD Maxamum193
Mucilaginous laxatives
Mucilaginous laxatives with

stimulants	. 34
Mucilax	
Mucolytics	
MultiADE	
Multiload Cu 375	
Multiload Cu 375 SL	66
Multiple Sclerosis	
Treatments	
Multivitamins	
Mupirocin	5/
Muscle Relaxants	
Myaccord Myambutol	
Mycobutin	00 20
Mycophenolate mofetil	00 154
Mycostatin	
Mydriacyl	
Mylan Fentanyl Patch	116
Mylanta P	26
Myleran	140
Myloc CR	
Myocrisin	
Myometrial and Vaginal Hormone	
Preparations	. 70
- N -	
Nadolol	51
Nadolol	
Nalcrom	27
Nalcrom Naloxone hydrochloride	27 138
Nalcrom Naloxone hydrochloride Naltraccord	27 138 138
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride	27 138 138 138
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate	27 138 138 138 72
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride	27 138 138 138 72 170
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphcon Forte Naprosyn SR 1000	27 138 138 138 72 170 170 97
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphcon Forte Naprosyn SR 1000	27 138 138 138 72 170 170 97
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphcon Forte	27 138 138 138 72 170 170 97 97
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphcon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardiil	27 138 138 138 72 170 170 97 97 97 119
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphcon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen	27 138 138 138 72 170 170 97 97 97 119
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphazoline hydrochloride Naphazoline hydrochloride Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nasal Preparations Natulan	27 138 138 138 72 170 170 97 97 119 164 147
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphcon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nasal Preparations Natulan Nausicalm	27 138 138 72 170 170 97 97 119 164 147 125
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphazoline hydrochloride Naphozon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nasal Preparations Natulan Nausicalm Navelbine	27 138 138 72 170 170 97 97 119 164 147 125 148
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphozon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nasal Preparations Natulan Nausicalm Navelbine Navoban	27 138 138 72 170 170 97 97 119 164 147 125 148 126
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphcon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nasal Preparations Natulan Nausicalm Navelbine Navoban Nedocromil	27 138 138 138 72 170 170 97 119 164 147 125 148 126 163
Nalcrom Naloxone hydrochloride Naltraccord Naltrexone hydrochloride Nandrolone decanoate Naphazoline hydrochloride Naphocon Forte Naprosyn SR 1000 Naprosyn SR 750 Naproxen Nardil Nasal Preparations Natulan Nausicalm Nauselbine Navelbine Navoban Nedocromil	27 138 138 138 72 170 170 97 119 164 147 125 148 126 163 116
Nalcrom	27 138 138 72 170 170 97 97 119 164 147 125 148 126 163 116 76
Nalcrom	27 138 138 138 72 170 170 97 119 164 147 125 148 126 163 116 76 195
Nalcrom	27 138 138 138 72 170 170 97 119 164 147 125 148 126 163 116 76 195
Nalcrom	27 138 138 138 72 170 170 97 97 119 164 147 125 148 126 163 116 76 195 195
Nalcrom	27 138 138 138 72 170 170 97 97 119 164 147 125 148 126 163 116 76 195 195
Nalcrom	27 138 138 138 138 72 170 170 97 97 119 164 147 125 148 126 163 116 76 195 195 195 157 40
Nalcrom	27 138 138 138 72 170 170 97 97 119 164 147 125 148 126 163 116 76 195 195 157 40 97

Nepro (strawberry)	186
Nepro (vanilla)	186
Nerisone	59
Neulactil	128
NeuroKare	
Neurontin	122
Nevirapine	
Nicotine	139
Nicotinic acid	
Nifedipine	52
Nifuran	95
Nilstat	
Alimentary	36
Genito-Urinary	70
Infection	
Nipent	147
Nitrados	134
Nitrates	54
Nitrazepam	134
Nitroderm TTS	54
Nitrofurantoin	95
Nitrolingual Pumpspray	
Nizoral	84
Noctamid	134
Nodia	
Noflam 250	97
Noflam 500	97
Non-steroidal Anti-inflammatory	
Drugs (NSAIDs)	97
Nordette 28	68
Norethisterone	
Genito-Urinary	69
Hormone	76
Norethisterone with	
mestranol	
Norflex	
Norfloxacin	
Noriday 28	
Norimin	68
Norinyl-1/28	68
Normacol Plus	
Normison	
Norpress	
Nortriptyline hydrochloride	
Norvir	92
Nava Caura a Danal	
NovaSource Renal	
Novatretin	62
Novatretin NovoFine	62 33
Novatretin NovoFine NovoRapid	62 33 30
Novatretin NovoFine NovoRapid NovoRapid Penfill	62 33 30 30
Novatretin NovoFine NovoRapid NovoRapid Penfill Nozinan	62 33 30 30 30 128
Novatretin NovoFine NovoRapid NovoRapid Penfill	62 33 30 30 128 164

Nupentin       122         Nutraplus       61         Nutrient Modules       180         Nutrini Energy RTH       185         Nutrini RTH       185
NutriniDrink       185         NutriniDrink Multifibre       185         Nutrison Concentrated       186         Nutrison Energy Multi Fibre       189         Nutrison Multi Fibre       189         Nutrison Standard RTH       189         Nyefax Retard       52
Nystatin         Alimentary         36           Dermatological         58           Genito-Urinary         70           Infection         84           NZB Low Gluten Bread Mix         192           - O -         -
-
Octreotide (somatostatin analogue)152 Oestradiol74
Oestradiol valerate74 Oestradiol with
norethisterone75 Oestriol
Genito-Urinary
Oestrogens75 Oestrogens with medroxyprogesterone75
Oil in water emulsion61 Olanzapine128, 131 Olanzapine pamoate
monohydrate
Olanzine-D131 Olbetam44 Olsalazine27
Omeprazole29 Omezol Relief29
On Call Advanced
Ondansetron         126           One-Alpha         37           Onkotrone         147
Optium 5 second test
Strips
Ora-Blend SF177 Ora-Plus177

Ora-Sweet	176
Ora-Sweet SF	1/6
Orabase	
Oracort	36
Oral Supplements/Complete Diet	
(Nasogastric/Gastrostomy	
Tube Feed)	
Oratane	56
Orgran	
Ornidazole	85
Orphenadrine citrate	
Orphenadrine hydrochloride	115
Ortho All-flex	
Ortho-tolidine	71
Oruvail SR	
Osmolite	
Osmolite RTH	
Ospamox	
Ospamox Paediatric Drops	
Other Endocrine Agents	78
Other Oestrogen Preparations	75
Othor Progestagen	. 75
Other Progestogen Preparations	75
Other Skin Preparations	75
	05
Ovestin	70
Genito-Urinary	
Hormone	
Ox-Pam	
Oxaliplatin	
Oxaliplatin Ebewe	
Oxazepam	
Oxis Turbuhaler	
Oxybutynin	71
Oxycodone hydrochloride	118
OxyContin	118
OxyNorm	118
Oxypentifylline	
Oxytocin	70
Ozole	84
- P -	
Pacifen	113
Pacific Atenolol	
Pacific Buspirone	
Paclitaxel	147
Paclitaxel Actavis	
Paclitaxel Ebewe	
Paediatric Seravit	27
Pamidronate disodium	100
Pamisol	
Panadol	
Pancreatic enzyme	
Pantocid IV	29



Pantoprazole29
Panzytrat
Papaverine hydrochloride54
Paracare
Paracare Double Strength116
Paracare Junior116
Paracetamol
Paracetamol + Codeine
Paracetamol + Codeine
(Relieve)118
Paracetamol with codeine118
ParaCode118
Parafast116
Paraffin62
Paraffin liquid with soft white
paraffin 170
Paraffin liquid with wool fat
liquid
Paraldehyde121
Paramax125
Parasiticidal Preparations
Parnate
Paroxetine hydrochloride120
Paxam121
Peak flow meter165
Pedialyte - Bubblegum44
Pedialyte - Fruit44
Pedialyte - Plain44
Pediasure
Pediasure RTH185
Pegasys94
Pegasys RBV Combination
Pack
Pegylated interferon alpha-2a94
Penicillamine
PenMix 30
PenMix 40
PenMix 50
Pentasa27
Pentostatin
(deoxycoformycin)147
Pepti Junior Gold196
Peptisoothe29
Peptisorb187
Pergolide114
Perhexiline maleate
Pericyazine128
Perindopril
Permax114
Permethrin
Persantin41
Pethidine hydrochloride118
Pevaryl
Pexsig

Pharmacare116
Phenelzine sulphate119
Phenobarbitone123
Phenobarbitone sodium177
Phenoxybenzamine
hydrochloride 47
Phenoxymethylpenicillin
(Penicillin V)82
Phentolamine mesylate47
Phenylephrine
hydrochloride 170
Phenytoin sodium121, 123
Phlexy 10194
Phosphate-Sandoz44
Phytomenadione41
Pilocarpine
Pimafucort60
Pindolol51
Pinetarsol64
Pinorax
Pinorax Forte
Pioglitazone
Piportil
Pipothiazine palmitate
Pizaccord
Pizotifen125
PKU Anamix Infant194
PKU Lophlex LQ194
Plaquenil
Plendil ER52
Podophyllotovin 65
Podophyllotoxin65 Polaramine159
Poloxamer
Poly-Tears169
Poly-Visc170
Polycal
Polyvinyl alcohol169
Ponstan
Postinor-169
Potassium bicarbonate44
Potassium chloride
Potassium citrate
Potassium iodate
Povidone iodine
Pradaxa42
Pravachol42
Pravaction45 Pravastatin45
Prazosin hydrochloride45
Prazosini nyurochionue47
Pred Forte
Pred Mild167
Prednisolone acetate
Prednisolone sodium
phosphate73

Prednisone73
Prefrin170
Pregnancy Tests - hCG Urine70
Pregnancy tests - HCG urine70
Premarin
Premia 2.5 Continuous75
Premia 2.5 Continuous
Premia 5 Continuous75
Prezista92
Priadel128
Primidone123
Primolut N76
Probenecid113
Probenecid-AFT113
Procaine penicillin82
Procarbazine hydrochloride
Prochlorperazine
Proctosedyl
Procyclidine hydrochloride115
Prodopa53
Prograf158
Progynova74
Promethazine hydrochloride160
Promethazine theoclate126
Promethazine Winthrop
Elixir
Promod
Propafenone hydrochloride
Propamidine isethionate166
Propranolol51
Propylene glycol177
Protamine sulphate42
Protaphane
Protaphane Penfill
Protifar182
Provera75, 76
PSO198-201
Psoriasis and Eczema
Preparations
Pulmicort Turbuhaler
Pulmocare
Pulmozyme164
Purinethol144
Pyrazinamide85
Pyridostigmine bromide97
PyridoxADE37
Pyridoxine hydrochloride37
Pytazen SR41
-0-
~
Q 200
Q 300
Questran-Lite45
Quetapel128

Quinapril
Quinapril with
hydrochlorothiazide
Quinine sulphate113
- B -
-н- RA-Morph117
Raloxifene hydrochloride
Raltegravir potassium
Ranbaxy-Cefaclor
Ranitidine hydrochloride
Rapamune
Redipred73
Regitine
Renilon 7.5186
Resonium-A
Resource Beneprotein
Resource Diabetic
Respigen162
Respiratory Devices
Respiratory Stimulants
ReTrieve
Retrovir
Retrovir
Genito-Urinary
Infection
Revataz
Ridal
Ridaura
Rifabutin85
Rifadin
Rifampicin86
Rifinah85
Riodine
Risperdal129
Risperdal Consta
Risperdal Quicklet
Risperidone129–131
Risperon
Ritalin
Ritalin LA137
Ritalin SR136
Ritonavir
Rituximab155
Rivacol
Rivaroxaban
Rivotril
Rizatriptan benzoate
Rocaltrol solution
Roferon-A94
Ropin
110pin

Quetiapine .....128

Ropinirole hydrochloride Roxithromycin Rubifen SR Rythmodan Rytmonorm - S -	81 .136 .136 50 50
S26LBW Gold RTF	.194
Sabril	
Salamol	.162
Salapin	.162
Salazopyrin	27
Salazopyrin EN	27
Salbutamol	.162
Salbutamol with ipratropium	
bromide	
Salicylic acid	
Salmeterol	.161
Sandomigran	
Sandostatin	.152
Sandostatin LAR	
SC Profi-Fine	
Scalp Preparations Scopoderm TTS	64
Sebizole	
Sedatives and Hypnotics	12/
Selegiline hydrochloride	11/
Senna	
Senokot	
SensoCard	
Serenace	
Seretide	
Seretide Accuhaler	
Serevent	.161
Serevent Accuhaler	.161
Serophene	78
Seroquel	
Sertraline	
Sevredol	.117
Sex Hormones Non	
Contraceptive	
Shield 49	
Shield Blue	
Shield XL	
Sildenafil	
Silver sulphadiazine	
Simvastatin Sindopa	
Sinemet	
Sinemet CR	
Sirolimus	
Siterone	
	-

Slow-Lopresor51 Sodibic44
Sodium acid phosphate35
Sodium alginate26
Sodium aurothiomalate98
Sodium bicarbonate
Blood43–44
Extemporaneous177
Sodium calcium edetate
Sodium
carboxymethylcellulose
Sodium chloride
Blood43
Respiratory164
Sodium citrate with sodium lauryl
sulphoacetate
Sodium citro-tartrate71
Sodium cromoglycate
Alimentary
Respiratory
Sensory167
Sodium fluoride
Sodium nitroprusside
Sodium polystyrene
sulphonate
Sodium tetradecyl sulphate41
Sodium valproate124
Sofradex
Soframycin166
Solian
Solifenacin succinate
Solox
Solu-Cortef72 Solu-Medrol72
Solu-Medroi
Sottacor
Sotalol
Space Chamber165 Space Chamber Plus165
Space chamber Plus
Spacer device autoclavable
Spacer device autoclavable
Span-K
Spironolactone
Spirotone
Sprycel
Stavudine [d4T]92 Stelazine
Stemetil
Stesolid121 Stimulants/ADHD
Treatments
Stocrin91

INDEX Generic Chemicals and Brands

Stomahesive
Strattera135
Sucralfate
Sulindac
Sulphasalazine27
Sulphur64
Sumatriptan125
Sunitinib151
Sunscreens64
Sunscreens, proprietary64
Suplena187
Surgam98
Sustagen Hospital Formula
Sustanon Ampoules73
Sutent
Symbicort Turbuhaler 100/6
Symbicort Turbuhaler 200/6162
Symbicort Turbuhaler
400/12
Symmetrel114
Sympathomimetics54
Synacthen73
Synacthen Depot73
Synermox81
Synthroid76
Syntocinon70
0
Syntometrine
Syrup (pharmaceutical
Syrup (pharmaceutical grade) 177
Syrup (pharmaceutical
Syrup (pharmaceutical grade) 177
Syrup (pharmaceutical grade)
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         50           Tambocor CR         50         50           Tamoxifen citrate         153         153           Tamsulosin hydrochloride         70         70
Syrup (pharmaceutical grade)
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         50           Tambocor CR         50         50           Tamsulosin hydrochloride         70         70           Tap water         177         72           Tar with triethanolamine lauryl sulphate and fluorescein         64
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         50           Tambocor CR         50         50           Tamsulosin hydrochloride         70         70           Tamsulosin-Rex         70         70           Tar with triethanolamine lauryl sulphate and fluorescein         64           Tarceva         150
Syrup (pharmaceutical grade)
Syrup (pharmaceutical grade)         177           - T -         -           Tacrolimus         158           Tambocor         50           Tambocor CR         50           Tamoxifen citrate         153           Tamsulosin hydrochloride         70           Tap water         177           Tar with triethanolamine lauryl sulphate and fluorescein         64           Tarceva         150           Tasmar         114           Taxotere         146
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         Tambocor CR         50           Tamoxifen citrate         153         Tamsulosin hydrochloride         70           Tamsulosin-Rex         70         Tam sulphate and fluorescein         64           Tarceva         150         Taxaar         114           Taxcotere         146         Tegretol         121
Syrup (pharmaceutical grade)         177           - T -         - T -           Tacrolimus         158           Tambocor         50           Tambocor CR         50           Tamoxifen citrate         153           Tamsulosin hydrochloride         70           Tamsulosin-Rex         70           Tam water         177           Tar with triethanolamine lauryl sulphate and fluorescein         64           Tacreva         150           Taxnar         114           Taxotere         146           Tegretol         121           Tegretol CR         121
Syrup (pharmaceutical grade)         177           - T -         -           Tacrolimus         158           Tambocor         50           Tambocor CR         50           Tamoxifen citrate         153           Tamsulosin hydrochloride         70           Tamsulosin-Rex         70           Tam water         177           Tar with triethanolamine lauryl         sulphate and fluorescein           sulphate and fluorescein         64           Tarceva         150           Tasmar         114           Tactere         146           Tegretol         121           Tegretol CR         121           Telfast         159
Syrup (pharmaceutical grade)         177           - T -         - T -           Tacrolimus         158           Tambocor         50           Tambocor CR         50           Tamoxifen citrate         153           Tamsulosin hydrochloride         70           Tamsulosin-Rex         70           Tam water         177           Tar with triethanolamine lauryl sulphate and fluorescein         64           Tacreva         150           Taxnar         114           Taxotere         146           Tegretol         121           Tegretol CR         121
Syrup (pharmaceutical grade)         177           - T -         -           Tacrolimus         158           Tambocor         50           Tambocor CR         50           Tamoxifen citrate         153           Tamsulosin hydrochloride         70           Tamsulosin-Rex         70           Tam water         177           Tar with triethanolamine lauryl         sulphate and fluorescein           sulphate and fluorescein         64           Tarceva         150           Tasmar         114           Tactere         146           Tegretol         121           Tegretol CR         121           Telfast         159
Syrup (pharmaceutical grade)         177           -T -         Tacrolimus         158           Tambocor         50         Tambocor CR         50           Tamoxifen citrate         153         Tamsulosin hydrochloride         70           Tamsulosin hydrochloride         70         Tamsulosin-Rex         70           Tar with triethanolamine lauryl sulphate and fluorescein         64         Tarceva         150           Taxotere         114         Taxotere         146         Tegretol         121           Tegretol CR         121         Tegretol CR         159         Temazepam         134           Temodal         148         148         148         148
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         Tambocor CR         50           Tamoxifen citrate         153         Tamsulosin hydrochloride         70           Tamsulosin-Rex         70         Tap water         177           Tar with triethanolamine lauryl sulphate and fluorescein         64           Tarceva         150           Tasxotere         146           Tegretol CR         121           Telfast         159           Temazepam         134           Temodal         148
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         Tambocor         50           Tamoxifen citrate         153         Tamsulosin hydrochloride         70           Tamsulosin hydrochloride         70         Tamsulosin-Rex         70           Tap water         177         Tar with triethanolamine lauryl sulphate and fluorescein         64           Tarceva         150         Tasmar         114           Taxotere         146         Tegretol CR         121           Tegretol CR         121         159         Temazepam           Temodal         148         Temozolomide         148           Temozolomide         148         Temofovir disoproxil furmarate         88
Syrup (pharmaceutical grade)         177           - T -         Tacrolimus         158           Tambocor         50         Tambocor CR         50           Tamoxifen citrate         153         Tamsulosin hydrochloride         70           Tamsulosin-Rex         70         Tap water         177           Tar with triethanolamine lauryl sulphate and fluorescein         64         Tarceva           Taxotere         114         Taxotere         146           Tegretol CR         121         Tegretol CR         121           Telfast         159         Temazepam         134           Temodal         148         Temozolomide         148

Terbinafine ......85

Terbutaline sulphate162
Teriparatide110
Testosterone73
Testosterone cypionate73
Testosterone esters73
Testosterone undecanoate
Tetrabenazine
Tetrabromophenol
Tetracosactrin
Teva145
Thalidomide148
Thalomid148
Theophylline164
Thiamine hydrochloride
Thioguanine144
Thiotepa141
Thymol glycerin
Thyroid and Antithyroid
Agents76
Tiaprofenic acid98
Tiberal85
Tilade163
Tilcotil
Timolol maleate
Cardiovascular51
Sensory167
Timoptol XE167
Tiotropium bromide167
Titralac
TMP84
Tobramycin
Infection84
Sensory167
Tobrex167
Tofranil119
Tolcapone114
Tolvon119
Topamax124
Topiramate124
Topilallale
Total parenteral nutrition
(TPN)
TPN44
Tracleer55
Tramadol hydrochloride116
Trandate
Trandolapril48
Tranexamic acid41
Tranylcypromine sulphate119
Trastuzumab156
Travatan
Travoprost
Treatments for Dementia
Treatments for Opioid

Overdose	138
Treatments for Substance	
Dependence	138
Trental 400	54
Tretinoin	
Dermatological	56
Oncology	148
Triamcinolone acetonide	00
Alimentary Dermatological	
Hormone	
Triamcinolone acetonide with	73
gramicidin, neomycin and nys	tatin
Dermatological	
Sensory	166
Triazolam	
Trichozole	
Triclosan	
Trifluoperazine	
hydrochloride	129
Trimeprazine tartrate	
Trimethoprim	84
Trisequens	75
Trisul	
Trophic Hormones	
Tropicamide	
Tropisetron	126
Trusopt	
Two Cal HN	191
Tyloxapol	169
- U -	
Ultraproct	
Univent	
Ural	
Urea	
Urex Forte Urinary Agents	
Urinary Tract Infections	
Uromitexan	
Ursodeoxycholic acid	/ ۱۹ ۱۹۷
- V -	
Vaccines	
Valaciclovir	
Vallergan Forte	
Valtrex Vancomycin hydrochloride	88
Vancomycin nydrochioride	04 160
Varenicline tartrate	120
Vasodilators	
Vasopressin Agonists	
Velcade	145
Venlafaxine	

			INDEX	
Generic	Chemicals	and	Brands	

Ventavis	
Ventolin	
Vepesid	147
Veracol	
Verapamil hydrochloride	53
Vergo 16	125
Vermox	79
Verpamil SR	53
Vesanoid	148
Vesicare	71
Viaderm KC	60
Viagra	
Vicrom	
Videx EC	91
Vigabatrin	
Vimpat	122
Vinblastine sulphate	148
Vincristine sulphate	148
Vinorelbine	148
Vinorelbine Ebewe	
Viramune	91
Viramune Suspension	91
Viread	
Vistil	169
Vistil Forte	169
Vitabdeck	
Vitadol C	37
Vital HN	186
Vitala-C	37
Vitamin A with vitamins D and	
С	37

Vitamin B complex	37
Vitamins	37–38
Vivonex Pediatric	195
Vivonex TEN	187
Volibris	55
Voltaren	
Voltaren D	97
Voltaren Ophtha	167
Volumatic	165
Vosol	166
Vytorin	46
- W -	

Warfarin sodium	43
Wart Preparations	ô4
Wasp venom allergy	
treatment1	59
Water	
Blood	44
Extemporaneous1	77
Wool fat with mineral oil	61

### 

Xylocaine Viscous ......115

- Z -		
Zantac	29	
Zapril	47	
Zarontin1		
Zavedos14	47	
Zeffix	87	
Zeldox1		
Zerit	92	
Zetop1	59	
Ziagen		
Zidovudine [AZT]	92	
Zidovudine [AZT] with		
lamivudine	92	
Zinacef	79	
Zinc and castor oil	61	
Zinc sulphate	39	
Zincaps	39	
Zinnat	79	
Ziprasidone12	29	
Zoladex	77	
Zoledronic acid1	11	
Zopiclone1		
Zostrix HP	65	
Zovirax1	66	
Zuclopenthixol decanoate13	31	
Zuclopenthixol		
hydrochloride12		
Zyban1	38	
Zyprexa12		
Zyprexa Relprevv1	30	
Zyprexa Zydis1	31	

NOTES

# AUTHORITY TO SUBSTITUTE

## Dear Pharmacist

Where I refer in a prescription to a medicine by its trade mark or trade name (brand), or by the name of its manufacturer, I give authority to substitute an alternative brand of the same medicine in the following situations:

## **Sole Supply Products**

Where PHARMAC has entered into sole supply arrangement for the medicine you may substitute the sole supply brand, except if the patient chooses to pay for the non-sole supply brand.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

## Other subsidised products

Where PHARMAC has listed one or more brands of the medicine on the Pharmaceutical Schedule (and the brand that I have prescribed is not listed or has a Manufacturer's Price that is greater than the Subsidy) you may substitute with a listed brand, except if the patient specifically requests the brand prescribed.

This includes repeat dispensings where the brand I have prescribed is no longer subsidised or is partly subsidised.

## Exceptions

I do not want substitution to occur for the following chemical entities, unless I am contacted verbally in each specific case.

This authority to substitute replaces all previous authorities relating to these particular pharmaceuticals which I may have provided previously.

This authority to substitute is valid unless I have indicated on the prescription an instruction not to substitute.

This authority is valid whether or not there is a financial implication for the Funder.

Please inform my patient that I have authorised substitution.

Name:	NZMC:
Signature:	Date:
	to change a prescribed medicine in this way is

Authority for the dispensing pharmacist to change a prescribed medicine in this way is contained in regulation 42 (4) of the Medicines Regulations 1984.

NOTES